letrozole has been researched along with Breast Cancer in 1236 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)." | 9.69 | Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. ( Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Carañana, V; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil Gil, MJ; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-De Dueñas, E; Mina, L; Pérez-García, JM; Ruiz Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P, 2023) |
| "The phase IIIb, BioItaLEE trial (NCT03439046) collected sera from postmenopausal patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated with first-line ribociclib plus letrozole at baseline, day 15 of cycle 1 (C1D15), day 1 of cycle 2 (C2D1), and at first imaging." | 9.69 | Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. ( Allegrini, G; Arpino, G; Benelli, M; Bianchi, GV; Bianchini, G; Caputo, R; Castelletti, D; Cazzaniga, ME; Colleoni, M; De Laurentiis, M; Del Mastro, L; Di Marino, M; Guarneri, V; Malorni, L; Montemurro, F; Orditura, M; Paris, I; Puglisi, F; Tamberi, S; Zamagni, C; Zambelli, A, 2023) |
| "Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape." | 9.69 | Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con ( Bayaxi, N; Cheng, Y; Geng, C; Hu, C; Hu, X; Li, W; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wei, W; Wu, X; Xie, W; Xu, B; Xu, J; Yan, M; Yan, X; Zeng, X; Zhang, H; Zhang, P; Zhang, Q; Zhong, J; Zhu, X, 2023) |
| "The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase inhibitor (AI)-based therapy." | 9.69 | Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. ( Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Rastogi, P; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wolmark, N, 2023) |
| "Postmenopausal breast cancer patients starting adjuvant letrozole were eligible." | 9.69 | Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurem ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2023) |
| "This non-randomized, multicohort, phase II study evaluated the efficacy and safety of the anti-PD-1 antibody nivolumab 240 mg administered every 2 weeks in combination with the CDK4/6 inhibitor abemaciclib 150 mg twice daily and either fulvestrant (FUL) or letrozole (LET) as a first-line or second-line treatment for HR-positive HER2-negative metastatic breast cancer." | 9.69 | Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). ( Aogi, K; Futamura, M; Hosonaga, M; Imamura, CK; Iwasa, T; Iwata, H; Kawabata, H; Masuda, J; Masuda, N; Matsumoto, K; Miura, S; Mukohara, T; Sakai, H; Takahashi, M; Takano, T; Tanabe, Y; Tomioka, N; Tsurutani, J; Yamochi, T; Yasojima, H; Yoshimura, K, 2023) |
| "AMEERA-4 (NCT04191382) was a WOO study undertaken to compare the pharmacodynamic effects of amcenestrant, a selective estrogen receptor degrader, with those of letrozole in postmenopausal women with newly diagnosed, operable estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer." | 9.69 | AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. ( Bidard, FC; Campone, M; De Giorgi, U; Dong, Y; Herold, C; Ling, B; Neven, P; Paux, G; Wang, L, 2023) |
| "This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC)." | 9.51 | Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. ( Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS, 2022) |
| "The phase IIIb CompLEEment-1 study evaluated ribociclib plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)." | 9.51 | Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial. ( Abdel-Razeq, H; Cardoso, F; Cottu, P; De Laurentiis, M; Marchetti, P; Martín, M; Menon-Singh, L; Ring, A; Salvador Bofill, J; Wu, J, 2022) |
| "In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer." | 9.51 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. ( André, F; Arteaga, CL; Burris, HA; Cameron, DA; Campone, M; Chakravartty, A; Conte, P; Hart, L; Hortobagyi, GN; Janni, W; Le Gac, F; O'Shaughnessy, J; Petrakova, K; Serra, P; Sonke, GS; Stemmer, SM; Taran, T; Winer, EP; Yap, YS; Zarate, JP, 2022) |
| "NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes." | 9.51 | Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. ( Callens, C; Cottu, P; D'Hondt, V; Dalenc, F; Delaloge, S; Desmoulins, I; Duhoux, FP; Dureau, S; Frenel, JS; Gentien, D; Heudel, PE; Jouannaud, C; Lemonnier, J; Lerebours, F; Levy, C; Manduzio, H; Mouret-Reynier, MA; Nguyen, S; Rapinat, A; Venat-Bouvet, L; Vincent-Salomon, A, 2022) |
| "Patients with advanced ER+/HER2- breast cancer were treated with lenvatinib plus letrozole in a phase Ib/II trial." | 9.51 | Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. ( Ang, YLE; Chan, GHJ; Chee, CE; Chong, WQ; Choo, JRE; Goh, BC; Jain, S; Lee, M; Lee, SC; Lim, JSJ; Lim, SE; Lim, YW; Ngoi, NYL; Ow, SGW; Soo, RA; Sundar, R; Tai, BC; Tan, DSP; Tan, HL; Wang, L; Wong, ALA; Yadav, K; Yong, WP, 2022) |
| "The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2- ABC (MONALEESA-7)." | 9.51 | Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. ( Beniak, J; Borstnar, S; Gal-Yam, EN; Kudela, P; Palacova, M; Papazisis, K; Rubovszky, G; Timcheva, C; Łacko, A, 2022) |
| "Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) in the Phase 3b CompLEEment-1 trial." | 9.51 | Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. ( Ballatore, Z; Ballestrero, A; Caputo, R; Coltelli, L; De Laurentiis, M; Fabi, A; Ferro, A; Frassoldati, A; Generali, D; Grasso, D; Mansutti, M; Marchetti, P; Masetti, R; Mazza, M; Michelotti, A; Sarobba, MG; Spazzapan, S; Torrisi, R; Vici, P; Zamagni, C; Zambelli, A, 2022) |
| "The cyclin-dependent kinase 4/6 inhibitor palbociclib has demonstrated efficacy and a manageable safety profile in combination with endocrine therapy in women with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in international phase 3 trials." | 9.51 | Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. ( Cheng, Y; Chia, YH; Cui, S; Geng, C; Hu, X; Huang, CS; Li, W; Ngan, RKC; Shen, K; Song, E; Sriuranpong, V; Sun, T; Tong, Z; Wang, S; Wang, X; Xu, B; Zhang, Q; Zhao, H, 2022) |
| " We aimed to compare extended therapy with letrozole for 5 years versus the standard duration of 2-3 years of letrozole in postmenopausal patients with breast cancer who have already received 2-3 years of tamoxifen." | 9.41 | Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. ( Amaducci, L; Arpino, G; Ballestrero, A; Barone, C; Bighin, C; Bisagni, G; Bruzzi, P; Campadelli, E; Cognetti, F; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Frassoldati, A; Garrone, O; Gori, S; Lambertini, M; Mansutti, M; Michelotti, A; Montemurro, F; Moretti, G; Mura, S; Poggio, F; Ponzone, R; Puglisi, F; Sanna, G; Tamberi, S; Urracci, Y, 2021) |
| "The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic effects, not necessarily related to estrogen-suppression, may be involved in this well-known "lack of cross-resistance"." | 9.41 | Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. ( Bahrami, N; Geisler, J; Geisler, SB; Gravdehaug, B; Jabeen, S; Kristensen, V; Reitsma, LC; Sauer, T; Selsås, K; Tahiri, A; Ødegård, HP, 2021) |
| "The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer." | 9.41 | Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. ( Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil-Gil, M; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-de Dueñas, E; Pérez-García, JM; Ruíz-Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P, 2021) |
| "According to the current literature, there is an overall tendency towards a mild and transient thyroid dysfunction, that is, subclinical hypothyroidism in tamoxifen-treated patients." | 9.41 | Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review. ( Andersson, M; Buch-Larsen, K; Gillberg, L; Marina, D; Rasmussen, ÅK; Schwarz, P, 2023) |
| "In the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer." | 9.41 | Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. ( Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mukai, H; Muramatsu, Y; Ohno, S; Ohtani, S; Rai, Y; Shimizu, C; Toi, M; Umeyama, Y, 2021) |
| "In the randomised phase II LEO trial, we investigated the effect of adding everolimus (EVE) to letrozole (LET) in ovarian-suppressed premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent/metastatic breast cancer." | 9.41 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. ( Ahn, JH; Cheon, J; Jeong, JH; Jung, KH; Kim, GM; Kim, JE; Kim, SB; Koh, SJ; Lee, KS; Park, IH; Sim, SH; Sohn, J, 2021) |
| "This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 9.41 | Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. ( André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK, 2021) |
| "In a prospective study of breast cancer patients switching to letrozole treatment after previous tamoxifen, plasma estrogen levels were measured at baseline and after 3- and 12-months using LC-MS/MS." | 9.41 | Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2021) |
| "Postmenopausal women with ER-positive, HER2-negative breast cancer who had a primary tumor > 2 cm or positive axillary lymph node(s) proofed by biopsy were randomly (1,1) enrolled to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles before surgery." | 9.41 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. ( Chen, J; Deng, H; He, Z; Jin, L; Liu, J; Nie, Y; Rao, N; Su, F; Wu, W; Yang, Y; Yao, Y, 2021) |
| "Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2." | 9.34 | TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. ( Carey, LA; Delossantos, JF; Forero-Torres, A; Grizzle, WE; Li, Y; Lin, NU; Liu, MC; LoBuglio, AF; Myers, RM; Nanda, R; Puhalla, S; Roberts, BS; Rugo, HS; Saleh, MN; Storniolo, AM; Vaklavas, C; Varley, KE, 2020) |
| "Participants were postmenopausal women with ER+, HER2 normal operable breast cancer assigned to 4 months of neoadjuvant letrozole." | 9.34 | Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. ( Ejlertsen, B; Jensen, MB; Knoop, AS; Laenkholm, AV; Skriver, SK, 2020) |
| "Palbociclib is a highly selective, reversible, oral inhibitor of cyclin-dependent kinases 4 and 6 that is approved to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer." | 9.34 | Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. ( Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Muramatsu, Y; Nishimura, R; Ohno, S; Takahashi, M; Toi, M; Umeyama, Y, 2020) |
| "Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC)." | 9.34 | Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). ( Bananis, E; Boer, K; Bondarenko, I; Ettl, J; Finn, RS; Huang, X; Kim, S; McRoy, L; Patel, R; Pinter, T; Schmidt, M; Shparyk, YV; Slamon, DJ; Thummala, A; Voitko, N; Wilner, K, 2020) |
| "Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicities with palbociclib plus endocrine therapy, supporting the ongoing investigation of palbociclib plus endocrine therapy in early breast cancer (NCT02513394)." | 9.30 | Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. ( Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Huang Bartlett, C; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Slamon, DJ; Turner, NC, 2019) |
| "The cyclin-dependent kinase 4/6 inhibitor palbociclib has emerged as a novel therapeutic agent in metastatic breast cancer." | 9.30 | Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer. ( Aslam, R; Deac, O; Kennedy, J; O'Dwyer, R; Sukor, S; Tierney, A; Watson, GA, 2019) |
| "BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early breast cancer." | 9.30 | Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. ( Bonnefoi, H; Coates, AS; Colleoni, M; de Azambuja, E; Del Mastro, L; Di Leo, A; Ejlertsen, B; Gelber, RD; Gianni, L; Giobbie-Hurder, A; Gladieff, L; Goldhirsch, A; Harvey, VJ; Jakobsen, EH; Jassem, J; Jensen, MB; Kralidis, E; Láng, I; Neven, P; Piccart-Gebhart, M; Regan, MM; Rochlitz, C; Ruhstaller, T; Simoncini, E; Spazzapan, S; Thürlimann, B; Tondini, C; Veyret, C; Zaman, K, 2019) |
| " Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo." | 9.30 | Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Graham, ML; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Paik, S; Rastogi, P; Seay, TE; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wickerham, DL; Wolmark, N, 2019) |
| "In PALOMA-2, palbociclib-letrozole significantly improved progression-free survival (PFS) vs placebo-letrozole in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC) in the first-line setting." | 9.30 | Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ( Hashigaki, S; Iwata, H; Lu, DR; Masuda, N; Mori, Y; Mukai, H; Muramatsu, Y; Nagasawa, T; Nishimura, R; Ohno, S; Ohsumi, S; Ohtani, S; Sato, N; Shimizu, C; Takahashi, M; Toi, M; Umeyama, Y; Yamamoto, Y, 2019) |
| "To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer." | 9.30 | Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. ( Bernhard, J; Coates, AS; Colleoni, M; Dellapasqua, S; Di Leo, A; Gelber, RD; Gianni, L; Goldhirsch, A; Gray, KP; Johansson, H; Kammler, R; Maibach, R; Munzone, E; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Rubino, D; Ruepp, B; Viale, G, 2019) |
| "Fertility preservation (FP) protocols in case of breast cancer (BC) include mature oocyte cryopreservation following letrozole associated controlled ovarian hyperstimulation (Let-COH)." | 9.30 | Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. ( De Maertelaer, V; Dechène, J; Delbaere, A; Demeestere, I; Devreker, F; Gervy, C; Goldrat, O; Gonzalez-Merino, E; Van Den Steen, G, 2019) |
| "In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0." | 9.30 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. ( Bartlett, CH; Castrellon, A; Diéras, V; Ettl, J; Finn, RS; Gauthier, ER; Gelmon, KA; Harbeck, N; Iyer, S; Joy, AA; Lipatov, O; Lu, DR; Mori, A; Rugo, HS; Slamon, DJ, 2019) |
| "In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer." | 9.30 | Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. ( Abdi, E; Aebi, S; Barbeaux, A; Bernhard, J; Biganzoli, L; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Foukakis, T; Francis, PA; Gelber, RD; Goldhirsch, A; Gomez, HL; Graas, MP; Graiff, C; Jerusalem, G; Karlsson, P; Luo, W; Maibach, R; Müller, B; Neven, P; Pagani, O; Rabaglio, M; Regan, MM; Ribi, K; Ruhstaller, T; Vorobiof, D, 2019) |
| "The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor-positive (HR+) tumours." | 9.30 | Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. ( Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V, 2019) |
| "Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2- advanced breast cancer." | 9.27 | Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. ( Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E, 2018) |
| "In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole." | 9.27 | Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. ( Aebi, S; Bernhard, J; Burstein, H; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Gavilá, J; Gelber, RD; Goldhirsch, A; Gombos, A; Graas, MP; Hitre, E; Jerusalem, G; Kamby, C; Karlsson, P; Kuroi, K; Loibl, S; Luo, W; Maibach, R; Marth, C; Müller, B; Neven, P; O'Reilly, S; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Ruhstaller, T; Simoncini, E; Thompson, A; Viale, G, 2018) |
| "Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer." | 9.27 | Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. ( Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C, 2018) |
| "A total of 119 postmenopausal women with ER-positive, HER2-negative operable breast cancer were assigned to four months of neoadjuvant letrozole before definitive surgery." | 9.27 | Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). ( Christiansen, P; Ejlertsen, B; Grundtmann, B; Handler, J; Jensen, MB; Knoop, AS; Laenkholm, AV; Rasmussen, BB; Skriver, SK; Tvedskov, TF, 2018) |
| "A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients." | 9.27 | Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study. ( Anan, K; Doihara, H; Fujisawa, T; Ikeda, T; Jinno, H; Kanbayashi, C; Kimura, M; Komaki, K; Kusama, M; Mitsuyama, S; Miyauchi, K; Sano, M; Sato, N; Shien, T; Yanagita, Y, 2018) |
| "In this prospective, open-label phase II study, postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative early-stage breast cancer received neoadjuvant letrozole (LET) for one month, followed by treatment with a single dose of zoledronic acid." | 9.27 | Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. ( Gondo, N; Hamazaki, Y; Ikeda, T; Kanao, S; Masuda, N; Minato, N; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Toi, M; Uozumi, R; Yamagami, K; Yamauchi, A, 2018) |
| "This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases." | 9.27 | Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. ( Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC, 2018) |
| "This single-arm, open-label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer evaluated the efficacy, safety, and pharmacokinetics of first-line palbociclib (125 mg once daily, 3 weeks on/1 week off) coadministered with letrozole (2." | 9.27 | Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ( Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Muramatsu, Y; Nagasawa, T; Nishimura, R; Ohno, S; Takahashi, M; Toi, M; Umeyama, Y, 2018) |
| "The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)." | 9.27 | First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. ( Alba, E; Auñón, PZ; Bachelot, T; Beck, TJ; Campone, M; Diab, S; Esteva, FJ; Gil-Gil, M; Janni, W; Kral, Z; Lopez, R; Miller, M; Pluard, TJ; Richards, P; Ryvo, L; Sutradhar, S; Tsai, M; Ward, P, 2018) |
| "Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole." | 9.27 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. ( Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C, 2018) |
| "Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treated with first-line ribociclib plus letrozole." | 9.27 | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. ( Alba, E; Burris, HA; Campone, M; Chandiwana, D; Dalal, AA; Janni, W; Monaco, M; O'Shaughnessy, J; Sutradhar, S; Verma, S, 2018) |
| "The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 9.27 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ( Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS, 2018) |
| "UMIN000001331 Phase II study of neoadjuvant letrozole combined with low-dose metronomic cyclophosphamide for postmenopausal women with endocrine-responsive breast cancer (JBCRG-07)." | 9.27 | A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. ( Akiyama, F; Kamigaki, S; Kurosumi, M; Masuda, N; Mikami, Y; Morimoto, T; Morita, S; Tanaka, S; Toi, M; Tsuda, H; Ueno, T, 2018) |
| "In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole." | 9.27 | Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. ( Ballman, KV; Barry, W; Cohen, HJ; Dickler, MN; Hahn, OM; Hudis, CA; Hurria, A; Jatoi, A; Lafky, JM; Li, D; McCall, LM; Muss, HB; Schneider, B; Tripathy, D; Winer, EP, 2018) |
| "In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer." | 9.27 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. ( Babu, KG; Bardia, A; Campos-Gomez, S; Carlson, G; Chow, L; Colleoni, M; De Laurentiis, M; Diaz-Padilla, I; El-Saghir, N; Franke, F; Germa, C; Harbeck, N; Hirawat, S; Hughes, G; Hurvitz, SA; Im, SA; Im, YH; Jung, KH; Kuemmel, S; Lee, KS; Liu, MC; Lu, YS; Sohn, J; Tripathy, D; Villanueva Vazquez, R; Wheatley-Price, P, 2018) |
| "This phase Ib study (NCT00960960) evaluated pictilisib (GDC-0941; pan-phosphatidylinositol 3-kinase inhibitor) plus paclitaxel, with and without bevacizumab or trastuzumab, or in combination with letrozole, in patients with locally recurrent or metastatic breast cancer." | 9.27 | A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. ( Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E, 2018) |
| " Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2." | 9.27 | Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. ( Callens, C; Canon, JL; Cottu, P; D'Hondt, V; Dalenc, F; Delaloge, S; Desmoulins, I; Duhoux, FP; Dureau, S; Ferrero, JM; Frenel, JS; Gentien, D; Grenier, J; Heudel, PE; Jouannaud, C; Lemonnier, J; Lerebours, F; Levy, C; Mouret-Reynier, MA; Nguyen, S; Venat-Bouvet, L; Vincent-Salomon, A, 2018) |
| "AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group's trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs)." | 9.24 | Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98. ( Alkner, S; Bendahl, PO; Fernö, M; Jensen, MB; Mouridsen, H; Rasmussen, BB; Rydén, L, 2017) |
| "Women with stage I-III breast cancer starting adjuvant letrozole and 25(OH)D level ≤40 ng/ml were eligible." | 9.24 | Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. ( Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; Nydegger, JL; Reddy, PS; Sharma, P; Yeh, HW, 2017) |
| "Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy." | 9.24 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. ( Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O, 2017) |
| "Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery." | 9.24 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ( Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N, 2017) |
| "In a randomized, multicenter trial of postmenopausal women with early-stage breast cancer starting treatment with letrozole (n = 241) or exemestane (n = 228), plasma estrogen concentrations at baseline and after 3 months were quantitated using a sensitive mass spectrometry-based assay." | 9.24 | Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. ( Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Hertz, D; Li, L; Nguyen, AT; Rae, JM; Robarge, JD; Skaar, TC; Stearns, V; Storniolo, AM, 2017) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "This randomised open label phase III trial recruited postmenopausal women from 29 Australian and New Zealand sites, with hormone receptor-positive early breast cancer, who had completed ≥4 years of endocrine therapy [aromatase inhibitor (AI), tamoxifen, ovarian suppression, or sequential combination] ≥1 year prior, to oral letrozole 2." | 9.22 | Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. ( Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N, 2016) |
| "Background Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer." | 9.22 | Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment. ( Bell, T; Bhattacharyya, H; Crown, JP; Finn, RS; Huang Bartlett, C; Huang, X; Kim, S; Lang, I; Randolph, S; Slamon, D; Zanotti, G, 2016) |
| "To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor-positive metastatic breast cancer (MBC)." | 9.22 | Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). ( Barry, WT; Carey, LA; Cirrincione, CT; Dickler, MN; Ellis, MJ; Hahn, O; Hudis, CA; Hurria, A; Innocenti, F; Lake, DE; Moynahan, ME; Rugo, HS; Schneider, BP; Tripathy, D; Winer, EP, 2016) |
| "Vitamin D3 supplementation significantly improved serum 25-hydroxy vitamin D concentrations and decreased letrozole-induced arthralgia." | 9.22 | Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole. ( Ananthanarayanan, PH; Arul Vijaya Vani, S; Harichandrakumar, KT; Kadambari, D; Nandeesha, H; Niranjjan, R, 2016) |
| " In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer (20." | 9.22 | Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. ( Bartlett, CH; Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Huang, X; Kim, ST; Lang, I; Nadanaciva, S; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Schnell, P; Slamon, DJ, 2016) |
| "Neo-ALL-IN (NCT 01275859) is a single-center, phase II study aimed to evaluate the efficacy and safety profiles of neoadjuvant letrozole plus lapatinib, as well as potential biomarkers, in postmenopausal women with ER- and HER2-positive (ER+HER2+) breast cancer." | 9.22 | Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne ( Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH, 2016) |
| "In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease." | 9.22 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. ( Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D, 2016) |
| "A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer." | 9.22 | Palbociclib and Letrozole in Advanced Breast Cancer. ( Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Harbeck, N; Im, SA; Jones, S; Lipatov, ON; Lu, DR; Martin, M; Moulder, S; Randolph, S; Rugo, HS; Slamon, DJ; Walshe, JM, 2016) |
| "The addition of palbociclib to letrozole in this phase 2 study significantly improved progression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast cancer." | 9.20 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. ( Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Fowst, C; Huang, X; Kim, ST; Kulyk, SO; Lang, I; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Shparyk, Y; Slamon, DJ; Thummala, AR; Voytko, NL, 2015) |
| "A multicenter, randomized, open-label, phase III, binational (Spain and Germany) study added bevacizumab (15 mg/kg every 3 weeks) to ET (ET-B; letrozole or fulvestrant) as first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -negative and hormone receptor-positive advanced breast cancer." | 9.20 | Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. ( Aktas, B; Anton, A; Carrasco, E; De la Haba-Rodriguez, JR; Garcia-Saenz, JÁ; Gil, M; Guerrero, A; Liedtke, C; Loibl, S; Margeli, M; Martín, M; Martinez, N; Mehta, K; Morales, S; Muñoz, M; Ramos, M; Schoenegg, W; von Minckwitz, G; Wachsmann, G, 2015) |
| "A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months." | 9.20 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. ( Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND, 2015) |
| "This phase I/II dose-escalation study evaluated the efficacy, safety, and pharmacokinetics of pilaralisib (SAR245408), a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, or voxtalisib (SAR245409), a PI3K and mammalian target of rapamycin inhibitor, in combination with letrozole in hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative, non-steroidal aromatase inhibitor-refractory, recurrent or metastatic breast cancer." | 9.20 | Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ( Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM, 2015) |
| "The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL)." | 9.19 | FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. ( Baier, M; Beckmann, MW; Berghorn, M; Fasching, PA; Grab, D; Hanf, V; Hauschild, M; Jud, SM; Kahlert, S; Kreienberg, R; Krocker, J; Kühn, T; Kümmel, S; Lux, MP; Müller, T; Muth, M; Paepke, S; Schulz-Wendtland, R; Schütte, M; Stickeler, E; Wackwitz, B; Warm, M; Wolf, C, 2014) |
| "This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2) -negative operable breast cancer." | 9.19 | Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. ( Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E, 2014) |
| "This study will provide direct evidence of the anti-tumor effect of metformin in non-diabetic, postmenopausal patients with ER-positive breast cancer." | 9.19 | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). ( Ahn, SH; Chae, BJ; Choi, SY; Han, S; Han, W; Jeong, J; Jeong, SS; Jung, SY; Jung, Y; Kang, E; Kang, HS; Kang, T; Kim, EK; Kim, J; Kim, KS; Kim, LS; Kim, MK; Kim, SI; Kim, SW; Kim, TH; Lee, JE; Lim, W; Moon, HG; Nam, SJ; Noh, DY; Paik, NS; Park, CH; Yoo, YB; Yoon, JH; Yu, JH, 2014) |
| "Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and xenografts, alone and with endocrine therapy." | 9.19 | Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. ( Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT, 2014) |
| " Women receiving adjuvant letrozole for T1-3N0-3M0 breast cancer with a body mass index (BMI) ≥ 24 kg/m(2) were eligible." | 9.19 | Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. ( Blackburn, GL; Findlay, B; Goodwin, PJ; Gralow, JR; Levine, M; Ligibel, JA; Mukherjee, S; Pond, GR; Pritchard, KI; Robidoux, A; Segal, RJ; Vallis, M, 2014) |
| "In premenopausal women with breast cancer, standard adjuvant endocrine therapy has been 5 years of tamoxifen." | 9.19 | Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. ( Barry, W; Block, CC; Borges, V; DeSantis, SD; Guo, H; Partridge, AH; Ruddy, KJ; Winer, EP, 2014) |
| " Zoledronic acid will be administered once during preoperative hormonal therapy with letrozole for 24 weeks in postmenopausal women with Estrogen Receptor (ER)-positive , Human Epidermal Growth Factor Receptor 2 (HER2)-negative, clinical T1 or T2 N0M0 breast cancer." | 9.19 | Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. ( Ikeda, T; Minato, N; Shimizu, A; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Teramukai, S; Toi, M; Yoshimura, K, 2014) |
| "5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response." | 9.17 | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. ( Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bonardi, S; Bottini, A; Cappelletti, MR; Foroni, C; Fox, SB; Generali, D; Giardini, R; Gussago, F; Harris, AL; Martinotti, M; Milani, M; Strina, C; Zanoni, V, 2013) |
| "This trial evaluated the effect of adding lapatinib to letrozole after clinical resistance to aromatase inhibitor (IA) treatment in hormone receptor-positive metastatic breast cancer." | 9.17 | Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06. ( Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT, 2013) |
| "Adding temsirolimus to letrozole did not improve PFS as first-line therapy in patients with AI-naive advanced breast cancer." | 9.17 | Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. ( Berkenblit, A; Bondarenko, I; Brincat, S; Chan, A; Chow, L; Cincotta, M; Fumoleau, P; Garin, AM; Guimaraes, RC; Hachemi, S; Hayes, DF; Kang, LL; Krygowski, M; Lazar, AA; Moore, L; Neskovic-Konstantinovic, Z; Strahs, A; Sun, Y; Wolff, AC, 2013) |
| "The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC)." | 9.16 | Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. ( Azim, HA; Barsoum, M; Baumgärtner, AK; Beckmann, MW; Fasching, PA; Harbeck, N; Huober, J; Kubista, E; May, C; Nimmrich, I; Paepke, S; Petruzelka, L; Ragosch, V; Reimer, T; Thomssen, C; Wallwiener, D, 2012) |
| "Letrozole is a proven and effective adjuvant therapy in postmenopausal women with hormone receptor-positive (HR(+)) early breast cancer (EBC)." | 9.16 | Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. ( Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP, 2012) |
| "Letrozole is superior to tamoxifen in terms of response and breast preservation rates as primary systemic therapy (PST) in postmenopausal women with ER-positive early breast cancer." | 9.16 | Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. ( Buch, E; Carañana, V; Fuster Diana, C; Galán, A; Guerrero, Á; Guillem Porta, V; Llombart-Cussac, A; Rodríguez-Lescure, Á; Ruiz, A, 2012) |
| " The aim of this study was to evaluate an upfront or delayed strategy of bone protection therapy with zoledronic acid administered at 4 mg every 6 months in postmenopausal Japanese women with early breast cancer to compare with results of the Z-FAST and ZO-FAST studies in western countries." | 9.16 | Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. ( Fukunaga, M; Horiguchi, J; Hozumi, Y; Ishikawa, T; Iwase, T; Kohno, N; Nakamura, S; Noguchi, S; Taguchi, T; Takahashi, M; Takahashi, S, 2012) |
| "We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone receptor-positive breast cancer who enrolled in the randomized, phase III double-blind Breast International Group (BIG) 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment." | 9.16 | CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. ( Biasi, MO; Bouzyk, M; Coates, AS; Debled, M; Dell'orto, P; Ditzel, HJ; Gelber, RD; Goldhirsch, A; Kammler, R; Leyland-Jones, B; Lyng, MB; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Tang, W; Thürlimann, B; Viale, G, 2012) |
| "A phase 3 trial comparing tamoxifen, letrozole or letrozole+zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients." | 9.16 | Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. ( Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V, 2012) |
| "To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8." | 9.16 | Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. ( Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B, 2012) |
| "Three hundred seventy-seven postmenopausal women with clinical stage II to III ER-positive (Allred score 6-8) breast cancer were randomly assigned to receive neoadjuvant exemestane, letrozole, or anastrozole." | 9.15 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int ( Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA, 2011) |
| "Compare first-line lapatinib plus letrozole (L + Let) versus letrozole monotherapy (Let) in hormone-receptor-positive HER2 + metastatic breast cancer, employing Q-TWiST (quality-adjusted time without symptoms and toxicity) analysis to account for differences in progression times, with offsets for the impact of adverse events during the treatment period." | 9.15 | Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. ( Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B, 2011) |
| "BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other." | 9.15 | Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. ( Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A, 2011) |
| "The addition of ZOL to letrozole was safe and efficacious in maintaining LS BMD in postmenopausal patients with hormone receptor-positive breast cancer and who were receiving letrozole following 2." | 9.15 | The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. ( Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I, 2011) |
| "Two hundred seventy postmenopausal women with operable ER-positive breast cancer were randomly assigned to receive 4 months of neoadjuvant treatment with letrozole (2." | 9.14 | Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. ( Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P, 2009) |
| "PURPOSE We compared the endocrine effects of 6 and 12 months of adjuvant letrozole versus tamoxifen in postmenopausal patients with hormone-responsive early breast cancer within an ongoing phase III trial." | 9.14 | Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. ( Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E, 2009) |
| "In this multicenter study, postmenopausal women with early hormone receptor-positive breast cancer receiving adjuvant letrozole were randomized to receive up-front or delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months) for 5 years." | 9.14 | Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. ( Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM, 2009) |
| "To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial." | 9.14 | Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. ( Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B, 2009) |
| "Aromatase inhibitors provide superior disease control when compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer." | 9.14 | Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. ( Gelber, RD; Giobbie-Hurder, A; Price, KN, 2009) |
| "The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer." | 9.14 | Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. ( Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B, 2009) |
| " Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer." | 9.14 | A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. ( Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O, 2010) |
| "Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD." | 9.14 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. ( Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA, 2010) |
| "Letrozole radiosensitises breast cancer cells in vitro." | 9.14 | Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. ( Azria, D; Belkacemi, Y; Coelho, M; Crompton, NE; Fenoglietto, P; Gourgou, S; Gutowski, M; Lemanski, C; Moscardo, CL; Ozsahin, M; Romieu, G; Rosenstein, B; Zaman, K, 2010) |
| "To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC)." | 9.14 | Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. ( Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS, 2010) |
| "Goserelin and letrozole in premenopausal patients can result in clinical outcomes comparable to those obtained by letrozole alone in postmenopausal patients with metastatic breast cancer (MBC)." | 9.14 | Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. ( Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J, 2010) |
| " We designed a pilot study to assess the feasibility and short-term efficacy of neoadjuvant letrozole and bevacizumab (anti-VEGF) in postmenopausal women with stage II and III estrogen receptor/progesterone receptor-positive breast cancer." | 9.14 | Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. ( Bernreuter, WK; Bland, KI; Carpenter, JT; Caterinicchia, V; De Los Santos, JF; Falkson, CI; Forero-Torres, A; Galleshaw, JA; Jones, CF; Krontiras, H; Li, Y; LoBuglio, AF; Meredith, RF; Nabell, LM; O'Malley, JP; Percent, IJ; Saleh, MN; Shah, JJ; Urist, MM, 2010) |
| "A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients." | 9.14 | Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. ( Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B, 2010) |
| "The interim (12-month) results of two similarly designed, ongoing studies (the Zometa-Femara Adjuvant Synergy Trials [Z-FAST and ZO-FAST]) suggest that zoledronic acid (4 mg intravenously every 6 months) when initiated with adjuvant letrozole increases bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal women with early-stage breast cancer compared with patients who receive zoledronic acid only when bone loss became clinically significant or a fragility fracture occurred." | 9.13 | Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. ( Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N, 2008) |
| "To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone receptor-positive breast cancers." | 9.13 | Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. ( Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y, 2008) |
| "To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer." | 9.13 | Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. ( Braye, SG; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Knox, F; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Olszewski, WP; Orosz, Z; Price, KN; Regan, MM; Thürlimann, B; Viale, G, 2008) |
| "In the primary core analysis of BIG 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced the risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 9.13 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. ( Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O, 2008) |
| "This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy." | 9.13 | A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. ( Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM, 2008) |
| "To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone." | 9.13 | The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. ( Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U, 2008) |
| "The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer." | 9.13 | Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. ( Altermatt, HJ; Braye, S; Castiglione-Gertsch, M; Coates, AS; Del Curto, B; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Henriksen, KL; Lacroix-Triki, M; Lykkesfeldt, AE; Mastropasqua, MG; Méry, E; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G, 2008) |
| "To compare the endocrine effects of 6 months of adjuvant treatment with letrozole + triptorelin or tamoxifen + triptorelin in premenopausal patients with early breast cancer within an ongoing phase 3 trial (Hormonal Adjuvant Treatment Bone Effects study)." | 9.13 | Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. ( Botti, G; D'Aiuto, G; D'Aiuto, M; De Maio, E; de Matteis, A; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E, 2008) |
| "Letrozole is safe and effective in postmenopausal women with estrogen receptor-positive early breast cancer, but long-term aromatase inhibitor use may cause bone loss and increase fracture risk." | 9.13 | Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. ( Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G, 2008) |
| "17 randomly assigned 5,187 postmenopausal, hormone-receptor-positive patients with early breast cancer who completed 5 years of tamoxifen to receive either letrozole or placebo." | 9.13 | Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. ( Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ, 2008) |
| "17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer." | 9.13 | Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2008) |
| "Fifty-four postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2." | 9.13 | Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. ( A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O, 2008) |
| "Five hundred twenty-two patients estrogen receptor-positive metastatic breast cancer were randomly assigned to receive first-line hormone therapy with letrozole or tamoxifen." | 9.13 | Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. ( Ali, SM; Brown-Shimer, S; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Gaur, V; Hamer, P; Leitzel, K; Lipton, A; Pierce, K, 2008) |
| "PI3K, phospho-AKT (pAKT) and phospho-mTOR were assessed by immunohistochemistry on tumor specimens collected at baseline and after 6 months of treatment in 113 elderly breast cancer patients consecutively enrolled in a randomized phase II trial of primary letrozole therapy and letrozole associated with metronomic cyclophosphamide." | 9.13 | Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. ( Aguggini, S; Allevi, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Campo, L; Dionisio, R; Dogliotti, L; Fox, SB; Generali, D; Giardini, R; Harris, AL; Milani, M; Vergoni, F, 2008) |
| " The LETLOB study is a European multicenter, placebo-controlled, randomized phase II trial in postmenopausal patients with hormone-sensitive, HER2-negative, stage II-IIIA (T > 2 cm, N0-1, M0) breast cancer, in which letrozole or the combination of letrozole plus lapatinib will be administered for 6 months before surgery." | 9.13 | Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). ( Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F, 2008) |
| "The addition of palbociclib to endocrine therapy has been shown to improve progression free survival in hormone receptor positive metastatic breast cancer patients." | 9.12 | [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?] ( Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L, 2021) |
| "Sixty-three postmenopausal women with large primary breast cancers were treated with neoadjuvant letrozole (2." | 9.12 | Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. ( Anderson, TJ; Dixon, JM; Miller, WR; Murray, J; Renshaw, L; White, S, 2006) |
| "To investigate the activity of letrozole plus/minus oral metronomic cyclophosphamide as primary systemic treatment (PST) in elderly breast cancer patients." | 9.12 | Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. ( Aguggini, S; Allevi, G; Bernardi, C; Berruti, A; Bersiga, A; Bodini, G; Bonardi, S; Bottini, A; Brizzi, MP; Bruzzi, P; Dionisio, R; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M; Montruccoli, A, 2006) |
| "Patients with ER+ and/or PgR+ and HER2+ (IHC 2+ or 3+ or FISH+) advanced breast cancer were treated with trastuzumab plus letrozole until disease progression or unacceptable toxicity." | 9.12 | The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. ( Ellis, MJ; Harris, L; Isaacs, C; Kommarreddy, A; Mann, G; Marcom, PK; Novielli, N; Tao, Y; Wong, ZW, 2007) |
| "17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer." | 9.12 | Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. ( Goss, PE; Ingle, JN; Moy, B; Pater, JL; Shepherd, LE; Tu, D; Whelan, TJ, 2006) |
| "With 1 year of follow-up, results of the primary end point of the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in postmenopausal women receiving adjuvant letrozole for early-stage breast cancer." | 9.12 | Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. ( Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E, 2007) |
| "Four thousand nine hundred twenty-two of the 8,028 postmenopausal women with receptor-positive early breast cancer randomly assigned (double-blind) to the BIG 1-98 trial were assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen; the remainder of women were assigned to receive the agents in sequence." | 9.12 | Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. ( Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A, 2007) |
| "Tamoxifen has been a standard first-line endocrine therapy for post-menopausal women with hormone-responsive advanced breast cancer, but more than half of patients fail to respond and time to progression is less than 12 months in responders." | 9.12 | Letrozole in advanced breast cancer: the PO25 trial. ( Mouridsen, HT, 2007) |
| "The aim of the study was to determine the potency of anastrozole to suppress serum E(2) levels in breast cancer patients undergoing COH." | 9.12 | Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. ( Azim, AA; Costantini-Ferrando, M; Lostritto, K; Oktay, K, 2007) |
| "To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer." | 9.12 | Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. ( Braye, S; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Orosz, Z; Price, KN; Raffoul, J; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G, 2007) |
| "The aim of the study was to identify changes in tumour expression profiling associated with short-term therapy of breast cancer patients with letrozole." | 9.12 | Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Hampton, G; Ho, S; Krause, A; Larionov, AA; Miller, WR; Murray, E; Murray, J; Renshaw, L; Walker, JR; White, S, 2007) |
| "The BIG 1-98 trial is a large, randomized, independently conducted clinical trial designed to compare the efficacy of upfront letrozole versus tamoxifen monotherapy and to compare sequential or up-front use of letrozole and/or tamoxifen as an early adjuvant therapy for patients with early breast cancer." | 9.12 | Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. ( Koeberle, D; Thuerlimann, B, 2007) |
| "To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC)." | 9.12 | Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. ( Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB, 2007) |
| "Eight thousand twenty-eight postmenopausal women with receptor-positive early breast cancer were randomly assigned (double-blind) between March 1998 and May 2003 to receive 5 years of adjuvant endocrine therapy with letrozole, tamoxifen, or a sequence of these agents." | 9.12 | Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B, 2007) |
| "The letrozole study 025 is a large (n = 907), international, double-blind, randomized, phase III trial in postmenopausal women with advanced breast cancer." | 9.11 | Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. ( Becquart, D; Chaudri-Ross, HA; Gershanovich, M; Lang, R; Mouridsen, H; Perez-Carrion, R; Sun, Y, 2004) |
| "To compare the efficacy, in regard to time to progression (TTP) and objective response rate (ORR), of letrozole (Femara; Novartis Pharma AG; Basel Switzerland), an oral aromatase inhibitor, with that of tamoxifen (Tamofen; Leiras OY; Turku, Finland) as first-line therapy in younger (<70 years) and older (>/=70 years) postmenopausal women with advanced breast cancer." | 9.11 | Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. ( Chaudri-Ross, HA; Mouridsen, H, 2004) |
| "The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA." | 9.11 | The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). ( Deangelis, D; Goss, PE; Heath, M; Ingle, JN; Liu, S; Palmer, MJ; Perez, EA; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM, 2005) |
| "To evaluate the clinical benefit and tolerability of letrozole after tamoxifen failure in locally advanced, recurrent or metastatic breast cancer in postmenopausal patients." | 9.11 | Efficacy of letrozole for advanced breast cancer in postmenopausal patients. ( Ansari, TN; Hussain, I; Mahmood, A; Samad, A, 2005) |
| "Results from a phase III study of postmenopausal women with advanced breast cancer demonstrated longer time to disease progression for patients taking letrozole versus tamoxifen." | 9.11 | Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. ( Cole, B; Gard, C; Glendenning, GA; Irish, W; Mouridsen, H; Sherrill, B, 2005) |
| "4 months), women in the letrozole arm had statistically significantly better DFS and distant DFS than women in the placebo arm (DFS: hazard ratio [HR] for recurrence or contralateral breast cancer = 0." | 9.11 | Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2005) |
| "The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen." | 9.11 | A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ( Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A, 2005) |
| "To compare the efficacy, safety and tolerability of letrozole, an advanced non-steroidal aromatase inhibitor, and fadrozole hydrochloride, an older-generation drug in this class, we conducted a randomised double-blind trial in postmenopausal women with advanced breast cancer." | 9.10 | Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. ( Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T, 2003) |
| "To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer." | 9.10 | Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. ( Apffelstaedt, J; Bapsy, PP; Becquart, D; Bhatnagar, A; Boni, C; Chaudri-Ross, H; Dank, M; Gershanovich, M; Jaenicke, F; Lang, R; Monnier, A; Mouridsen, H; Perez-Carrion, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Sun, Y; Wyld, P, 2003) |
| "We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy." | 9.10 | A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. ( Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D, 2003) |
| "It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer." | 9.10 | An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. ( Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O, 2003) |
| "Life table analyses are used to compare the costs and benefits [life years gained and quality-adjusted life years (QALYs) gained] of treating postmenopausal women with advanced breast cancer with first-line letrozole (with the option of second-line tamoxifen) compared with first-line tamoxifen (with the option of second-line letrozole)." | 9.10 | A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. ( Glendenning, A; Johnston, SR; Jones, T; Karnon, J, 2003) |
| "Letrozole, a third generation aromatase inhibitor, has been compared with tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy." | 9.10 | Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. ( Smith, IE, 2003) |
| "Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2." | 9.10 | Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. ( Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE, 2002) |
| "To determine the recommended clinical dose of CGS20267 (Letrozole), we conducted a randomized comparative study as a late phase II study (first part) in postmenopausal women with advanced or recurrent breast cancer." | 9.10 | [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]. ( Abe, R; Ikeda, S; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H, 2002) |
| "The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of letrozole on tamoxifen (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus letrozole; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination." | 9.09 | Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. ( Dowsett, M; Ingle, JN; Johnson, PA; Jordan, VC; Krook, JE; Loprinzi, CL; Mailliard, JA; Perez, EA; Suman, VJ; Wheeler, RH, 1999) |
| "This study examined whether the addition of tamoxifen to the treatment regimen of patients with advanced breast cancer being treated with the aromatase inhibitor letrozole led to any pharmacokinetic or pharmacodynamic interaction." | 9.09 | Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. ( Dowsett, M; Gundacker, H; Houston, SJ; Johnston, SR; Miles, DW; Pfister, C; Sioufi, A; Smith, IE; Verbeek, JA, 1999) |
| "The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens." | 9.09 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, Kh; Friedrich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, NO; Reichard, P; Romieu, G, 1999) |
| "To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer." | 9.09 | Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. ( Apffelstaedt, J; Bapsy, PP; Becquart, D; Boni, C; Chaudri-Ross, HA; Dank, M; Dugan, M; Gershanovich, M; Jänicke, F; Lassus, M; Monnier, A; Mouridsen, H; Pérez-Carrión, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Staffler, B; Sun, Y; Verbeek, JA, 2001) |
| "Given a favorable tolerability profile, once-daily dosing, and evidence of clinically relevant benefit, letrozole is equivalent to megestrol acetate and should be considered for use as an alternative treatment of advanced breast cancer in postmenopausal women after treatment failure with antiestrogens." | 9.09 | Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. ( Brady, C; Buzdar, A; Davidson, N; Douma, J; Elledge, R; Morgan, M; Nabholtz, J; Porter, L; Smith, R; Xiang, X, 2001) |
| "Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series with letrozole 2." | 9.09 | Letrozole as primary medical therapy for locally advanced and large operable breast cancer. ( Bellamy, CO; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Smith, H, 2001) |
| "Postmenopausal patients with estrogen- and/or progesterone receptor-positive (ER+ and/or PgR+) primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 months of neoadjuvant letrozole 2." | 9.09 | Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. ( Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B, 2001) |
| "Letrozole (trademark Femara) is a new orally active, potent and selective aromatase inhibitor for the hormonal treatment of advanced breast cancer in postmenopausal women." | 9.09 | Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. ( De Braud, F; Duval, M; Hornberger, U; Lelli, G; Martoni, A; Pfister, CU; Souppart, C; Zamagni, C, 2001) |
| "Three hundred thirty-seven postmenopausal women with ER and/or PgR positive primary untreated breast cancer were randomly assigned once daily treatment with either letrozole 2." | 9.09 | Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. ( Appfelstaedt, J; Borgs, M; Chaudri-Ross, HA; Dugan, M; Eiermann, W; Ellis, M; Eremin, J; Lassus, M; Llombart-Cussac, A; Mauriac, L; Paepke, S; Vinholes, J, 2001) |
| "In this Phase I trial, 23 heavily pretreated postmenopausal patients with metastatic breast cancer received letrozole at doses ranging from 0." | 9.08 | Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. ( Adlercruetz, H; Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ; Trunet, PF, 1995) |
| "To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens." | 9.08 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. ( Bellmunt, J; Bezwoda, W; Chaudri, HA; Dombernowsky, P; Falkson, G; Fornasiero, A; Gardin, G; Gudgeon, A; Hatschek, T; Hoffmann, W; Hornberger, U; Leonard, R; Michel, J; Morgan, M; Panasci, L; Smith, I; Tjabbes, T; Trunet, PF, 1998) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 9.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "Fadrozole Hydrochloride (CGS 16949A) and Letrozole (CGS 20267), are two of the newest non-steroidal, orally active aromatase inhibitors currently being evaluated as second line treatment of patients with hormone dependent forms of metastatic breast cancer." | 9.07 | Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. ( Demers, LM, 1994) |
| " Herein, we reported a case of hallucination related to anastrozole in a patient with metastatic breast cancer." | 9.01 | In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. ( Bozkaya, Y; Demirci, NS; Erdem, GU, 2019) |
| "We performed a network meta-analysis to compare the efficacies of fulvestrant and CDK4/6is plus AIs as the first-line treatment of postmenopausal breast cancer patients." | 9.01 | Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis. ( Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y, 2019) |
| "Palbociclib is the first cyclin-dependent kinase 4/6 inhibitor approved in the United States for HR+/HER2- advanced/metastatic breast cancer, in combination with letrozole as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression following endocrine therapy." | 8.95 | Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. ( Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D, 2017) |
| " It is indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, and in combination with fulvestrant (with or without a luteinizing hormone-releasing hormone agonist) in those previously treated with endocrine therapy." | 8.95 | Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. ( Kim, ES; Scott, LJ, 2017) |
| "We conducted a review of randomized trials to compare the overall survival (OS) with fulvestrant 500 mg versus alternative treatment for estrogen receptor-positive advanced breast cancer following endocrine therapy failure." | 8.93 | Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. ( Batson, S; Jones, N; Livings, C; Telford, C, 2016) |
| "In the first-line setting, the phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial randomized patients to receive letrozole alone or letrozole plus palbociclib 125 mg daily for 3 weeks, followed by 1 week off, as initial therapy for advanced breast cancer." | 8.91 | Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. ( Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R, 2015) |
| "To assess the effects of tamoxifen or letrozole, in addition to standard COS protocols, on the breast cancer-free interval in premenopausal women with ER positive breast cancer who undergo COS for embryo or oocyte cryopreservation." | 8.89 | Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. ( Balkenende, E; Dahhan, T; Goddijn, M; Linn, S; van Wely, M, 2013) |
| "Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen." | 8.88 | Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). ( Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R, 2012) |
| "The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer." | 8.87 | Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. ( Gelber, RD; Giobbie-Hurder, A; Price, KN; Regan, MM; Thürlimann, B, 2011) |
| "Third-generation aromatase inhibitors (AIs) have proven to be superior to tamoxifen in terms of time to disease progression in patients with hormone receptor (HR) positive (HR+) status and, nowadays, are used in the adjuvant and neoadjuvant settings, and first-line therapy for advanced breast cancer." | 8.87 | An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. ( Barnadas, A; Estévez, LG; Lluch-Hernández, A; Rodriguez-Lescure, A; Rodriguez-Sanchez, C; Sanchez-Rovira, P, 2011) |
| " Food and Drug Administration converted letrozole (Femara®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) from accelerated to full approval for adjuvant and extended adjuvant (following 5 years of tamoxifen) treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 8.87 | Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval. ( Cohen, MH; Johnson, JR; Justice, R; Pazdur, R, 2011) |
| " In a large phase III trial (EGF30008) in 1286 postmenopausal women with hormone receptor (HR)-positive, metastatic breast cancer who had not received previous therapy for advanced or metastatic disease, the primary endpoint of median progression-free survival in a HER2-positive population of 219 women was significantly longer with lapatinib plus letrozole than with letrozole plus placebo (8." | 8.86 | Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. ( Curran, MP, 2010) |
| " Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy." | 8.85 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. ( Guarneri, V, 2009) |
| " PubMed and MEDLINE were searched for descriptions of clinical trials published from 1990 to 2007 using the terms breast cancer, extended adjuvant, aromatase inhibitor, anastrozole, exemestane, and letrozole." | 8.84 | Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. ( Jahanzeb, M, 2007) |
| "The third-generation aromatase inhibitor letrozole offers a promising approach to treating hormone-sensitive breast cancer for postmenopausal women, through potent and specific inhibition of estrogen synthesis." | 8.83 | Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. ( Koeberle, D; Thuerlimann, B, 2006) |
| "Letrozole is a highly selective, nonsteroidal, third-generation aromatase inhibitor approved for first-line and extended adjuvant therapy in postmenopausal women with hormone-responsive, early-stage breast cancer." | 8.83 | Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. ( Keam, SJ; Scott, LJ, 2006) |
| "Breast cancer remains a leading cause of cancer death in women worldwide, and the risk for disease recurrence continues despite improvements in screening and treatment and the use of prophylactic estrogen-inhibiting therapies such as tamoxifen." | 8.83 | Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long? ( Kaufmann, M; Rody, A, 2006) |
| "Letrozole (Femara), an aromatase inhibitor that blocks estrogen synthesis by inhibiting the final step of the estrogen biosynthetic pathway, is approved for use in a wide range of breast cancer settings." | 8.83 | Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. ( Dunn, C; Keam, SJ, 2006) |
| "Therapeutics that interfere with estrogen receptor function (antiestrogens, eg, tamoxifen; aromatase inhibitors, eg, letrozole) have contributed to a dramatic reduction in breast cancer mortality; however, not all estrogen-receptor-positive breast cancers respond." | 8.83 | Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. ( Lane, HA; Lebwohl, D, 2006) |
| "Letrozole (Femara), a nonsteroidal, third-generation aromatase inhibitor administered orally once daily, has shown efficacy in the treatment of postmenopausal women with early-stage or advanced, hormone-sensitive breast cancer." | 8.82 | Letrozole: a review of its use in postmenopausal women with breast cancer. ( Curran, MP; Perry, CM; Simpson, D, 2004) |
| "The objective of this study is to evaluate the cost-effectiveness of letrozole compared with tamoxifen as first-line therapy in post-menopausal women with advanced breast cancer in Japan." | 8.82 | Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. ( Kondo, M; Miki, S; Ochiai, T; Okubo, I; Toi, M, 2005) |
| "Fulvestrant, a new type of oestrogen receptor antagonist with no agonist effects, is now licensed in the EU and USA for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antioestrogen therapy." | 8.82 | A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. ( Dodwell, D; Vergote, I, 2005) |
| "Letrozole, a third-generation aromatase inhibitor, has been the only aromatase inhibitor to date to show unequivocal superiority to tamoxifen as first-line treatment of metastatic postmenopausal breast cancer." | 8.81 | Letrozole for the management of breast cancer. ( Goss, PE; Smith, RE, 2002) |
| "In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | 8.80 | Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 8.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "As breast cancer cells transition from letrozole-sensitive to letrozole-resistant, they over-express epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and human epidermal growth factor receptor 2 (HER2) while acquiring enhanced motility and epithelial-to-mesenchymal transition (EMT)-like characteristics that are attenuated and reversed by glyceollin treatment, respectively." | 8.31 | Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. ( Banjara, B; Boué, SM; Burow, ME; Davidson, AM; Ohemeng, A; Patel, JR; Tilghman, SL, 2023) |
| " Since this a case of advanced breast cancer, we initiated treatment with bevacizumab plus paclitaxel." | 8.31 | [Chemotherapy-Resistant Breast Cancer and Carcinomatous Pleuritis Successfully Treated with Abemaciclib plus Letrozole Therapy]. ( Kamo, N; Konishi, J; Nozaki, Y; Tanaka, N; Yamamuro, M, 2023) |
| "Palbociclib, the first available cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC)." | 8.31 | Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. ( Brufsky, A; Layman, RM; Li, B; Liu, X; McRoy, L; Rugo, HS, 2023) |
| "A 73-year-old female patient with breast cancer with axillary lymph node, adrenal gland and bone metastases was started on ribociclib letrozole and denosumab treatment." | 8.31 | Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab. ( Aktürk Esen, S; Bayram, D; Köş, FT; Uçar, G, 2023) |
| "We report a case of a 72-year-old woman with metastatic breast cancer who developed visual hallucinations after receiving ribociclib, a CDK 4/6 inhibitor, and letrozole for 3 days." | 8.31 | Ribociclib-induced visual hallucination in a patient with metastatic breast cancer. ( Bulut, N; Demirer, S; Erdem, GU; Kapagan, T, 2023) |
| "We believe that trastuzumab, leuprorelin, letrozole, and palbociclib is a feasible and effective treatment for HER2-positive and HR-positive metastatic breast cancer in premenopausal patients who cannot tolerate first-line chemotherapy." | 8.31 | Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report. ( Cai, L; Chen, M; Sun, M, 2023) |
| "Palbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone receptor‒positive (HR+)/human epidermal growth factor receptor‒2 negative (HER2-) advanced breast cancer (ABC)." | 8.31 | Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. ( Benfield, JRGR; Chuken, YL; Damian, F; Fein, L; Franco, S; Korbenfeld, E; Lazaretti, N; Lobaton, J; Lu, DR; Mano, MS; Mori, A; Patyna, SJ, 2023) |
| "Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)." | 8.12 | Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australi ( Alam, M; Binko, J; Boyle, F; Doval, DC; Gore, V; Karapetis, CS; Khasraw, M; Kim, S; Loi, S; Lu, DR; McCarthy, N; Oakman, C; Redfern, A; White, M, 2022) |
| " We previously demonstrated that glyceollin inhibits proliferation, survival, and migration of hormone-independent letrozole-resistant breast cancer." | 8.12 | Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. ( Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC, 2022) |
| "Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer." | 8.12 | The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. ( Fu, F; Guindy, M; Kano, J; Ma, J, 2022) |
| "CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules investigated in this setting." | 8.12 | Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. ( Farhat, F; Gharib, KE; Karak, FE; Kattan, J; Macaron, W; Salloum, MA; Smith, M, 2022) |
| "Our results show that COSTLES for fertility preservation in breast cancer patients using GnRHa trigger reduces serum progesterone levels compared to ovarian stimulation without letrozole." | 8.12 | Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? ( Cedrin-Durnerin, I; Comtet, M; Grynberg, M; Krief, F; Labrosse, J; Lalami, I; Peigne, M; Sifer, C; Vinolas, C, 2022) |
| "The objective of the study was to develop PEGylated protamine letrozole nanoparticles to combat human breast cancer by modifying the release pattern of letrozole." | 8.12 | PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines. ( Amirzada, MI; Asad, MHHB; Bashir, H; Javed, MA; Khan, MT; Rajoka, MSR; Shah, N; Shaikh, AJ; Uddin, Z, 2022) |
| "This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice." | 8.12 | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. ( Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P, 2022) |
| "Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells." | 8.12 | In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. ( Ahmadi, S; Akbarzadeh, I; Bazzazan, S; Chiani, M; Hosseini, S; Mostafavi, E; Saffar, S; Seraj, M, 2022) |
| "Results obtained from the in silico and in vitro studies suggest that Letrozole loaded nanoparticles are ideal for breast cancer treatment." | 8.02 | In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer. ( Banjare, L; Jain, A; Jain, AK; Mishra, K; Ratre, P; Thareja, S; Verma, SK, 2021) |
| "Letrozole, an aromatase inhibitor (AI), is the first-line adjuvant drug for treating hormone receptor-positive (HR+) breast cancer in postmenopausal women." | 8.02 | Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer. ( Adithan, C; Aibor Dkhar, S; Dubashi, B; Kadambari, D; Kumar, NAN; Muthuvel, SK; Umamaheswaran, G, 2021) |
| " This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC) treated in routine clinical practice in the USA." | 8.02 | Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. ( Brufsky, A; Cristofanilli, M; DeMichele, A; Emir, B; Finn, RS; Layman, RM; Liu, X; Mardekian, J; McRoy, L; Rugo, HS; Torres, MA, 2021) |
| " Palbociclib with letrozole may be a good treatment in the preoperative stage for luminal breast cancer that is resistant to chemotherapy." | 8.02 | Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021) |
| "We report a ribociclib-induced grade 3 AKI in an elderly woman who was treated for metastatic breast cancer." | 8.02 | Ribociclib induced acute kidney injury: A case report. ( Erdal, GS; Gulturk, I; Ozmen, A; Tacar, SY; Tural, D; Yilmaz, M, 2021) |
| " In this study, the effects of two Aromatase Inhibitor (Letrozole and Exemestane), and one mTOR Inhibitor (Everolimus) on cell mechanical properties, actin content/distribution, and nuclear areas of two invasive and non-invasive breast cancer cell line after 24 h treatment with concentrations previously reported were investigated." | 8.02 | Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus. ( Habibi-Anbouhi, M; Mohammadi, E; Tabatabaei, M; Tafazzoli-Shadpour, M, 2021) |
| "In the field of oncofertility, patients with breast cancer are often administered letrozole as an adjuvant drug before and after oocyte retrieval to prevent an increase in circulating estradiol." | 8.02 | Severe hemoperitoneum resulting from restart of letrozole after oocyte retrieval procedure: a case report. ( Gomi, Y; Huang, H; Ichinose, S; Itaya, Y; Matsunaga, S; Narita, T; Ono, Y; Saitoh, M; Samejima, K; Seki, H; Takai, Y, 2021) |
| "To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2‒ MBC) in routine US clinical practice." | 8.02 | Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. ( Brufsky, A; Layman, RM; Li, B; Liu, X; McRoy, L, 2021) |
| "Chemotherapy using cytotoxic agents, such as letrozole (LTZ), is one of the most effective treatments for hormone-dependent breast cancer." | 7.96 | Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment. ( Kashanian, S; Yassemi, A; Zhaleh, H, 2020) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 7.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia." | 7.96 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| "Letrozole (LTZ), an aromatase inhibitor used for the treatment of hormonally-positive breast cancer in postmenopausal women, has poor water solubility, rapid metabolism, and a range of side effects." | 7.91 | Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy. ( Alemrayat, B; Elhissi, A; Younes, HM, 2019) |
| "This was a single-center, retrospective cohort study of all postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer patients who received palbociclib and letrozole as a second-line endocrine therapy or beyond (and no prior cyclin-dependent kinases 4 and 6 inhibitor therapy) between February 1, 2015, and July 31, 2016." | 7.91 | Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer. ( Berger, MJ; Lustberg, M; Palettas, M; Schickli, MA; Vargo, CA, 2019) |
| "To understand treatment satisfaction in patients with advanced or metastatic breast cancer receiving palbociclib plus an aromatase inhibitor or palbociclib plus fulvestrant in a real-world setting." | 7.91 | Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. ( Band, J; Darden, C; Davis, K; Iyer, S; McSorley, D; Mitra, D, 2019) |
| "The addition of ribociclib (RIB) to letrozole (LET) significantly increases progression free survival for patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)." | 7.91 | Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. ( Ma, J; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y, 2019) |
| "Our findings clearly demonstrate that letrozole improves cisplatin sensitivity of breast cancer cells overexpressing aromatase via down-regulation of FEN1 and suggest that a combined use of letrozole and cisplatin may be a potential treatment protocol for relieving cisplatin resistance in human breast cancer." | 7.91 | Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1. ( Chen, B; Chen, M; Jiang, X; Li, S; Wang, Y; Zhu, L; Zou, J, 2019) |
| "Three CDK4/6 inhibitors, palbociclib (PAL), ribociclib (RIB), and abemaciclib, when combined with letrozole (LET), have been approved as first-line therapy for postmenopausal women with metastatic HR+, HER2- breast cancer." | 7.91 | Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. ( Long, EF; Zhang, B, 2019) |
| "Among patients with HR-positive advanced breast cancer, the estimated PFS in patients treated with fulvestrant and palbociclib was comparable to a previously reported phase 3 trial." | 7.91 | Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. ( Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L, 2019) |
| "The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) based on phase III study results." | 7.91 | Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. ( Iyer, S; Milligan, G; Mitra, D; Mycock, K; Taylor-Stokes, G; Waller, J; Zhan, L, 2019) |
| "EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor-positive breast cancer." | 7.91 | Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. ( Baake, G; Baier, B; Bayer, CM; Beckmann, MW; Belleville, E; Breitbach, GP; Brucker, C; Brucker, SY; Dall, P; de Waal, J; Deuker, JU; Fasching, PA; Fehm, T; Feisst, M; Fischer, G; Guggenberger, M; Hadji, P; Harbeck, N; Hartkopf, A; Hein, A; Henschen, S; Heyl, V; Hohn, A; Janni, W; Kohls, A; Kolberg, HC; Krauss, T; Kuhn, T; Kümmel, S; Landthaler, R; Mundhenke, C; Nabieva, N; Noesselt, T; Popovic, M; Praetz, T; Rauh, C; Rezai, M; Rezek, D; Richter, B; Schmidt, K; Siebers, JW; Tesch, H; Thomssen, C; Vollert, HW; Wachsmann, G; Wallwiener, D; Wallwiener, M; Warm, M; Wolf, C; Wuerstlein, R, 2019) |
| "6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH." | 7.88 | Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels? ( Del Pup, L; Peccatori, FA, 2018) |
| " regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) advanced or metastatic breast cancer." | 7.88 | Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. ( Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K, 2018) |
| "The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer." | 7.88 | Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. ( Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; Hettle, R; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K, 2018) |
| "Letrozole (LTZ) is effective for the treatment of hormone-receptor-positive breast cancer in postmenopausal women." | 7.88 | Preparation and optimization of monodisperse polymeric microparticles using modified vibrating orifice aerosol generator for controlled delivery of letrozole in breast cancer therapy. ( Alany, RG; Alemrayat, B; Elhissi, A; Elrayess, MA; Younes, HM, 2018) |
| "The aromatase inhibitor (AI) letrozole is a first-line drug in the adjuvant treatment of breast cancer in postmenopausal women." | 7.88 | Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. ( Borrie, AE; Choi, YH; Dinniwell, R; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, RV; Sexton, T; Teft, WA; Tyndale, RF; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2018) |
| "In health resource-limited settings, adjuvant endocrine therapy with letrozole is a cost-effective strategy compared to tamoxifen in women with early breast cancer." | 7.88 | Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. ( Lu, J; Wu, B; Yang, F; Ye, M, 2018) |
| "Palbociclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor that was conditionally approved in the United States (February 2015) and Canada (March 2016) with letrozole as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer." | 7.88 | Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. ( Brufsky, AM; Cotter, MJ; Dequen, F; Joy, AA; Lu, DR; Stearns, V; Verma, S, 2018) |
| " The aim of this study was to investigate the effect of co-administration of fucoidan, derived from Undaria pinnatifida, on the pharmacokinetics of 2 commonly used hormonal therapies, letrozole and tamoxifen, in patients with breast cancer." | 7.88 | The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer. ( Fitton, JH; Lowenthal, RM; McGuinness, G; Olesen, I; Oliver, LJ; Patel, R; Peterson, GM; Shastri, M; Tocaciu, S, 2018) |
| "Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score." | 7.85 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. ( Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG, 2017) |
| "Transcriptional silencing of estrogen receptor α (ERα) expression is an important etiology contributing to the letrozole-resistance in ERα-positive breast cancer (BCa) cells, but the transcription factors responsible for this transcriptional repression remain largely unidentified." | 7.85 | Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells. ( Cui, MK; Li, J; Li, S; Liu, XY; Wang, EH; Zhang, Q; Zhao, Z, 2017) |
| "The addition of palbociclib to letrozole improves progression-free survival in the first-line treatment of hormone receptor positive advanced breast cancer (ABC)." | 7.85 | Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. ( Helou, J; Naimark, DM; Pritchard, KI; Raphael, J, 2017) |
| "Raloxifene, an anti-osteoporotic drug, is recently approved for prevention of breast cancer in postmenopausal women and thus the drug may be employed to combat the bony adverse effects of letrozole, another anticancer drug." | 7.85 | Combined Raloxifene and Letrozole for Breast Cancer Patients. ( Kalam, A; Leekha, A; Talegaonkar, S; Verma, AK; Vohora, D, 2017) |
| "Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC)." | 7.85 | Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. ( Beom, SH; Han, SW; Han, W; Im, SA; Kim, TY; Lee, KH; Moon, HG; Noh, DY; Oh, DY; Oh, J; Suh, KJ; Yang, Y, 2017) |
| " This study was carried out to investigate the effect of NOB on the activity and expression of aromatase, and to compare this property with letrozole (LET) as aromatase inhibitor in the MCF-7 breast cancer cell line." | 7.85 | Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line. ( Hoseini, M; Keramatipour, M; Koohdani, F; Nourbakhsh, M; Rahideh, ST; Shidfar, F; Talebi, S, 2017) |
| "This study was designed to explore whether zoledronic acid could prevent expected loss of bone mineral density (BMD) in postmenopausal women with pre-existing osteopenia or osteoporosis who were initiating adjuvant letrozole therapy for primary breast cancer." | 7.83 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. ( Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N, 2016) |
| "A limited number of studies have been conducted on the effects of hormonal therapy with tamoxifen (TMX) or aromatase inhibitors (AIs) on plasma levels of leptin and adiponectin, as well as body composition in breast cancer (BC) patients." | 7.83 | The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study. ( Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y, 2016) |
| " We aimed to investigate the long-term safety of FP via controlled ovarian stimulation with letrozole supplementation (COSTLES) prior to breast cancer treatment." | 7.83 | Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. ( Kim, J; Oktay, K; Turan, V, 2016) |
| "The authors reviewed retrospective cases of 2 women - one aged 78 years and the other aged 86 years - with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treated with combination palbociclib/letrozole who presented with hyperuricemia." | 7.83 | Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer. ( Bromberg, DJ; Nanjappa, S; Pabbathi, S; Valenzuela, M, 2016) |
| "The primary objective of this study is to compare the oocyte yield in breast cancer patients undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins with patients undergoing COS with standard gonadotropins for elective cryopreservation of oocytes." | 7.83 | Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†. ( Cordeiro, CN; Hancock, K; Lekovich, JP; Pereira, N; Rosenwaks, Z; Schattman, GL, 2016) |
| "Variable dose letrozole-FSH protocol can maintain lower peak estradiol levels and reduce estrogen exposure after breast cancer operation and chemotherapy." | 7.83 | Twin delivery after IVF-ET with variable dose letrozole-FSH protocol of lower estradiol in a patient previously treated for breast cancer: a case report. ( Diao, H; Hu, GZ; Zhang, CJ; Zhang, Y, 2016) |
| "3% metastatic) from the EGF30008 phase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor." | 7.83 | Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. ( Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M, 2016) |
| "The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women with metastatic HR-positive, HER2-negative breast cancer, according to findings presented at a meeting of the European Society for Medical Oncology." | 7.83 | Ribociclib Lengthens Breast Cancer Survival. ( , 2016) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 7.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC)." | 7.81 | Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. ( Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V, 2015) |
| " When added to the aromatase inhibitor letrozole in a randomized phase II trial for first-line therapy of estrogen receptor-positive, HER2-negative metastatic breast cancer, palbociclib significantly increased progression-free survival compared with letrozole alone [palbociclib + letrozole: 20." | 7.81 | Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. ( Henry, NL; Morikawa, A, 2015) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | 7.81 | [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report]. ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| " Letrozole, an endocrine therapy drug, is usually prescribed for post-menopausal status early and advanced stage breast cancer." | 7.81 | Drug Use Evaluation of Letrozole in Breast Cancer Patients at Regional Cancer Hospitals in Thailand. ( Ketkaew, C; Kiatying-Angsulee, N, 2015) |
| "Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction." | 7.81 | Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. ( Bagnardi, V; Balduzzi, A; Cancello, G; Cardillo, A; Colleoni, M; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Intra, M; Iorfida, M; Luini, A; Montagna, E; Sandri, MT; Viale, G, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 7.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors." | 7.81 | Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line. ( Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I, 2015) |
| "Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor, remains unproven in non-HER2-amplified metastatic breast cancer (MBC)." | 7.80 | Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. ( Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF, 2014) |
| "In this paper, computational studies were carried out on anastrozole and letrozole, chemotherapy drugs used against breast cancer." | 7.80 | Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer. ( Akçay, HT; Bayrak, R, 2014) |
| "We identified the first dispensing of tamoxifen, anastrozole or letrozole for women diagnosed with invasive breast cancer in the 45 and Up Study from 2004-2009 (N = 1266)." | 7.80 | Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. ( Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C, 2014) |
| "The present work focuses on the design of a drug delivery system for systemic, controlled release of the poorly soluble breast cancer drug, letrozole." | 7.80 | Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: a controlled drug delivery system for treatment of breast cancer. ( Adhikari, B; Chaudhury, K; Siddiqa, AJ, 2014) |
| "The aim of this study was to investigate the prevalence and causes of early discontinuation and non-adherence to upfront and extended adjuvant letrozole therapy in breast cancer patients." | 7.80 | Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting. ( Ah, YM; Im, SA; Kim, HS; Lee, BK; Lee, HS; Lee, JY; Noh, DY, 2014) |
| "Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past." | 7.80 | Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker. ( Agarwal, V; Cawkwell, L; Drew, PJ; Fox, JN; Garimella, V; Hussain, T; Kneeshaw, PJ; Lind, MJ; Long, ED; Mahapatra, TK; McManus, PL; Radhakrishna, S, 2014) |
| "Aromatase inhibitors, such as letrozole, have become the first-line treatment for postmenopausal women with estrogen-dependent breast cancer." | 7.79 | Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. ( Bratton, MR; Carriere, PP; Llopis, SD; Preyan, LC; Skripnikova, E; Tilghman, SL; Townley, I; Wang, G; Williams, CC; Zhang, Q; Zhong, Q; Zou, J, 2013) |
| "To assess the advantages and disadvantages of using letrozole for controlled ovarian stimulation (COH) in young patients with estrogen receptor-positive (ER+) breast cancer, wishing to cryopreserve oocytes." | 7.79 | Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? ( Anserini, P; Delle Piane, L; Levi Setti, PE; Merlo, DF; Porcu, E; Revelli, A, 2013) |
| "To investigate the safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole protocol for fertility preservation in breast cancer patients." | 7.79 | Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. ( Bedoschi, G; Moy, F; Oktay, K; Turan, V, 2013) |
| "The objective of this study was to determine radiation, doxorubicin, tamoxifen and letrozole sensitivity of breast cancer cells in response to functional inhibition of the ubiquitin conjugating enzyme UBE2C." | 7.79 | Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. ( Gopal, G; Rajkumar, T; Rawat, A; Selvaluxmy, G, 2013) |
| "To establish a human breast cancer MCF-7 cell model stably overexpressing the aromatase gene (MCF-7-aromatase) and aromatase inhibitor letrozole-resistant MCF-7 cell model (MCF-7-LR)." | 7.79 | [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model]. ( Chen, HY; Liu, ZH, 2013) |
| "To estimate the budget impact of everolimus as the first and second treatment option after letrozole or anastrozole (L/A) failure for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)." | 7.79 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. ( De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H, 2013) |
| "The study aim was to identify early (within 14 days) and late changes (by 3 months) in breast cancer gene expression profiles associated with neoadjuvant therapy with letrozole." | 7.78 | Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Larionov, A; Miller, WR, 2012) |
| " Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking." | 7.78 | Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). ( Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K, 2012) |
| "The purpose of this study was to report a patient with choroidal and optic disc metastases from breast cancer and the response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab." | 7.78 | Choroidal and optic disc metastases from breast cancer and their response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab. ( Iwaki, M; Mizumoto, K; Naito, E; Takeyama, M; Zako, M, 2012) |
| " Correspondingly in breast cancer tumors, expression of estradiol- and Runx2-regulated genes was inversely correlated, and letrozole increased expression of Runx2-stimulated genes, as defined in the MCF7/Rx2(dox) model." | 7.78 | Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. ( Baniwal, SK; Berman, BP; Chimge, NO; Coetzee, S; Ellis, MJ; Frenkel, B; Khalid, O; Luo, J; Tripathy, D, 2012) |
| "Postmenopausal women with risk factors for developing breast cancer were given letrozole 2." | 7.78 | A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density. ( Andreopoulou, E; Axelrod, D; Carapetyan, K; Checka, C; Diflo, T; Dilawari, A; Guth, A; Muggia, F; Reich, E; Smith, J; Toth, H; Ursin, G; Utate, M, 2012) |
| " She was diagnosed with right locally advanced breast cancer (cT4bN2aM0, stageIIIB) and received hormone therapy with letrozole." | 7.78 | [A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole]. ( Hibino, M; Nakamura, M; Okuyama, M; Sasaki, Y; Tenma, K, 2012) |
| "Low-dose (LD, 150 IU; n = 34) versus high-dose (HD, >150 IU; n = 117) FSH start in 151 patients with breast cancer (BCa) undergoing ovarian stimulation for embryo cryopreservation with letrozole (LE) before cancer treatment." | 7.78 | Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? ( Lee, S; Oktay, K, 2012) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 7.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells." | 7.78 | Letrozole: advancing hormone therapy in breast cancer. ( Armstrong, AC; Lee, RJ; Wardley, AM, 2012) |
| " We retrospectively investigated the activity of letrozole plus GnRH analogue (GnRH-a) administered concurrently with preoperative chemotherapy and as adjuvant treatment in premenopausal women with locally advanced ER positive breast cancer consecutively admitted at the European Institute of Oncology." | 7.77 | Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. ( Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011) |
| " We evaluated the efficacy of the aromatase inhibitor letrozole in patients with metastatic breast cancer (MBC) as related to DNA polymorphisms of CYP19A1." | 7.77 | Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. ( Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J, 2011) |
| "To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC)." | 7.77 | Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. ( Alappat, RM; Heytens, E; Lee, S; Moy, F; Oktay, K; Ozkavukcu, S, 2011) |
| "We used two aromatase overexpressing human breast cancer cell lines MCF-7-CA cells and AC1 cells and their letrozole resistant counterparts as study models." | 7.77 | GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. ( Abrhale, T; Brodie, A; Macedo, L; Sabnis, G; Serrero, G; Tian, C; Yue, B, 2011) |
| " Here we report a case of lobular breast cancer metastasizing to a leiomyoma in a patient using letrozole." | 7.77 | Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment. ( Aydinli, K; Basgul, AY; Calay, Z; Dünder, I; Güdücü, N; Işçi, H, 2011) |
| "Patients with early oestrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer treated with letrozole from February 2001 to September 2009 were reviewed." | 7.77 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. ( Balakrishnan, A; Ravichandran, D, 2011) |
| " This study was conducted to determine the prevalence of suboptimal vitamin D levels in women initiating adjuvant letrozole for breast cancer and to determine whether supplementation with 50,000 IU of vitamin D3 weekly could reduce musculoskeletal symptoms and fatigue in women who have suboptimal vitamin D levels." | 7.76 | Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. ( Baxa, SE; Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; O'Dea, AP; Reddy, PS; Sharma, P, 2010) |
| " We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)." | 7.76 | Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. ( Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B, 2010) |
| " In this study we demonstrated the preclinical therapeutic efficacy of combining the aromatase inhibitor letrozole with the multi-kinase inhibitor sorafenib in aromatase-expressing breast cancer cell lines." | 7.76 | Synergistic activity of letrozole and sorafenib on breast cancer cells. ( Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG, 2010) |
| "Roscovitine treatment can reverse intrinsic or acquired resistance to letrozole due to LMW-E expression in breast cancer cells." | 7.76 | Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. ( Akli, S; Biernacka, A; Bui, T; Hunt, KK; Keyomarsi, K; Moulder, S; Tucker, SL; Wingate, H, 2010) |
| "Aromatase-expressing breast cancer cells were treated with letrozole and ZA either simultaneously or in sequence, and the resulting apoptosis was assessed by staining with Hoechst 33342 and propidium iodide and examined using a fluorescent inverted Leica DMIRB microscope and a UV filter." | 7.76 | Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. ( Coleman, RE; Holen, I; Neville-Webbe, HL, 2010) |
| "The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen." | 7.76 | Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010) |
| "The aromatase inhibitor letrozole effectively treats breast cancer by decreasing estrogen levels in postmenopausal women." | 7.76 | Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer. ( Chetver, L; Hussein, O; Zidan, J; Zucker, M, 2010) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 7.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "4%), who have participated in the international, randomized, phase III clinical trial PO25 comparing letrozole with tamoxifen in 907 patients with advanced breast cancer." | 7.75 | An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. ( Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB, 2009) |
| "FOXP3+ Tregs were quantified in tumor samples collected at baseline by incisional biopsy and after 6 months at definitive surgery in 83 elderly breast cancer patients (T2-4 N0-1) enrolled in a randomized phase II trial based on 6 months of primary letrozole (2." | 7.75 | Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. ( Aguggini, S; Allevi, G; Banham, AH; Bates, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Campo, L; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M, 2009) |
| "Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer." | 7.75 | Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Renshaw, L; Sing, T; Walker, JR, 2009) |
| "Eight hundred eighty-five women with stage I-III breast cancer who completed 4 to 6 years of tamoxifen in 2004 with no documented recurrence were sent letters describing extended adjuvant letrozole in February 2005." | 7.75 | Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole. ( Ellard, SL; Gelmon, KA; Kennecke, HF; McArthur, HL; O'Reilly, SE; Olivotto, IA; Speers, CH, 2009) |
| "Genistein (GEN), a soy isoflavone, stimulates growth of estrogen-dependent human tumor cells (MCF-7) in a preclinical mouse model for postmenopausal breast cancer." | 7.74 | Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. ( Doerge, DR; Hartman, JA; Helferich, WG; Ju, YH; Kwak, J; Woodling, KA, 2008) |
| "Adjuvant tamoxifen therapy for 5 years reduces recurrence in hormone receptor positive, post-menopausal women with early breast cancer, but offers no advantage when prolonged to another 5 years, during which the risk of recurrence remains high." | 7.74 | Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. ( Brandman, J; Delea, T; El Ouagari, K; Karnon, J; Talbot, W, 2007) |
| "Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer." | 7.74 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007) |
| "We examined 12 consecutive non-metastatic breast cancer patients who reported severe musculoskeletal pain under a third generation AI; 11 were on letrozole and 1 on exemestane." | 7.74 | Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. ( Amant, F; Berteloot, P; Christiaens, MR; De Smet, L; Leunen, K; Morales, L; Neven, P; Pans, S; Paridaens, R; Smeets, A; Timmerman, D; Van den Bogaert, W; Van Limbergen, E; Vergote, I; Verhaeghe, J; Weltens, C; Westhovens, R; Wildiers, H, 2007) |
| "In Breast International Group (BIG) 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 7.74 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. ( Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK, 2007) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 7.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "These radiobiological results may form the basis for concurrent use of letrozole and radiation as postsurgical adjuvant therapy for breast cancer." | 7.73 | Letrozole sensitizes breast cancer cells to ionizing radiation. ( Azria, D; Cunat, S; Evans, DB; Gourgou, S; Larbouret, C; Martineau, P; Ozsahin, M; Pèlegrin, A; Pujol, P; Romieu, G, 2005) |
| "To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen." | 7.73 | Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. ( Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G, 2005) |
| "Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro." | 7.73 | Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005) |
| "The introduction of third generation aromatase inhibitors [anastrozole, letrozole, and exemestane] has certainly improved outcomes inpatients with early breast cancer." | 7.73 | Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. ( Gltick, S, 2005) |
| "A premenopausal woman with early stage breast cancer became amenorrheic with adjuvant chemotherapy, and remained so during 5 years of daily tamoxifen." | 7.73 | Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. ( Hargis, JB; Nakajima, ST, 2006) |
| "To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure." | 7.73 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. ( Alba, E; Barnadas, A; Carabante, F; Colomer, R; Fernández, R; Gil, M; González, J; Llombart, A; Mayordomo, JI; Palomero, I; Ramos, M; Ribelles, N; Ruiz, M; Soriano, V; Tusquets, I; Vera, R, 2006) |
| "To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors." | 7.73 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006) |
| "To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen." | 7.73 | Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. ( Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC, 2006) |
| "Stages I-IIIA breast cancer patients (n = 47) received 5 mg/d letrozole and 150-300 IU FSH to cryopreserve embryos or oocytes." | 7.73 | Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. ( Bang, H; Cil, A; Hourvitz, A; Oktay, K; Oktem, O; Safro, B; Sahin, G, 2006) |
| "Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced breast cancer." | 7.72 | A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. ( Jones, T; Karnon, J, 2003) |
| "Morphological characteristics, grading features, proliferation marker MIB1, apoptosis (by Tdt-mediated duTP-biotin nick-end labelling (TUNEL)), Bcl-2 expression, oestrogen receptor (ER) and progesterone receptor (PgR) status were compared in ER-positive breast cancers before and after 3 months of neoadjuvant therapy with either letrozole or tamoxifen." | 7.72 | Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. ( Anderson, TJ; Cameron, D; Dixon, JM; Macfarlane, L; Miller, WR, 2003) |
| "Recent randomized clinical trials (RCT) comparing anastrozole (Arimidex) and letrozole (Femara) to tamoxifen in the first-line treatment of postmenopausal women with advanced hormone-sensitive breast cancer have demonstrated that both agents were at least as effective as tamoxifen." | 7.72 | Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. ( Dranitsaris, G; Trudeau, M; Verma, S, 2003) |
| "We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months." | 7.72 | Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. ( Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M, 2003) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 7.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "Tamoxifen treatment inhibited breast cancer cell growth and increased BMD but caused uterine hypertrophy in this preclinical model of postmenopausal breast cancer." | 7.72 | Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. ( Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN, 2004) |
| "To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer." | 7.72 | Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L, 2004) |
| "To simulate the treatment of postmenopausal women with advanced breast cancer from second-line hormone therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the incremental cost effectiveness of letrozole, expressed as cost per life-years gained." | 7.70 | Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. ( Meester, L; Nuijten, M; Waibel, F; Wait, S, 1999) |
| "Twenty patients (pts) with metastatic breast cancer with disease progression, previously treated with chemotherapy and tamoxifen, were administered oral letrozole (2." | 7.70 | Letrozole for the treatment of pretreated advanced breast cancer patients: preliminary report. ( Cappellini, GC; Casali, A; Casali, M; Giuntini, T; Sega, FM; Terzoli, E, 2000) |
| "Randomized trials comparing the aromatase inhibitors, anastrozole and letrozole, to megestrol acetate (MA) in postmenopausal women with advanced breast cancer demonstrated that both agents are better tolerated than MA with comparable efficacy." | 7.70 | Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. ( Dranitsaris, G; Leung, P; Mather, J; Oza, A, 2000) |
| "Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy." | 7.30 | A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. ( Acosta, EP; Elkhanany, AM; Forero-Torres, A; Grizzle, WE; Li, Y; Ryan, KJ; Stringer-Reasor, EM; Theuer, CP; Vaklavas, C; Wei, S; Yang, ES, 2023) |
| "Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (MBC)." | 7.30 | Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial. ( Hu, ZY; Li, J; Liu, B; Liu, L; Luo, T; Ouyang, Q; Ran, L; Sun, T; Xiao, H; Xie, N; Xiong, H; Yan, M; Yang, X; Zhong, J, 2023) |
| "Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small." | 7.11 | Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. ( Goss, PE; Ingle, JN; Li, Y; Parulekar, WR; Qin, G; Tu, D; Zheng, X, 2022) |
| " Rates of all-grade and Grade ≥3 adverse events (AEs) were 99." | 7.11 | Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. ( Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R, 2022) |
| "Current therapies for HER2-positive breast cancer have limited efficacy in patients with triple-positive breast cancer (TPBC)." | 7.11 | A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. ( Cai, Z; Chen, G; de Faria Castro Fleury, E; Gu, X; Guo, W; Han, H; He, G; Huang, Y; Huo, S; Jahromi, AH; Jerusalem, G; Jiang, X; Li, H; Li, J; Li, K; Li, P; Li, Y; Li, Z; Liu, C; Liu, T; Niu, N; Qiu, F; Tripodi, D; Xu, H; Xu, Q; Xue, J; Zhang, D; Zhang, G; Zhang, H; Zhang, P; Zhao, Y; Zheng, X, 2022) |
| "Women with HER2-positive breast tumors measuring ≥2 cm (median = 5 cm) were randomized in a 1:2 ratio to 12 versus 24 weeks of lapatinib and trastuzumab." | 6.94 | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. ( De Angelis, C; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Jiralerspong, S; Krop, I; Nanda, R; Nangia, JR; Niravath, P; Osborne, CK; Pavlick, A; Rexer, BN; Rimawi, MF; Schiff, R; Storniolo, AM; Veeraraghavan, J; Wang, T; Wolff, AC, 2020) |
| "Estrogen receptor positive (ER+) breast cancer constitutes almost 85% of all breast cancer patients and are a genetically highly heterogenic group." | 6.94 | Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. ( Ahlborn, LB; Ejlertsen, B; Eriksen, JO; Jensen, MB; Knoop, AS; Laenkholm, AV; Rossing, M; Skriver, SK, 2020) |
| "Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule." | 6.90 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. ( Barry, P; Batten, LM; Bliss, JM; Boileau, JF; Cheang, MCU; Cornman, C; Dodson, A; Dolling, D; Dowsett, M; Fisher, K; Holcombe, C; Huang Bartlett, C; Jacobs, SA; Jeffs, LK; Johnston, S; Julian, TB; Koehler, M; MacKenzie, M; Martins, V; McIntosh, SA; Modi, A; Morden, J; Osborne, CK; Perry, S; Pogue-Geile, KL; Provencher, L; Puhalla, S; Rimawi, M; Ring, A; Robidoux, A; Shalaby, I; Snowdon, C; Stein, RC; Thirlwell, M; Wheatley, D; Wilcox, M; Wolmark, N, 2019) |
| "The development of joint pain was similar in the two groups." | 6.90 | Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Wolf, C; Wuerstlein, R, 2019) |
| " Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period." | 6.90 | Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. ( Apala, JV; Colomer, R; Gonzalez-Cortijo, L; Guerra, J; Hornedo, J; Malon, D; Mouron, S; Quintela-Fandino, M, 2019) |
| " Palbociclib, when administered with letrozole at the recommended therapeutic dosing regimen, did not prolong the QT interval to a clinically relevant extent." | 6.87 | Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. ( Durairaj, C; Ettl, J; Finn, RS; Gauthier, ER; Hoffman, JT; Huang, X; Joy, AA; Lu, DR; Rugo, HS; Ruiz-Garcia, A; Wang, DD; Wilner, KD; Zheng, J, 2018) |
| " Further studies are needed to determine the feasibility of selecting an effective AI dosing schedule with better tolerability." | 6.82 | Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk. ( Boughey, JC; Chow, HH; Frank, D; Hsu, CH; Lang, JE; Ley, M; López, AM; Perloff, M; Pruthi, S; Taverna, JA, 2016) |
| "We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors." | 6.82 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016) |
| "Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97." | 6.80 | Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. ( Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G, 2015) |
| "Letrozole-treated patients with rs2077647 (T>C) variants CC and TC had a reduced risk of bone AE (HR = 0." | 6.80 | ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. ( Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B, 2015) |
| "Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures." | 6.77 | Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. ( Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G, 2012) |
| "Women with previous unilateral breast cancer or prior prophylactic oophorectomy are more likely to enter a medical prevention trial." | 6.77 | Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. ( Baudry, K; Berthet, P; Bignon, YJ; Chabbert-Buffet, N; Chiesa, J; Clough, KB; Delaloge, S; Delnatte, C; Dreyfus, H; Dugast, C; Fricker, JP; Gesta, P; Gladieff, L; Lasset, C; Lemonnier, J; Lesur, A; Lortholary, A; Martin, AL; Mijonnet, S; Nogues, C; Prieur, F; Pujol, P; Roca, L; Tennevet, I; This, P; Vennin, P, 2012) |
| "Endocrine therapy for breast cancer may affect cognition." | 6.76 | Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. ( Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Sun, Z; Thompson, A; Thürlimann, B, 2011) |
| "Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2." | 6.76 | [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011) |
| "In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen." | 6.75 | Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. ( Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Stephens, A; Sun, Z; Thompson, A; Thürlimann, B, 2010) |
| "Postmenopausal women with breast cancer (BC) are at increased risk for bone loss." | 6.74 | Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. ( Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA, 2009) |
| "A total of 215 women with breast cancer were prospectively evaluated for fertility preservation before adjuvant chemotherapy." | 6.73 | Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. ( Azim, AA; Costantini-Ferrando, M; Oktay, K, 2008) |
| "Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67." | 6.73 | Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D, 2008) |
| "The incidence of bone fractures, observed more often in the letrozole group, did not differ by age." | 6.73 | Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. ( Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B, 2008) |
| "Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment." | 6.71 | Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. ( Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L, 2004) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| " Drug-related adverse events occurred in 35." | 6.70 | [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. ( Ikeda, S; Kimijima, I; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H, 2002) |
| "Letrozole is an orally competitive aromatase inhibitor." | 6.69 | Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. ( Bajetta, E; Bichisao, E; Celio, L; Di Leo, A; Dowsett, M; Guillevin, L; Marchianò, A; Martinetti, A; Pozzi, P; Stani, S; Zilembo, N, 1999) |
| "Letrozole appears to be a very promising new antiaromatase drug." | 6.68 | Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ( Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF, 1996) |
| "Because incidence of breast cancer and comorbidities increase with age, it is important to determine treatment benefit in elderly patients." | 6.58 | Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. ( Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S, 2018) |
| "Sorafenib is an oral multikinase inhibitor with anti-angiogenic and anti-proliferative activity that is indicated for use in hepatocellular and renal cell carcinomas." | 6.48 | Sorafenib in locally advanced or metastatic breast cancer. ( Gradishar, WJ, 2012) |
| "To review the clinical effectiveness and cost-effectiveness evidence base for lapatinib (LAP) in combination with an aromatase inhibitor (AI) and trastuzumab (TRA) in combination with an AI for the first-line treatment of patients who have hormone receptor-positive (HR+)/human epidermal growth factor 2-positive (HER2+) mBC." | 6.47 | Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. ( Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N, 2011) |
| "Letrozole (Femara) is a third-generation, nonsteroidal aromatase inhibitor." | 6.45 | Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. ( Keating, GM, 2009) |
| "Letrozole is a potent third-generation aromatase inhibitor that suppresses plasma estrogen levels to near-undetectable levels in postmenopausal women." | 6.44 | Update on the use of letrozole in breast cancer. ( Goss, PE; Wu, M, 2007) |
| "Breast cancer is a leading cause of cancer death among women worldwide." | 6.44 | Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. ( Dodwell, D; Williamson, D, 2008) |
| "Letrozole was also superior to tamoxifen in first-line treatment for advanced breast cancer, as well as in systemic preoperative (neoadjuvant) treatment of locally advanced breast cancer." | 6.43 | Letrozole in the treatment of breast cancer. ( Bhatnagar, AS; Mouridsen, HT, 2005) |
| "Women undergoing treatment for breast cancer often have a number of pre-existing risk factors for bone loss, including existing or induced postmenopausal status." | 6.43 | Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. ( Aapro, M, 2006) |
| "Letrozole is an oral drug given once daily and the first choice for the treatment of patients with steroid receptor positive or receptor-unknown locally advanced or metastatic postmenopausal breast cancer." | 6.43 | [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer]. ( Tsukagoshi, S, 2006) |
| "Letrozole is an oral reversible nonsteroidal aromatase inhibitor." | 6.40 | Letrozole. A review of its use in postmenopausal women with advanced breast cancer. ( Adkins, JC; Lamb, HM, 1998) |
| "Letrozole is a new orally, active, potent, and highly specific non-steroidal aromatase inhibitor." | 6.39 | Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. ( Bhatnagar, AS; Chaudri, HA; Hornberger, U; Trunet, PF, 1996) |
| "Approximately 70% of breast cancers are estrogen receptor(ER)positive, an indication for endocrine therapy." | 5.91 | [ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib]. ( Hayashi, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R, 2023) |
| "The endocrine therapy resistance of breast cancer is the difficulty and challenge to be urgently solved in the current treatment." | 5.72 | LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway. ( Fang, SQ; Hu, H; Li, LW; Li, XY; Liu, H; Liu, YW; Lu, ZX; Wang, H; Wu, TW; Xiang, Y; Zhan, Y; Zong, QB, 2022) |
| "Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease." | 5.72 | Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia. ( Annovazzi, A; Barberi, V; Cognetti, F; Ferretti, G; Renna, D; Russillo, M, 2022) |
| "Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)." | 5.69 | Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial. ( Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Carañana, V; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil Gil, MJ; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-De Dueñas, E; Mina, L; Pérez-García, JM; Ruiz Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P, 2023) |
| "The phase IIIb, BioItaLEE trial (NCT03439046) collected sera from postmenopausal patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) treated with first-line ribociclib plus letrozole at baseline, day 15 of cycle 1 (C1D15), day 1 of cycle 2 (C2D1), and at first imaging." | 5.69 | Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. ( Allegrini, G; Arpino, G; Benelli, M; Bianchi, GV; Bianchini, G; Caputo, R; Castelletti, D; Cazzaniga, ME; Colleoni, M; De Laurentiis, M; Del Mastro, L; Di Marino, M; Guarneri, V; Malorni, L; Montemurro, F; Orditura, M; Paris, I; Puglisi, F; Tamberi, S; Zamagni, C; Zambelli, A, 2023) |
| "In POETIC 4480 postmenopausal patients with primary ER and/or PgR + breast cancer were randomised 2:1 to 2 weeks' presurgical AI (anastrozole or letrozole) or no presurgical treatment (control)." | 5.69 | Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015). ( Banerji, J; Bliss, JM; Detre, S; Dodson, A; Dowsett, M; Evans, A; Hills, M; Holcombe, C; Horgan, K; Kilburn, L; Mallon, E; Morden, JP; Robertson, JFR; Skene, A; Smith, I; Tovey, H; Vidya, R; Zabaglo, L, 2023) |
| "Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape." | 5.69 | Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con ( Bayaxi, N; Cheng, Y; Geng, C; Hu, C; Hu, X; Li, W; Ouyang, Q; Pan, Y; Shi, Y; Sun, T; Teng, Y; Tong, Z; Wang, X; Wang, Y; Wei, W; Wu, X; Xie, W; Xu, B; Xu, J; Yan, M; Yan, X; Zeng, X; Zhang, H; Zhang, P; Zhang, Q; Zhong, J; Zhu, X, 2023) |
| "The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase inhibitor (AI)-based therapy." | 5.69 | Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer. ( Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Rastogi, P; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wolmark, N, 2023) |
| "Postmenopausal breast cancer patients starting adjuvant letrozole were eligible." | 5.69 | Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurem ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2023) |
| "This non-randomized, multicohort, phase II study evaluated the efficacy and safety of the anti-PD-1 antibody nivolumab 240 mg administered every 2 weeks in combination with the CDK4/6 inhibitor abemaciclib 150 mg twice daily and either fulvestrant (FUL) or letrozole (LET) as a first-line or second-line treatment for HR-positive HER2-negative metastatic breast cancer." | 5.69 | Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). ( Aogi, K; Futamura, M; Hosonaga, M; Imamura, CK; Iwasa, T; Iwata, H; Kawabata, H; Masuda, J; Masuda, N; Matsumoto, K; Miura, S; Mukohara, T; Sakai, H; Takahashi, M; Takano, T; Tanabe, Y; Tomioka, N; Tsurutani, J; Yamochi, T; Yasojima, H; Yoshimura, K, 2023) |
| "AMEERA-4 (NCT04191382) was a WOO study undertaken to compare the pharmacodynamic effects of amcenestrant, a selective estrogen receptor degrader, with those of letrozole in postmenopausal women with newly diagnosed, operable estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer." | 5.69 | AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer. ( Bidard, FC; Campone, M; De Giorgi, U; Dong, Y; Herold, C; Ling, B; Neven, P; Paux, G; Wang, L, 2023) |
| "Median PFS for patients with bone-only metastases (n = 54) was not reached (95% CI 18." | 5.62 | Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. ( Armaghani, AJ; Costa, RLB; Czerniecki, BJ; Han, HS; Hoover, SJ; Khakpour, N; Khong, HT; Kiluk, JV; Laronga, C; Lee, MC; Loftus, LS; Ma, J; Soliman, HH; Soyano-Muller, AE; Sun, J; Sun, W; Zhong, X, 2021) |
| "Letrozole is an aromatase inhibitor (AI) which has shown better clinical efficacy when combined with HER2 inhibitors in treating patients with HER2-positive and HR-positive breast cancer than has hormonal therapy alone." | 5.62 | Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report. ( Li, J; Ouyang, Q; Shui, Z, 2021) |
| "Retrospective cohort study of 118 breast cancer patients undergoing fertility preservation treatment between 2008 and 2018." | 5.62 | Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients. ( Almog, B; Azem, F; Cohen, Y; Fouks, Y; Kalma, Y; Shulman, Y, 2021) |
| "Letrozole is a risk factor for worse oocyte morphology." | 5.56 | The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation. ( Alves, VR; Bercaire, LMN; Cavagna, F; Cavagna, M; Donadio, NF; Dzik, A; Gebrim, LH; Nahas, EAP; Portela, R; Rocha, AR; Santos, TBB, 2020) |
| "Musculoskeletal adverse events (MS-AEs) and vasomotor symptoms (VMSs) are the major side-effects of newer generation non-steroidal aromatase inhibitor (AI), letrozole." | 5.56 | Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity. ( Adithan, C; Damodaran, SE; Devi, J; Dkhar, SA; Dubashi, B; Kadambari, D; Kalaivani, S; Muthuvel, SK; Pradhan, SC; Umamaheswaran, G, 2020) |
| "This was a Japanese subpopulation analysis of MONARCH 3, a randomized, double-blind, placebo-controlled phase 3 study of abemaciclib plus nonsteroidal aromatase inhibitors (NSAIs) for initial therapy for advanced breast cancer (ABC)." | 5.51 | Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. ( Goetz, MP; Kawaguchi, T; Mori, J; Takahashi, M; Tanizawa, Y; Toi, M; Tokunaga, E; van der Walt, JS, 2022) |
| "The phase IIIb CompLEEment-1 study evaluated ribociclib plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)." | 5.51 | Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial. ( Abdel-Razeq, H; Cardoso, F; Cottu, P; De Laurentiis, M; Marchetti, P; Martín, M; Menon-Singh, L; Ring, A; Salvador Bofill, J; Wu, J, 2022) |
| "In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer." | 5.51 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. ( André, F; Arteaga, CL; Burris, HA; Cameron, DA; Campone, M; Chakravartty, A; Conte, P; Hart, L; Hortobagyi, GN; Janni, W; Le Gac, F; O'Shaughnessy, J; Petrakova, K; Serra, P; Sonke, GS; Stemmer, SM; Taran, T; Winer, EP; Yap, YS; Zarate, JP, 2022) |
| "NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes." | 5.51 | Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. ( Callens, C; Cottu, P; D'Hondt, V; Dalenc, F; Delaloge, S; Desmoulins, I; Duhoux, FP; Dureau, S; Frenel, JS; Gentien, D; Heudel, PE; Jouannaud, C; Lemonnier, J; Lerebours, F; Levy, C; Manduzio, H; Mouret-Reynier, MA; Nguyen, S; Rapinat, A; Venat-Bouvet, L; Vincent-Salomon, A, 2022) |
| "Patients with advanced ER+/HER2- breast cancer were treated with lenvatinib plus letrozole in a phase Ib/II trial." | 5.51 | Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. ( Ang, YLE; Chan, GHJ; Chee, CE; Chong, WQ; Choo, JRE; Goh, BC; Jain, S; Lee, M; Lee, SC; Lim, JSJ; Lim, SE; Lim, YW; Ngoi, NYL; Ow, SGW; Soo, RA; Sundar, R; Tai, BC; Tan, DSP; Tan, HL; Wang, L; Wong, ALA; Yadav, K; Yong, WP, 2022) |
| " Letrozole is a proven, potent aromatase inhibitor, extensively tested and used in the treatment of ER positive breast cancer." | 5.51 | Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. ( Bommer, C; du Bois, A; Dutilh, G; Heinzelmann-Schwarz, V; Klar, M; Kurzeder, C; Marth, C; McLaughlin, PMJ; Reuss, A; Schade-Brittinger, C; Vetter, M; Zwimpfer, TA, 2022) |
| "The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2- ABC (MONALEESA-7)." | 5.51 | Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. ( Beniak, J; Borstnar, S; Gal-Yam, EN; Kudela, P; Palacova, M; Papazisis, K; Rubovszky, G; Timcheva, C; Łacko, A, 2022) |
| "In the Exemestane and Letrozole Pharmacogenetics (ELPh) study, postmenopausal patients with HR + non-metastatic breast cancer were randomized to letrozole or exemestane." | 5.51 | Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms. ( Desta, Z; Douglas, JA; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Miller, RM; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM, 2022) |
| "In the phase II CORALLEEN trial, patients with PAM50 luminal B early breast cancer (EBC) were randomised to neoadjuvant ribociclib plus letrozole (R + L) or chemotherapy based on anthracyclines and taxanes." | 5.51 | Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. ( Arumí, M; Ciruelos, E; Falato, C; Ferrer, N; Gavilá, J; Gil-Gil, M; Gómez, G; González-Santiago, S; Hernando, C; Izarzugaza, Y; Montaño, A; Muñoz, M; Najera-Zuloaga, J; Paré, L; Pascual, T; Prat, A; Saura, C; Villacampa, G; Villagrasa, P, 2022) |
| "Ribociclib plus letrozole demonstrated manageable safety and efficacy profiles in hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) in the Phase 3b CompLEEment-1 trial." | 5.51 | Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. ( Ballatore, Z; Ballestrero, A; Caputo, R; Coltelli, L; De Laurentiis, M; Fabi, A; Ferro, A; Frassoldati, A; Generali, D; Grasso, D; Mansutti, M; Marchetti, P; Masetti, R; Mazza, M; Michelotti, A; Sarobba, MG; Spazzapan, S; Torrisi, R; Vici, P; Zamagni, C; Zambelli, A, 2022) |
| "The cyclin-dependent kinase 4/6 inhibitor palbociclib has demonstrated efficacy and a manageable safety profile in combination with endocrine therapy in women with oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in international phase 3 trials." | 5.51 | Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. ( Cheng, Y; Chia, YH; Cui, S; Geng, C; Hu, X; Huang, CS; Li, W; Ngan, RKC; Shen, K; Song, E; Sriuranpong, V; Sun, T; Tong, Z; Wang, S; Wang, X; Xu, B; Zhang, Q; Zhao, H, 2022) |
| "HER2DX predicts response following neoadjuvant letrozole in combination with dual HER2 blockade with trastuzumab and pertuzumab in early-stage HER2-positive/hormone receptor-positive breast cancer." | 5.51 | HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial. ( Blasco, P; Bottosso, M; Bras-Maristany, F; Castillo, O; Conte, P; Dieci, MV; Galv N, P; Giorgi, CA; Griguolo, G; Guarneri, V; Mar Ín-Aguilera, M; Miglietta, F; Par, L; Parker, JS; Perou, CM; Prat, A; Villagrasa, P; Vivancos, A, 2022) |
| "We report a case of primary advanced breast cancer that was locally controlled by treatment with bevacizumab." | 5.48 | [A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole]. ( Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Hirano, T; Ono, Y; Sakurai, K; Waga, E, 2018) |
| "Women with breast cancer and diabetes mellitus (DM) have poorer survival." | 5.43 | Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. ( Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D, 2016) |
| "Letrozole was subcutaneously injected daily for 23 days at a dose of 1." | 5.43 | Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. ( Belosay, A; Churchwell, MI; Doerge, DR; Hartman, JA; Helferich, WG; Iwaniec, UT; Song, H; Turner, RT; Wang, W; Yang, X, 2016) |
| "Fulvestrant is an efficient treatment option for these AI-resistant breast cancer cells, and the cell lines will be useful tools to disclose the underlying molecular mechanism for resistance to the different AIs." | 5.42 | New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. ( Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW, 2015) |
| "Letrozole-resistant breast cancer cells (LTLT-Ca) were treated with a novel phytoalexin, glyceollin I, and exhibited morphological characteristics synonymous with an epithelial phenotype and decreased proliferation." | 5.42 | Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1. ( Boué, SM; Burks, H; Burow, ME; Carriere, PP; Collins-Burow, B; Davenport, IR; Davidson, AM; Hilliard, A; Llopis, SD; Naiki, AC; Nguyen, G; Nguyen, MM; Nguyen, TA; Parker-Lemieux, K; Payton-Stewart, F; Phan, T; Pratt, J; Preyan, LC; Tilghman, SL; Williams, CC; Yearby, L, 2015) |
| " We aimed to compare extended therapy with letrozole for 5 years versus the standard duration of 2-3 years of letrozole in postmenopausal patients with breast cancer who have already received 2-3 years of tamoxifen." | 5.41 | Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. ( Amaducci, L; Arpino, G; Ballestrero, A; Barone, C; Bighin, C; Bisagni, G; Bruzzi, P; Campadelli, E; Cognetti, F; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Frassoldati, A; Garrone, O; Gori, S; Lambertini, M; Mansutti, M; Michelotti, A; Montemurro, F; Moretti, G; Mura, S; Poggio, F; Ponzone, R; Puglisi, F; Sanna, G; Tamberi, S; Urracci, Y, 2021) |
| "The aromatase inactivator exemestane may cause clinical disease stabilization following progression on non-steroidal aromatase inhibitors like letrozole in patients with metastatic breast cancer, indicating that additional therapeutic effects, not necessarily related to estrogen-suppression, may be involved in this well-known "lack of cross-resistance"." | 5.41 | Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. ( Bahrami, N; Geisler, J; Geisler, SB; Gravdehaug, B; Jabeen, S; Kristensen, V; Reitsma, LC; Sauer, T; Selsås, K; Tahiri, A; Ødegård, HP, 2021) |
| "The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer." | 5.41 | Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. ( Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil-Gil, M; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-de Dueñas, E; Pérez-García, JM; Ruíz-Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P, 2021) |
| "According to the current literature, there is an overall tendency towards a mild and transient thyroid dysfunction, that is, subclinical hypothyroidism in tamoxifen-treated patients." | 5.41 | Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review. ( Andersson, M; Buch-Larsen, K; Gillberg, L; Marina, D; Rasmussen, ÅK; Schwarz, P, 2023) |
| "In the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer." | 5.41 | Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3. ( Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mukai, H; Muramatsu, Y; Ohno, S; Ohtani, S; Rai, Y; Shimizu, C; Toi, M; Umeyama, Y, 2021) |
| "Compared to tamoxifen, adjuvant treatment with aromatase inhibitors improves disease outcomes of postmenopausal women with hormone receptor-positive early breast cancer." | 5.41 | Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. ( Bonnefoi, H; Castiglione, M; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Harvey, VJ; Láng, I; Maibach, R; Neven, P; Rabaglio, M; Regan, MM; Ruepp, B; Sun, Z; Thürlimann, B; Wardley, A, 2021) |
| "In the randomised phase II LEO trial, we investigated the effect of adding everolimus (EVE) to letrozole (LET) in ovarian-suppressed premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent/metastatic breast cancer." | 5.41 | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. ( Ahn, JH; Cheon, J; Jeong, JH; Jung, KH; Kim, GM; Kim, JE; Kim, SB; Koh, SJ; Lee, KS; Park, IH; Sim, SH; Sohn, J, 2021) |
| "This post hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 5.41 | Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials. ( André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK, 2021) |
| "In a prospective study of breast cancer patients switching to letrozole treatment after previous tamoxifen, plasma estrogen levels were measured at baseline and after 3- and 12-months using LC-MS/MS." | 5.41 | Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial. ( Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L, 2021) |
| "Letrozole is a nonsteroidal aromatase inhibitor used to treat hormone-receptor-positive breast cancer." | 5.41 | Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. ( Desta, Z; Douglas, JA; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM, 2021) |
| "Postmenopausal women with ER-positive, HER2-negative breast cancer who had a primary tumor > 2 cm or positive axillary lymph node(s) proofed by biopsy were randomly (1,1) enrolled to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles before surgery." | 5.41 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. ( Chen, J; Deng, H; He, Z; Jin, L; Liu, J; Nie, Y; Rao, N; Su, F; Wu, W; Yang, Y; Yao, Y, 2021) |
| "Treatment with everolimus or letrozole resulted in growth inhibition of SCs in a dose-dependent manner." | 5.40 | Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. ( Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X, 2014) |
| "Therefore, advanced breast cancer with left-sided pleural effusion and metastases to the pleura and bone was diagnosed." | 5.39 | [An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report]. ( Nakamura, H; Yoneyama, K, 2013) |
| "Neoplastic meningitis from breast cancer has a dismal prognosis and short survival." | 5.37 | Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report. ( Bouboukas, G; Kalofonos, H; Koutras, A; Makatsoris, T; Onyenadum, A; Peroukides, S; Starakis, I, 2011) |
| " In addition to providing evidence suggesting the potential use of ERβ agonists in combination with letrozole in treating AI resistant breast cancer and prolonging sensitivity to AI, we also provide mechanistic evidence supporting the role of ERβ in altering the expression profile associated with resistance." | 5.37 | Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. ( Ganapathy, M; Kirma, NB; Nair, HB; Tekmal, RR; Vadlamudi, RK, 2011) |
| "It was suspected that breast cancer could be metastasized to the scalp, but mammography, ultrasound, and positron emission tomography showed no particular metastases in her breast and other organs." | 5.37 | [A case of scalp metastases from breast cancer successfully treated with letrozole]. ( Ishiba, T; Kubota, K; Kuwayama, T; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H, 2011) |
| "Letrozole is a potent nonsteroidal aromatase inhibitor that is registered for the treatment of postmenopausal women with advanced metastatic breast cancers and in the neoadjuvant, early, and extended adjuvant indications." | 5.35 | The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. ( Chen, B; Chen, S; Evans, DB; Lisztwan, J; Pornon, A, 2008) |
| "The antiangiogenic agent bevacizumab showed synergistic effects when combined with chemotherapy in advanced breast cancer." | 5.35 | Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. ( Bagnardi, V; Bertolini, F; Calleri, A; Cardillo, A; Colleoni, M; Goldhirsch, A; Luini, A; Mancuso, P; Orlando, L; Scarano, E; Torrisi, R; Viale, G, 2008) |
| "We used human ER-positive breast cancer cells stably transfected with the aromatase gene (MCF-7Ca)." | 5.35 | Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. ( Brodie, A; Goloubeva, O; Macedo, L; Sabnis, G; Schayowitz, A, 2009) |
| "Letrozole was chosen for the next therapy." | 5.35 | [A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy]. ( Kihara, M; Miyauchi, A, 2008) |
| "This exploratory study suggests that FES-PET heterogeneity may potentially identify the subset of ER positive, metastatic breast cancer patients who benefit from letrozole combined with CDK inhibition." | 5.34 | Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. ( Boers, J; de Vries, EFJ; Elias, SG; Glaudemans, AWJM; Hospers, GAP; Kwee, TC; Martens, JWM; Schröder, CP; Schuuring, E; Venema, CM, 2020) |
| "Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive, HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2." | 5.34 | TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. ( Carey, LA; Delossantos, JF; Forero-Torres, A; Grizzle, WE; Li, Y; Lin, NU; Liu, MC; LoBuglio, AF; Myers, RM; Nanda, R; Puhalla, S; Roberts, BS; Rugo, HS; Saleh, MN; Storniolo, AM; Vaklavas, C; Varley, KE, 2020) |
| "The aromatase inhibitors (AIs), letrozole (Femar®/Femara®) and exemestane (Aromasin®), are widely used to treat estrogen receptor (ER) positive breast cancer in postmenopausal patients." | 5.34 | Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane. ( Bahrami, N; Chang, G; Chen, S; Geisler, J; Gravdehaug, B; Kanaya, N; Loeng, M; Park, D; Sauer, T, 2020) |
| " The present study compared clinical outcomes in women with metastatic breast cancer who received letrozole as first-line monotherapy in oncology practices across the United States versus patients in the letrozole-alone cohort of the PALOMA-2 phase 3 trial." | 5.34 | Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. ( Bourla, AB; Cotter, MJ; Huang Bartlett, C; Huang, X; Mardekian, J; Parrinello, CM; Zhang, Z, 2020) |
| "Participants were postmenopausal women with ER+, HER2 normal operable breast cancer assigned to 4 months of neoadjuvant letrozole." | 5.34 | Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. ( Ejlertsen, B; Jensen, MB; Knoop, AS; Laenkholm, AV; Skriver, SK, 2020) |
| "Palbociclib is a highly selective, reversible, oral inhibitor of cyclin-dependent kinases 4 and 6 that is approved to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer." | 5.34 | Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study. ( Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Muramatsu, Y; Nishimura, R; Ohno, S; Takahashi, M; Toi, M; Umeyama, Y, 2020) |
| "Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC)." | 5.34 | Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). ( Bananis, E; Boer, K; Bondarenko, I; Ettl, J; Finn, RS; Huang, X; Kim, S; McRoy, L; Patel, R; Pinter, T; Schmidt, M; Shparyk, YV; Slamon, DJ; Thummala, A; Voitko, N; Wilner, K, 2020) |
| "Somatic mutations were investigated in 21 patients with postmenopausal estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER-2)-positive (ER+HER2+) breast cancer (BC) treated with neoadjuvant letrozole and lapatinib, to identify their distinct molecular landscape." | 5.34 | Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. ( Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, D; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH, 2020) |
| "Brain metastases from breast cancer have a poor prognosis." | 5.33 | Letrozole for brain and scalp metastases from breast cancer--a case report. ( Bhatt, ML; Kirti, S; Kumar, S; Madhup, R; Srivastava, M; Srivastava, PK, 2006) |
| "Breast cancer is the most common malignancy and the second most common cause of cancer-related death in women." | 5.33 | Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. ( Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O, 2006) |
| "Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis." | 5.31 | Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. ( Bairaktari, ET; Elisaf, MS; Kakaidi, B; Katsaraki, A; Nicolaides, C; Pavlidis, NA; Tzallas, CS, 2001) |
| "Letrozole (2." | 5.31 | Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. ( Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R, 2002) |
| "Postmenopausal women with untreated stage I-III HR+/HER2-negative breast cancer were randomized (1:1:1) to receive 3 weeks of letrozole (LTZ) 2." | 5.30 | Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. ( Adamo, B; Amillano, K; Bellet, M; Blanch, S; Canes, J; Ciruelos, E; Galván, P; Gómez-Pardo, P; González, X; González-Farré, B; López-González, A; Martinez, N; Murillo, L; Paré, L; Pascual, T; Pérez Fidalgo, JA; Prat, A; Vidal, M; Villagrasa, P, 2019) |
| "Based on these long-term safety analyses, there is no evidence of specific cumulative or delayed toxicities with palbociclib plus endocrine therapy, supporting the ongoing investigation of palbociclib plus endocrine therapy in early breast cancer (NCT02513394)." | 5.30 | Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. ( Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Huang Bartlett, C; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Slamon, DJ; Turner, NC, 2019) |
| "NEOS is a phase 3 clinical trial of hormonal therapy ± adjuvant chemotherapy for postmenopausal patients with ER+, HER2-negative, clinically node-negative breast cancer, after six months of neoadjuvant letrozole and breast surgery." | 5.30 | Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. ( Akabane, H; Bailey, H; Chao, C; Cherbavaz, DB; Fujisawa, T; Hasegawa, Y; Iwata, H; Jakubowski, DM; Kashiwaba, M; Masuda, N; Nakamura, R; Ohashi, Y; Ohtani, S; Sakai, T; Sakamaki, K; Sasano, H; Shibahara, Y; Sugiyama, N; Taira, N; Toyama, T; Yamaguchi, T; Yamamoto, Y, 2019) |
| "The cyclin-dependent kinase 4/6 inhibitor palbociclib has emerged as a novel therapeutic agent in metastatic breast cancer." | 5.30 | Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer. ( Aslam, R; Deac, O; Kennedy, J; O'Dwyer, R; Sukor, S; Tierney, A; Watson, GA, 2019) |
| "BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early breast cancer." | 5.30 | Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. ( Bonnefoi, H; Coates, AS; Colleoni, M; de Azambuja, E; Del Mastro, L; Di Leo, A; Ejlertsen, B; Gelber, RD; Gianni, L; Giobbie-Hurder, A; Gladieff, L; Goldhirsch, A; Harvey, VJ; Jakobsen, EH; Jassem, J; Jensen, MB; Kralidis, E; Láng, I; Neven, P; Piccart-Gebhart, M; Regan, MM; Rochlitz, C; Ruhstaller, T; Simoncini, E; Spazzapan, S; Thürlimann, B; Tondini, C; Veyret, C; Zaman, K, 2019) |
| " Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer, who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor, were randomly assigned (1:1) to receive 5 years of letrozole (2·5 mg orally per day) or placebo." | 5.30 | Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Graham, ML; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Paik, S; Rastogi, P; Seay, TE; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wickerham, DL; Wolmark, N, 2019) |
| "In PALOMA-2, palbociclib-letrozole significantly improved progression-free survival (PFS) vs placebo-letrozole in women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC) in the first-line setting." | 5.30 | Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. ( Hashigaki, S; Iwata, H; Lu, DR; Masuda, N; Mori, Y; Mukai, H; Muramatsu, Y; Nagasawa, T; Nishimura, R; Ohno, S; Ohsumi, S; Ohtani, S; Sato, N; Shimizu, C; Takahashi, M; Toi, M; Umeyama, Y; Yamamoto, Y, 2019) |
| "To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer." | 5.30 | Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. ( Bernhard, J; Coates, AS; Colleoni, M; Dellapasqua, S; Di Leo, A; Gelber, RD; Gianni, L; Goldhirsch, A; Gray, KP; Johansson, H; Kammler, R; Maibach, R; Munzone, E; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Rubino, D; Ruepp, B; Viale, G, 2019) |
| "Fertility preservation (FP) protocols in case of breast cancer (BC) include mature oocyte cryopreservation following letrozole associated controlled ovarian hyperstimulation (Let-COH)." | 5.30 | Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. ( De Maertelaer, V; Dechène, J; Delbaere, A; Demeestere, I; Devreker, F; Gervy, C; Goldrat, O; Gonzalez-Merino, E; Van Den Steen, G, 2019) |
| "In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0." | 5.30 | Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. ( Bartlett, CH; Castrellon, A; Diéras, V; Ettl, J; Finn, RS; Gauthier, ER; Gelmon, KA; Harbeck, N; Iyer, S; Joy, AA; Lipatov, O; Lu, DR; Mori, A; Rugo, HS; Slamon, DJ, 2019) |
| "In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer." | 5.30 | Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. ( Abdi, E; Aebi, S; Barbeaux, A; Bernhard, J; Biganzoli, L; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Foukakis, T; Francis, PA; Gelber, RD; Goldhirsch, A; Gomez, HL; Graas, MP; Graiff, C; Jerusalem, G; Karlsson, P; Luo, W; Maibach, R; Müller, B; Neven, P; Pagani, O; Rabaglio, M; Regan, MM; Ribi, K; Ruhstaller, T; Vorobiof, D, 2019) |
| "The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor-positive (HR+) tumours." | 5.30 | Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. ( Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V, 2019) |
| " MONALEESA-2 demonstrated that ribociclib plus letrozole significantly improved progression-free survival compared with placebo plus letrozole as first-line therapy in postmenopausal patients with HR-positive, HER2-negative advanced breast cancer." | 5.30 | MONALEESA clinical program: a review of ribociclib use in different clinical settings. ( Yardley, DA, 2019) |
| "Determine the efficacy and safety of first-line ribociclib plus letrozole in elderly patients with HR+, HER2- advanced breast cancer." | 5.27 | Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. ( Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E, 2018) |
| "In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole." | 5.27 | Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. ( Aebi, S; Bernhard, J; Burstein, H; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Gavilá, J; Gelber, RD; Goldhirsch, A; Gombos, A; Graas, MP; Hitre, E; Jerusalem, G; Kamby, C; Karlsson, P; Kuroi, K; Loibl, S; Luo, W; Maibach, R; Marth, C; Müller, B; Neven, P; O'Reilly, S; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Ruhstaller, T; Simoncini, E; Thompson, A; Viale, G, 2018) |
| "Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer." | 5.27 | Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. ( Arteaga, CL; Beck, JT; Cameron, DA; Conte, P; Germa, C; Hart, LL; Hortobagyi, GN; Jakobsen, E; Lindquist, D; Mondal, S; O'Shaughnessy, J; Petrakova, K; Sonke, GS; Souami, F; Villanueva, C, 2018) |
| "A total of 119 postmenopausal women with ER-positive, HER2-negative operable breast cancer were assigned to four months of neoadjuvant letrozole before definitive surgery." | 5.27 | Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG). ( Christiansen, P; Ejlertsen, B; Grundtmann, B; Handler, J; Jensen, MB; Knoop, AS; Laenkholm, AV; Rasmussen, BB; Skriver, SK; Tvedskov, TF, 2018) |
| "A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients." | 5.27 | Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study. ( Anan, K; Doihara, H; Fujisawa, T; Ikeda, T; Jinno, H; Kanbayashi, C; Kimura, M; Komaki, K; Kusama, M; Mitsuyama, S; Miyauchi, K; Sano, M; Sato, N; Shien, T; Yanagita, Y, 2018) |
| "Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence." | 5.27 | Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( Ejlertsen, B; Giobbie-Hurder, A; Iversen, BR; Jensen, MB; Kirkegaard, T; Lykkesfeldt, AE; Rasmussen, BB; Reiter, BE, 2018) |
| "In this prospective, open-label phase II study, postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative early-stage breast cancer received neoadjuvant letrozole (LET) for one month, followed by treatment with a single dose of zoledronic acid." | 5.27 | Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer. ( Gondo, N; Hamazaki, Y; Ikeda, T; Kanao, S; Masuda, N; Minato, N; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Toi, M; Uozumi, R; Yamagami, K; Yamauchi, A, 2018) |
| "17R was a Canadian Cancer Trials Group-led phase III randomized controlled trial comparing letrozole to placebo after 5 years of aromatase inhibitor as adjuvant therapy for hormone receptor-positive breast cancer." | 5.27 | Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. ( Brundage, MD; Celano, P; Goss, PE; Gralow, J; Ingle, JN; Lemieux, J; Muss, H; Parulekar, WR; Pritchard, KI; Strasser-Weippl, K; Tu, D; Whelan, K; Whelan, TJ, 2018) |
| "This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) with or without visceral metastases." | 5.27 | Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. ( Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC, 2018) |
| "This single-arm, open-label, phase II study in 42 Japanese postmenopausal patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer evaluated the efficacy, safety, and pharmacokinetics of first-line palbociclib (125 mg once daily, 3 weeks on/1 week off) coadministered with letrozole (2." | 5.27 | Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study. ( Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Muramatsu, Y; Nagasawa, T; Nishimura, R; Ohno, S; Takahashi, M; Toi, M; Umeyama, Y, 2018) |
| " The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone)." | 5.27 | Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. ( Bartlett, CHUANG; Bhattacharyya, H; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Harbeck, N; Iyer, S; Johnston, S; Lu, DR; Martin, M; Mori, A; Neven, P; Rugo, HS; Shparyk, Y; Slamon, DJ, 2018) |
| "The phase 3 MONALEESA-2 study demonstrated that addition of ribociclib (RIB) to letrozole (LET) significantly improved progression-free survival (PFS) in patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)." | 5.27 | First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial. ( Alba, E; Auñón, PZ; Bachelot, T; Beck, TJ; Campone, M; Diab, S; Esteva, FJ; Gil-Gil, M; Janni, W; Kral, Z; Lopez, R; Miller, M; Pluard, TJ; Richards, P; Ryvo, L; Sutradhar, S; Tsai, M; Ward, P, 2018) |
| "Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole." | 5.27 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. ( Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C, 2018) |
| "5 or 5 years of extended letrozole, after completing 5 years of endocrine therapy for hormone receptor-positive early breast cancer." | 5.27 | Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer. ( Blok, EJ; Duijm-de Carpentier, M; Kroep, JR; Liefers, GJ; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Rutgers, EJT; Seynaeve, CM; van de Velde, CJH, 2018) |
| "Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treated with first-line ribociclib plus letrozole." | 5.27 | Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. ( Alba, E; Burris, HA; Campone, M; Chandiwana, D; Dalal, AA; Janni, W; Monaco, M; O'Shaughnessy, J; Sutradhar, S; Verma, S, 2018) |
| "The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer." | 5.27 | Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ( Arteaga, CL; Blackwell, KL; Burris, HA; Cameron, DA; Campone, M; Conte, P; Elmeliegy, M; Germa, C; Hortobagyi, GN; Janni, W; Miller, M; Mondal, S; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Stemmer, SM; Su, F; Verma, S; Winer, EP; Yap, YS, 2018) |
| "UMIN000001331 Phase II study of neoadjuvant letrozole combined with low-dose metronomic cyclophosphamide for postmenopausal women with endocrine-responsive breast cancer (JBCRG-07)." | 5.27 | A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. ( Akiyama, F; Kamigaki, S; Kurosumi, M; Masuda, N; Mikami, Y; Morimoto, T; Morita, S; Tanaka, S; Toi, M; Tsuda, H; Ueno, T, 2018) |
| "In hormone receptor-positive advanced breast cancer, a progression-free survival benefit was reported with addition of bevacizumab to first-line letrozole." | 5.27 | Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. ( Ballman, KV; Barry, W; Cohen, HJ; Dickler, MN; Hahn, OM; Hudis, CA; Hurria, A; Jatoi, A; Lafky, JM; Li, D; McCall, LM; Muss, HB; Schneider, B; Tripathy, D; Winer, EP, 2018) |
| "In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer." | 5.27 | Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. ( Babu, KG; Bardia, A; Campos-Gomez, S; Carlson, G; Chow, L; Colleoni, M; De Laurentiis, M; Diaz-Padilla, I; El-Saghir, N; Franke, F; Germa, C; Harbeck, N; Hirawat, S; Hughes, G; Hurvitz, SA; Im, SA; Im, YH; Jung, KH; Kuemmel, S; Lee, KS; Liu, MC; Lu, YS; Sohn, J; Tripathy, D; Villanueva Vazquez, R; Wheatley-Price, P, 2018) |
| "This phase Ib study (NCT00960960) evaluated pictilisib (GDC-0941; pan-phosphatidylinositol 3-kinase inhibitor) plus paclitaxel, with and without bevacizumab or trastuzumab, or in combination with letrozole, in patients with locally recurrent or metastatic breast cancer." | 5.27 | A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. ( Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E, 2018) |
| " Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2." | 5.27 | Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. ( Callens, C; Canon, JL; Cottu, P; D'Hondt, V; Dalenc, F; Delaloge, S; Desmoulins, I; Duhoux, FP; Dureau, S; Ferrero, JM; Frenel, JS; Gentien, D; Grenier, J; Heudel, PE; Jouannaud, C; Lemonnier, J; Lerebours, F; Levy, C; Mouret-Reynier, MA; Nguyen, S; Venat-Bouvet, L; Vincent-Salomon, A, 2018) |
| "The PARP inhibitor olaparib is efficacious as monotherapy and has potential application in combination with endocrine therapy for the treatment of breast cancer." | 5.27 | Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours. ( Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM, 2018) |
| "Post-menopausal women enrolled on a prospective trial initiating AI therapy for early-stage breast cancer were randomized to exemestane or letrozole." | 5.24 | Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. ( Flockhart, DA; Hayes, DF; Henry, NL; Kadakia, KC; Kidwell, KM; Otte, JL; Seewald, NJ; Snyder, CF; Stearns, V; Storniolo, AM, 2017) |
| "AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group's trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs)." | 5.24 | Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98. ( Alkner, S; Bendahl, PO; Fernö, M; Jensen, MB; Mouridsen, H; Rasmussen, BB; Rydén, L, 2017) |
| "Women with stage I-III breast cancer starting adjuvant letrozole and 25(OH)D level ≤40 ng/ml were eligible." | 5.24 | Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. ( Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; Nydegger, JL; Reddy, PS; Sharma, P; Yeh, HW, 2017) |
| "Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine therapy." | 5.24 | MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. ( Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O, 2017) |
| "Forty postmenopausal women with non-metastatic ER-positive, HER2-negative invasive breast cancer with a primary tumor > 2 cm or positive axillary lymph node(s) proved by biopsy will be randomly (1:1) enrolled from Sun Yat-Sen Memorial Hospital to receive neoadjuvant everolimus plus letrozole for 18 weeks or fluorouracil, epirubicin plus cyclophosphamide (FEC) for six cycles before surgery." | 5.24 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. ( Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N, 2017) |
| "In a randomized, multicenter trial of postmenopausal women with early-stage breast cancer starting treatment with letrozole (n = 241) or exemestane (n = 228), plasma estrogen concentrations at baseline and after 3 months were quantitated using a sensitive mass spectrometry-based assay." | 5.24 | Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. ( Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Hertz, D; Li, L; Nguyen, AT; Rae, JM; Robarge, JD; Skaar, TC; Stearns, V; Storniolo, AM, 2017) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "A STEPP analysis was used to explore patterns of absolute and relative treatment effects for varying levels of a breast cancer biomarker, Ki-67, in the phase III Breast International Group 1-98 randomized clinical trial, comparing letrozole to tamoxifen as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer." | 5.22 | Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP. ( Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA; Yip, WK, 2016) |
| "Post-menopausal patients with stage I-II breast cancer (n = 150) were enrolled and assigned to either concurrent (arm A) or sequential radiotherapy (RT)-letrozole (arm B)." | 5.22 | Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial. ( Azria, D; Bourgier, C; Crompton, N; Fenoglietto, P; Gourgou, S; Gutowski, M; Kerns, S; Lacombe, J; Lemanski, C; Ozsahin, M; Pèlegrin, A; Romieu, G; Rosenstein, B, 2016) |
| "This randomised open label phase III trial recruited postmenopausal women from 29 Australian and New Zealand sites, with hormone receptor-positive early breast cancer, who had completed ≥4 years of endocrine therapy [aromatase inhibitor (AI), tamoxifen, ovarian suppression, or sequential combination] ≥1 year prior, to oral letrozole 2." | 5.22 | Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. ( Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N, 2016) |
| "Women age 40 to 49 with estrogen receptor-positive breast cancer who had ceased menstruating with adjuvant cyclophosphamide-based chemotherapy, had postmenopausal serum estradiol (E2), and had received tamoxifen for ≥ 1 year were treated with letrozole (2." | 5.22 | Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole. ( Asmar, L; Collea, RP; Diggikar, SM; Fox, PS; Hellerstedt, BA; Holmes, FA; Krekow, LK; O'Shaughnessy, J; Papish, S; Peck, SR; Reddy, PK; Resta, R; Vukelja, SJ; Wang, Y, 2016) |
| "Background Palbociclib is a recently approved drug for use in combination with letrozole as initial endocrine-based therapy for the treatment of postmenopausal women with advanced estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer." | 5.22 | Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment. ( Bell, T; Bhattacharyya, H; Crown, JP; Finn, RS; Huang Bartlett, C; Huang, X; Kim, S; Lang, I; Randolph, S; Slamon, D; Zanotti, G, 2016) |
| "To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line letrozole as treatment of hormone receptor-positive metastatic breast cancer (MBC)." | 5.22 | Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). ( Barry, WT; Carey, LA; Cirrincione, CT; Dickler, MN; Ellis, MJ; Hahn, O; Hudis, CA; Hurria, A; Innocenti, F; Lake, DE; Moynahan, ME; Rugo, HS; Schneider, BP; Tripathy, D; Winer, EP, 2016) |
| "The BIG 1-98 trial is a double-blind trial that randomly assigned 6,193 postmenopausal women with hormone receptor-positive early breast cancer in the four-arm option to 5 years of tamoxifen (Tam), letrozole (Let), or the agents in sequence (Let-Tam, Tam-Let)." | 5.22 | Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. ( Chirgwin, JH; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B, 2016) |
| "Vitamin D3 supplementation significantly improved serum 25-hydroxy vitamin D concentrations and decreased letrozole-induced arthralgia." | 5.22 | Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole. ( Ananthanarayanan, PH; Arul Vijaya Vani, S; Harichandrakumar, KT; Kadambari, D; Nandeesha, H; Niranjjan, R, 2016) |
| "3 years, there were 165 events involving disease recurrence or the occurrence of contralateral breast cancer (67 with letrozole and 98 with placebo) and 200 deaths (100 in each group)." | 5.22 | Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. ( Beck, JT; Gelmon, K; Goss, PE; Gralow, J; Hudis, C; Ingle, JN; Kaur, JS; Muss, H; Parulekar, WR; Pritchard, KI; Robert, NJ; Rubin, S; Stopeck, A; Strasser-Weippl, K; Sturtz, K; Tu, D; Whelan, K; Whelan, T; Winer, E; Wolff, AC, 2016) |
| " In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival (PFS) compared with letrozole alone as first-line treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer (20." | 5.22 | Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. ( Bartlett, CH; Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Huang, X; Kim, ST; Lang, I; Nadanaciva, S; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Schnell, P; Slamon, DJ, 2016) |
| "Neo-ALL-IN (NCT 01275859) is a single-center, phase II study aimed to evaluate the efficacy and safety profiles of neoadjuvant letrozole plus lapatinib, as well as potential biomarkers, in postmenopausal women with ER- and HER2-positive (ER+HER2+) breast cancer." | 5.22 | Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne ( Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH, 2016) |
| "In this randomized, placebo-controlled, phase 3 trial, we evaluated the efficacy and safety of the selective CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative recurrent or metastatic breast cancer who had not received previous systemic therapy for advanced disease." | 5.22 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. ( Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D, 2016) |
| "A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer." | 5.22 | Palbociclib and Letrozole in Advanced Breast Cancer. ( Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Harbeck, N; Im, SA; Jones, S; Lipatov, ON; Lu, DR; Martin, M; Moulder, S; Randolph, S; Rugo, HS; Slamon, DJ; Walshe, JM, 2016) |
| "The addition of palbociclib to letrozole in this phase 2 study significantly improved progression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast cancer." | 5.20 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. ( Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Fowst, C; Huang, X; Kim, ST; Kulyk, SO; Lang, I; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Shparyk, Y; Slamon, DJ; Thummala, AR; Voytko, NL, 2015) |
| "A multicenter, randomized, open-label, phase III, binational (Spain and Germany) study added bevacizumab (15 mg/kg every 3 weeks) to ET (ET-B; letrozole or fulvestrant) as first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -negative and hormone receptor-positive advanced breast cancer." | 5.20 | Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. ( Aktas, B; Anton, A; Carrasco, E; De la Haba-Rodriguez, JR; Garcia-Saenz, JÁ; Gil, M; Guerrero, A; Liedtke, C; Loibl, S; Margeli, M; Martín, M; Martinez, N; Mehta, K; Morales, S; Muñoz, M; Ramos, M; Schoenegg, W; von Minckwitz, G; Wachsmann, G, 2015) |
| "A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront (274 patients) or delayed (277 patients) ZA at a dose of 4 mg intravenously every 6 months." | 5.20 | 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. ( Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND, 2015) |
| "A total of 107 women with T2-4 N0-1 and estrogen receptor-positive breast cancer were randomly assigned to 6 months of primary letrozole (2." | 5.20 | Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response. ( Aguggini, S; Allevi, G; Ardine, M; Bedussi, F; Berruti, A; Bertoni, R; Bottini, A; Brugnoli, G; Cappelletti, MR; Ferrero, G; Forti, M; Fox, SB; Generali, D; Harris, AL; Milani, M; Strina, C; Vailati, ME; Zanotti, L, 2015) |
| " This phase III open-label study compared the impact of tamoxifen and AI on verbal episodic memory (Rey auditory verbal learning test-RAVLT) and other cognitive functions (visual memory, psychomotor speed, and executive functions) after 6 and 12 months of treatment in breast cancer patients undergoing adjuvant hormonotherapy." | 5.20 | A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. ( Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E, 2015) |
| "This phase I/II dose-escalation study evaluated the efficacy, safety, and pharmacokinetics of pilaralisib (SAR245408), a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, or voxtalisib (SAR245409), a PI3K and mammalian target of rapamycin inhibitor, in combination with letrozole in hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative, non-steroidal aromatase inhibitor-refractory, recurrent or metastatic breast cancer." | 5.20 | Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. ( Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM, 2015) |
| "The objective of this prospectively randomized phase II trial (Trial registration: EUCTR2004-004007-37-DE) was to compare the clinical response of primary breast cancer patients to neoadjuvant therapy with letrozole alone (LET) or letrozole and zoledronic acid (LET + ZOL)." | 5.19 | FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. ( Baier, M; Beckmann, MW; Berghorn, M; Fasching, PA; Grab, D; Hanf, V; Hauschild, M; Jud, SM; Kahlert, S; Kreienberg, R; Krocker, J; Kühn, T; Kümmel, S; Lux, MP; Müller, T; Muth, M; Paepke, S; Schulz-Wendtland, R; Schütte, M; Stickeler, E; Wackwitz, B; Warm, M; Wolf, C, 2014) |
| "The aim of this multicenter, prospective, longitudinal phase IV study was to establish the optimal duration of neoadjuvant letrozole that would allow breast conservation surgery (BCS) in patients with early breast cancer who were initially unsuitable." | 5.19 | Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. ( Andrews, C; Carpenter, R; Cordiner, C; Doughty, JC; Ellis, G; Gandhi, A; Gui, G; Moss, N; Skene, AI; Wilson, C, 2014) |
| "This is a randomized, double-blind, placebo-controlled study aimed to evaluate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/human epidermal growth factor receptor 2 (HER2) -negative operable breast cancer." | 5.19 | Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. ( Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E, 2014) |
| "This study will provide direct evidence of the anti-tumor effect of metformin in non-diabetic, postmenopausal patients with ER-positive breast cancer." | 5.19 | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). ( Ahn, SH; Chae, BJ; Choi, SY; Han, S; Han, W; Jeong, J; Jeong, SS; Jung, SY; Jung, Y; Kang, E; Kang, HS; Kang, T; Kim, EK; Kim, J; Kim, KS; Kim, LS; Kim, MK; Kim, SI; Kim, SW; Kim, TH; Lee, JE; Lim, W; Moon, HG; Nam, SJ; Noh, DY; Paik, NS; Park, CH; Yoo, YB; Yoon, JH; Yu, JH, 2014) |
| "Buparlisib, an oral reversible inhibitor of all class I phosphoinositide-3-kinases, has shown antitumoral activity against estrogen receptor (ER)-positive breast cancer cell lines and xenografts, alone and with endocrine therapy." | 5.19 | Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. ( Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT, 2014) |
| " Women receiving adjuvant letrozole for T1-3N0-3M0 breast cancer with a body mass index (BMI) ≥ 24 kg/m(2) were eligible." | 5.19 | Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. ( Blackburn, GL; Findlay, B; Goodwin, PJ; Gralow, JR; Levine, M; Ligibel, JA; Mukherjee, S; Pond, GR; Pritchard, KI; Robidoux, A; Segal, RJ; Vallis, M, 2014) |
| "In premenopausal women with breast cancer, standard adjuvant endocrine therapy has been 5 years of tamoxifen." | 5.19 | Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen. ( Barry, W; Block, CC; Borges, V; DeSantis, SD; Guo, H; Partridge, AH; Ruddy, KJ; Winer, EP, 2014) |
| " Zoledronic acid will be administered once during preoperative hormonal therapy with letrozole for 24 weeks in postmenopausal women with Estrogen Receptor (ER)-positive , Human Epidermal Growth Factor Receptor 2 (HER2)-negative, clinical T1 or T2 N0M0 breast cancer." | 5.19 | Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol. ( Ikeda, T; Minato, N; Shimizu, A; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Teramukai, S; Toi, M; Yoshimura, K, 2014) |
| " We prospectively evaluated reasons for treatment discontinuation in women with hormone receptor-positive breast cancer initiating adjuvant AI through a multicenter, prospective, randomized clinical trial of exemestane versus letrozole." | 5.17 | Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. ( Carpenter, JS; Dantzer, J; Desta, Z; Flockhart, DA; Gersch, C; Hayes, DF; Henry, NL; Kidwell, K; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM, 2013) |
| "5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response." | 5.17 | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. ( Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bonardi, S; Bottini, A; Cappelletti, MR; Foroni, C; Fox, SB; Generali, D; Giardini, R; Gussago, F; Harris, AL; Martinotti, M; Milani, M; Strina, C; Zanoni, V, 2013) |
| "This trial evaluated the effect of adding lapatinib to letrozole after clinical resistance to aromatase inhibitor (IA) treatment in hormone receptor-positive metastatic breast cancer." | 5.17 | Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06. ( Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT, 2013) |
| "Postmenopausal women with breast cancer who were initiating adjuvant AI therapy were enrolled onto a multicentre, randomised clinical trial of exemestane vs letrozole, designed to identify associations between AI-induced change in MPD and single-nucleotide polymorphisms in candidate genes." | 5.17 | Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. ( Chan, HP; Dantzer, J; Desta, Z; Flockhart, DA; Goswami, CP; Hadjiiski, L; Hayes, DF; Helvie, MA; Henry, NL; Khouri, N; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Pinsky, R; Rae, JM; Robarge, J; Skaar, TC; Stearns, V; Storniolo, AM; Zhou, C, 2013) |
| "Adding temsirolimus to letrozole did not improve PFS as first-line therapy in patients with AI-naive advanced breast cancer." | 5.17 | Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. ( Berkenblit, A; Bondarenko, I; Brincat, S; Chan, A; Chow, L; Cincotta, M; Fumoleau, P; Garin, AM; Guimaraes, RC; Hachemi, S; Hayes, DF; Kang, LL; Krygowski, M; Lazar, AA; Moore, L; Neskovic-Konstantinovic, Z; Strahs, A; Sun, Y; Wolff, AC, 2013) |
| "The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC)." | 5.16 | Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. ( Azim, HA; Barsoum, M; Baumgärtner, AK; Beckmann, MW; Fasching, PA; Harbeck, N; Huober, J; Kubista, E; May, C; Nimmrich, I; Paepke, S; Petruzelka, L; Ragosch, V; Reimer, T; Thomssen, C; Wallwiener, D, 2012) |
| "Letrozole is a proven and effective adjuvant therapy in postmenopausal women with hormone receptor-positive (HR(+)) early breast cancer (EBC)." | 5.16 | Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. ( Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP, 2012) |
| "17 trial showed that letrozole was significantly better than placebo in disease-free survival (DFS) for postmenopausal women with hormone receptor-positive breast cancer following about 5 years of tamoxifen therapy." | 5.16 | Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. ( Goss, PE; Jin, H; Shepherd, LE; Tu, D; Zhao, N, 2012) |
| "Letrozole is superior to tamoxifen in terms of response and breast preservation rates as primary systemic therapy (PST) in postmenopausal women with ER-positive early breast cancer." | 5.16 | Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. ( Buch, E; Carañana, V; Fuster Diana, C; Galán, A; Guerrero, Á; Guillem Porta, V; Llombart-Cussac, A; Rodríguez-Lescure, Á; Ruiz, A, 2012) |
| " The aim of this study was to evaluate an upfront or delayed strategy of bone protection therapy with zoledronic acid administered at 4 mg every 6 months in postmenopausal Japanese women with early breast cancer to compare with results of the Z-FAST and ZO-FAST studies in western countries." | 5.16 | Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. ( Fukunaga, M; Horiguchi, J; Hozumi, Y; Ishikawa, T; Iwase, T; Kohno, N; Nakamura, S; Noguchi, S; Taguchi, T; Takahashi, M; Takahashi, S, 2012) |
| "Women with early-stage breast cancer initiating AI therapy were enrolled onto a multicenter, prospective, open-label randomized trial of exemestane versus letrozole." | 5.16 | Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. ( Azzouz, F; Desta, Z; Flockhart, DA; Hayden, J; Hayes, DF; Henry, NL; Lemler, S; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Tarpinian, K; Yakim, E, 2012) |
| "We obtained tumor tissues and isolated DNA from 4861 of 8010 postmenopausal women with hormone receptor-positive breast cancer who enrolled in the randomized, phase III double-blind Breast International Group (BIG) 1-98 trial between March 1998 and May 2003 and received tamoxifen and/or letrozole treatment." | 5.16 | CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. ( Biasi, MO; Bouzyk, M; Coates, AS; Debled, M; Dell'orto, P; Ditzel, HJ; Gelber, RD; Goldhirsch, A; Kammler, R; Leyland-Jones, B; Lyng, MB; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Tang, W; Thürlimann, B; Viale, G, 2012) |
| "A phase 3 trial comparing tamoxifen, letrozole or letrozole+zoledronic acid in patients with hormone receptor-positive early breast cancer was conducted; triptorelin was given to premenopausal patients." | 5.16 | Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study. ( Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V, 2012) |
| "To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8." | 5.16 | Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. ( Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B, 2012) |
| "Among postmenopausal women with endocrine-responsive breast cancer, the aromatase inhibitor letrozole, when compared with tamoxifen, has been shown to significantly improve disease-free survival (DFS) and time to distant recurrence (TDR)." | 5.15 | Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. ( Chirgwin, J; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, R; Pienkowski, T; Price, KN; Regan, MM; Smith, I; Thürlimann, B; Wardley, A, 2011) |
| "On average, aromatase inhibitors are better than tamoxifen when used as initial or sequential therapy for postmenopausal women with endocrine-responsive early breast cancer." | 5.15 | Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. ( Coates, AS; Colleoni, M; Dell'Orto, P; Forbes, JF; Gelber, RD; Goldhirsch, A; Gusterson, BA; Láng, I; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G, 2011) |
| "Three hundred seventy-seven postmenopausal women with clinical stage II to III ER-positive (Allred score 6-8) breast cancer were randomly assigned to receive neoadjuvant exemestane, letrozole, or anastrozole." | 5.15 | Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int ( Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA, 2011) |
| "Compare first-line lapatinib plus letrozole (L + Let) versus letrozole monotherapy (Let) in hormone-receptor-positive HER2 + metastatic breast cancer, employing Q-TWiST (quality-adjusted time without symptoms and toxicity) analysis to account for differences in progression times, with offsets for the impact of adverse events during the treatment period." | 5.15 | Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. ( Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B, 2011) |
| "BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other." | 5.15 | Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. ( Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A, 2011) |
| "The addition of ZOL to letrozole was safe and efficacious in maintaining LS BMD in postmenopausal patients with hormone receptor-positive breast cancer and who were receiving letrozole following 2." | 5.15 | The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial. ( Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I, 2011) |
| "Two hundred seventy postmenopausal women with operable ER-positive breast cancer were randomly assigned to receive 4 months of neoadjuvant treatment with letrozole (2." | 5.14 | Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. ( Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P, 2009) |
| "PURPOSE We compared the endocrine effects of 6 and 12 months of adjuvant letrozole versus tamoxifen in postmenopausal patients with hormone-responsive early breast cancer within an ongoing phase III trial." | 5.14 | Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. ( Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E, 2009) |
| "In this multicenter study, postmenopausal women with early hormone receptor-positive breast cancer receiving adjuvant letrozole were randomized to receive up-front or delayed-start zoledronic acid (ZA; 4 mg intravenously every 6 months) for 5 years." | 5.14 | Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. ( Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM, 2009) |
| "To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial." | 5.14 | Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. ( Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B, 2009) |
| "One hundred fifteen postmenopausal women with >2 cm, estrogen receptor (ER) or progesterone receptor (PgR)-positive breast cancer were enrolled in a trial of 16 to 24 weeks of letrozole 2." | 5.14 | Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. ( Bae, K; Budd, GT; Carey, LA; Commean, P; Ellis, MJ; Esserman, LJ; Fleming, GF; Giuntoli, T; Harris, LA; Leight, GS; Luo, J; Marcom, PK; Olson, JA, 2009) |
| "Aromatase inhibitors provide superior disease control when compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer." | 5.14 | Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. ( Gelber, RD; Giobbie-Hurder, A; Price, KN, 2009) |
| "Primary tumor material was retrospectively collected from 88 patients who participated in a randomized clinical trial comparing the AI letrozole to the anti-estrogen tamoxifen for first-line treatment of advanced breast cancer." | 5.14 | In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer. ( Ejlertsen, B; Evans, DB; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB; Sasano, H, 2009) |
| "The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer." | 5.14 | Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. ( Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B, 2009) |
| "The BIG 1-98 study update with median follow up of 76 months confirms a significant reduction in the risk of breast cancer recurrence and a trend towards improved overall survival with letrozole as compared to tamoxifen, and no unexpected safety concerns with letrozole." | 5.14 | Update of the BIG 1-98 Trial: where do we stand? ( Joerger, M; Thürlimann, B, 2009) |
| " Letrozole, an Investigation of Quality Of Life and Tolerability) was a prospective, open-label, randomized pharmacodynamic study designed to assess the effects of aromatase inhibitors (AIs) on bone turnover in healthy postmenopausal women with estrogen receptor-positive breast cancer." | 5.14 | A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. ( Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O, 2010) |
| "Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD." | 5.14 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. ( Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA, 2010) |
| "Letrozole radiosensitises breast cancer cells in vitro." | 5.14 | Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. ( Azria, D; Belkacemi, Y; Coelho, M; Crompton, NE; Fenoglietto, P; Gourgou, S; Gutowski, M; Lemanski, C; Moscardo, CL; Ozsahin, M; Romieu, G; Rosenstein, B; Zaman, K, 2010) |
| "To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC)." | 5.14 | Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. ( Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS, 2010) |
| "Goserelin and letrozole in premenopausal patients can result in clinical outcomes comparable to those obtained by letrozole alone in postmenopausal patients with metastatic breast cancer (MBC)." | 5.14 | Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. ( Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J, 2010) |
| "Postmenopausal women with large primary oestrogen-receptor (ER)-rich breast cancers were treated neoadjuvantly with letrozole (2." | 5.14 | Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. ( Larionov, A; Miller, WR, 2010) |
| " We designed a pilot study to assess the feasibility and short-term efficacy of neoadjuvant letrozole and bevacizumab (anti-VEGF) in postmenopausal women with stage II and III estrogen receptor/progesterone receptor-positive breast cancer." | 5.14 | Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer. ( Bernreuter, WK; Bland, KI; Carpenter, JT; Caterinicchia, V; De Los Santos, JF; Falkson, CI; Forero-Torres, A; Galleshaw, JA; Jones, CF; Krontiras, H; Li, Y; LoBuglio, AF; Meredith, RF; Nabell, LM; O'Malley, JP; Percent, IJ; Saleh, MN; Shah, JJ; Urist, MM, 2010) |
| "A phase III trial compared lapatinib plus letrozole (L + Let) with letrozole plus placebo (Let) as first-line therapy for hormone receptor (HR)(+) metastatic breast cancer (MBC) patients." | 5.14 | Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib. ( Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B, 2010) |
| "The interim (12-month) results of two similarly designed, ongoing studies (the Zometa-Femara Adjuvant Synergy Trials [Z-FAST and ZO-FAST]) suggest that zoledronic acid (4 mg intravenously every 6 months) when initiated with adjuvant letrozole increases bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal women with early-stage breast cancer compared with patients who receive zoledronic acid only when bone loss became clinically significant or a fragility fracture occurred." | 5.13 | Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. ( Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N, 2008) |
| "To evaluate the influence of the third-generation aromatase inhibitor letrozole (Femara) on breast cancer tissue levels of estrone (E(1)), estradiol (E(2)), and estrone sulfate (E(1)S) in postmenopausal women undergoing primary treatment for locally advanced estrogen receptor/progesterone receptor-positive breast cancers." | 5.13 | Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. ( Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y, 2008) |
| "To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer." | 5.13 | Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. ( Braye, SG; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Knox, F; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Olszewski, WP; Orosz, Z; Price, KN; Regan, MM; Thürlimann, B; Viale, G, 2008) |
| "In the primary core analysis of BIG 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive (HR+) early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced the risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 5.13 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. ( Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O, 2008) |
| "This study assessed the clinical efficacy of the farnesyltransferase inhibitor, tipifarnib, combined with letrozole in patients with advanced breast cancer and disease progression following antiestrogen therapy." | 5.13 | A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. ( Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM, 2008) |
| "To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone." | 5.13 | The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. ( Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U, 2008) |
| "The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer." | 5.13 | Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. ( Altermatt, HJ; Braye, S; Castiglione-Gertsch, M; Coates, AS; Del Curto, B; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Henriksen, KL; Lacroix-Triki, M; Lykkesfeldt, AE; Mastropasqua, MG; Méry, E; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G, 2008) |
| "To compare the endocrine effects of 6 months of adjuvant treatment with letrozole + triptorelin or tamoxifen + triptorelin in premenopausal patients with early breast cancer within an ongoing phase 3 trial (Hormonal Adjuvant Treatment Bone Effects study)." | 5.13 | Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer. ( Botti, G; D'Aiuto, G; D'Aiuto, M; De Maio, E; de Matteis, A; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E, 2008) |
| "Letrozole is safe and effective in postmenopausal women with estrogen receptor-positive early breast cancer, but long-term aromatase inhibitor use may cause bone loss and increase fracture risk." | 5.13 | Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. ( Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G, 2008) |
| "Postmenopausal women with hormone-sensitive breast cancer were given three months of letrozole 2." | 5.13 | Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. ( Chow, LW; Loo, WT; Toi, M; Yip, AY, 2008) |
| "17 trial, conducted by the National Cancer Institute of Canada Clinical Trials Group, 5170 breast cancer patients (median age = 62 years; range = 32-94 years) who were disease free after approximately 5 years of adjuvant tamoxifen treatment were randomly assigned to treatment with letrozole (2583 women) or placebo (2587 women)." | 5.13 | Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. ( Chapman, JA; Goss, PE; Ingle, JN; Meng, D; Muss, HB; Palmer, M; Parulekar, W; Shepherd, L; Yu, C, 2008) |
| "17 randomly assigned 5,187 postmenopausal, hormone-receptor-positive patients with early breast cancer who completed 5 years of tamoxifen to receive either letrozole or placebo." | 5.13 | Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. ( Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ, 2008) |
| "17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of adjuvant tamoxifen in postmenopausal hormone receptor-positive early-stage breast cancer." | 5.13 | Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2008) |
| "Fifty-four postmenopausal women with estrogen receptor-positive breast cancer receiving aromatase inhibitors (AIs) as part of their adjuvant therapy were randomly assigned to receive either 3 months of anastrozole (1 mg) followed by 3 months of letrozole (2." | 5.13 | Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. ( A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O, 2008) |
| "Five hundred twenty-two patients estrogen receptor-positive metastatic breast cancer were randomly assigned to receive first-line hormone therapy with letrozole or tamoxifen." | 5.13 | Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. ( Ali, SM; Brown-Shimer, S; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Gaur, V; Hamer, P; Leitzel, K; Lipton, A; Pierce, K, 2008) |
| "PI3K, phospho-AKT (pAKT) and phospho-mTOR were assessed by immunohistochemistry on tumor specimens collected at baseline and after 6 months of treatment in 113 elderly breast cancer patients consecutively enrolled in a randomized phase II trial of primary letrozole therapy and letrozole associated with metronomic cyclophosphamide." | 5.13 | Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. ( Aguggini, S; Allevi, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Campo, L; Dionisio, R; Dogliotti, L; Fox, SB; Generali, D; Giardini, R; Harris, AL; Milani, M; Vergoni, F, 2008) |
| " The LETLOB study is a European multicenter, placebo-controlled, randomized phase II trial in postmenopausal patients with hormone-sensitive, HER2-negative, stage II-IIIA (T > 2 cm, N0-1, M0) breast cancer, in which letrozole or the combination of letrozole plus lapatinib will be administered for 6 months before surgery." | 5.13 | Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB). ( Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F, 2008) |
| "The addition of palbociclib to endocrine therapy has been shown to improve progression free survival in hormone receptor positive metastatic breast cancer patients." | 5.12 | [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?] ( Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L, 2021) |
| "A 72-year-old woman with metastatic ER/PR-positive breast cancer who had been on ribociclib and letrozole for 1 year developed severe life-threatening colitis." | 5.12 | CDK4/6 inhibitor-induced colitis: a case report and review of the literature. ( Abbas, H; Lim, Z; Malik, AA; Oo, ZM, 2021) |
| "Five years of letrozole therapy appears to be cost effective from the NHS perspective and should be considered in women with early breast cancer, following tamoxifen adjuvant therapy." | 5.12 | Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. ( Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J, 2006) |
| "Sixty-three postmenopausal women with large primary breast cancers were treated with neoadjuvant letrozole (2." | 5.12 | Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. ( Anderson, TJ; Dixon, JM; Miller, WR; Murray, J; Renshaw, L; White, S, 2006) |
| "17 was a double-blind placebo-controlled trial involving 5187 postmenopausal women that established letrozole to be of value in reducing recurrence of breast cancer when given in the extended adjuvant therapy setting after about 5 years of tamoxifen." | 5.12 | Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2006) |
| "Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer." | 5.12 | The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. ( Forbes, JF, 2006) |
| "For patients with hormone-receptor-positive breast cancer, the risk of relapse remains significant even after successfully completing 5 years of adjuvant tamoxifen." | 5.12 | Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. ( Goss, PE, 2006) |
| "To investigate the activity of letrozole plus/minus oral metronomic cyclophosphamide as primary systemic treatment (PST) in elderly breast cancer patients." | 5.12 | Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. ( Aguggini, S; Allevi, G; Bernardi, C; Berruti, A; Bersiga, A; Bodini, G; Bonardi, S; Bottini, A; Brizzi, MP; Bruzzi, P; Dionisio, R; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M; Montruccoli, A, 2006) |
| "Patients with ER+ and/or PgR+ and HER2+ (IHC 2+ or 3+ or FISH+) advanced breast cancer were treated with trastuzumab plus letrozole until disease progression or unacceptable toxicity." | 5.12 | The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. ( Ellis, MJ; Harris, L; Isaacs, C; Kommarreddy, A; Mann, G; Marcom, PK; Novielli, N; Tao, Y; Wong, ZW, 2007) |
| "17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer." | 5.12 | Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. ( Goss, PE; Ingle, JN; Moy, B; Pater, JL; Shepherd, LE; Tu, D; Whelan, TJ, 2006) |
| "Breast density, a strong risk factor for breast cancer, is reduced by the anti-estrogen, tamoxifen (TAM)." | 5.12 | Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. ( Goss, PE; Gottardt, H; Ingle, JN; Olson, JE; Scott, CG; Suman, VJ; Vachon, CM, 2007) |
| "With 1 year of follow-up, results of the primary end point of the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that upfront zoledronic acid therapy prevents bone loss in the LS in postmenopausal women receiving adjuvant letrozole for early-stage breast cancer." | 5.12 | Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. ( Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E, 2007) |
| "Four thousand nine hundred twenty-two of the 8,028 postmenopausal women with receptor-positive early breast cancer randomly assigned (double-blind) to the BIG 1-98 trial were assigned to 5 years of continuous adjuvant therapy with either letrozole or tamoxifen; the remainder of women were assigned to receive the agents in sequence." | 5.12 | Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. ( Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A, 2007) |
| "The objective of this study was to determine if 6 months of the aromatase inhibitor letrozole, administered to postmenopausal women taking a stable dose of hormone replacement remedy, would be safe and would modulate biomarkers of breast cancer risk." | 5.12 | Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. ( Fabian, CJ; Khan, QJ; Kimler, BF; Mayo, MS; Metheny, T; Petroff, BK; Phillips, TA; Simonsen, M; Zalles, CM, 2007) |
| "Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should be given upfront or sequentially with tamoxifen." | 5.12 | Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. ( Castiglione-Gertsch, M; Coates, AS; Debled, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Láng, I; Mauriac, L; Monnier, A; Mouridsen, H; Nogaret, JM; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Viale, G; Wardley, A; Zabaznyi, N, 2007) |
| "Tamoxifen has been a standard first-line endocrine therapy for post-menopausal women with hormone-responsive advanced breast cancer, but more than half of patients fail to respond and time to progression is less than 12 months in responders." | 5.12 | Letrozole in advanced breast cancer: the PO25 trial. ( Mouridsen, HT, 2007) |
| "The aim of the study was to determine the potency of anastrozole to suppress serum E(2) levels in breast cancer patients undergoing COH." | 5.12 | Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. ( Azim, AA; Costantini-Ferrando, M; Lostritto, K; Oktay, K, 2007) |
| "Aromatase inhibitors such as anastrozole and letrozole are highly effective suppressants of estrogen synthesis in postmenopausal women and are the most effective endocrine treatments for hormone receptor positive breast cancer in such women." | 5.12 | Molecular response to aromatase inhibitor treatment in primary breast cancer. ( Ashworth, A; Dexter, T; Dixon, JM; Dowsett, M; Drury, S; Evans, DB; Fenwick, K; Larionov, A; Mackay, A; Miller, WR; Urruticoechea, A; White, S; Young, O, 2007) |
| "Fifty patients with primary breast cancer were treated with 3 months of chemotherapy and 53 with 3 months of neoadjuvant letrozole." | 5.12 | Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring. ( Cameron, DA; Dixon, MJ; Green, RV; Julian, HS; Thomas, JS, 2007) |
| "To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer." | 5.12 | Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. ( Braye, S; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Orosz, Z; Price, KN; Raffoul, J; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G, 2007) |
| "The aim of the study was to identify changes in tumour expression profiling associated with short-term therapy of breast cancer patients with letrozole." | 5.12 | Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Hampton, G; Ho, S; Krause, A; Larionov, AA; Miller, WR; Murray, E; Murray, J; Renshaw, L; Walker, JR; White, S, 2007) |
| "Relapse after completing adjuvant tamoxifen therapy is a persistent threat for women with hormone-responsive breast cancer." | 5.12 | Letrozole in the extended adjuvant setting: MA.17. ( Goss, PE, 2007) |
| "The BIG 1-98 trial is a large, randomized, independently conducted clinical trial designed to compare the efficacy of upfront letrozole versus tamoxifen monotherapy and to compare sequential or up-front use of letrozole and/or tamoxifen as an early adjuvant therapy for patients with early breast cancer." | 5.12 | Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. ( Koeberle, D; Thuerlimann, B, 2007) |
| "Third-generation nonsteroidal aromatase inhibitors (AIs), letrozole and anastrozole, are superior to tamoxifen as initial therapy for early breast cancer but have not been directly compared in a head-to-head adjuvant trial." | 5.12 | A decade of letrozole: FACE. ( O'Shaughnessy, J, 2007) |
| "To compare time to progression (TTP) with a steroidal aromatase inhibitor (AI) atamestane (ATA) combined with toremifene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast cancer (ABC)." | 5.12 | Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. ( Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB, 2007) |
| "Eight thousand twenty-eight postmenopausal women with receptor-positive early breast cancer were randomly assigned (double-blind) between March 1998 and May 2003 to receive 5 years of adjuvant endocrine therapy with letrozole, tamoxifen, or a sequence of these agents." | 5.12 | Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. ( Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B, 2007) |
| "The letrozole study 025 is a large (n = 907), international, double-blind, randomized, phase III trial in postmenopausal women with advanced breast cancer." | 5.11 | Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. ( Becquart, D; Chaudri-Ross, HA; Gershanovich, M; Lang, R; Mouridsen, H; Perez-Carrion, R; Sun, Y, 2004) |
| "To compare the efficacy, in regard to time to progression (TTP) and objective response rate (ORR), of letrozole (Femara; Novartis Pharma AG; Basel Switzerland), an oral aromatase inhibitor, with that of tamoxifen (Tamofen; Leiras OY; Turku, Finland) as first-line therapy in younger (<70 years) and older (>/=70 years) postmenopausal women with advanced breast cancer." | 5.11 | Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. ( Chaudri-Ross, HA; Mouridsen, H, 2004) |
| "The purpose of this study was to evaluate changes in serum lipid parameters {cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and lipoprotein(a) [Lp(a)]}, in postmenopausal women receiving letrozole or placebo after adjuvant tamoxifen for early stage breast cancer (NCIC CTG MA." | 5.11 | The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). ( Deangelis, D; Goss, PE; Heath, M; Ingle, JN; Liu, S; Palmer, MJ; Perez, EA; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM, 2005) |
| "To evaluate the clinical benefit and tolerability of letrozole after tamoxifen failure in locally advanced, recurrent or metastatic breast cancer in postmenopausal patients." | 5.11 | Efficacy of letrozole for advanced breast cancer in postmenopausal patients. ( Ansari, TN; Hussain, I; Mahmood, A; Samad, A, 2005) |
| "Results from a phase III study of postmenopausal women with advanced breast cancer demonstrated longer time to disease progression for patients taking letrozole versus tamoxifen." | 5.11 | Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer. ( Cole, B; Gard, C; Glendenning, GA; Irish, W; Mouridsen, H; Sherrill, B, 2005) |
| "4 months), women in the letrozole arm had statistically significantly better DFS and distant DFS than women in the placebo arm (DFS: hazard ratio [HR] for recurrence or contralateral breast cancer = 0." | 5.11 | Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. ( Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D, 2005) |
| "The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen." | 5.11 | A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ( Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A, 2005) |
| "To compare the efficacy, safety and tolerability of letrozole, an advanced non-steroidal aromatase inhibitor, and fadrozole hydrochloride, an older-generation drug in this class, we conducted a randomised double-blind trial in postmenopausal women with advanced breast cancer." | 5.10 | Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. ( Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T, 2003) |
| "Five hundred sixty-two estrogen receptor-positive metastatic breast cancer patients were randomized to first-line hormone therapy with either letrozole or tamoxifen." | 5.10 | Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. ( Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P, 2003) |
| "To analyze overall survival (OS) and update efficacy data for letrozole versus tamoxifen as first-line therapy in postmenopausal women with locally advanced or metastatic breast cancer." | 5.10 | Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. ( Apffelstaedt, J; Bapsy, PP; Becquart, D; Bhatnagar, A; Boni, C; Chaudri-Ross, H; Dank, M; Gershanovich, M; Jaenicke, F; Lang, R; Monnier, A; Mouridsen, H; Perez-Carrion, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Sun, Y; Wyld, P, 2003) |
| "This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endocrine therapy, usually tamoxifen, and on the estrogen receptor (ER) antagonist fulvestrant ('Faslodex')." | 5.10 | Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. ( Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I, 2003) |
| "We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy." | 5.10 | A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. ( Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D, 2003) |
| "It was previously shown that letrozole (Femara) was significantly more potent than anastrozole (Arimidex) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer." | 5.10 | An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. ( Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O, 2003) |
| "The biological basis for the superior efficacy of neoadjuvant letrozole versus tamoxifen for postmenopausal women with estrogen receptor (ER)-positive locally advanced breast cancer was investigated by analyzing tumor proliferation and expression of estrogen-regulated genes before and after the initiation of therapy." | 5.10 | Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. ( Chaudri-Ross, HA; Coop, A; Ellis, MJ; Evans, DB; Jänicke, F; Llombart-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B; Tao, Y, 2003) |
| "Life table analyses are used to compare the costs and benefits [life years gained and quality-adjusted life years (QALYs) gained] of treating postmenopausal women with advanced breast cancer with first-line letrozole (with the option of second-line tamoxifen) compared with first-line tamoxifen (with the option of second-line letrozole)." | 5.10 | A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. ( Glendenning, A; Johnston, SR; Jones, T; Karnon, J, 2003) |
| "Letrozole, a third generation aromatase inhibitor, has been compared with tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy." | 5.10 | Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. ( Smith, IE, 2003) |
| "Twelve postmenopausal women with estrogen receptor-positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2." | 5.10 | Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. ( Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE, 2002) |
| "To determine the recommended clinical dose of CGS20267 (Letrozole), we conducted a randomized comparative study as a late phase II study (first part) in postmenopausal women with advanced or recurrent breast cancer." | 5.10 | [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]. ( Abe, R; Ikeda, S; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H, 2002) |
| "The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of letrozole on tamoxifen (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus letrozole; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination." | 5.09 | Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. ( Dowsett, M; Ingle, JN; Johnson, PA; Jordan, VC; Krook, JE; Loprinzi, CL; Mailliard, JA; Perez, EA; Suman, VJ; Wheeler, RH, 1999) |
| "This study examined whether the addition of tamoxifen to the treatment regimen of patients with advanced breast cancer being treated with the aromatase inhibitor letrozole led to any pharmacokinetic or pharmacodynamic interaction." | 5.09 | Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. ( Dowsett, M; Gundacker, H; Houston, SJ; Johnston, SR; Miles, DW; Pfister, C; Sioufi, A; Smith, IE; Verbeek, JA, 1999) |
| "The study compares letrozole (Femara and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with anti-estrogens." | 5.09 | [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, Kh; Friedrich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, NO; Reichard, P; Romieu, G, 1999) |
| "To compare the efficacy and tolerability of tamoxifen with that of letrozole, an oral aromatase inhibitor, with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer." | 5.09 | Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. ( Apffelstaedt, J; Bapsy, PP; Becquart, D; Boni, C; Chaudri-Ross, HA; Dank, M; Dugan, M; Gershanovich, M; Jänicke, F; Lassus, M; Monnier, A; Mouridsen, H; Pérez-Carrión, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Staffler, B; Sun, Y; Verbeek, JA, 2001) |
| "Given a favorable tolerability profile, once-daily dosing, and evidence of clinically relevant benefit, letrozole is equivalent to megestrol acetate and should be considered for use as an alternative treatment of advanced breast cancer in postmenopausal women after treatment failure with antiestrogens." | 5.09 | Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. ( Brady, C; Buzdar, A; Davidson, N; Douma, J; Elledge, R; Morgan, M; Nabholtz, J; Porter, L; Smith, R; Xiang, X, 2001) |
| "Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series with letrozole 2." | 5.09 | Letrozole as primary medical therapy for locally advanced and large operable breast cancer. ( Bellamy, CO; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Smith, H, 2001) |
| "Postmenopausal patients with estrogen- and/or progesterone receptor-positive (ER+ and/or PgR+) primary breast cancer ineligible for breast-conserving surgery were randomly assigned to 4 months of neoadjuvant letrozole 2." | 5.09 | Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. ( Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B, 2001) |
| "Letrozole (trademark Femara) is a new orally active, potent and selective aromatase inhibitor for the hormonal treatment of advanced breast cancer in postmenopausal women." | 5.09 | Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. ( De Braud, F; Duval, M; Hornberger, U; Lelli, G; Martoni, A; Pfister, CU; Souppart, C; Zamagni, C, 2001) |
| "Three hundred thirty-seven postmenopausal women with ER and/or PgR positive primary untreated breast cancer were randomly assigned once daily treatment with either letrozole 2." | 5.09 | Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. ( Appfelstaedt, J; Borgs, M; Chaudri-Ross, HA; Dugan, M; Eiermann, W; Ellis, M; Eremin, J; Lassus, M; Llombart-Cussac, A; Mauriac, L; Paepke, S; Vinholes, J, 2001) |
| "In this Phase I trial, 23 heavily pretreated postmenopausal patients with metastatic breast cancer received letrozole at doses ranging from 0." | 5.08 | Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. ( Adlercruetz, H; Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ; Trunet, PF, 1995) |
| "To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated with antiestrogens." | 5.08 | Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. ( Bellmunt, J; Bezwoda, W; Chaudri, HA; Dombernowsky, P; Falkson, G; Fornasiero, A; Gardin, G; Gudgeon, A; Hatschek, T; Hoffmann, W; Hornberger, U; Leonard, R; Michel, J; Morgan, M; Panasci, L; Smith, I; Tjabbes, T; Trunet, PF, 1998) |
| "The study compares letrozole and aminoglutethimide (AG), a standard therapy for postmenopausal women with advanced breast cancer, previously treated with antioestrogens." | 5.08 | Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). ( Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G, 1998) |
| "Fadrozole Hydrochloride (CGS 16949A) and Letrozole (CGS 20267), are two of the newest non-steroidal, orally active aromatase inhibitors currently being evaluated as second line treatment of patients with hormone dependent forms of metastatic breast cancer." | 5.07 | Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. ( Demers, LM, 1994) |
| " Herein, we describe a case of DI-SCLE in association with palbociclib and letrozole treatment for metastatic breast cancer." | 5.05 | Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review. ( Nazarian, RM; Russell-Goldman, E, 2020) |
| "Letrozole is a targeted aromatase inhibitor which has primarily been used in post-menopausal women with breast cancer." | 5.05 | A review of the physiology behind letrozole applications in infertility: are current protocols optimal? ( Brown, SE; Rose, BI, 2020) |
| " Herein, we reported a case of hallucination related to anastrozole in a patient with metastatic breast cancer." | 5.01 | In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. ( Bozkaya, Y; Demirci, NS; Erdem, GU, 2019) |
| "Ultimately, our study established that letrozole plus zoledronic acid may be an optimal treatment based on its current rank in a neoadjuvant setting for HR+ breast cancer." | 5.01 | Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis. ( Dong, S; Feng, F; Qi, L; Sun, C; Tian, J; Wang, X; Yao, Y; Zhang, T; Zhou, C, 2019) |
| "We performed a network meta-analysis to compare the efficacies of fulvestrant and CDK4/6is plus AIs as the first-line treatment of postmenopausal breast cancer patients." | 5.01 | Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis. ( Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y, 2019) |
| "Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had advanced breast cancer and progressed while receiving endocrine therapy." | 4.98 | The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis. ( Chen, L; Ding, W; Li, Z; Ruan, G; Tu, C; Wang, C, 2018) |
| "Palbociclib is the first cyclin-dependent kinase 4/6 inhibitor approved in the United States for HR+/HER2- advanced/metastatic breast cancer, in combination with letrozole as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression following endocrine therapy." | 4.95 | Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. ( Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D, 2017) |
| " It is indicated for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, and in combination with fulvestrant (with or without a luteinizing hormone-releasing hormone agonist) in those previously treated with endocrine therapy." | 4.95 | Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. ( Kim, ES; Scott, LJ, 2017) |
| "A literature search was carried out using PubMed, Medline and ASCO and ESMO annual-meeting abstracts by using the following search keywords; "palbociclib", "abemaciclib", "ribociclib", "cyclin-dependent kinase inhibitors" and "CDK 4/6" in metastatic breast cancer (MBC)." | 4.95 | A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. ( Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B, 2017) |
| "We performed a network meta-analysis for a comprehensive analysis of 6 first-line endocrine monotherapies (letrozole, anastrozole, exemestane, tamoxifen, fulvestrant 250 mg and 500 mg) for HR+ HER2- metastatic or locally advanced breast cancer in postmenopausal patients." | 4.95 | Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. ( He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S, 2017) |
| ", letrozole, have proven successful in reducing the death rate for breast cancer patients whose initial tumors express ERα." | 4.95 | Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. ( Klinge, CM; Muluhngwi, P, 2017) |
| "We conducted a review of randomized trials to compare the overall survival (OS) with fulvestrant 500 mg versus alternative treatment for estrogen receptor-positive advanced breast cancer following endocrine therapy failure." | 4.93 | Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. ( Batson, S; Jones, N; Livings, C; Telford, C, 2016) |
| "RCTs investigating 3 different anticancer strategies in metastatic breast cancer were identified: (1) new hormonal therapy, (2) new targeted therapies in hormone receptor positive tumours (everolimus or palbociclib), and (3) new anti-HER2 therapies." | 4.93 | Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. ( Niraula, S; Ocana, A, 2016) |
| " Palbociclib, in combination with letrozole, was recently approved in the US for the first-line treatment of advanced breast cancer." | 4.91 | Palbociclib: first global approval. ( Dhillon, S, 2015) |
| "In the first-line setting, the phase II PALbociclib: Ongoing trials in the Management of breast cAncer (PALOMA)-1 trial randomized patients to receive letrozole alone or letrozole plus palbociclib 125 mg daily for 3 weeks, followed by 1 week off, as initial therapy for advanced breast cancer." | 4.91 | Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer. ( Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R, 2015) |
| " For instance, palbociclib (PD0332991) is a first-in-class, oral, highly selective inhibitor of CDK4/6 and, in combination with letrozole (Phase II; PALOMA-1) or with fulvestrant (Phase III; PALOMA-3), it has significantly prolonged progression-free survival, in patients with metastatic estrogen receptor-positive, HER2-negative breast cancer, in comparison with that observed in patients using letrozole, or fulvestrant alone, respectively." | 4.91 | Development of cell-cycle checkpoint therapy for solid tumors. ( Tamura, K, 2015) |
| "A PubMed search (1966-July 2014) was conducted using the key terms breast cancer risk reduction, with anastrozole, exemestane, or letrozole, or aromatase inhibitors." | 4.90 | Aromatase inhibitors in breast cancer prevention. ( Olin, JL; St Pierre, M, 2014) |
| " A meta-analysis revealed an advantage for AIs over tamoxifen in the monotherapy setting for recurrence but not breast cancer mortality, and an advantage in both of these parameters for switching to an AI after several years of tamoxifen." | 4.89 | Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. ( Ingle, JN, 2013) |
| "To assess the effects of tamoxifen or letrozole, in addition to standard COS protocols, on the breast cancer-free interval in premenopausal women with ER positive breast cancer who undergo COS for embryo or oocyte cryopreservation." | 4.89 | Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction. ( Balkenende, E; Dahhan, T; Goddijn, M; Linn, S; van Wely, M, 2013) |
| "Third-generation aromatase inhibitors (letrozole, anastrozole) have shown superior efficacy in early and advanced breast cancer compared with tamoxifen." | 4.88 | Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). ( Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R, 2012) |
| "The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer." | 4.87 | Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. ( Gelber, RD; Giobbie-Hurder, A; Price, KN; Regan, MM; Thürlimann, B, 2011) |
| "Third-generation aromatase inhibitors (AIs) have proven to be superior to tamoxifen in terms of time to disease progression in patients with hormone receptor (HR) positive (HR+) status and, nowadays, are used in the adjuvant and neoadjuvant settings, and first-line therapy for advanced breast cancer." | 4.87 | An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. ( Barnadas, A; Estévez, LG; Lluch-Hernández, A; Rodriguez-Lescure, A; Rodriguez-Sanchez, C; Sanchez-Rovira, P, 2011) |
| " Food and Drug Administration converted letrozole (Femara®; Novartis Pharmaceuticals Corporation, East Hanover, NJ) from accelerated to full approval for adjuvant and extended adjuvant (following 5 years of tamoxifen) treatment of postmenopausal women with hormone receptor-positive early breast cancer." | 4.87 | Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval. ( Cohen, MH; Johnson, JR; Justice, R; Pazdur, R, 2011) |
| "Letrozole is a well-tolerated and effective drug in metastatic breast cancer in postmenopausal women." | 4.86 | Letrozole. ( Colleoni, M; Dellapasqua, S, 2010) |
| "To undertake a systematic review of three first-line treatments (letrozole, anastrozole and exemestane) for hormone sensitive advanced or metastatic breast cancer (MBC) in post-menopausal women." | 4.86 | Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. ( Amonkar, MM; Forbes, CA; Kessels, A; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R, 2010) |
| " In a large phase III trial (EGF30008) in 1286 postmenopausal women with hormone receptor (HR)-positive, metastatic breast cancer who had not received previous therapy for advanced or metastatic disease, the primary endpoint of median progression-free survival in a HER2-positive population of 219 women was significantly longer with lapatinib plus letrozole than with letrozole plus placebo (8." | 4.86 | Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. ( Curran, MP, 2010) |
| " Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy." | 4.85 | Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. ( Guarneri, V, 2009) |
| "Extended adjuvant letrozole reduced the risk of recurrence by 42% and the risk of distant metastases by 40%, it was well tolerated compared to placebo; among lymph node-positive patients, overall survival was significantly improved." | 4.84 | Never too late: reducing late breast cancer relapse risk. ( Harbeck, N, 2008) |
| "Third-generation aromatase inhibitors (AIs), including letrozole, are now standard therapy for initial adjuvant endocrine treatment of postmenopausal women with early breast cancer." | 4.84 | Understanding the BIG results: Insights from the BIG 1-98 trial analyses. ( Wardley, AM, 2008) |
| "To establish the clinical and cost-effectiveness of aromatase inhibitors (AIs) anastrozole, letrozole and exemestane compared with tamoxifen in the adjuvant treatment of early oestrogen receptor-positive breast cancer in postmenopausal women." | 4.84 | Hormonal therapies for early breast cancer: systematic review and economic evaluation. ( Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L, 2007) |
| "The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women." | 4.84 | The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. ( Fabian, CJ, 2007) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| " PubMed and MEDLINE were searched for descriptions of clinical trials published from 1990 to 2007 using the terms breast cancer, extended adjuvant, aromatase inhibitor, anastrozole, exemestane, and letrozole." | 4.84 | Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. ( Jahanzeb, M, 2007) |
| "A systematic review was undertaken to review the evidence for the use of third-generation aromatase inhibitors (anastrozole, letrozole and exemestane) as adjuvant therapy for post-menopausal women with early-stage, hormone receptor-positive breast cancer and to develop and support recommendations for their use, with regard to three areas: aromatase inhibitors compared to tamoxifen, aromatase inhibitors in sequence with tamoxifen for a total of five years, and aromatase inhibitors given after five years of tamoxifen therapy." | 4.84 | Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. ( Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M, 2008) |
| "This paper describes the clinical evidence for using the aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, as adjuvant therapy for postmenopausal women with early breast cancer." | 4.84 | Aromatase inhibitors in early breast-cancer treatment: The story so far. ( Cuzick, J, 2008) |
| "The third-generation aromatase inhibitor letrozole offers a promising approach to treating hormone-sensitive breast cancer for postmenopausal women, through potent and specific inhibition of estrogen synthesis." | 4.83 | Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer. ( Koeberle, D; Thuerlimann, B, 2006) |
| " The potent aromatase inhibitor letrozole (Femara) has emerged as a viable alternative to tamoxifen for the treatment of advanced, metastatic breast cancer, as well as in the neoadjuvant and extended adjuvant settings." | 4.83 | The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98. ( Monnier, A, 2006) |
| "Combined application of tamoxifen and radiotherapy improves survival and local control in breast cancer." | 4.83 | [Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment]. ( Fodor, J, 2006) |
| "Letrozole is a highly selective, nonsteroidal, third-generation aromatase inhibitor approved for first-line and extended adjuvant therapy in postmenopausal women with hormone-responsive, early-stage breast cancer." | 4.83 | Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. ( Keam, SJ; Scott, LJ, 2006) |
| "Breast cancer remains a leading cause of cancer death in women worldwide, and the risk for disease recurrence continues despite improvements in screening and treatment and the use of prophylactic estrogen-inhibiting therapies such as tamoxifen." | 4.83 | Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long? ( Kaufmann, M; Rody, A, 2006) |
| "Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive early breast cancer." | 4.83 | Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data. ( Grana, G, 2006) |
| "Letrozole (Femara), an aromatase inhibitor that blocks estrogen synthesis by inhibiting the final step of the estrogen biosynthetic pathway, is approved for use in a wide range of breast cancer settings." | 4.83 | Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. ( Dunn, C; Keam, SJ, 2006) |
| "Therapeutics that interfere with estrogen receptor function (antiestrogens, eg, tamoxifen; aromatase inhibitors, eg, letrozole) have contributed to a dramatic reduction in breast cancer mortality; however, not all estrogen-receptor-positive breast cancers respond." | 4.83 | Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. ( Lane, HA; Lebwohl, D, 2006) |
| "Patients with all stages of primary breast cancer are at continuing risk of relapse following 5 years of adjuvant tamoxifen therapy, even in the absence of lymph node involvement." | 4.83 | Extended adjuvant therapy with letrozole: reducing the risk of recurrence. ( Dixon, JM, 2006) |
| "It is clear that letrozole and anastrozole provide significant benefits for patients with breast cancer." | 4.83 | Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. ( Monnier, A, 2006) |
| "Adjuvant hormonal therapy for patients with endocrine sensitive breast cancer has been dominated for several decades by the gold standard tamoxifen." | 4.83 | The emerging role of aromatase inhibitors in the adjuvant management of breast cancer. ( Gligorov, J; Nabholtz, JM, 2006) |
| " For more than 20 years, standard first-line treatment for postmenopausal women with metastatic breast cancer has been the antiestrogen tamoxifen, a selective estrogen receptor modulator (SERM) with differential effects on breast, endometrial, bone, and vascular tissues." | 4.82 | Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. ( Brodie, AH; Mouridsen, HT, 2003) |
| "Aromatase inhibitors (AIs) have been approved as second-line treatment for estrogen receptor-positive (ER+) metastatic breast cancer after first-line treatment with the selective estrogen receptor modulator (SERM) tamoxifen." | 4.82 | Emerging role of aromatase inhibitors in the adjuvant setting. ( Goss, PE, 2003) |
| "Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy." | 4.82 | A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003) |
| "Six years ago, we reviewed the selective aromatase inhibitors, anastrozole and letrozole, for the treatment of women with breast cancer." | 4.82 | Should aromatase inhibitors replace tamoxifen? ( , 2003) |
| "The latest generation of nonsteroidal aromatase inhibitors (anastrozole and letrozole) has been approved by the US Food and Drug Administration for use in the first- and second-line treatment of postmenopausal women with hormone receptor-positive (or unknown) breast cancer." | 4.82 | Pharmacokinetics of third-generation aromatase inhibitors. ( Lønning, P; Martoni, A; Pfister, C; Zamagni, C, 2003) |
| "Recent advances have been made in the hormonal treatment of breast cancer with the advent of third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane)." | 4.82 | Aromatase inhibitors in breast cancer therapy. ( Buzdar, AU, 2003) |
| " These agents are active against breast cancer in hormone-naïve postmenopausal women and in women who have experienced failure of tamoxifen or failure of tamoxifen plus other hormonal therapy." | 4.82 | Aromatase inhibitors for breast cancer in postmenopausal women. ( Campos, SM, 2004) |
| " Until recently, tamoxifen was the drug of choice for the treatment of hormone-responsive early and advanced breast cancer." | 4.82 | Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? ( Sainsbury, R, 2004) |
| "Letrozole (Femara), a nonsteroidal, third-generation aromatase inhibitor administered orally once daily, has shown efficacy in the treatment of postmenopausal women with early-stage or advanced, hormone-sensitive breast cancer." | 4.82 | Letrozole: a review of its use in postmenopausal women with breast cancer. ( Curran, MP; Perry, CM; Simpson, D, 2004) |
| "Anastrozole, letrozole, and exemestane are the 3 commercially available aromatase inhibitors approved by the US Food and Drug Administration for the treatment of hormone receptor-positive breast cancer in postmenopausal women." | 4.82 | Role of aromatase inhibitors in the treatment of breast cancer. ( Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK, 2004) |
| " These agents have been shown to be more effective than tamoxifen in first-line treatment of oestrogen receptor-positive advanced and metastatic breast cancer." | 4.82 | Aromatase inhibitors and breast cancer: time for a change? ( Fentiman, IS, 2004) |
| " In women with hormone-sensitive breast cancer, three of these agents, letrozole, anastrozole, and exemestane, provide an important alternative endocrine therapy to the antiestrogen tamoxifen, which blocks estrogen activation of the estrogen receptor." | 4.82 | Aromatase inhibitors in advanced breast cancer. ( Mouridsen, HT, 2004) |
| "Five years of tamoxifen is standard adjuvant therapy for hormone-sensitive early breast cancer, but women remain at appreciable risk of recurrence for many years following that therapy, and further tamoxifen does not appear to be beneficial." | 4.82 | Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer. ( Goss, PE, 2004) |
| "Third-generation aromatase inhibitors, letrozole, anastrozole, and exemestane, are active and well tolerated in postmenopausal patients with hormone-sensitive advanced or metastatic breast cancer, as either first- or second-line therapy." | 4.82 | Aromatase inhibitors in early breast cancer therapy. ( Smith, IE, 2004) |
| "Several adjuvant trials evaluating aromatase inhibitors in postmenopausal women with early breast cancer have shown significant improvement upon, or extension of the efficacy benefits of, standard therapy with tamoxifen, and treatments were generally well tolerated." | 4.82 | Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit. ( Henderson, IC, 2004) |
| "The objective of this study is to evaluate the cost-effectiveness of letrozole compared with tamoxifen as first-line therapy in post-menopausal women with advanced breast cancer in Japan." | 4.82 | Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. ( Kondo, M; Miki, S; Ochiai, T; Okubo, I; Toi, M, 2005) |
| "Fulvestrant, a new type of oestrogen receptor antagonist with no agonist effects, is now licensed in the EU and USA for the treatment of postmenopausal women with hormone-sensitive advanced breast cancer following progression on prior antioestrogen therapy." | 4.82 | A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer. ( Dodwell, D; Vergote, I, 2005) |
| "In postmenopausal women with advanced breast cancer, numerous phase III trials have been performed comparing the third-generation non-steroidal aromatase inhibitors (NS-AIs) anastrozole and letrozole and the steroidal AI (S-AI) exemestane in the "first-line" setting against tamoxifen and in the "second-line" setting against megestrol acetate." | 4.82 | Aromatase inhibitors for therapy of advanced breast cancer. ( Ingle, JN; Suman, VJ, 2005) |
| " (1) The presentation of the first results of the study BIG 1-98 -- letrozole as adjuvant, endocrine therapy in postmenopausal women with hormone-sensitive breast cancer -- showed a relative risk reduction in the disease-free survival of 19% when compared to tamoxifen." | 4.82 | [Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)]. ( Senn, HJ; Thürlimann, B, 2005) |
| "Because of its proven efficacy profile based on long-term data, tamoxifen has been the standard adjuvant endocrine therapy for hormone-sensitive early breast cancer for the past 30 years." | 4.82 | Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women. ( Gradishar, WJ, 2005) |
| "New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC)." | 4.82 | New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E, 2005) |
| "The third-generation aromatase inhibitors, letrozole, anastrozole, and exemestane, have been shown to be effective both as alternatives to tamoxifen in first-line treatment of hormone-sensitive advanced breast cancer in postmenopausal women and following failure of first-line tamoxifen for endocrine therapy." | 4.82 | Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. ( Mouridsen, HT; Robert, NJ, 2005) |
| "Letrozole, a third-generation aromatase inhibitor, has been the only aromatase inhibitor to date to show unequivocal superiority to tamoxifen as first-line treatment of metastatic postmenopausal breast cancer." | 4.81 | Letrozole for the management of breast cancer. ( Goss, PE; Smith, RE, 2002) |
| "Third-generation aromatase inhibitors (anastrozole, letrozole, and exemestane) have emerged as an alternative first-line endocrine treatment for postmenopausal breast cancer patients with hormone-responsive disease." | 4.81 | Recent advances in aromatase inhibitor therapy for breast cancer. ( Assikis, VJ; Buzdar, A, 2002) |
| "Anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) are members of the third generation of aromatase inhibitors that has now replaced aminoglutethimide (Cytadren), the progestins, and tamoxifen (Nolvadex) as the hormonal therapy of choice in estrogen-receptor-positive, postmenopausal, metastatic breast cancer." | 4.81 | Nonsteroidal and steroidal aromatase inhibitors in breast cancer. ( Hamilton, A; Volm, M, 2001) |
| "Tamoxifen is the standard first-line therapy for advanced breast cancer." | 4.81 | Role of anti-aromatase agents in postmenopausal advanced breast cancer. ( Murray, R, 2001) |
| "The new generation of selective aromatase inhibitors (anastrozole, letrozole and exemestane) offer a significant efficacy and safety advantage over both older agents in this class (aminoglutethimide) and the progestins (megestrol acetate (MA)), as second-line treatment for postmenopausal women with advanced hormone-dependent breast cancer who have failed on tamoxifen therapy." | 4.81 | A summary of second-line randomized studies of aromatase inhibitors. ( Buzdar, AU, 2001) |
| "With recent results showing letrozole and anastrozole to be superior to tamoxifen as initial therapy for advanced disease, the aromatase inhibitors are poised to establish their place in the adjuvant therapy of postmenopausal receptor-positive breast cancer." | 4.81 | Preliminary data from ongoing adjuvant aromatase inhibitor trials. ( Goss, PE, 2001) |
| "During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion." | 4.81 | [Antiestrogen therapy in the treatment of breast neoplasms]. ( Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G, 2002) |
| "5 mg/d) against megestrol acetate and aminoglutethimide, respectively, in patients with locally advanced or metastatic breast cancer." | 4.80 | Pivotal trials of letrozole: a new aromatase inhibitor. ( Smith, IE, 1998) |
| "Three new aromatase inhibitors have recently completed phase III evaluation as treatment of metastatic breast cancer in post-menopausal women whose disease has progressed despite tamoxifen therapy: anastrozole (ARIMIDEX, Zeneca), letrozole (FEMARA, Novartis) and vorozole (RIVIZOR, Janssen)." | 4.80 | The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. ( Hamilton, A; Piccart, M, 1999) |
| "Aromatase inhibitors used in breast cancer, are drugs that inhibit the transformation of androstenedione and testosterone, respectively in estradiol and estrone." | 4.80 | [Aromatase inhibitors]. ( Bonneterre, J; Feutrie, ML, 1999) |
| "In patients with metastatic breast cancer, second-line therapy with aromatase inhibitors can improve survival in comparison with megestrol." | 4.80 | Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. ( Cattel, F; Messori, A; Trippoli, S; Vaiani, M, 2000) |
| "To increase the therapeutic index of second line hormonal treatment of breast cancer, new aromatase inhibitors have been synthetized; they belong to two groups: type I (formestane and exemestane) are steroidal irreversible and specific inhibitors, type II (anastrozole, letrozole and vorozole) are non steroidal reversible inhibitors, interfering with the aromatase heme." | 4.80 | [Aromatase inhibitors: a review of clinical trials]. ( Kerbrat, P; Lefeuvre, C, 2000) |
| "Aminoglutethimide was the first aromatase inhibitor to be used in breast cancer therapy but, since it interacts with the synthetic glucocorticoids, hydrocortisone must also be given as a replacement." | 4.78 | Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer. ( Borja, J; Pérez, N, 1992) |
| "This retrospective study included women with confirmed hormone receptor-positive/human epidermal growth factor 2 negative locally advanced or metastatic breast cancer treated with either palbociclib, abemaciclib or ribociclib combined with letrozole or fulvestrant." | 4.31 | Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy. ( Adam, JP; Chabot, I; David, MÈ; Lessard-Hurtubise, R; Marineau, A; St-Pierre, C, 2023) |
| "We aimed at evaluating the effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women." | 4.31 | Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study. ( Alhassanin, SA; El-Attar, AA; Essa, ES; Ibrahim, OM; Mostafa, TM, 2023) |
| "ctDNA was isolated from 216 plasma samples collected from 51 patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (MBC) on a phase II trial of palbociclib combined with letrozole or fulvestrant (NCT03007979)." | 4.31 | Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. ( Ademuyiwa, FO; Clifton, K; Dai, C; Davis, AA; Dong, X; Du, P; Frith, A; Haas, B; Hernandez-Aya, LF; Jia, S; King, BL; Krishnamurthy, J; Luo, J; Luo, SJ; Ma, CX; Peterson, LL; Rearden, TP; Rigden, C; Summa, T; Suresh, R; Tan, L; Tandra, PK; Thomas, S; Wang, X; Weilbaecher, K; Zheng, T; Zhou, K, 2023) |
| " We included women aged ≥ 65 years with newly diagnosed hormone receptor-positive breast cancer and who had initiated AET (anastrozole, letrozole, exemestane, or tamoxifen)." | 4.31 | Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer. ( Han, S; Heo, JH; Mehta, S; Park, C; Spencer, JC, 2023) |
"Women with hormone receptor positive, invasive, nonmetastatic, and early breast cancer (| 4.31 | Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers. ( Bhaskaran, R; Louis, DM; Nair, LM; Narmadha, MP; Vallonthaiel, AG; Vijaykumar, DK; Yesodharan, J, 2023) | |
| "As breast cancer cells transition from letrozole-sensitive to letrozole-resistant, they over-express epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK), and human epidermal growth factor receptor 2 (HER2) while acquiring enhanced motility and epithelial-to-mesenchymal transition (EMT)-like characteristics that are attenuated and reversed by glyceollin treatment, respectively." | 4.31 | Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. ( Banjara, B; Boué, SM; Burow, ME; Davidson, AM; Ohemeng, A; Patel, JR; Tilghman, SL, 2023) |
| " Since this a case of advanced breast cancer, we initiated treatment with bevacizumab plus paclitaxel." | 4.31 | [Chemotherapy-Resistant Breast Cancer and Carcinomatous Pleuritis Successfully Treated with Abemaciclib plus Letrozole Therapy]. ( Kamo, N; Konishi, J; Nozaki, Y; Tanaka, N; Yamamuro, M, 2023) |
| "Palbociclib, the first available cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC)." | 4.31 | Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer. ( Brufsky, A; Layman, RM; Li, B; Liu, X; McRoy, L; Rugo, HS, 2023) |
| "An effective treatment for hormone-dependent breast cancer is chemotherapy using cytotoxic agents such as letrozole (LTZ)." | 4.31 | Synthesis and Characterization of Folic Acid-Functionalized DPLA-co-PEG Nanomicelles for the Targeted Delivery of Letrozole. ( Abdouss, M; Bencherif, SA; Choupani, E; Davarnejad, R; Gomari, MM; Heidari, R; Moeinzadeh, A; Rostami, N, 2023) |
| "A 73-year-old female patient with breast cancer with axillary lymph node, adrenal gland and bone metastases was started on ribociclib letrozole and denosumab treatment." | 4.31 | Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab. ( Aktürk Esen, S; Bayram, D; Köş, FT; Uçar, G, 2023) |
| "We report a case of a 72-year-old woman with metastatic breast cancer who developed visual hallucinations after receiving ribociclib, a CDK 4/6 inhibitor, and letrozole for 3 days." | 4.31 | Ribociclib-induced visual hallucination in a patient with metastatic breast cancer. ( Bulut, N; Demirer, S; Erdem, GU; Kapagan, T, 2023) |
| "We believe that trastuzumab, leuprorelin, letrozole, and palbociclib is a feasible and effective treatment for HER2-positive and HR-positive metastatic breast cancer in premenopausal patients who cannot tolerate first-line chemotherapy." | 4.31 | Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report. ( Cai, L; Chen, M; Sun, M, 2023) |
| "The third-generation of aromatase inhibitors (AIs)-Exemestane (Exe), Letrozole (Let), and Anastrozole (Ana)-is the main therapeutic approach applied for estrogen receptor-positive (ER+) breast cancer (BC), the most common neoplasm in women worldwide." | 4.31 | ( Almeida, CF; Amaral, C; Bezerra, PHA; Correia-da-Silva, G; Teixeira, N; Torqueti, MR, 2023) |
| "Palbociclib is a cyclin-dependent kinase 4/6 inhibitor that is approved in the United States for the treatment of hormone receptor‒positive (HR+)/human epidermal growth factor receptor‒2 negative (HER2-) advanced breast cancer (ABC)." | 4.31 | Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate. ( Benfield, JRGR; Chuken, YL; Damian, F; Fein, L; Franco, S; Korbenfeld, E; Lazaretti, N; Lobaton, J; Lu, DR; Mano, MS; Mori, A; Patyna, SJ, 2023) |
| "The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC)." | 4.31 | Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. ( André, F; Arteaga, CL; Babbar, N; Bardia, A; Chia, S; Hortobagyi, G; Lteif, A; Lu, YS; Neven, P; Slamon, D; Solovieff, N; Su, F; Taran, T; Tripathy, D, 2023) |
| "Palbociclib was approved in the United States in 2015 to treat estrogen receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)." | 4.12 | Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australi ( Alam, M; Binko, J; Boyle, F; Doval, DC; Gore, V; Karapetis, CS; Khasraw, M; Kim, S; Loi, S; Lu, DR; McCarthy, N; Oakman, C; Redfern, A; White, M, 2022) |
| "Currently there are no assays that can simultaneously quantify serum levels of the third-generation aromatase inhibitors (AIs): letrozole, anastrozole, and exemestane, and the ultra-low levels of estrogens in postmenopausal breast cancer patients on AI treatment." | 4.12 | Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. ( Almås, B; Bertelsen, BE; Geisler, J; Hagland, M; Helland, T; Lende, TH; Lønning, PE; Mellgren, G; Sagen, JV; Søiland, H; Viste, K, 2022) |
| "Out of 3537 older women with breast cancer, anastrozole was the most commonly prescribed (n = 1945, 55." | 4.12 | Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. ( Ng, BP; Park, C; Park, SK; Woo, A, 2022) |
| "The study population included patients diagnosed of ER+/HER2- metastatic breast cancer who started first-line treatment with anastrozole or letrozole between November 18, 2014, and November 18, 2015." | 4.12 | Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer. ( Adamson, BJ; Bargo, D; Baxi, S; Briggs, A; Ghosh, S; Ramsey, S; Tan, K; Wang, X, 2022) |
| " We previously demonstrated that glyceollin inhibits proliferation, survival, and migration of hormone-independent letrozole-resistant breast cancer." | 4.12 | Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. ( Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC, 2022) |
| "Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) metastatic breast cancer." | 4.12 | The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. ( Fu, F; Guindy, M; Kano, J; Ma, J, 2022) |
| "CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules investigated in this setting." | 4.12 | Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. ( Farhat, F; Gharib, KE; Karak, FE; Kattan, J; Macaron, W; Salloum, MA; Smith, M, 2022) |
| "Our results show that COSTLES for fertility preservation in breast cancer patients using GnRHa trigger reduces serum progesterone levels compared to ovarian stimulation without letrozole." | 4.12 | Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? ( Cedrin-Durnerin, I; Comtet, M; Grynberg, M; Krief, F; Labrosse, J; Lalami, I; Peigne, M; Sifer, C; Vinolas, C, 2022) |
| "The objective of the study was to develop PEGylated protamine letrozole nanoparticles to combat human breast cancer by modifying the release pattern of letrozole." | 4.12 | PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines. ( Amirzada, MI; Asad, MHHB; Bashir, H; Javed, MA; Khan, MT; Rajoka, MSR; Shah, N; Shaikh, AJ; Uddin, Z, 2022) |
| "This study aimed to reveal the treatment patterns and clinical outcomes of diverse palbociclib-based regimens in Han patients with estrogen receptor-positive (ER+) metastatic breast cancer in routine clinical practice." | 4.12 | Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. ( Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P, 2022) |
| " First, we conducted an observational study that carefully adjusted for confounding to estimate the treatment effect of fulvestrant plus palbociclib relative to letrozole plus palbociclib as a second-line therapy among estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer patients." | 4.12 | Transporting observational study results to a target population of interest using inverse odds of participation weighting. ( Chandross, KJ; Desai, M; Jreich, R; Kapphahn, K; Ling, AY; Meng, Z; Montez-Rath, ME, 2022) |
| "Results indicated that niosomes could be a promising drug carrier for the delivery of letrozole to breast cancer cells." | 4.12 | In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment. ( Ahmadi, S; Akbarzadeh, I; Bazzazan, S; Chiani, M; Hosseini, S; Mostafavi, E; Saffar, S; Seraj, M, 2022) |
| "Results obtained from the in silico and in vitro studies suggest that Letrozole loaded nanoparticles are ideal for breast cancer treatment." | 4.02 | In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer. ( Banjare, L; Jain, A; Jain, AK; Mishra, K; Ratre, P; Thareja, S; Verma, SK, 2021) |
| "Previous reports identified a global proteomic signature of estrogen-independent letrozole resistant breast cancer cells, however, it remains unclear how letrozole-resistance is impacted when cells remain estrogen receptor positive (ER+)." | 4.02 | Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade. ( Bratton, MR; Davidson, AM; Gallegos, KM; Lemieux, KP; Tilghman, SL; Walker, RR; Wang, G; Zhang, K, 2021) |
| "Letrozole, an aromatase inhibitor (AI), is the first-line adjuvant drug for treating hormone receptor-positive (HR+) breast cancer in postmenopausal women." | 4.02 | Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer. ( Adithan, C; Aibor Dkhar, S; Dubashi, B; Kadambari, D; Kumar, NAN; Muthuvel, SK; Umamaheswaran, G, 2021) |
| " This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC) treated in routine clinical practice in the USA." | 4.02 | Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. ( Brufsky, A; Cristofanilli, M; DeMichele, A; Emir, B; Finn, RS; Layman, RM; Liu, X; Mardekian, J; McRoy, L; Rugo, HS; Torres, MA, 2021) |
| " Palbociclib with letrozole may be a good treatment in the preoperative stage for luminal breast cancer that is resistant to chemotherapy." | 4.02 | Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report. ( Choi, JH; Jeon, CW; Jung, M; Jung, SU, 2021) |
| "We report a ribociclib-induced grade 3 AKI in an elderly woman who was treated for metastatic breast cancer." | 4.02 | Ribociclib induced acute kidney injury: A case report. ( Erdal, GS; Gulturk, I; Ozmen, A; Tacar, SY; Tural, D; Yilmaz, M, 2021) |
| "The patient received hormone therapy using letrozole based on a clinical diagnosis of occult breast cancer with peritoneal dissemination and right axillary lymph node metastasis." | 4.02 | Long-term response on letrozole for gastric cancer: A case report. ( Hiramatsu, T; Hongo, K; Iida, Y; Ishihara, Y; Kita, Y; Kobayashi, R; Kuriki, K; Onoda, T; Takabayashi, N, 2021) |
| " In this study, the effects of two Aromatase Inhibitor (Letrozole and Exemestane), and one mTOR Inhibitor (Everolimus) on cell mechanical properties, actin content/distribution, and nuclear areas of two invasive and non-invasive breast cancer cell line after 24 h treatment with concentrations previously reported were investigated." | 4.02 | Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus. ( Habibi-Anbouhi, M; Mohammadi, E; Tabatabaei, M; Tafazzoli-Shadpour, M, 2021) |
| "In the field of oncofertility, patients with breast cancer are often administered letrozole as an adjuvant drug before and after oocyte retrieval to prevent an increase in circulating estradiol." | 4.02 | Severe hemoperitoneum resulting from restart of letrozole after oocyte retrieval procedure: a case report. ( Gomi, Y; Huang, H; Ichinose, S; Itaya, Y; Matsunaga, S; Narita, T; Ono, Y; Saitoh, M; Samejima, K; Seki, H; Takai, Y, 2021) |
| "We conducted a proof of principle study in seven postmenopausal women with stage I-III breast cancer who were enrolled in pre-surgical studies of the AKT inhibitor MK-2206 (n = 4) or the aromatase inhibitors exemestane (n = 2) and letrozole (n = 1)." | 4.02 | Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer. ( Accordino, MK; Altoe, ML; Crew, KD; Franks, LE; Hershman, DL; Hielscher, AH; Kalinsky, K; Kim, HK; Lee, SM; Marone, A; McGuinness, JE; Tejada, M; Trivedi, MS, 2021) |
| "To evaluate the real-world tumor response of palbociclib plus letrozole (PAL+LET) versus LET alone as first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (HR+/HER2‒ MBC) in routine US clinical practice." | 4.02 | Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. ( Brufsky, A; Layman, RM; Li, B; Liu, X; McRoy, L, 2021) |
| "Chemotherapy using cytotoxic agents, such as letrozole (LTZ), is one of the most effective treatments for hormone-dependent breast cancer." | 3.96 | Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment. ( Kashanian, S; Yassemi, A; Zhaleh, H, 2020) |
| "The tamoxifen metabolite, Z-endoxifen, demonstrated promising antitumor activity in endocrine-resistant estrogen receptor-positive (ER+) breast cancer." | 3.96 | Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. ( Ames, MM; Bruinsma, ES; Buhrow, SA; Carter, JM; Cheng, J; Goetz, MP; Hawse, JR; Hoskin, TL; Hou, X; Ingle, JN; Jayaraman, S; Kalari, KR; Kuffel, MJ; McGovern, RM; Monroe, DG; Reid, JM; Reinicke, KE; Safgren, SL; Suman, VJ; Tang, X; Walden, CA; Zeldenrust, MA, 2020) |
| "A consecutive cohort of ER( +)/HER2( -) advanced breast cancer patients who received palbociclib between 2017 and 2018 was analyzed." | 3.96 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer. ( Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J, 2020) |
| "Our results suggested that BMI and AI drug (letrozole versus anastrozole) were clinical predictors of arthralgia, while genetic variants rs4775936, rs9322336, rs2234693, and rs9340799 were genetic predictors of AI-induced arthralgia." | 3.96 | Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. ( Borrie, AE; Choi, YH; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, FA; Sexton, T; Teft, WA; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2020) |
| " Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy." | 3.96 | Complete response of leptomeningeal carcinomatosis secondary to breast cancer. ( Canova, C; Klausner, G; Troussier, I, 2020) |
| "A promising drug, palbociclib, received accelerated approval as a first line treatment when used with the aromatase inhibitor, letrozole, for postmenopausal women with hormone receptor positive advanced or metastatic breast cancer." | 3.91 | Verapamil as a culprit of palbociclib toxicity. ( Gowarty, JL; Herrington, JD, 2019) |
| "Letrozole (LTZ), an aromatase inhibitor used for the treatment of hormonally-positive breast cancer in postmenopausal women, has poor water solubility, rapid metabolism, and a range of side effects." | 3.91 | Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy. ( Alemrayat, B; Elhissi, A; Younes, HM, 2019) |
| "This was a single-center, retrospective cohort study of all postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer patients who received palbociclib and letrozole as a second-line endocrine therapy or beyond (and no prior cyclin-dependent kinases 4 and 6 inhibitor therapy) between February 1, 2015, and July 31, 2016." | 3.91 | Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer. ( Berger, MJ; Lustberg, M; Palettas, M; Schickli, MA; Vargo, CA, 2019) |
| "To understand treatment satisfaction in patients with advanced or metastatic breast cancer receiving palbociclib plus an aromatase inhibitor or palbociclib plus fulvestrant in a real-world setting." | 3.91 | Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. ( Band, J; Darden, C; Davis, K; Iyer, S; McSorley, D; Mitra, D, 2019) |
| "The addition of ribociclib (RIB) to letrozole (LET) significantly increases progression free survival for patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC)." | 3.91 | Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China. ( Ma, J; Peng, L; Tan, C; Wan, X; Zeng, X; Zhang, Y, 2019) |
| "Letrozole is an aromatase inhibitor, used to treat postmenopausal women with hormone receptor-positive or unknown advanced breast cancer." | 3.91 | Hair analysis to discriminate voluntary doping vs inadvertent ingestion of the aromatase inhibitor letrozole. ( El Mazloum, R; Favretto, D; Pertile, R; Snenghi, R; Tucci, M; Visentin, S; Vogliardi, S, 2019) |
| "We aimed to evaluate the effect of co-administration of letrozole and gonadotropins during ovarian stimulation on oocyte yield and maturation in breast cancer patients prior to chemotherapy." | 3.91 | Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes. ( Ben-Haroush, A; Klochendler, E; Oron, G; Sapir, O; Shufaro, Y; Wertheimer, A, 2019) |
| "Our findings clearly demonstrate that letrozole improves cisplatin sensitivity of breast cancer cells overexpressing aromatase via down-regulation of FEN1 and suggest that a combined use of letrozole and cisplatin may be a potential treatment protocol for relieving cisplatin resistance in human breast cancer." | 3.91 | Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1. ( Chen, B; Chen, M; Jiang, X; Li, S; Wang, Y; Zhu, L; Zou, J, 2019) |
| "Bone health in women with HR+ breast cancer enrolled on the prospective randomized Exemestane and Letrozole Pharmacogenetics (ELPh) trial was determined by measuring bone turnover markers (BTM) and bone mineral density (BMD) pre-treatment and after 3 BTM and 24 BMD months of treatment with either the steroidal AI exemestane or the nonsteroidal AI letrozole." | 3.91 | Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. ( Clark, BL; Gersch, CL; Gregory, BJ; Hayes, DF; Henry, NL; Hertz, DL; Kamdem, LK; Kidwell, KM; Rae, JM; Stearns, V; Storniolo, AM; Xi, J, 2019) |
| "Three CDK4/6 inhibitors, palbociclib (PAL), ribociclib (RIB), and abemaciclib, when combined with letrozole (LET), have been approved as first-line therapy for postmenopausal women with metastatic HR+, HER2- breast cancer." | 3.91 | Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. ( Long, EF; Zhang, B, 2019) |
| "Among patients with HR-positive advanced breast cancer, the estimated PFS in patients treated with fulvestrant and palbociclib was comparable to a previously reported phase 3 trial." | 3.91 | Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. ( Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L, 2019) |
| "The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) based on phase III study results." | 3.91 | Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. ( Iyer, S; Milligan, G; Mitra, D; Mycock, K; Taylor-Stokes, G; Waller, J; Zhan, L, 2019) |
| "EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor-positive breast cancer." | 3.91 | Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. ( Baake, G; Baier, B; Bayer, CM; Beckmann, MW; Belleville, E; Breitbach, GP; Brucker, C; Brucker, SY; Dall, P; de Waal, J; Deuker, JU; Fasching, PA; Fehm, T; Feisst, M; Fischer, G; Guggenberger, M; Hadji, P; Harbeck, N; Hartkopf, A; Hein, A; Henschen, S; Heyl, V; Hohn, A; Janni, W; Kohls, A; Kolberg, HC; Krauss, T; Kuhn, T; Kümmel, S; Landthaler, R; Mundhenke, C; Nabieva, N; Noesselt, T; Popovic, M; Praetz, T; Rauh, C; Rezai, M; Rezek, D; Richter, B; Schmidt, K; Siebers, JW; Tesch, H; Thomssen, C; Vollert, HW; Wachsmann, G; Wallwiener, D; Wallwiener, M; Warm, M; Wolf, C; Wuerstlein, R, 2019) |
| " We aimed to investigate the effects of different aromatase inhibitors, including letrozole, anastrozole, and exemestane, on the lipid profile of eastern Chinese breast cancer patients." | 3.88 | Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study. ( Deng, Y; Tian, W; Wu, M, 2018) |
| "Recently, the palbociclib/letrozole combination therapy was granted accelerated US FDA approval for the treatment of estrogen receptor (ER)-positive breast cancer." | 3.88 | Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. ( Benton, HP; Fang, M; Forsberg, EM; Goetz, L; Granados, A; Huan, T; Johnson, CH; Raffeiner, P; Siuzdak, G; Warth, B, 2018) |
| "6 ng/mL) during the luteal phase were found in a small study of breast cancers patients undergoing controlled ovarian stimulation (COS) with letrozole plus recombinant FSH." | 3.88 | Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels? ( Del Pup, L; Peccatori, FA, 2018) |
| "Hormonal therapy is a useful adjunct for chemoprevention in breast cancer; however, use of letrozole in patients undergoing reconstruction with pedicled TRAM can lead to increase in certain complication rates." | 3.88 | The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications. ( Clayman, E; Huber, KM; Kumar, A; Smith, P, 2018) |
| " regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with hormone receptor-positive (HR+)/human epidermal receptor 2-negative (HER2-) advanced or metastatic breast cancer." | 3.88 | Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. ( Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K, 2018) |
| "The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer." | 3.88 | Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. ( Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; Hettle, R; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K, 2018) |
| "Letrozole (LTZ) is effective for the treatment of hormone-receptor-positive breast cancer in postmenopausal women." | 3.88 | Preparation and optimization of monodisperse polymeric microparticles using modified vibrating orifice aerosol generator for controlled delivery of letrozole in breast cancer therapy. ( Alany, RG; Alemrayat, B; Elhissi, A; Elrayess, MA; Younes, HM, 2018) |
| "The aromatase inhibitor (AI) letrozole is a first-line drug in the adjuvant treatment of breast cancer in postmenopausal women." | 3.88 | Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. ( Borrie, AE; Choi, YH; Dinniwell, R; Hahn, K; Kim, RB; Lenehan, J; Lock, M; Logan, D; Perera, FE; Potvin, K; Read, N; Rose, RV; Sexton, T; Teft, WA; Tyndale, RF; Vandenberg, TA; Welch, S; Yaremko, B; Younus, J; Yu, E, 2018) |
| "In health resource-limited settings, adjuvant endocrine therapy with letrozole is a cost-effective strategy compared to tamoxifen in women with early breast cancer." | 3.88 | Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting. ( Lu, J; Wu, B; Yang, F; Ye, M, 2018) |
| "Palbociclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor that was conditionally approved in the United States (February 2015) and Canada (March 2016) with letrozole as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer." | 3.88 | Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. ( Brufsky, AM; Cotter, MJ; Dequen, F; Joy, AA; Lu, DR; Stearns, V; Verma, S, 2018) |
| " The aim of this study was to investigate the effect of co-administration of fucoidan, derived from Undaria pinnatifida, on the pharmacokinetics of 2 commonly used hormonal therapies, letrozole and tamoxifen, in patients with breast cancer." | 3.88 | The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer. ( Fitton, JH; Lowenthal, RM; McGuinness, G; Olesen, I; Oliver, LJ; Patel, R; Peterson, GM; Shastri, M; Tocaciu, S, 2018) |
| "Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score." | 3.85 | Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. ( Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG, 2017) |
| "To evaluate the hormonal profile in three breast cancer patients who underwent controlled ovarian stimulation in the presence of the aromatase inhibitor letrozole." | 3.85 | High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients. ( Alviggi, C; Conforti, A; De Laurentiis, M; De Placido, G; De Rosa, P; Di Rella, F; Marci, R; Picarelli, S; Strina, I; Vallone, R; Yding Andersen, C, 2017) |
| "Transcriptional silencing of estrogen receptor α (ERα) expression is an important etiology contributing to the letrozole-resistance in ERα-positive breast cancer (BCa) cells, but the transcription factors responsible for this transcriptional repression remain largely unidentified." | 3.85 | Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells. ( Cui, MK; Li, J; Li, S; Liu, XY; Wang, EH; Zhang, Q; Zhao, Z, 2017) |
| "The addition of palbociclib to letrozole improves progression-free survival in the first-line treatment of hormone receptor positive advanced breast cancer (ABC)." | 3.85 | Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. ( Helou, J; Naimark, DM; Pritchard, KI; Raphael, J, 2017) |
| "Raloxifene, an anti-osteoporotic drug, is recently approved for prevention of breast cancer in postmenopausal women and thus the drug may be employed to combat the bony adverse effects of letrozole, another anticancer drug." | 3.85 | Combined Raloxifene and Letrozole for Breast Cancer Patients. ( Kalam, A; Leekha, A; Talegaonkar, S; Verma, AK; Vohora, D, 2017) |
| "We tested the levels of CYR61 expression of 36 primary breast cancer patients who received neo-adjuvant endocrine therapy for at least 3 months by immunohistochemistry staining before and after administrating letrozole, an oral non-steroidal aromatase inhibitor (AI) for the treatment of hormone-responsive breast cancer." | 3.85 | CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma. ( Cheng, J; Jia, X; Liu, G; Shao, Z; Shen, Z, 2017) |
| "Letrozole showed efficacy and generally favorable toxicities, along with the convenience of oral administration in postmenopausal patients with hormone receptor (HR)-positive metastatic breast cancer (MBC)." | 3.85 | Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea. ( Beom, SH; Han, SW; Han, W; Im, SA; Kim, TY; Lee, KH; Moon, HG; Noh, DY; Oh, DY; Oh, J; Suh, KJ; Yang, Y, 2017) |
| "The EvAluate-TM study is a prospective, multicenter noninterventional study in which treatment with the aromatase inhibitor letrozole was evaluated in postmenopausal women with hormone receptor-positive primary breast cancer." | 3.85 | Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. ( Baake, G; Baier, B; Bayer, CM; Beckmann, MW; Belleville, E; Breitbach, GP; Brucker, C; Brucker, SY; Dall, P; de Waal, J; Deuker, JU; Fasching, PA; Fehm, T; Fersis, N; Fischer, G; Guggenberger, M; Hack, CC; Hadji, P; Harbeck, N; Hein, A; Henschen, S; Heyl, V; Hohn, A; Jacob, A; Janni, W; Kohls, A; Kolberg, HC; Krauss, T; Kuhn, T; Kümmel, S; Landthaler, R; Mundhenke, C; Noesslet, T; Paepke, D; Praetz, T; Rauh, C; Rezai, M; Rezek, D; Richter, B; Schmidt, K; Siebers, JW; Tesch, H; Thomssen, C; Vollert, HW; Wachsmann, G; Wallwiener, D; Warm, M; Wolf, C; Wuerstlein, R, 2017) |
| " This study was carried out to investigate the effect of NOB on the activity and expression of aromatase, and to compare this property with letrozole (LET) as aromatase inhibitor in the MCF-7 breast cancer cell line." | 3.85 | Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line. ( Hoseini, M; Keramatipour, M; Koohdani, F; Nourbakhsh, M; Rahideh, ST; Shidfar, F; Talebi, S, 2017) |
| "Subcutaneous testosterone-letrozole was an effective treatment for this patient's breast cancer and did not interfere with chemotherapy." | 3.85 | Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications. ( Dimitrakakis, C; Glaser, RL; York, AE, 2017) |
| "This study was designed to explore whether zoledronic acid could prevent expected loss of bone mineral density (BMD) in postmenopausal women with pre-existing osteopenia or osteoporosis who were initiating adjuvant letrozole therapy for primary breast cancer." | 3.83 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. ( Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N, 2016) |
| "A limited number of studies have been conducted on the effects of hormonal therapy with tamoxifen (TMX) or aromatase inhibitors (AIs) on plasma levels of leptin and adiponectin, as well as body composition in breast cancer (BC) patients." | 3.83 | The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study. ( Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y, 2016) |
| " We aimed to investigate the long-term safety of FP via controlled ovarian stimulation with letrozole supplementation (COSTLES) prior to breast cancer treatment." | 3.83 | Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. ( Kim, J; Oktay, K; Turan, V, 2016) |
| "The authors reviewed retrospective cases of 2 women - one aged 78 years and the other aged 86 years - with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treated with combination palbociclib/letrozole who presented with hyperuricemia." | 3.83 | Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer. ( Bromberg, DJ; Nanjappa, S; Pabbathi, S; Valenzuela, M, 2016) |
| "The primary objective of this study is to compare the oocyte yield in breast cancer patients undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins with patients undergoing COS with standard gonadotropins for elective cryopreservation of oocytes." | 3.83 | Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†. ( Cordeiro, CN; Hancock, K; Lekovich, JP; Pereira, N; Rosenwaks, Z; Schattman, GL, 2016) |
| "Variable dose letrozole-FSH protocol can maintain lower peak estradiol levels and reduce estrogen exposure after breast cancer operation and chemotherapy." | 3.83 | Twin delivery after IVF-ET with variable dose letrozole-FSH protocol of lower estradiol in a patient previously treated for breast cancer: a case report. ( Diao, H; Hu, GZ; Zhang, CJ; Zhang, Y, 2016) |
| "3% metastatic) from the EGF30008 phase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast cancer and no prior therapy for advanced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor." | 3.83 | Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. ( Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M, 2016) |
| "The combination of antiestrogen therapy and ribociclib, an investigational CDK4/6 inhibitor, led to improved outcomes in women with metastatic HR-positive, HER2-negative breast cancer, according to findings presented at a meeting of the European Society for Medical Oncology." | 3.83 | Ribociclib Lengthens Breast Cancer Survival. ( , 2016) |
| "The aim of this study was to determine the budget impact of everolimus (in combination with letrozole/anastrozole) as a second-line treatment for ER+ HER2- negative advanced and metastatic breast cancer in post-menopausal women." | 3.81 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. ( Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M, 2015) |
| "To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC)." | 3.81 | Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. ( Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V, 2015) |
| " A near clinical complete response was achieved by EC systemic chemotherapy(6 months)followed by endocrine therapy(letrozole), but 3 months later she was diagnosed cytologically with carcinomatous cardiac tamponade." | 3.81 | [Long-term survival of a breast cancer patient with carcinomatous pleuritis and carcinomatous cardiac tamponade successfully treated by multimodality therapy]. ( Kitamura, T; Tanaka, Y; Tsuboi, K; Tsuda, S; Tsujii, S; Yagi, K; Yamamoto, A, 2015) |
| "Developing depressive disorders are at higher risk in breast cancer survivors aged 40-59 who received adjuvant treatments including chemotherapy, radiotherapy, tamoxifen, AIs or trastuzumab." | 3.81 | Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study. ( Chang, CH; Chen, SJ; Liu, CY, 2015) |
| "Pretreatment and on-treatment (after 2 weeks and 3 months) biopsies were obtained from 89 postmenopausal women who had estrogen receptor-alpha positive breast cancer and were receiving neoadjuvant letrozole for transcript profiling." | 3.81 | Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. ( Arthur, LM; Dixon, JM; Dowsett, M; Dunbier, AK; Kay, C; Larionov, AA; Renshaw, L; Sims, AH; Thomas, JS; Turnbull, AK, 2015) |
| " When added to the aromatase inhibitor letrozole in a randomized phase II trial for first-line therapy of estrogen receptor-positive, HER2-negative metastatic breast cancer, palbociclib significantly increased progression-free survival compared with letrozole alone [palbociclib + letrozole: 20." | 3.81 | Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. ( Henry, NL; Morikawa, A, 2015) |
| "We have previously reported an approach to ovarian stimulation for the purpose of fertility preservation (FP) in women with breast cancer via embryo freezing with the concurrent use of letrozole." | 3.81 | Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. ( Bedoschi, G; Moy, F; Oktay, K; Pacheco, FS; Turan, V, 2015) |
| "This study shows that trastuzumab-based adjuvant treatment of small HER2-positive breast cancer is mostly based on chemotherapy-mainly paclitaxel/docetaxel." | 3.81 | Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice. ( Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R, 2015) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | 3.81 | [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report]. ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| " Letrozole, an endocrine therapy drug, is usually prescribed for post-menopausal status early and advanced stage breast cancer." | 3.81 | Drug Use Evaluation of Letrozole in Breast Cancer Patients at Regional Cancer Hospitals in Thailand. ( Ketkaew, C; Kiatying-Angsulee, N, 2015) |
| "Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction." | 3.81 | Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study. ( Bagnardi, V; Balduzzi, A; Cancello, G; Cardillo, A; Colleoni, M; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Intra, M; Iorfida, M; Luini, A; Montagna, E; Sandri, MT; Viale, G, 2015) |
| "Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy." | 3.81 | Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis. ( Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A, 2015) |
| "Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following aromatase inhibitors." | 3.81 | Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line. ( Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I, 2015) |
| "Three strong candidates for repurposing have been identified- Letrozole and GDC-0941 against lung cancer, and Ribavirin against breast cancer." | 3.81 | A computational method for drug repositioning using publicly available gene expression data. ( Abdul Nazeer, KA; Palakal, M; Pradhan, M; Shabana, KM, 2015) |
| "A total of 148 postmenopausal women (including bilateral ovariectomy) with hormone dependent metastatic breast cancer receiving aromatase inhibitors (letrozole, anastrozole or exemestane) were analyzed retrospectively." | 3.81 | [Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases]. ( Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M, 2015) |
| "Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor, remains unproven in non-HER2-amplified metastatic breast cancer (MBC)." | 3.80 | Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. ( Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF, 2014) |
| "There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen." | 3.80 | Symptoms of endocrine treatment and outcome in the BIG 1-98 study. ( Bonnefoi, H; Coates, AS; Cole, BF; Colleoni, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Huober, J; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wu, J, 2014) |
| "In this paper, computational studies were carried out on anastrozole and letrozole, chemotherapy drugs used against breast cancer." | 3.80 | Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer. ( Akçay, HT; Bayrak, R, 2014) |
| "We identified the first dispensing of tamoxifen, anastrozole or letrozole for women diagnosed with invasive breast cancer in the 45 and Up Study from 2004-2009 (N = 1266)." | 3.80 | Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice. ( Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C, 2014) |
| "The present work focuses on the design of a drug delivery system for systemic, controlled release of the poorly soluble breast cancer drug, letrozole." | 3.80 | Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: a controlled drug delivery system for treatment of breast cancer. ( Adhikari, B; Chaudhury, K; Siddiqa, AJ, 2014) |
| "Although aromatase inhibitors (AIs; for example, letrozole) are highly effective in treating estrogen receptor positive (ER+) breast cancer, a significant percentage of patients either do not respond to AIs or become resistant to them." | 3.80 | Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. ( Brodie, AH; Chumsri, S; Gilani, RA; Goloubeva, O; Kazi, AA; Kronsberg, S; Sabnis, G; Schech, AJ; Shah, P, 2014) |
| "Although the addition of dasatinib to letrozole improved progression-free survival in postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer compared with letrozole alone, the clinical benefit was the same for both groups." | 3.80 | Dasatinib-letrozole gets split verdict. ( , 2014) |
| "Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer." | 3.80 | Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014) |
| " In the clinical scenario, germline variation in VAV3 was associated with the response to tamoxifen in Japanese breast cancer patients (rs10494071 combined P value = 8." | 3.80 | VAV3 mediates resistance to breast cancer endocrine therapy. ( Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W, 2014) |
| "The aim of this study was to investigate the prevalence and causes of early discontinuation and non-adherence to upfront and extended adjuvant letrozole therapy in breast cancer patients." | 3.80 | Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting. ( Ah, YM; Im, SA; Kim, HS; Lee, BK; Lee, HS; Lee, JY; Noh, DY, 2014) |
| "Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past." | 3.80 | Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker. ( Agarwal, V; Cawkwell, L; Drew, PJ; Fox, JN; Garimella, V; Hussain, T; Kneeshaw, PJ; Lind, MJ; Long, ED; Mahapatra, TK; McManus, PL; Radhakrishna, S, 2014) |
| "Postmenopausal women with an early breast cancer scheduled to start adjuvant endocrine therapy with an AI or tamoxifen were recruited." | 3.80 | Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. ( Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H, 2014) |
| "In the process of anti-cancer drug discovery, to find new potential anti-breast cancer agents, we designed and synthesized a novel series of letrozole analogs." | 3.80 | Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs. ( Ardestani, SK; Asadipour, A; Dadgar, A; Firoozpour, L; Foroumadi, A; Moshafi, MH; Pordeli, M; Rodaki, A; Safavi, M; Vosooghi, M, 2014) |
| "Aromatase inhibitors, such as letrozole, have become the first-line treatment for postmenopausal women with estrogen-dependent breast cancer." | 3.79 | Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. ( Bratton, MR; Carriere, PP; Llopis, SD; Preyan, LC; Skripnikova, E; Tilghman, SL; Townley, I; Wang, G; Williams, CC; Zhang, Q; Zhong, Q; Zou, J, 2013) |
| "Aromatase inhibitors (AIs) have been reported to exert their antiproliferative effects in postmenopausal women with hormone receptor-positive breast cancer not only by reducing estrogen production but also by unmasking the inhibitory effects of androgens such as testosterone (TS) and dihydrotestosterone (DHT)." | 3.79 | Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. ( Gohno, T; Hanamura, T; Hayashi, S; Ito, K; Kobayashi, Y; Konno, H; Kurosumi, M; Nishikawa, S; Niwa, T; Takei, H; Tazawa, C; Yamaguchi, Y, 2013) |
| "To assess the advantages and disadvantages of using letrozole for controlled ovarian stimulation (COH) in young patients with estrogen receptor-positive (ER+) breast cancer, wishing to cryopreserve oocytes." | 3.79 | Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? ( Anserini, P; Delle Piane, L; Levi Setti, PE; Merlo, DF; Porcu, E; Revelli, A, 2013) |
| "To investigate the safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole protocol for fertility preservation in breast cancer patients." | 3.79 | Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. ( Bedoschi, G; Moy, F; Oktay, K; Turan, V, 2013) |
| "The objective of this study was to determine radiation, doxorubicin, tamoxifen and letrozole sensitivity of breast cancer cells in response to functional inhibition of the ubiquitin conjugating enzyme UBE2C." | 3.79 | Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. ( Gopal, G; Rajkumar, T; Rawat, A; Selvaluxmy, G, 2013) |
| "To establish a human breast cancer MCF-7 cell model stably overexpressing the aromatase gene (MCF-7-aromatase) and aromatase inhibitor letrozole-resistant MCF-7 cell model (MCF-7-LR)." | 3.79 | [Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model]. ( Chen, HY; Liu, ZH, 2013) |
| "To estimate the budget impact of everolimus as the first and second treatment option after letrozole or anastrozole (L/A) failure for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (ABC)." | 3.79 | Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. ( De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H, 2013) |
| "The study aim was to identify early (within 14 days) and late changes (by 3 months) in breast cancer gene expression profiles associated with neoadjuvant therapy with letrozole." | 3.78 | Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Larionov, A; Miller, WR, 2012) |
| " Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking." | 3.78 | Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). ( Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K, 2012) |
| "The purpose of this study was to report a patient with choroidal and optic disc metastases from breast cancer and the response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab." | 3.78 | Choroidal and optic disc metastases from breast cancer and their response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab. ( Iwaki, M; Mizumoto, K; Naito, E; Takeyama, M; Zako, M, 2012) |
| "We examined the efficacy of chemoendocrine therapy using capecitabine as a chemotherapeutic agent in premenopausal and postmenopausal models with estrogen receptor (ER)-positive human breast cancer xenografts." | 3.78 | Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts. ( Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H, 2012) |
| " Correspondingly in breast cancer tumors, expression of estradiol- and Runx2-regulated genes was inversely correlated, and letrozole increased expression of Runx2-stimulated genes, as defined in the MCF7/Rx2(dox) model." | 3.78 | Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. ( Baniwal, SK; Berman, BP; Chimge, NO; Coetzee, S; Ellis, MJ; Frenkel, B; Khalid, O; Luo, J; Tripathy, D, 2012) |
| "Postmenopausal women with risk factors for developing breast cancer were given letrozole 2." | 3.78 | A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density. ( Andreopoulou, E; Axelrod, D; Carapetyan, K; Checka, C; Diflo, T; Dilawari, A; Guth, A; Muggia, F; Reich, E; Smith, J; Toth, H; Ursin, G; Utate, M, 2012) |
| "Here, we investigated the role of AIB1 in the deregulation of ER target genes occurring as a consequence of AI resistance using tissue microarrays of patients with breast cancer and cell line models of resistance to the AI letrozole." | 3.78 | AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells. ( Bane, F; Byrne, C; Conroy, RM; Gaora, PÓ; Hao, Y; Hill, AD; McBryan, J; McIlroy, M; O'Hara, J; Tibbitts, P; Vareslija, D; Young, LS, 2012) |
| " She was diagnosed with right locally advanced breast cancer (cT4bN2aM0, stageIIIB) and received hormone therapy with letrozole." | 3.78 | [A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole]. ( Hibino, M; Nakamura, M; Okuyama, M; Sasaki, Y; Tenma, K, 2012) |
| "Low-dose (LD, 150 IU; n = 34) versus high-dose (HD, >150 IU; n = 117) FSH start in 151 patients with breast cancer (BCa) undergoing ovarian stimulation for embryo cryopreservation with letrozole (LE) before cancer treatment." | 3.78 | Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? ( Lee, S; Oktay, K, 2012) |
| " Postmenopausal women with breast cancer and MR imaging findings of the contralateral unaffected breast, before and during 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June 2010 were retrospectively identified (n = 149)." | 3.78 | Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging. ( Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS, 2012) |
| "To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -positive breast cancer." | 3.78 | Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. ( A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L, 2012) |
| "Novel ruthenium-letrozole complexes have been prepared, and cell viability of two human cancer cell types (breast and glioblastoma) was determined." | 3.78 | New ruthenium(II)-letrozole complexes as anticancer therapeutics. ( Castonguay, A; Doucet, C; Juhas, M; Maysinger, D, 2012) |
| "Letrozole is a type 2 aromatase inhibitor, which reduces availability of estrogen in postmenopausal women, thereby decreasing its ability to stimulate breast cancer cells." | 3.78 | Letrozole: advancing hormone therapy in breast cancer. ( Armstrong, AC; Lee, RJ; Wardley, AM, 2012) |
| "The combination of PLD with cisplatin and infusional fluorouracil (CCF) for 8 courses was investigated in patients with primary or recurrent T2-T4a-d N0-3 M0 breast cancer." | 3.77 | Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. ( Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Iorfida, M; Luini, A; Montagna, E; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011) |
| " We retrospectively investigated the activity of letrozole plus GnRH analogue (GnRH-a) administered concurrently with preoperative chemotherapy and as adjuvant treatment in premenopausal women with locally advanced ER positive breast cancer consecutively admitted at the European Institute of Oncology." | 3.77 | Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. ( Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011) |
| "We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen." | 3.77 | Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. ( Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H, 2011) |
| "A gene expression signature derived from ER(+) breast cancer cells with acquired hormone independence predicted tumor response to aromatase inhibitors and associated with clinical markers of resistance to tamoxifen." | 3.77 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. ( Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H, 2011) |
| " We evaluated the efficacy of the aromatase inhibitor letrozole in patients with metastatic breast cancer (MBC) as related to DNA polymorphisms of CYP19A1." | 3.77 | Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. ( Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J, 2011) |
| "To predict embryo/oocyte cryopreservation cycle (ECC) outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone for fertility preservation based on observed anti-mullerian hormone (AMH) levels and antral follicle counts (AFC)." | 3.77 | Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. ( Alappat, RM; Heytens, E; Lee, S; Moy, F; Oktay, K; Ozkavukcu, S, 2011) |
| "We used two aromatase overexpressing human breast cancer cell lines MCF-7-CA cells and AC1 cells and their letrozole resistant counterparts as study models." | 3.77 | GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells. ( Abrhale, T; Brodie, A; Macedo, L; Sabnis, G; Serrero, G; Tian, C; Yue, B, 2011) |
| " Here we report a case of lobular breast cancer metastasizing to a leiomyoma in a patient using letrozole." | 3.77 | Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment. ( Aydinli, K; Basgul, AY; Calay, Z; Dünder, I; Güdücü, N; Işçi, H, 2011) |
| "Patients with early oestrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer treated with letrozole from February 2001 to September 2009 were reviewed." | 3.77 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. ( Balakrishnan, A; Ravichandran, D, 2011) |
| "To assess the use of letrozole with follicle-stimulating hormone (FSH) in gonadotropin-releasing hormone (GnRH) analogue protocols, based on reported attempts to avoid the estradiol (E2) increase during controlled ovarian hyperstimulation for embryo cryopreservation in breast cancer patients using a combination of low dose FSH and aromatase inhibitor (letrozole) in a GnRH-antagonist protocol." | 3.77 | High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols. ( Ben-Aharon, I; Ben-Haroush, A; Farhi, J; Fisch, B; Pinkas, H; Sapir, O, 2011) |
| " This study was conducted to determine the prevalence of suboptimal vitamin D levels in women initiating adjuvant letrozole for breast cancer and to determine whether supplementation with 50,000 IU of vitamin D3 weekly could reduce musculoskeletal symptoms and fatigue in women who have suboptimal vitamin D levels." | 3.76 | Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. ( Baxa, SE; Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; O'Dea, AP; Reddy, PS; Sharma, P, 2010) |
| "Tamoxifen (TAM) is a selective estrogen-receptor modulator that is widely used in the prevention and treatment of estrogen-receptor-positive breast cancer." | 3.76 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. ( Lazarus, P; Sun, D, 2010) |
| " We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor-positive metastatic breast cancer (MBC)." | 3.76 | Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. ( Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B, 2010) |
| "We performed ovarian stimulation in 126 women with breast cancer by using letrozole and gonadotropins for the purpose of fertility preservation by embryo or oocyte cryopreservation." | 3.76 | Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. ( Babayev, SN; Barad, D; Kim, JY; Oktay, K, 2010) |
| " In this study we demonstrated the preclinical therapeutic efficacy of combining the aromatase inhibitor letrozole with the multi-kinase inhibitor sorafenib in aromatase-expressing breast cancer cell lines." | 3.76 | Synergistic activity of letrozole and sorafenib on breast cancer cells. ( Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG, 2010) |
| "Roscovitine treatment can reverse intrinsic or acquired resistance to letrozole due to LMW-E expression in breast cancer cells." | 3.76 | Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. ( Akli, S; Biernacka, A; Bui, T; Hunt, KK; Keyomarsi, K; Moulder, S; Tucker, SL; Wingate, H, 2010) |
| "Aromatase-expressing breast cancer cells were treated with letrozole and ZA either simultaneously or in sequence, and the resulting apoptosis was assessed by staining with Hoechst 33342 and propidium iodide and examined using a fluorescent inverted Leica DMIRB microscope and a UV filter." | 3.76 | Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. ( Coleman, RE; Holen, I; Neville-Webbe, HL, 2010) |
| "These data suggest that AEE788 plus letrozole in breast cancer overexpressing HER2 may provide superior anti-tumour activity, compared with single agents." | 3.76 | EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. ( Dowsett, M; Evans, AH; Evans, DB; Farmer, I; Johnston, SR; Martin, LA; Pancholi, S; Thornhill, A, 2010) |
| "In an earlier study, we have observed an increase of alpha-tocopherol in breast cancer patients treated with third-generation aromatase inhibitors that was related to tamoxifen withdrawal." | 3.76 | Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol. ( Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Melichar, B; Plísek, J; Solichová, D; Studentová, H, 2010) |
| "The Breast International Group (BIG) 1-98 and Arimidex, Tamoxifen Alone or in Combination (ATAC) trials demonstrated that, in postmenopausal women with hormone receptor positive (HR+) early-stage breast cancer, 5 years of initial adjuvant endocrine therapy with letrozole or anastrozole is superior to tamoxifen." | 3.76 | Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer. ( Delea, TE; Guo, A; Lipsitz, M, 2010) |
| " As an example, STEPP methodology is used to explore patterns of treatment effect for varying levels of the biomarker Ki-67 in the BIG (Breast International Group) 1-98 randomized clinical trial comparing letrozole with tamoxifen as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer." | 3.76 | Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. ( Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA, 2010) |
| "The aromatase inhibitor letrozole effectively treats breast cancer by decreasing estrogen levels in postmenopausal women." | 3.76 | Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer. ( Chetver, L; Hussein, O; Zidan, J; Zucker, M, 2010) |
| "We report a 69-year-old woman with breast cancer who was effectively treated with letrozole as a second-line therapy after becoming resistant to anastrozole." | 3.76 | [Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy]. ( Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S, 2010) |
| "4%), who have participated in the international, randomized, phase III clinical trial PO25 comparing letrozole with tamoxifen in 907 patients with advanced breast cancer." | 3.75 | An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. ( Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB, 2009) |
| "FOXP3+ Tregs were quantified in tumor samples collected at baseline by incisional biopsy and after 6 months at definitive surgery in 83 elderly breast cancer patients (T2-4 N0-1) enrolled in a randomized phase II trial based on 6 months of primary letrozole (2." | 3.75 | Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. ( Aguggini, S; Allevi, G; Banham, AH; Bates, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Campo, L; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M, 2009) |
| "Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer." | 3.75 | Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. ( Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Renshaw, L; Sing, T; Walker, JR, 2009) |
| "Eight hundred eighty-five women with stage I-III breast cancer who completed 4 to 6 years of tamoxifen in 2004 with no documented recurrence were sent letters describing extended adjuvant letrozole in February 2005." | 3.75 | Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole. ( Ellard, SL; Gelmon, KA; Kennecke, HF; McArthur, HL; O'Reilly, SE; Olivotto, IA; Speers, CH, 2009) |
| "Taken together, data indicate that SERMs/antiestrogens and aromatase inhibitors exhibit opposed effects on the ER expression of breast cancer cells: tamoxifen and fulvestrant up-regulate ERalpha expression, while aromatase inhibitors increase ERbeta expression, which may contribute to the aromatase inhibitors' therapeutic superiority over antiestrogens." | 3.75 | Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells. ( Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P, 2009) |
| "Genistein (GEN), a soy isoflavone, stimulates growth of estrogen-dependent human tumor cells (MCF-7) in a preclinical mouse model for postmenopausal breast cancer." | 3.74 | Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. ( Doerge, DR; Hartman, JA; Helferich, WG; Ju, YH; Kwak, J; Woodling, KA, 2008) |
| "Tumors from 228 postmenopausal women with confirmed ER+ stage 2 and 3 breast cancers in the P024 neoadjuvant endocrine therapy trial, which compared letrozole and tamoxifen for 4 months before surgery, were analyzed for posttreatment ER status, Ki67 proliferation index, histological grade, pathological tumor size, node status, and treatment response." | 3.74 | Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. ( A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A, 2008) |
| "A total of 103 breast cancer survivors: 35 using TMXg, 34 using letrozole group (LTZg) and 34 using no endocrine treatment group (NETg) were evaluated." | 3.74 | Sonographic evaluation of endothelial function in letrozole and tamoxifen users. ( Dos Reis, FJ; Ferriani, RA; Filho, FM; Martins, WP; Nastri, CO, 2008) |
| "Adjuvant tamoxifen therapy for 5 years reduces recurrence in hormone receptor positive, post-menopausal women with early breast cancer, but offers no advantage when prolonged to another 5 years, during which the risk of recurrence remains high." | 3.74 | Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. ( Brandman, J; Delea, T; El Ouagari, K; Karnon, J; Talbot, W, 2007) |
| "Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer." | 3.74 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007) |
| "We examined 12 consecutive non-metastatic breast cancer patients who reported severe musculoskeletal pain under a third generation AI; 11 were on letrozole and 1 on exemestane." | 3.74 | Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. ( Amant, F; Berteloot, P; Christiaens, MR; De Smet, L; Leunen, K; Morales, L; Neven, P; Pans, S; Paridaens, R; Smeets, A; Timmerman, D; Van den Bogaert, W; Van Limbergen, E; Vergote, I; Verhaeghe, J; Weltens, C; Westhovens, R; Wildiers, H, 2007) |
| "The aromatase inhibitors Anastrozole, Letrozole (type 2 nonsteroidal aromatase inhibitors: n-SAI) and Exemestane (type 1 steroidal aromatase inactivator) are used respectively as first- and second-line hormonal therapy in postmenopausal metastatic breast cancer women." | 3.74 | Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. ( Alimonti, A; Bria, E; Carlini, P; Cognetti, F; Cresti, N; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Michelotti, A; Milella, M; Papaldo, P; Pellegrini, M; Ricci, S; Ruggeri, EM; Salesi, N, 2007) |
| "Aromatase inhibitors that block the synthesis of estrogen are proving to be superior to antiestrogens and may replace tamoxifen as first-line treatment for postmenopausal estrogen receptor (ER)-positive breast cancer patients." | 3.74 | Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens. ( Brodie, A; Goloubeva, O; Jelovac, D; Sabnis, G; Schayowitz, A, 2007) |
| "In Breast International Group (BIG) 1-98, a randomized, double-blind trial comparing 5 years of initial adjuvant therapy with letrozole versus tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer, letrozole significantly improved disease-free survival by 19% and reduced risk of breast cancer recurrence by 28% and distant recurrence by 27%." | 3.74 | Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. ( Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK, 2007) |
| "Five years with the aromatase inhibitors letrozole or anastrozole is clinically superior to 5 years tamoxifen in postmenopausal women with early breast cancer." | 3.74 | Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. ( Barghout, V; Delea, T; Karnon, J, 2008) |
| "In this specifically designed, prospective study, the authors addressed the predictive value of circulating levels of the extracellular domain (ECD) of HER2 in patients with metastatic breast cancer who were treated with letrozole." | 3.74 | High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study. ( Alba, E; Barnadas, A; Colomer, R; Constenla, M; Fernández, R; Gil, M; Gilabert, M; Llombart-Cussac, A; Lloveras, B; Mayordomo, JI; Ramos, M; Tusquets, I, 2007) |
| " Clinical response was assessed by serial ultrasound measurements in postmenopausal women with large, primary, estrogen receptor-rich breast cancers who received neoadjuvant treatment with letrozole for 3 months." | 3.74 | Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. ( Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Walker, JR, 2008) |
| "To evaluate the efficacy of treatment with the aromatase inhibitor letrozole in breast cancer patients segregated with respect to DNA polymorphisms of the aromatase gene CYP19." | 3.74 | A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. ( Alba, E; Artells, R; Baena, JM; Barnadas, A; Calvo, L; Carabantes, F; Colomer, R; Crespo, C; Gilabert, M; Llombart, A; Lloveras, B; Monzo, M; Muñoz, M; Plazaola, A; Rifa, J; Tusquets, I, 2008) |
| "These radiobiological results may form the basis for concurrent use of letrozole and radiation as postsurgical adjuvant therapy for breast cancer." | 3.73 | Letrozole sensitizes breast cancer cells to ionizing radiation. ( Azria, D; Cunat, S; Evans, DB; Gourgou, S; Larbouret, C; Martineau, P; Ozsahin, M; Pèlegrin, A; Pujol, P; Romieu, G, 2005) |
| "Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance." | 3.73 | Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. ( Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A, 2005) |
| "To present the basis of the decision of the Food and Drug Administration to grant accelerated approval for letrozole for extended adjuvant treatment of early-stage breast cancer in postmenopausal women after completion of adjuvant tamoxifen." | 3.73 | Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. ( Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G, 2005) |
| "Two third-generation aromatase inhibitors, letrozole and anastrozole, and the antiestrogen tamoxifen, were compared for growth-inhibiting activity in two estrogen receptor (ER)-positive aromatase-overexpressing human breast cancer cell lines, MCF-7aro and T-47Daro." | 3.73 | Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. ( Chen, S; Itoh, T; Kijima, I, 2005) |
| "The steroidal aromatase inactivator exemestane has demonstrated activity after prior failure of non-steroidal aromatase inhibitors (including third-generation inhibitors letrozole and anastrozole) in postmenopausal women with advanced breast cancer." | 3.73 | Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. ( Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F, 2005) |
| "We have investigated the effect of HER-2 overexpression on resistance to the aromatase inhibitor letrozole in MCF-7 breast cancer cells stably expressing cellular aromatase (MCF-7/CA)." | 3.73 | ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. ( Arteaga, CL; Miller, T; Shin, I, 2006) |
| "The introduction of third generation aromatase inhibitors [anastrozole, letrozole, and exemestane] has certainly improved outcomes inpatients with early breast cancer." | 3.73 | Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition. ( Gltick, S, 2005) |
| "A premenopausal woman with early stage breast cancer became amenorrheic with adjuvant chemotherapy, and remained so during 5 years of daily tamoxifen." | 3.73 | Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors. ( Hargis, JB; Nakajima, ST, 2006) |
| "To investigate the value of baseline serum levels of VEGF, bFGF, endostatin and their ratio as predictive factors of response to endocrine therapy in patients with metastatic breast cancer (MBC) and positive ER treated with letrozole after tamoxifen failure." | 3.73 | Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. ( Alba, E; Barnadas, A; Carabante, F; Colomer, R; Fernández, R; Gil, M; González, J; Llombart, A; Mayordomo, JI; Palomero, I; Ramos, M; Ribelles, N; Ruiz, M; Soriano, V; Tusquets, I; Vera, R, 2006) |
| "To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors." | 3.73 | Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. ( Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C, 2006) |
| "To estimate the cost-effectiveness of extended adjuvant letrozole in postmenopausal women with early breast cancer and estrogen or progesterone receptor-positive tumors who had completed 5 years of adjuvant tamoxifen." | 3.73 | Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. ( Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC, 2006) |
| "Stages I-IIIA breast cancer patients (n = 47) received 5 mg/d letrozole and 150-300 IU FSH to cryopreserve embryos or oocytes." | 3.73 | Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. ( Bang, H; Cil, A; Hourvitz, A; Oktay, K; Oktem, O; Safro, B; Sahin, G, 2006) |
| "Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced breast cancer." | 3.72 | A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. ( Jones, T; Karnon, J, 2003) |
| "Morphological characteristics, grading features, proliferation marker MIB1, apoptosis (by Tdt-mediated duTP-biotin nick-end labelling (TUNEL)), Bcl-2 expression, oestrogen receptor (ER) and progesterone receptor (PgR) status were compared in ER-positive breast cancers before and after 3 months of neoadjuvant therapy with either letrozole or tamoxifen." | 3.72 | Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. ( Anderson, TJ; Cameron, D; Dixon, JM; Macfarlane, L; Miller, WR, 2003) |
| "Tamoxifen (TAM) provides an effective agent for treatment of hormone-dependent breast cancer but resistance uniformly ensues upon continued use." | 3.72 | New approaches to the understanding of tamoxifen action and resistance. ( Berstein, LM; Harada, H; Lykkesfeldt, AE; Naftolin, F; Santen, RJ; Shanabrough, M; Wang, JP; Yue, W; Zheng, H, 2003) |
| "Recent randomized clinical trials (RCT) comparing anastrozole (Arimidex) and letrozole (Femara) to tamoxifen in the first-line treatment of postmenopausal women with advanced hormone-sensitive breast cancer have demonstrated that both agents were at least as effective as tamoxifen." | 3.72 | Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. ( Dranitsaris, G; Trudeau, M; Verma, S, 2003) |
| "We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months." | 3.72 | Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. ( Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M, 2003) |
| "An economic evaluation was conducted comparing anastrozole, exemestane, letrozole and megestrol for the second-line treatment of postmenopausal patients with hormone-sensitive metastatic breast cancer who had failed tamoxifen." | 3.72 | Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer. ( Rocchi, A; Verma, S, 2003) |
| "Aromatase inhibitors (AIs) are now under investigation for the treatment of early stage breast cancer and for disease prevention as alternatives to standard treatment with tamoxifen." | 3.72 | Role of biologic markers in patient selection and application to disease prevention. ( Dowsett, M; Ellis, MJ, 2003) |
| "The antiestrogen tamoxifen has potent activity against estrogen receptor-positive breast cancer, but two nonsteroidal aromatase inhibitors, letrozole and anastrozole, show considerable advantages over tamoxifen with respect to patient survival and tolerability." | 3.72 | Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A, 2004) |
| "Tamoxifen treatment inhibited breast cancer cell growth and increased BMD but caused uterine hypertrophy in this preclinical model of postmenopausal breast cancer." | 3.72 | Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer. ( Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN, 2004) |
| "In this cost-effectiveness analysis using previously published clinical data and year-2003 cost data from a community hospital in the Italian National Health Service, anastrozole and letrozole were both cost-effective alternatives to tamoxifen for first-line therapy of postmenopausal women with advanced estrogen receptor-positive breast cancer." | 3.72 | Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service. ( Caruggi, M; Colombo, G; Marchetti, M, 2004) |
| "To optimize treatment strategies for postmenopausal breast cancer patients, we investigated the efficacy of the steroidal aromatase inhibitor exemestane alone or in combination with the antiestrogen tamoxifen in a xenograft model of postmenopausal breast cancer." | 3.72 | Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. ( Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L, 2004) |
| " This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR)." | 3.71 | Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? ( Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM, 2001) |
| "To determine the effects of aromatase inhibitors on oestrogen uptake, in situ aromatase activity and endogenous oestrogens in the breast, postmenopausal women with large primary ER-rich breast cancers have been treated neoadjuvantly for 3 months with either letrozole (2." | 3.71 | Local endocrine effects of aromatase inhibitors within the breast. ( Dixon, JM; Miller, WR, 2001) |
| "Postmenopausal women with large primary oestrogen receptor-rich (>20 fmol/mg protein or 80 histoscore) breast cancers have been treated neoadjuvantly with either letrozole (2." | 3.71 | Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. ( Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR, 2001) |
| "High-dose estrogen was generally considered the endocrine therapy of choice for postmenopausal women with breast cancer prior to the introduction of tamoxifen." | 3.71 | Estrogen as therapy for breast cancer. ( Ingle, JN, 2002) |
| "Although the antiestrogen tamoxifen has been the mainstay of therapy for estrogen receptor (ER)-positive breast cancer, successful treatment of responsive tumors is often followed by the acquisition of tamoxifen resistance." | 3.70 | Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. ( Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L, 1998) |
| "To simulate the treatment of postmenopausal women with advanced breast cancer from second-line hormone therapy to death, and to generate estimates of the cost and effectiveness of letrozole and megestrol in order to determine the incremental cost effectiveness of letrozole, expressed as cost per life-years gained." | 3.70 | Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. ( Meester, L; Nuijten, M; Waibel, F; Wait, S, 1999) |
| "Twenty patients (pts) with metastatic breast cancer with disease progression, previously treated with chemotherapy and tamoxifen, were administered oral letrozole (2." | 3.70 | Letrozole for the treatment of pretreated advanced breast cancer patients: preliminary report. ( Cappellini, GC; Casali, A; Casali, M; Giuntini, T; Sega, FM; Terzoli, E, 2000) |
| "Randomized trials comparing the aromatase inhibitors, anastrozole and letrozole, to megestrol acetate (MA) in postmenopausal women with advanced breast cancer demonstrated that both agents are better tolerated than MA with comparable efficacy." | 3.70 | Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. ( Dranitsaris, G; Leung, P; Mather, J; Oza, A, 2000) |
| "Estrogen receptor (ER)-positive endometrial cancers (ECs) are characterized by phosphatidylinositol 3-kinase (PI3K) and receptor tyrosine kinase (RTK)/RAS/β-catenin (CTNNB1) pathway alterations in approximately 90% and 80% of cases, respectively." | 3.30 | A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. ( Bouberhan, S; Bowes, B; Campos, S; Castro, C; Cheng, SC; Hayes, M; Horowitz, N; Kolin, DL; Konstantinopoulos, PA; Krasner, C; Lee, EK; Liu, JF; Matulonis, UA; Needham, H; Penson, RT; Polak, M; Sawyer, H; Shea, M; Wright, AA; Xiong, N; Yeku, O, 2023) |
| "Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy." | 3.30 | A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. ( Acosta, EP; Elkhanany, AM; Forero-Torres, A; Grizzle, WE; Li, Y; Ryan, KJ; Stringer-Reasor, EM; Theuer, CP; Vaklavas, C; Wei, S; Yang, ES, 2023) |
| "Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (MBC)." | 3.30 | Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial. ( Hu, ZY; Li, J; Liu, B; Liu, L; Luo, T; Ouyang, Q; Ran, L; Sun, T; Xiao, H; Xie, N; Xiong, H; Yan, M; Yang, X; Zhong, J, 2023) |
| "Women with hormone receptor positive breast cancer may receive 5 years of treatment with aromatase inhibitors but the magnitude of benefit was relatively small." | 3.11 | Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. ( Goss, PE; Ingle, JN; Li, Y; Parulekar, WR; Qin, G; Tu, D; Zheng, X, 2022) |
| " Rates of all-grade and Grade ≥3 adverse events (AEs) were 99." | 3.11 | Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial. ( Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R, 2022) |
| "Current therapies for HER2-positive breast cancer have limited efficacy in patients with triple-positive breast cancer (TPBC)." | 3.11 | A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer. ( Cai, Z; Chen, G; de Faria Castro Fleury, E; Gu, X; Guo, W; Han, H; He, G; Huang, Y; Huo, S; Jahromi, AH; Jerusalem, G; Jiang, X; Li, H; Li, J; Li, K; Li, P; Li, Y; Li, Z; Liu, C; Liu, T; Niu, N; Qiu, F; Tripodi, D; Xu, H; Xu, Q; Xue, J; Zhang, D; Zhang, G; Zhang, H; Zhang, P; Zhao, Y; Zheng, X, 2022) |
| "Instituto de Salud Carlos III, Breast Cancer Now, the Breast Cancer Research Foundation, the American Association for Cancer Research, Fundació La Marató TV3, the European Union's Horizon 2020 Research and Innovation Programme, Pas a Pas, Save the Mama, Fundación Científica Asociación Española Contra el Cáncer, PhD4MDgrant of "Departament de Salut", exp SLT008/18/00122, Fundación SEOM and ESMO." | 3.01 | Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. ( Adamo, B; Bellet, M; Brasó-Maristany, F; Carey, LA; Chic, N; Ciruelos, E; Cortés, J; Galván, P; Gavilá, J; González-Farré, B; Martínez, D; Martínez-Sáez, O; Muñoz, M; Oliveira, M; Pascual, T; Pernas, S; Perou, CM; Prat, A; Sanfeliu, E; Saura, C; Schettini, F; Soberino, J; Vidal, M, 2021) |
| "Women with HER2-positive breast tumors measuring ≥2 cm (median = 5 cm) were randomized in a 1:2 ratio to 12 versus 24 weeks of lapatinib and trastuzumab." | 2.94 | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. ( De Angelis, C; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Jiralerspong, S; Krop, I; Nanda, R; Nangia, JR; Niravath, P; Osborne, CK; Pavlick, A; Rexer, BN; Rimawi, MF; Schiff, R; Storniolo, AM; Veeraraghavan, J; Wang, T; Wolff, AC, 2020) |
| "Patients with breast cancer (BC) show strong interest in complementary and alternative medicine (CAM), particularly for adverse effects of adjuvant endocrine treatment - e." | 2.94 | Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Willer, L; Wolf, C; Wuerstlein, R, 2020) |
| "Up to 75% of breast cancers express the oestrogen receptor or progesterone receptor (hormone-receptor-positive)." | 2.94 | Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page? ( Bascialla, L; De Giorgi, A; Gallerani, E; Giaquinto, A; Grigioni, E; Gueli, R; Marrazzo, C; Nigro, O; Pinotti, G; Vallini, I, 2020) |
| "Primary endocrine therapy for ductal carcinoma in situ (DCIS) as a potential alternative to surgery has been understudied." | 2.94 | Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance). ( Bedrosian, I; Caudle, A; Chen, YY; Dickson-Witmer, D; Duong, S; Esserman, L; Guenther, J; Hardman, T; Hendrix, LH; Hieken, T; Hoefer, R; Hudis, CA; Hwang, ES; Hylton, N; Hyslop, T; Krings, G; Lyss, AP; Marks, J; Ollila, DW; Price, E; Winer, E, 2020) |
| "Estrogen receptor positive (ER+) breast cancer constitutes almost 85% of all breast cancer patients and are a genetically highly heterogenic group." | 2.94 | Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients. ( Ahlborn, LB; Ejlertsen, B; Eriksen, JO; Jensen, MB; Knoop, AS; Laenkholm, AV; Rossing, M; Skriver, SK, 2020) |
| "Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule." | 2.90 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. ( Barry, P; Batten, LM; Bliss, JM; Boileau, JF; Cheang, MCU; Cornman, C; Dodson, A; Dolling, D; Dowsett, M; Fisher, K; Holcombe, C; Huang Bartlett, C; Jacobs, SA; Jeffs, LK; Johnston, S; Julian, TB; Koehler, M; MacKenzie, M; Martins, V; McIntosh, SA; Modi, A; Morden, J; Osborne, CK; Perry, S; Pogue-Geile, KL; Provencher, L; Puhalla, S; Rimawi, M; Ring, A; Robidoux, A; Shalaby, I; Snowdon, C; Stein, RC; Thirlwell, M; Wheatley, D; Wilcox, M; Wolmark, N, 2019) |
| "AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors." | 2.90 | Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. ( Baker, GM; Brown, M; Colleoni, M; Hazra, A; Heng, YJ; Kammler, R; Kensler, KH; Pyle, ME; Regan, MM; Schnitt, SJ; Tamimi, RM; Thürlimann, B; Viale, G, 2019) |
| "The development of joint pain was similar in the two groups." | 2.90 | Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. ( Almstedt, K; Baake, G; Bayer, CM; Beckmann, MW; Brodkorb, T; Brucker, C; Brucker, SY; Fasching, PA; Fehm, T; Fischer, G; Fridman, A; Gass, P; Graf, H; Häberle, L; Hack, CC; Harbeck, N; Hartkopf, AD; Hein, A; Heindl, F; Hoffmann, O; Janni, W; Kohls, A; Kolberg, HC; Krabisch, P; Kuemmel, S; Lindner, C; Loehberg, CR; Lux, MP; Maass, N; Malter, W; Martin, B; Nabieva, N; Pelzer, V; Rack, B; Rauh, C; Rody, A; Schulz, V; Steinfeld-Birg, D; Thomssen, C; Volz, B; Walter, CB; Weigel, M; Wolf, C; Wuerstlein, R, 2019) |
| " Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period." | 2.90 | Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. ( Apala, JV; Colomer, R; Gonzalez-Cortijo, L; Guerra, J; Hornedo, J; Malon, D; Mouron, S; Quintela-Fandino, M, 2019) |
| " Palbociclib, when administered with letrozole at the recommended therapeutic dosing regimen, did not prolong the QT interval to a clinically relevant extent." | 2.87 | Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. ( Durairaj, C; Ettl, J; Finn, RS; Gauthier, ER; Hoffman, JT; Huang, X; Joy, AA; Lu, DR; Rugo, HS; Ruiz-Garcia, A; Wang, DD; Wilner, KD; Zheng, J, 2018) |
| "Chemotherapy for breast cancer may have a negative impact on reproductive function due to gonadotoxicity." | 2.84 | Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. ( Balkenende, EME; Beerendonk, CCM; Bos, AME; Cantineau, AEP; Dahhan, T; de Bruin, JP; Fleischer, K; Goddijn, M; Kopeika, Y; Lambalk, CB; Linn, SC; Louwé, LA; Reddy, N; Schats, R; Schipper, I; Smeenk, JMJ; Stoop, D; van der Veen, F; van Golde, RJT; van Wely, M, 2017) |
| "NBRST IHC/FISH HR+/HER2- breast cancer patients (n = 474) were classified into four molecular subgroups by MammaPrint/BluePrint subtyping: Luminal A, Luminal B, HER2, and Basal type." | 2.84 | Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping. ( Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P, 2017) |
| "Letrozole is a powerful endocrine medication that targets and inhibits the aromatase, often known as an aromatase inhibitor (AI)." | 2.82 | Letrozole: Pharmacology, toxicity and potential therapeutic effects. ( Chakraborty, R; Dey, A; Gopalakrishnan, AV; K K, V; Mukherjee, AG; Nagarajan, D; P, JP; Renu, K; T, TP; V, A; Vellingiri, B; Wanjari, UR, 2022) |
| " Further studies are needed to determine the feasibility of selecting an effective AI dosing schedule with better tolerability." | 2.82 | Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk. ( Boughey, JC; Chow, HH; Frank, D; Hsu, CH; Lang, JE; Ley, M; López, AM; Perloff, M; Pruthi, S; Taverna, JA, 2016) |
| "We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors." | 2.82 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016) |
| "Women with tubular/cribriform breast cancer had the best outcomes for all end points compared with the other three histotypes, and had less breast cancer recurrence (97." | 2.80 | Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial. ( Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G, 2015) |
| "Letrozole-treated patients with rs2077647 (T>C) variants CC and TC had a reduced risk of bone AE (HR = 0." | 2.80 | ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. ( Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B, 2015) |
| "Symptom clusters in breast cancer survivors that are present before the initiation of adjuvant AI therapy may have a negative impact on a patient's persistence with therapy." | 2.79 | Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. ( Carpenter, J; Clauw, DJ; Flockhart, DA; Harte, SE; Hayes, DF; Henry, NL; Kidwell, KM; Stearns, V; Storniolo, AM; Williams, DA, 2014) |
| "Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures." | 2.77 | Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. ( Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G, 2012) |
| "Women with previous unilateral breast cancer or prior prophylactic oophorectomy are more likely to enter a medical prevention trial." | 2.77 | Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial. ( Baudry, K; Berthet, P; Bignon, YJ; Chabbert-Buffet, N; Chiesa, J; Clough, KB; Delaloge, S; Delnatte, C; Dreyfus, H; Dugast, C; Fricker, JP; Gesta, P; Gladieff, L; Lasset, C; Lemonnier, J; Lesur, A; Lortholary, A; Martin, AL; Mijonnet, S; Nogues, C; Prieur, F; Pujol, P; Roca, L; Tennevet, I; This, P; Vennin, P, 2012) |
| "Endocrine therapy for breast cancer may affect cognition." | 2.76 | Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. ( Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Sun, Z; Thompson, A; Thürlimann, B, 2011) |
| "Additionally, breast cancer patients with new onset or worsening of pain over the study period had a significantly smaller change in mean DHEAS concentration from baseline to 3 months (P = 0." | 2.76 | Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. ( Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B, 2011) |
| "However, not all breast cancer patients respond to aromatase inhibitors (AI), and many patients become unresponsive or relapse." | 2.76 | Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. ( Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC, 2011) |
| "Put-analysis in 40 patients with breast cancer, to chanalicular infiltrated, eligible were treated in a prospective study, to double blind person, using per os: letrozol, 2." | 2.76 | [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer]. ( Amador, DD; Font López, KC; Novoa Vargas, A, 2011) |
| "Letrozole therapy was associated with a significant reduction in mean serum estradiol, estrone, and estrone sulfate levels at 12 months, but not at 24 months." | 2.75 | A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. ( Cigler, T; Findlay, B; Goss, PE; Hu, H; Johnston, D; Qi, S; Richardson, H; Tu, D; Verma, S; Yaffe, MJ, 2010) |
| "In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen." | 2.75 | Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. ( Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Stephens, A; Sun, Z; Thompson, A; Thürlimann, B, 2010) |
| "Postmenopausal women with breast cancer (BC) are at increased risk for bone loss." | 2.74 | Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. ( Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA, 2009) |
| "A total of 215 women with breast cancer were prospectively evaluated for fertility preservation before adjuvant chemotherapy." | 2.73 | Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. ( Azim, AA; Costantini-Ferrando, M; Oktay, K, 2008) |
| "The letrozole dose was fixed at 2." | 2.73 | A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. ( Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK, 2008) |
| "Corresponding mRNA in ovarian cancer cell lines treated with 17beta-estradiol (E2) was measured by quantitative RT-PCR." | 2.73 | Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. ( Cameron, DA; Langdon, SP; MacLeod, K; Smyth, JF; Walker, G; Williams, AR, 2007) |
| "Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67." | 2.73 | Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. ( Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D, 2008) |
| "The incidence of bone fractures, observed more often in the letrozole group, did not differ by age." | 2.73 | Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. ( Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B, 2008) |
| " The other therapies like hormonal therapy, surgery, radiotherapy, and immune therapy are in use but showed many side effects like bioavailability issues, non-selectivity, pharmacokinetic-pharmacodynamic problems." | 2.72 | Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. ( Arya, GC; Jaitak, V; Kaur, K, 2021) |
| "HER2-positive (HER2+) breast cancer represents a heterogeneous breast cancer subtype, including both oestrogen receptor (ER) positive and negative tumours." | 2.72 | CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. ( Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M, 2021) |
| "In patients who had metastatic breast cancer, decreased serum EGFR/normal serum HER-2 predicted shorter survival compared with patients who had normal levels of serum EGFR/HER-2." | 2.72 | Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer. ( Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Hackl, W; Hamer, P; Leitzel, K; Lipton, A; Souder, C, 2006) |
| "Using both IHC and FISH, advanced breast cancers show statistical evidence of decreasing incidence of Her2/neu expression after antiaromatase neoadjuvant treatment." | 2.71 | Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. ( Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L, 2004) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Distant metastases from breast cancer are incurable." | 2.71 | Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. ( Carpi, A; Nicolini, A, 2005) |
| " Drug-related adverse events occurred in 35." | 2.70 | [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. ( Ikeda, S; Kimijima, I; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H, 2002) |
| "Letrozole is an orally competitive aromatase inhibitor." | 2.69 | Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. ( Bajetta, E; Bichisao, E; Celio, L; Di Leo, A; Dowsett, M; Guillevin, L; Marchianò, A; Martinetti, A; Pozzi, P; Stani, S; Zilembo, N, 1999) |
| "Letrozole appears to be a very promising new antiaromatase drug." | 2.68 | Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. ( Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF, 1996) |
| "Letrozole is a new highly selective and potent aromatase inhibitor." | 2.68 | A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. ( Camoriano, JK; Gerstner, JB; Gesme, DH; Hartmann, LC; Hatfield, AK; Ingle, JN; Johnson, PA; Loprinzi, CL; Mailliard, JA; Suman, VJ, 1997) |
| " Adverse event rates were similar in age-stratified subsets." | 2.58 | Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review. ( Freedman, RA; Tolaney, SM, 2018) |
| "Because incidence of breast cancer and comorbidities increase with age, it is important to determine treatment benefit in elderly patients." | 2.58 | Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. ( Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S, 2018) |
| "Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide." | 2.49 | Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. ( Brauch, H; Precht, JC; Saladores, PH; Schroth, W; Schwab, M, 2013) |
| "tamoxifen." | 2.49 | Obesity and endocrine therapy: host factors and breast cancer outcome. ( Goodwin, PJ, 2013) |
| "Majority of breast cancer cases in India at presentation are locally advanced, that is large breast tumours (> 5 cm in diameter) with skin or chest wall involvement or with involvement of locoregional lymph nodes." | 2.49 | Neoadjuvant chemotherapy in breast cancer: review of literature. ( Batra, U; Doval, DC; Dutta, K; Talwar, V, 2013) |
| "Early hormone-receptor-positive breast cancer is a chronic relapsing disease that can remain clinically silent for many years." | 2.49 | Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. ( Goss, PE; Higgins, MJ; Liedke, PE, 2013) |
| "Sorafenib is an oral multikinase inhibitor with anti-angiogenic and anti-proliferative activity that is indicated for use in hepatocellular and renal cell carcinomas." | 2.48 | Sorafenib in locally advanced or metastatic breast cancer. ( Gradishar, WJ, 2012) |
| "The National Surgical Adjuvant Study of Breast Cancer (N-SAS-BC06) New primary Endocrine-therapy Origination Study (NEOS) is a randomized phase III trial conducted in Japanese centers." | 2.47 | Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept. ( Iwata, H, 2011) |
| "To review the clinical effectiveness and cost-effectiveness evidence base for lapatinib (LAP) in combination with an aromatase inhibitor (AI) and trastuzumab (TRA) in combination with an AI for the first-line treatment of patients who have hormone receptor-positive (HR+)/human epidermal growth factor 2-positive (HER2+) mBC." | 2.47 | Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. ( Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N, 2011) |
| "HER2-positive breast cancer accounts for 20 to 25% of breast cancers." | 2.46 | [Management of metastatic HER2-positive breast cancer: present and future]. ( Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S, 2010) |
| "Estrogen-dependent breast cancer (EDBC) is a kind of common malignant tumor in postmenopausal women with growing tendency in recent years." | 2.46 | Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer. ( Jiao, J; Liao, Q; Xiang, H, 2010) |
| "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels." | 2.46 | Women and bone health: maximizing the benefits of aromatase inhibitor therapy. ( Tang, SC, 2010) |
| "We have developed a breast cancer intratumoral aromatase model to simulate the postmenopausal breast cancer patient in order to compare the antitumor efficacy of aromatase inhibitors (AIs) and antiestrogens (AEs)." | 2.45 | Aromatase inhibitors and breast cancer. ( Brodie, A; Macedo, LF; Sabnis, G, 2009) |
| "Given the common hormonal dependence of breast cancer and the potential synergistic effect of these two treatment modalities, this strategy has been increasing in the adjuvant setting." | 2.45 | [Adjuvant breast cancer treatment with hormono-radiotherapy]. ( Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K, 2009) |
| "Letrozole (Femara) is a third-generation, nonsteroidal aromatase inhibitor." | 2.45 | Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. ( Keating, GM, 2009) |
| "Medico-economic evaluation of breast cancer is very significant and valuable and is expected to stimulate efficient utilization of healthcare resources." | 2.44 | Economic evaluation of the prevention and treatment of breast cancer--present status and open issues. ( Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K, 2007) |
| "The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs." | 2.44 | [Advancement in endocrine therapy for breast cancer]. ( Lian, ZQ; Yang, MT, 2007) |
| "Letrozole has been found to be well tolerated in the initial adjuvant treatment setting, and these data have been confirmed by long-term safety data from the monotherapy analysis in the BIG 1-98 study." | 2.44 | The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer. ( Monnier, AM, 2007) |
| "Women with early breast cancer are exposed to an ongoing risk of relapse, even after successful surgical resection of the primary tumor and, where given, radiotherapy." | 2.44 | Reducing the risk of late recurrence in hormone-responsive breast cancer. ( Cufer, T, 2007) |
| "Letrozole has greater potency than other AIs, including anastrozole, exemestane, formestane, and aminoglutethimide." | 2.44 | The discovery and mechanism of action of letrozole. ( Bhatnagar, AS, 2007) |
| "Breast cancer is the most frequent cancer in reproductive age women." | 2.44 | Assisted reproduction and breast cancer. ( Atabekoglu, C; Sonmezer, M, 2007) |
| "Letrozole is a potent third-generation aromatase inhibitor that suppresses plasma estrogen levels to near-undetectable levels in postmenopausal women." | 2.44 | Update on the use of letrozole in breast cancer. ( Goss, PE; Wu, M, 2007) |
| "Breast cancer is a leading cause of cancer death among women worldwide." | 2.44 | Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer. ( Dodwell, D; Williamson, D, 2008) |
| "Patients treated surgically for early breast cancer show a peak recurrence 2 years following surgery." | 2.44 | A review of the BIG results: the Breast International Group 1-98 trial analyses. ( Doughty, JC, 2008) |
| "Hormone receptor-positive breast cancer is increasingly considered a chronic disease, as there remains an ongoing risk of local and distant relapse for years after diagnosis." | 2.44 | The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer. ( Pennery, E, 2008) |
| "All women with early breast cancer, even those with small tumors and negative nodes, remain at appreciable risk of recurrence after surgery over the subsequent 10-15 years." | 2.43 | Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. ( Kaufmann, M; Rody, A, 2005) |
| "They are effective as therapies for breast cancer only in postmenopausal women whose tumours express oestrogen or progesterone receptors." | 2.43 | The aromatase inhibitors in early breast cancer: who, when, and why? ( Hamilton, AL; Nordman, IC; Spillane, AJ, 2005) |
| "Letrozole was also superior to tamoxifen in first-line treatment for advanced breast cancer, as well as in systemic preoperative (neoadjuvant) treatment of locally advanced breast cancer." | 2.43 | Letrozole in the treatment of breast cancer. ( Bhatnagar, AS; Mouridsen, HT, 2005) |
| "Women undergoing treatment for breast cancer often have a number of pre-existing risk factors for bone loss, including existing or induced postmenopausal status." | 2.43 | Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. ( Aapro, M, 2006) |
| "Letrozole is an oral drug given once daily and the first choice for the treatment of patients with steroid receptor positive or receptor-unknown locally advanced or metastatic postmenopausal breast cancer." | 2.43 | [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer]. ( Tsukagoshi, S, 2006) |
| "Bone loss may be a potential side effect of implementing aromatase inhibitors in the adjuvant setting." | 2.43 | Bone safety of aromatase inhibitors versus tamoxifen. ( Lønning, PE, 2006) |
| "Anastrozole treatment has no impact on plasma lipid levels, whereas both letrozole and exemestane have an unfavorable effect." | 2.42 | Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. ( Buzdar, AU, 2003) |
| " Although published information about the side effects of AIs is scarce, it is likely that they will have adverse effects on bone and possibly also on lipid metabolism." | 2.42 | Safety issues surrounding the use of aromatase inhibitors in breast cancer. ( Dixon, JM; Jackson, J; Miller, WR, 2003) |
| "Risk factors of breast cancer are listed and evaluated individually." | 2.42 | [Perspectives for the hormonal therapy of breast cancer]. ( Eckhardt, S, 2003) |
| "The goal of endocrine therapy in breast cancer is to block the action of estrogen on the tumor cells either by inhibiting estrogen from binding to the specific estrogen receptor or by inhibiting its synthesis." | 2.42 | Challenges in the endocrine management of breast cancer. ( Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE, 2003) |
| "The death rate from breast cancer is falling rapidly in most developed countries due, at least in part, to the use of adjuvant endocrine therapy in women with endocrine responsive disease." | 2.42 | Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? ( Clemons, M; Coleman, RE; Verma, S, 2004) |
| " Clinical trials have begun to define the role of these agents and their unique side-effect profiles." | 2.42 | Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. ( Harwood, KV, 2004) |
| "Letrozole 2." | 2.41 | New generation aromatase inhibitors--from the advanced to the adjuvant setting. ( Buzdar, AU, 2002) |
| "Anastrozole treatment had no impact on plasma lipid levels, whereas both letrozole and exemestane had an unfavorable effect on plasma lipid levels." | 2.41 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. ( Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF, 2002) |
| "Letrozole has also been used in advanced breast cancer, both as second-line hormone treatment following tamoxifen failure, and more recently as first-line therapy." | 2.41 | Anti-tumor effects of letrozole. ( Anderson, TJ; Dixon, JM; Miller, WR, 2002) |
| "The number of breast cancer patients with hormone-dependent disease increases with age, as does the incidence of breast cancer." | 2.41 | Aromatase inhibitors and their application in breast cancer treatment*. ( Brodie, AM; Njar, VC, 2000) |
| "Formestane has been studied in elderly patients with breast cancer and has been found to induce an overall response rate of 51% (95% CI, 35-67%)." | 2.41 | Steroidal aromatase inhibitors in elderly patients. ( Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N, 2000) |
| "Letrozole was shown to be a better AI than fadrozole by prospective randomized double blind examination; however, it is not licenced yet." | 2.41 | [Developments of hormonal agents for breast cancer]. ( Tominaga, T, 2001) |
| "Thus, management of metastatic breast cancer has largely shifted from surgeons to medical oncologists." | 2.40 | Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. ( Buzdar, AU; Roseman, BJ; Singletary, SE, 1997) |
| "Letrozole is an oral reversible nonsteroidal aromatase inhibitor." | 2.40 | Letrozole. A review of its use in postmenopausal women with advanced breast cancer. ( Adkins, JC; Lamb, HM, 1998) |
| "Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks." | 2.40 | Use of aromatase inhibitors in breast carcinoma. ( Harvey, HA; Santen, RJ, 1999) |
| "Letrozole is a new orally, active, potent, and highly specific non-steroidal aromatase inhibitor." | 2.39 | Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. ( Bhatnagar, AS; Chaudri, HA; Hornberger, U; Trunet, PF, 1996) |
| "Hormone receptor-rich breast cancer (HR+ BC) was previously considered immunologically quiescent." | 1.91 | Neoadjuvant Endocrine Therapy: A Potential Way to Make Cold Hormone Receptor-Rich Breast Cancer Hot. ( Gong, X; Hu, K; Hu, Y; Qiu, J; Wang, K; Wu, Y; Yu, C; Zhang, S, 2023) |
| "Approximately 70% of breast cancers are estrogen receptor(ER)positive, an indication for endocrine therapy." | 1.91 | [ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib]. ( Hayashi, M; Hirata, A; Kimura, K; Morita, S; Takashima, Y; Terasawa, R, 2023) |
| "The overall response rate of the research group was statistically higher than that of the control group, and the incidence of adverse reactions was significantly lower." | 1.72 | Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma. ( Lu, X; Qian, C, 2022) |
| "Potent breast cancer drugs are Tamoxifen, Paclitaxel, Cyclophosphamide, Trastuzumab, etc." | 1.72 | ( Elancheran, R; Maruthanila, VL; Mirunalini, S, 2022) |
| "The endocrine therapy resistance of breast cancer is the difficulty and challenge to be urgently solved in the current treatment." | 1.72 | LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway. ( Fang, SQ; Hu, H; Li, LW; Li, XY; Liu, H; Liu, YW; Lu, ZX; Wang, H; Wu, TW; Xiang, Y; Zhan, Y; Zong, QB, 2022) |
| "Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease." | 1.72 | Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia. ( Annovazzi, A; Barberi, V; Cognetti, F; Ferretti, G; Renna, D; Russillo, M, 2022) |
| "The molecular classification of breast cancer (BC) dictates pharmacological treatment." | 1.72 | Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers. ( Acconcia, F, 2022) |
| "The treatment of letrozole plus palbociclib(CDK4/6 inhibitor)were continued for 3 months from May 2018, and this therapy made her bone lesions smaller, but palbociclib were stopped due to its severe neutropenia." | 1.72 | [A Case of Recurrent Breast Cancer with Multiple Bone Metastasis Effectively Treated by CDK4/6 Inhibitor in Addition to Aromatase Inhibitor]. ( Hara, M; Murakata, A; Ohinata, R; Osanai, T; Sakoma, T; Satoh, E; Sugano, N; Tanami, H; Toyofuku, Y; Uehira, D; Yonekura, K, 2022) |
| "Median PFS for patients with bone-only metastases (n = 54) was not reached (95% CI 18." | 1.62 | Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia. ( Armaghani, AJ; Costa, RLB; Czerniecki, BJ; Han, HS; Hoover, SJ; Khakpour, N; Khong, HT; Kiluk, JV; Laronga, C; Lee, MC; Loftus, LS; Ma, J; Soliman, HH; Soyano-Muller, AE; Sun, J; Sun, W; Zhong, X, 2021) |
| "Many breast cancer patients harbor high estrogen receptor (ER) expression in tumors that can be treated with endocrine therapy, which includes aromatase inhibitors (AI); unfortunately, resistance often occurs." | 1.62 | Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling. ( Chang, YL; Chen, S; Lee, HC; Tseng, LM; Tzeng, YD; Wang, SF; Wang, YZ; Wu, CL, 2021) |
| "Letrozole is an aromatase inhibitor (AI) which has shown better clinical efficacy when combined with HER2 inhibitors in treating patients with HER2-positive and HR-positive breast cancer than has hormonal therapy alone." | 1.62 | Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report. ( Li, J; Ouyang, Q; Shui, Z, 2021) |
| "We reviewed charts of women with breast cancer who contacted the FP patient navigator (PN) at Northwestern University from 01/2005-01/2018." | 1.62 | Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation. ( Confino, R; Gradishar, WJ; Jeruss, JS; Kazer, RR; Klock, SC; Lawson, AK; Moravek, MB; Pavone, ME; Smith, KN, 2021) |
| "Retrospective cohort study of 118 breast cancer patients undergoing fertility preservation treatment between 2008 and 2018." | 1.62 | Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients. ( Almog, B; Azem, F; Cohen, Y; Fouks, Y; Kalma, Y; Shulman, Y, 2021) |
| "Radiation induces adverse events on healthy tissues which may be augmented by certain factors." | 1.62 | Predictive Factors Increasing the Risk of Radiation Toxicity in Patients with Early Breast Cancer. ( Abdeltawab, AA; Ali, SA; Hassan, MA; Mostafa, HG, 2021) |
| "In HER2+/HR+ breast cancer, CES is useful for predicting chemo-endocrine sensitivity and provides additional prognostication beyond intrinsic subtype and clinicopathologic characteristics." | 1.62 | Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. ( Adamo, B; Carey, LA; Chic, N; Conte, B; Conte, P; Cortes, J; Dieci, MV; Fernandez-Martinez, A; Galvan, P; Gavila, J; Griguolo, G; Guarnieri, V; Llombart, A; Muñoz, M; Oliveira, M; Paré, L; Pascual, T; Pernas, S; Perou, CM; Prat, A; Tanioka, M; Vidal, M; Villagrasa, P, 2021) |
| "Unlike estrogen receptor (ER)-negative breast cancer, ER-positive breast cancer outcome is less influenced by lymphocyte content, indicating the presence of immune tolerance mechanisms that may be specific to this disease subset." | 1.56 | Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). ( Anurag, M; Burugu, S; Ellis, MJ; Gao, D; Hoog, J; Huang, C; Nielsen, T; Suman, V; Vasaikar, S; Wang, J; Zhang, B; Zhang, XH; Zhu, M, 2020) |
| "Letrozole is a risk factor for worse oocyte morphology." | 1.56 | The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation. ( Alves, VR; Bercaire, LMN; Cavagna, F; Cavagna, M; Donadio, NF; Dzik, A; Gebrim, LH; Nahas, EAP; Portela, R; Rocha, AR; Santos, TBB, 2020) |
| "Musculoskeletal adverse events (MS-AEs) and vasomotor symptoms (VMSs) are the major side-effects of newer generation non-steroidal aromatase inhibitor (AI), letrozole." | 1.56 | Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity. ( Adithan, C; Damodaran, SE; Devi, J; Dkhar, SA; Dubashi, B; Kadambari, D; Kalaivani, S; Muthuvel, SK; Pradhan, SC; Umamaheswaran, G, 2020) |
| "Steroidal drugs have been suggested for breast cancer treatment as aromatase enzymes inhibitors ." | 1.56 | Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment. ( Jamal, QMS, 2020) |
| "We report a case of local recurrence of breast cancer 8 years after mastectomy." | 1.56 | [Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report]. ( Adachi, K; Hirano, T; Sakurai, K; Suzuki, S, 2020) |
| "We experienced a case of late breast cancer recurrence 32 years after surgery." | 1.51 | [Late Recurrence of Breast Cancer 32 Years after Surgery-A Case Report]. ( Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Morisaki, T; Noda, S; Ohira, M; Onoda, N; Takada, K; Takashima, T, 2019) |
| "She had distant history of metastatic breast cancer treated with chemotherapy, surgical resection and tamoxifen." | 1.51 | Paraneoplastic syndrome - a rare but treatable cause of non-thyroid-related extraocular muscle enlargement. ( Diamond, T; Kumar, S, 2019) |
| "Enophthalmos in the setting of breast cancer metastatic to the orbit results primarily from the disease pathogenesis, or secondary to treatment effects." | 1.48 | Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma. ( Alameddine, RM; Kikkawa, DO; Ko, AC; Korn, BS; Lin, JH; Mimura, M; Parker, BA, 2018) |
| "We report a case of primary advanced breast cancer that was locally controlled by treatment with bevacizumab." | 1.48 | [A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole]. ( Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Hirano, T; Ono, Y; Sakurai, K; Waga, E, 2018) |
| "Metastases of breast carcinoma to the main bronchus and choroid are rare, but have been reported in relevant literature." | 1.48 | Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report. ( Cai, Q; Fu, S; Luo, Z; Wang, X; Zhai, L; Zhao, Y, 2018) |
| "Importantly, breast cancer patients who responded to letrozole expressed significantly lower Cdc6 than those patients who did not respond." | 1.46 | The prognostic significance of Cdc6 and Cdt1 in breast cancer. ( Bai, Y; Kwok, HF; Mahadevappa, R; McCrudden, CM; Neves, H; Wen, Q; Yuen, HF; Yuen, SM; Zhang, SD, 2017) |
| "To determine the impact on antitumor activity when active hexose correlated compound (AHCC) in combination with anticancer hormonal agents in orthotopic mouse models of human estrogen receptor positive breast cancer and evaluate impact of AHCC on aromatase activity." | 1.46 | Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models. ( Gaikwad, A; Gonzalez, A; Mathew, L; Nugent, EK; Smith, JA, 2017) |
| "Liver resection in patients with breast cancer liver metastasis proved to be cost-effective when compared with systemic therapy alone, particularly in estrogen receptor-positive tumors or when newer agents were used." | 1.46 | Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. ( Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A, 2017) |
| "This effect was ER dependent as breast cancer cells with undetectable levels of ER failed to exhibit metabolic plasticity." | 1.43 | miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. ( Bacci, M; Chiarugi, P; Dowsett, M; Fearns, A; Gao, Q; Giannoni, E; Isacke, CM; Martin, LA; Morandi, A; Pintus, G; Ribas, R; Taddei, ML, 2016) |
| "Invasive papillary carcinoma is a rare type of invasive ductal carcinoma." | 1.43 | Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved. ( Aruga, T; Goto, R; Honda, Y; Horiguchi, K; Horiguchi, S; Idera, N; Kuroi, K; Miyamoto, H; Saita, C; Yamashita, T, 2016) |
| "In the example of an early breast cancer trial for which a new treatment significantly delayed disease recurrence, our Bayesian analysis showed that with very reasonable assumptions on the effects of treatment after recurrence, there is a high probability that the new treatment improves overall survival." | 1.43 | Assessing survival benefit when treatment delays disease progression. ( Finkelstein, DM; Schoenfeld, DA, 2016) |
| "Women with breast cancer and diabetes mellitus (DM) have poorer survival." | 1.43 | Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17. ( Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D, 2016) |
| "Applying STEPP to data from a breast cancer treatment trial with multiple markers, we found that none of the three benefit functions identified a promising subgroup for further study." | 1.43 | Evaluating Markers for Guiding Treatment. ( Baker, SG; Bonetti, M, 2016) |
| "Letrozole was subcutaneously injected daily for 23 days at a dose of 1." | 1.43 | Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. ( Belosay, A; Churchwell, MI; Doerge, DR; Hartman, JA; Helferich, WG; Iwaniec, UT; Song, H; Turner, RT; Wang, W; Yang, X, 2016) |
| "We report a case of metastatic breast cancer in a 65-year-old woman who developed leptomeningeal carcinomatosis." | 1.43 | Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy. ( Almajed, MM; Esfahani, K; Panasci, L; Pelmus, M, 2016) |
| " However in vitro, NVP-AST487 was superior to letrozole in inhibiting the GDNF-induced motility and tumor spheroid growth of MCF7-AROM1 cells and required in combination with letrozole to inhibit GDNF-induced motility in BT474-AROM3 aromatase expressing cells." | 1.43 | Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts. ( Andreucci, E; Chiarugi, P; Fearns, A; Francica, P; Isacke, CM; Martin, LA; Morandi, A, 2016) |
| "Lapatinib is an orally bioavailable dual inhibitor of the intracellular domain of both the HER2 protein and the epidermal growth factor receptor." | 1.43 | [A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole]. ( Yamamoto, C; Yamamoto, D; Yamamoto, M, 2016) |
| "106 patients treated for breast cancer at Southampton University Hospital with PHT without surgery were identified (Mean age 84." | 1.42 | Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma. ( Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C, 2015) |
| "In presented case, we reported a breast cancer patient who has been receiving long-term trastuzumab." | 1.42 | Is there any cumulative dose for trastuzumab? ( Coşkun, HŞ; Mutlu, H, 2015) |
| "Up to 50% of breast cancer cases occur in patients over the age of 65 years." | 1.42 | Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience. ( Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I, 2015) |
| "Fulvestrant is an efficient treatment option for these AI-resistant breast cancer cells, and the cell lines will be useful tools to disclose the underlying molecular mechanism for resistance to the different AIs." | 1.42 | New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. ( Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW, 2015) |
| "Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined." | 1.42 | Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015) |
| "Early stage HR-positive breast cancer patients were enrolled in a randomized trial of exemestane versus letrozole." | 1.42 | Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. ( Dantzer, J; Desta, Z; Flockhart, DA; Hangartner, TN; Hayes, DF; Henry, NL; Kidwell, KM; Li, L; Nguyen, AT; Oesterreich, S; Peacock, M; Philips, S; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM; Van Poznak, CH, 2015) |
| "Letrozole-resistant breast cancer cells (LTLT-Ca) were treated with a novel phytoalexin, glyceollin I, and exhibited morphological characteristics synonymous with an epithelial phenotype and decreased proliferation." | 1.42 | Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1. ( Boué, SM; Burks, H; Burow, ME; Carriere, PP; Collins-Burow, B; Davenport, IR; Davidson, AM; Hilliard, A; Llopis, SD; Naiki, AC; Nguyen, G; Nguyen, MM; Nguyen, TA; Parker-Lemieux, K; Payton-Stewart, F; Phan, T; Pratt, J; Preyan, LC; Tilghman, SL; Williams, CC; Yearby, L, 2015) |
| "Treatment with everolimus or letrozole resulted in growth inhibition of SCs in a dose-dependent manner." | 1.40 | Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. ( Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X, 2014) |
| "Second, disease progression is monitored at regular clinic visits, and progression time is recorded as the first visit at which evidence of progression is detected." | 1.40 | A joint test for progression and survival with interval-censored data from a cancer clinical trial. ( Finkelstein, DM; Schoenfeld, DA, 2014) |
| "Most breast cancers at diagnosis are estrogen receptor-positive (ER(+)) and depend on estrogen for growth and survival." | 1.39 | GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. ( Dowsett, M; Gao, Q; Isacke, CM; Mackay, A; Martin, LA; Morandi, A; Pancholi, S; Plaza-Menacho, I; Robertson, D; Zvelebil, M, 2013) |
| "Tamoxifen or letrozole was added before or after irradiation, respectively." | 1.39 | Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment. ( Li, JH; Zeng, ZJ; Zhang, YJ; Zhao, ST, 2013) |
| "Estrogens have important roles in ductal carcinoma in situ (DCIS) of the breast." | 1.39 | Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment. ( Amano, G; Amari, M; Ebata, A; Hirakawa, H; Ishida, T; Kakugawa, Y; Miki, Y; Mori, N; Nakamura, Y; Ohuchi, N; Sasano, H; Suzuki, T; Takagi, K; Watanabe, M, 2013) |
| "Letrozole treatment leads to extensive rewiring of the breast tumor coexpression network." | 1.39 | Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole. ( Moore, JH; Penrod, NM, 2013) |
| "A significant proportion of elderly breast cancer patients in the UK have no surgical treatment recorded and appear to be treated with primary endocrine therapy (PET) only." | 1.39 | A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer. ( Ravichandran, D; Wylie, S, 2013) |
| " We propose to open a debate over the use of aromatase inhibitors in combination with FSH in ovulation induction treatment of breast cancer oncofertility patients." | 1.39 | The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate. ( Child, T; Fatum, M; McVeigh, E, 2013) |
| "Obesity is associated with an increased body aromatisation and may be a cause of insufficient estradiol depletion." | 1.39 | Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer. ( Dressel-Ban, G; Dubsky, P; Exner, R; Fitzal, F; Gnant, M; Hadji, P; Königsberg, R; Maroske, M; Pfeiler, G; Seifert, M; Singer, C; Zellinger, J, 2013) |
| "Primary breast carcinomas were obtained from 112 women who received AI therapy after failing adjuvant tamoxifen therapy and developing recurrent breast cancer." | 1.39 | Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness. ( Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S, 2013) |
| "Therefore, advanced breast cancer with left-sided pleural effusion and metastases to the pleura and bone was diagnosed." | 1.39 | [An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report]. ( Nakamura, H; Yoneyama, K, 2013) |
| "02) and grade III-IV adverse events." | 1.39 | Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients. ( Chen, ML; Li, K; Zhang, J; Zhu, ZL, 2013) |
| "Seventy-two patients with breast cancer who failed chemotherapy were treated at the Tumor Hospital of Harbin Medical University from January 2001 to January 2012." | 1.39 | [Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy]. ( Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP, 2013) |
| "Blepharitis was noted in 68 of 82 eyes (73%), decreased or poor tear function in 24 eyes (29%), conjunctival injection in 18 eyes (22%) and superficial punctate keratitis in 12 eyes (29%)." | 1.39 | Dry eye syndrome in aromatase inhibitor users. ( Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K, 2013) |
| "Estrogen is a risk factor of breast cancer." | 1.39 | Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells. ( Gildea, JJ; Wang, J; Yue, W, 2013) |
| "To improve the treatment of breast cancer, there has been a need for alternative aromatase inhibitors (AIs) that bring about adequate aromatase inhibition, while limiting side effects." | 1.38 | The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. ( Cushman, M; Flockhart, DA; Lu, WJ; Mayhoub, AS; Pei, Z; Xu, C, 2012) |
| "The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008." | 1.38 | Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012) |
| "The occurrence of primary breast cancer of the vulva is extremely rare (24 cases described in the English-language literature)." | 1.38 | Primary breast cancer of the vulva: a case report. ( Bernardino, M; Coelho, AM; Diniz da Costa, AT; Jorge, CC; Lourenço, AV; Ribeirinho, AL, 2012) |
| "Oestradiol concentrations of breast cancer patients on the letrozole protocol remained much lower than those of patients on the antagonist protocol." | 1.38 | The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. ( Brassesco, M; Carreras, R; Checa Vizcaíno, MA; Comadran, MG; Corchado, AR; Cuadri, ME, 2012) |
| "Breast cancer is the leading cause of neoplasia-related deaths among women, but no data are available in the literature on the safe use of oncological treatments in glucose 6-phosphate dehydrogenase (G6PD)-deficient patients." | 1.38 | Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report. ( Bramati, A; Farina, G; Girelli, S; La Verde, N; Mihali, D; Moretti, A; Piva, S; Sburlati, P, 2012) |
| "The median interval from diagnosis of breast cancer was 57 months (range: 11 - 189 mo)." | 1.38 | [Endobronchial metastases from breast cancer: a clinicopathological and survival analysis]. ( Cai, RG; Fan, Y; Li, J; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P, 2012) |
| "BC cell lines expressing aromatase (AROM) and modeling endocrine-sensitive (MCF7-AROM1) and human epidermal growth factor receptor 2 (HER2)-dependent de novo resistant disease (BT474-AROM3) and long-term estrogen-deprived (LTED) MCF7 cells that had acquired resistance associated with HER2 overexpression were treated in vitro and as subcutaneous xenografts with everolimus (RAD001-mTORC1 inhibitor), in combination with tamoxifen or letrozole." | 1.38 | Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. ( A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT, 2012) |
| "When anastrozole was compared with letrozole in the subgroup analysis no difference with regard to DFS and overall survival was detected." | 1.38 | Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index. ( Aksoy, S; Altundag, K; Sendur, MA; Zengin, N, 2012) |
| "Neoplastic meningitis from breast cancer has a dismal prognosis and short survival." | 1.37 | Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report. ( Bouboukas, G; Kalofonos, H; Koutras, A; Makatsoris, T; Onyenadum, A; Peroukides, S; Starakis, I, 2011) |
| "Three patients with a diagnosis of breast cancer requiring emergency fertility preservation in the late follicular or luteal phase of the menstrual cycle." | 1.37 | Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. ( Coşkun, U; Oktay, K; Sönmezer, M; Türkçüoğlu, I, 2011) |
| "In addition, approximately 25% of breast cancers do not express the estrogen receptor (ERα) and consequently, are innately resistant to endocrine therapy." | 1.37 | Aromatase inhibitors and xenograft studies. ( Brodie, AM; Chumsri, S; Howes, T; Sabnis, GJ, 2011) |
| " In addition to providing evidence suggesting the potential use of ERβ agonists in combination with letrozole in treating AI resistant breast cancer and prolonging sensitivity to AI, we also provide mechanistic evidence supporting the role of ERβ in altering the expression profile associated with resistance." | 1.37 | Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. ( Ganapathy, M; Kirma, NB; Nair, HB; Tekmal, RR; Vadlamudi, RK, 2011) |
| "Twelve patients (15%) had disease progression while taking PHT." | 1.37 | Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer? ( Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E, 2011) |
| "Neoadjuvant therapy in breast cancer has emerged as an important setting for the development of targeted drugs." | 1.37 | Neoadjuvant chemotherapy and targeted therapies: a promising strategy. ( de Azambuja, E; Metzger-Filho, O, 2011) |
| "It was suspected that breast cancer could be metastasized to the scalp, but mammography, ultrasound, and positron emission tomography showed no particular metastases in her breast and other organs." | 1.37 | [A case of scalp metastases from breast cancer successfully treated with letrozole]. ( Ishiba, T; Kubota, K; Kuwayama, T; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H, 2011) |
| "Seventy-four breast cancer patients who desired fertility preservation, with normal ovarian reserve and < 45 years of age received letrozole 5mg/day plus recombinant FSH 150-300 IU/day for ovarian stimulation." | 1.36 | GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. ( Oktay, K; Rodriguez-Wallberg, KA; Türkçüoğlu, I, 2010) |
| "Expression of aromatase in breast cancer tissue is driven by different promoters than those in noncancer tissues; thus, suppression of aromatase expression in cancer tissues through the down-regulation of breast tumor-specific promoters would reduce the side effects associated with whole-body suppression of estrogen biosynthesis by AIs." | 1.36 | The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression. ( Chen, S; Evans, D; Kijima, I; Ye, J, 2010) |
| "Endocrine therapy in the setting of breast cancer has undoubtedly advanced clinical outcomes in this disease, but treatment with endocrine therapy is accompanied by a wide spectrum of side effects." | 1.36 | Cognitive changes associated with endocrine therapy for breast cancer. ( Agrawal, K; Mortimer, JE; Onami, S; Pal, SK, 2010) |
| "Plasma samples of 310 breast cancer patients undergoing anti-estrogen therapy were analyzed." | 1.36 | Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study. ( Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B, 2010) |
| "Decrement of HSP-70 in breast carcinoma cells plays important roles in therapeutic mechanisms of AIs through suppressing tumor cell proliferation in breast cancer patients." | 1.36 | Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. ( Chan, MS; Chanplakorn, N; Chow, LW; Loo, WT; Sasano, H; Toi, M; Yiu, CC, 2010) |
| "The adjuvant setting of early breast cancer treatment is an evolving field where different modalities must be combined to improve outcomes; moreover, quality of life of breast cancer survivors emerges as a new important parameter to consider, thus implying a better understanding of toxicities of these modalities." | 1.36 | Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. ( Belkacemi, Y; Bese, N; Boussen, H; Gligorov, J; Koukourakis, MI; Kuten, A; Tsoutsou, PG, 2010) |
| "A case of solitary bone metastasis from breast cancer, where MRI assessment of treatment response was inaccurate and whole-body fluorodeoxyglucose ((18)FDG) positron emission tomography with computed tomography (PET-CT) proved more reliable and objective, is presented." | 1.36 | Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment. ( Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK, 2010) |
| "Letrozole is a potent nonsteroidal aromatase inhibitor that is registered for the treatment of postmenopausal women with advanced metastatic breast cancers and in the neoadjuvant, early, and extended adjuvant indications." | 1.35 | The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. ( Chen, B; Chen, S; Evans, DB; Lisztwan, J; Pornon, A, 2008) |
| "University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | 1.35 | Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008) |
| "The antiangiogenic agent bevacizumab showed synergistic effects when combined with chemotherapy in advanced breast cancer." | 1.35 | Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. ( Bagnardi, V; Bertolini, F; Calleri, A; Cardillo, A; Colleoni, M; Goldhirsch, A; Luini, A; Mancuso, P; Orlando, L; Scarano, E; Torrisi, R; Viale, G, 2008) |
| "Choroidal metastasis from breast carcinoma, with no other evidence of disease recurrence." | 1.35 | A case of prolonged disease-free survival in a patient with choroidal metastasis from breast cancer. ( Doherty, M; Hopkins, JJ; Jang, RW; Warner, E, 2009) |
| "In patients with breast cancer and co-existing pleural effusions, ascites and adnexal masses, the probability of disseminated disease is high." | 1.35 | A case of Meigs syndrome mimicking metastatic breast carcinoma. ( Al Mufti, R; Behranwala, K; Hadjiminas, DJ; Lanitis, S; Sivakumar, S; Zacharakis, E, 2009) |
| "We used human ER-positive breast cancer cells stably transfected with the aromatase gene (MCF-7Ca)." | 1.35 | Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. ( Brodie, A; Goloubeva, O; Macedo, L; Sabnis, G; Schayowitz, A, 2009) |
| " Efficacy of vitamin A as a chemopreventive agent for skin cancer could be demonstrated with a dose-response curve after a second-order discriminant analysis was employed." | 1.35 | Knowledge discovery processing and data mining in karyometry. ( Alberts, DS; Bartels, HG; Bartels, PH; Montironi, R; Scarpelli, M, 2009) |
| "Forty-year-old woman with breast cancer seeking fertility preservation before chemotherapy." | 1.35 | In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: description of a novel approach to fertility preservation. ( Chian, RC; Demirtas, E; Lostritto, K; Oktay, K; Son, WY; Tan, SL, 2008) |
| "Changes in breast cancer cell biology following hormonal treatment have been claimed as promising predictor markers of clinical benefit even outperforming clinical response." | 1.35 | Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. ( Aguilar, H; Capellà, G; Dowsett, M; Germà-Lluch, JR; Martin, LA; Solé, X; Urruticoechea, A, 2008) |
| "Letrozole was chosen for the next therapy." | 1.35 | [A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy]. ( Kihara, M; Miyauchi, A, 2008) |
| "Estrogens produced within breast tumors may play a pivotal role in growth stimulation of the breast cancer cells." | 1.33 | Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. ( Lykkesfeldt, AE; Sonne-Hansen, K, 2005) |
| "We present a case of late recurrence of breast cancer manifested with diabetes insipidus caused by isolated intracranial metastases." | 1.33 | Diabetes insipidus caused by isolated intracranial metatstases in patient with breast cancer. ( Ariad, S; Baumgarten, A; Bobilev, D; Lavrenkov, K; Man, S; Shelef, I; Tokar, M, 2005) |
| "When letrozole was combined with the pure antiestrogen fulvestrant, to down regulate ER, the combination was more effective than either letrozole or fulvestrant alone." | 1.33 | Model systems: mechanisms involved in the loss of sensitivity to letrozole. ( Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G, 2005) |
| "Letrozole (Femara) is an aromatase inhibitor used for treatment of postmenopausal women with hormone-dependent breast cancers." | 1.33 | Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. ( Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S, 2005) |
| "Brain metastases from breast cancer have a poor prognosis." | 1.33 | Letrozole for brain and scalp metastases from breast cancer--a case report. ( Bhatt, ML; Kirti, S; Kumar, S; Madhup, R; Srivastava, M; Srivastava, PK, 2006) |
| "Metastatic breast cancer (MBC) is incurable in most cases." | 1.33 | Does survival increase in metastatic breast cancer with recently available anticancer drugs? ( Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F, 2006) |
| "The primary use of ERalpha in breast cancer is for predicting likely response to hormone treatment." | 1.33 | Estrogen receptors: role in breast cancer. ( Duffy, MJ, 2006) |
| "Breast cancer is the most common malignancy and the second most common cause of cancer-related death in women." | 1.33 | Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. ( Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O, 2006) |
| "Modern treatment of cancer of the breast is based on established prognostic factors (patient age, receptor status, tumor size, lymph node involvement, tumor grading), and thus takes the patient's individual risk profile into account." | 1.32 | [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient]. ( Höffken, K; Sayer, HG, 2003) |
| "Letrozole was superior to anastrozole with respect to both quality of life and toxicity evaluations." | 1.32 | Examining quality of life issues in relation to endocrine therapy for breast cancer. ( Thomas, R, 2003) |
| "Treatment of breast cancer cells following a preoperative protocol showed a dose-dependent expression of VEGF and Angiopoetin-1." | 1.32 | Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer. ( Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D, 2004) |
| "Letrozole is a non-steroidal aromatase inhibitor that effectively blocks aromatase activity without interfering with adrenal steroid biosynthesis." | 1.31 | Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. ( Bairaktari, ET; Elisaf, MS; Kakaidi, B; Katsaraki, A; Nicolaides, C; Pavlidis, NA; Tzallas, CS, 2001) |
| "Letrozole was also effective in tumors failing to respond to tamoxifen, consistent with clinical findings." | 1.31 | Aromatase and COX-2 expression in human breast cancers. ( Blankenstein, MA; Blijham, GH; Brodie, AM; Chen, T; DeJong, PC; Elbers, JR; Fulton, A; Long, BJ; Lu, Q; Macpherson, N; Nortier, JW; Schipper, ME; Slee, PH; Thijssen, JH; van de Ven, J; van Gorp, JM, 2001) |
| "Letrozole (2." | 1.31 | Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. ( Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R, 2002) |
| "Letrozole was found to be a highly potent inhibitor of tumor proliferation and more effective than tamoxifen." | 1.30 | Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. ( Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W, 1998) |
| "MCF-7, human breast cancer cells transfected with the aromatase gene, inoculated into ovariectomized nude mice are able to synthesize sufficient estrogens to enhance cell proliferation and the development of tumors." | 1.30 | Intratumoral aromatase model: the effects of letrozole (CGS 20267). ( Brodie, A; Liu, Y; Lu, Q; Wang, J; Yue, W, 1998) |
| "Use of a breast cancer cell line (MCF-7) provided biologic confirmation of the role of aromatization in cell proliferation." | 1.30 | Macrophages, estrogen and the microenvironment of breast cancer. ( Berstein, LM; Diano, S; Eliza, M; Gutierrez, L; Harada, N; Lysiak, J; Mor, G; Naftolin, F; Santen, RJ; Wang, J; Yue, W, 1998) |
| "Both mammary adipose tissue and breast cancers have the ability to aromatize androgens into oestrogens." | 1.30 | Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. ( Miller, WR, 1999) |
| "About two-thirds of human breast carcinomas contain detectable levels of aromatase, the enzyme which converts androgens to oestrogens." | 1.29 | An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells. ( Ashworth, A; Detre, S; Dowsett, M; Lee, K; Macaulay, VM; Nicholls, JE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 51 (4.13) | 18.2507 |
| 2000's | 451 (36.49) | 29.6817 |
| 2010's | 551 (44.58) | 24.3611 |
| 2020's | 183 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Balunas, MJ | 1 |
| Su, B | 1 |
| Landini, S | 1 |
| Brueggemeier, RW | 2 |
| Kinghorn, AD | 1 |
| Lézé, MP | 1 |
| Palusczak, A | 1 |
| Hartmann, RW | 2 |
| Le Borgne, M | 1 |
| Muftuoglu, Y | 1 |
| Mustata, G | 1 |
| Stauffer, F | 1 |
| Furet, P | 1 |
| Floersheimer, A | 1 |
| Lang, M | 1 |
| Yin, L | 1 |
| Hu, Q | 1 |
| Amato, E | 1 |
| Bankemper, T | 1 |
| Kidney, R | 1 |
| Do, T | 1 |
| Onate, A | 1 |
| Thowfeik, FS | 1 |
| Merino, EJ | 1 |
| Paula, S | 1 |
| Ma, L | 2 |
| Lv, W | 1 |
| Liu, J | 4 |
| Skaar, TC | 8 |
| Flockhart, DA | 11 |
| Cushman, M | 2 |
| Thomas, MP | 1 |
| Potter, BV | 2 |
| Ghorab, MM | 1 |
| Alsaid, MS | 1 |
| Samir, N | 1 |
| Abdel-Latif, GA | 1 |
| Soliman, AM | 1 |
| Ragab, FA | 1 |
| Abou El Ella, DA | 1 |
| Spinello, A | 2 |
| Martini, S | 2 |
| Berti, F | 1 |
| Pennati, M | 1 |
| Pavlin, M | 2 |
| Sgrignani, J | 1 |
| Grazioso, G | 1 |
| Colombo, G | 2 |
| Zaffaroni, N | 2 |
| Magistrato, A | 2 |
| Arya, GC | 1 |
| Kaur, K | 1 |
| Jaitak, V | 1 |
| Caciolla, J | 1 |
| Turrini, E | 1 |
| Simonelli, F | 1 |
| Belluti, F | 1 |
| Rampa, A | 1 |
| Bisi, A | 1 |
| Fimognari, C | 1 |
| Gobbi, S | 1 |
| Giampietro, L | 1 |
| Gallorini, M | 1 |
| Gambacorta, N | 1 |
| Ammazzalorso, A | 1 |
| De Filippis, B | 1 |
| Della Valle, A | 1 |
| Fantacuzzi, M | 1 |
| Maccallini, C | 1 |
| Mollica, A | 1 |
| Cataldi, A | 1 |
| Nicolotti, O | 1 |
| Amoroso, R | 1 |
| Eissa, AG | 1 |
| Barrow, D | 1 |
| Gee, J | 1 |
| Powell, LE | 1 |
| Foster, PA | 2 |
| Simons, C | 1 |
| Khan, MZI | 1 |
| Uzair, M | 1 |
| Nazli, A | 1 |
| Chen, JZ | 1 |
| Del Mastro, L | 16 |
| Mansutti, M | 4 |
| Bisagni, G | 8 |
| Ponzone, R | 3 |
| Durando, A | 1 |
| Amaducci, L | 1 |
| Campadelli, E | 1 |
| Cognetti, F | 7 |
| Frassoldati, A | 10 |
| Michelotti, A | 4 |
| Mura, S | 1 |
| Urracci, Y | 1 |
| Sanna, G | 1 |
| Gori, S | 3 |
| De Placido, S | 5 |
| Garrone, O | 4 |
| Fabi, A | 7 |
| Barone, C | 1 |
| Tamberi, S | 2 |
| Bighin, C | 4 |
| Puglisi, F | 8 |
| Moretti, G | 3 |
| Arpino, G | 5 |
| Ballestrero, A | 3 |
| Poggio, F | 1 |
| Lambertini, M | 3 |
| Montemurro, F | 4 |
| Bruzzi, P | 3 |
| Bahrami, N | 2 |
| Jabeen, S | 1 |
| Tahiri, A | 1 |
| Sauer, T | 3 |
| Ødegård, HP | 1 |
| Geisler, SB | 1 |
| Gravdehaug, B | 2 |
| Reitsma, LC | 1 |
| Selsås, K | 1 |
| Kristensen, V | 1 |
| Geisler, J | 12 |
| Sun, J | 2 |
| Zhong, X | 1 |
| Ma, J | 3 |
| Sun, W | 2 |
| Han, HS | 1 |
| Soliman, HH | 1 |
| Loftus, LS | 1 |
| Costa, RLB | 1 |
| Armaghani, AJ | 1 |
| Soyano-Muller, AE | 1 |
| Czerniecki, BJ | 1 |
| Lee, MC | 1 |
| Kiluk, JV | 1 |
| Khakpour, N | 1 |
| Hoover, SJ | 1 |
| Laronga, C | 1 |
| Khong, HT | 1 |
| Wang, SF | 1 |
| Chang, YL | 1 |
| Tzeng, YD | 1 |
| Wu, CL | 1 |
| Wang, YZ | 1 |
| Tseng, LM | 2 |
| Chen, S | 14 |
| Lee, HC | 1 |
| Llombart-Cussac, A | 9 |
| Pérez-García, JM | 2 |
| Bellet, M | 6 |
| Dalenc, F | 6 |
| Gil-Gil, M | 3 |
| Ruíz-Borrego, M | 1 |
| Gavilá, J | 8 |
| Sampayo-Cordero, M | 2 |
| Aguirre, E | 2 |
| Schmid, P | 2 |
| Marmé, F | 2 |
| Di Cosimo, S | 6 |
| Gligorov, J | 5 |
| Schneeweiss, A | 2 |
| Albanell, J | 2 |
| Zamora, P | 2 |
| Wheatley, D | 3 |
| Martínez-de Dueñas, E | 2 |
| Amillano, K | 3 |
| Malfettone, A | 2 |
| Cortés, J | 4 |
| Li, J | 9 |
| Shui, Z | 1 |
| Ouyang, Q | 3 |
| McAndrew, NP | 1 |
| Finn, RS | 14 |
| Chen, CN | 1 |
| Chang, LT | 1 |
| Chen, CH | 1 |
| Tam, KW | 1 |
| Takahashi, M | 7 |
| Tokunaga, E | 1 |
| Mori, J | 1 |
| Tanizawa, Y | 1 |
| van der Walt, JS | 1 |
| Kawaguchi, T | 1 |
| Goetz, MP | 8 |
| Toi, M | 18 |
| Poetto, AS | 1 |
| Posocco, B | 1 |
| Gagno, S | 1 |
| Orleni, M | 1 |
| Zanchetta, M | 1 |
| Iacuzzi, V | 1 |
| Canil, G | 1 |
| Buzzo, M | 1 |
| Montico, M | 1 |
| Guardascione, M | 1 |
| Basile, D | 1 |
| Pelizzari, G | 1 |
| Alberti, M | 1 |
| Gerratana, L | 1 |
| Toffoli, G | 1 |
| Li, Y | 10 |
| Zheng, X | 4 |
| Tu, D | 22 |
| Ingle, JN | 32 |
| Goss, PE | 39 |
| Parulekar, WR | 3 |
| Qin, G | 1 |
| Loi, S | 6 |
| Karapetis, CS | 1 |
| McCarthy, N | 1 |
| Oakman, C | 2 |
| Redfern, A | 1 |
| White, M | 1 |
| Khasraw, M | 1 |
| Doval, DC | 2 |
| Gore, V | 1 |
| Alam, M | 1 |
| Binko, J | 1 |
| Lu, DR | 10 |
| Kim, S | 4 |
| Boyle, F | 4 |
| Bertelsen, BE | 1 |
| Viste, K | 1 |
| Helland, T | 1 |
| Hagland, M | 1 |
| Søiland, H | 1 |
| Lende, TH | 1 |
| Lønning, PE | 12 |
| Sagen, JV | 1 |
| Mellgren, G | 2 |
| Almås, B | 1 |
| Liang, JJ | 1 |
| Yu, WL | 1 |
| Yang, L | 1 |
| Xie, BH | 1 |
| Qin, KM | 1 |
| Yin, YP | 1 |
| Yan, JJ | 1 |
| Gong, S | 1 |
| Liu, TY | 1 |
| Zhou, HB | 1 |
| Hong, K | 1 |
| Park, C | 2 |
| Park, SK | 1 |
| Woo, A | 1 |
| Ng, BP | 1 |
| Wang, X | 10 |
| Adamson, BJ | 1 |
| Briggs, A | 1 |
| Tan, K | 1 |
| Bargo, D | 1 |
| Ghosh, S | 1 |
| Baxi, S | 1 |
| Ramsey, S | 1 |
| Mezni, E | 1 |
| Sabatier, R | 1 |
| Goncalves, A | 1 |
| Vicier, C | 1 |
| Cottu, P | 5 |
| Ring, A | 3 |
| Abdel-Razeq, H | 1 |
| Marchetti, P | 2 |
| Cardoso, F | 6 |
| Salvador Bofill, J | 2 |
| Martín, M | 9 |
| Menon-Singh, L | 2 |
| Wu, J | 5 |
| De Laurentiis, M | 10 |
| Muttiah, C | 1 |
| Whittle, JR | 1 |
| Lindeman, GJ | 1 |
| Hortobagyi, GN | 6 |
| Stemmer, SM | 4 |
| Burris, HA | 5 |
| Yap, YS | 4 |
| Sonke, GS | 5 |
| Hart, L | 2 |
| Campone, M | 12 |
| Petrakova, K | 4 |
| Winer, EP | 10 |
| Janni, W | 12 |
| Conte, P | 10 |
| Cameron, DA | 16 |
| André, F | 3 |
| Arteaga, CL | 9 |
| Zarate, JP | 1 |
| Chakravartty, A | 1 |
| Taran, T | 2 |
| Le Gac, F | 1 |
| Serra, P | 1 |
| O'Shaughnessy, J | 8 |
| Walker, RR | 2 |
| Patel, JR | 2 |
| Gupta, A | 2 |
| Davidson, AM | 4 |
| Williams, CC | 3 |
| Payton-Stewart, F | 2 |
| Boué, SM | 3 |
| Burow, ME | 3 |
| Khupse, R | 1 |
| Tilghman, SL | 7 |
| Fu, F | 1 |
| Kano, J | 1 |
| Guindy, M | 1 |
| Delaloge, S | 3 |
| Dureau, S | 2 |
| D'Hondt, V | 2 |
| Desmoulins, I | 2 |
| Heudel, PE | 2 |
| Duhoux, FP | 2 |
| Levy, C | 2 |
| Lerebours, F | 3 |
| Mouret-Reynier, MA | 6 |
| Frenel, JS | 2 |
| Jouannaud, C | 2 |
| Venat-Bouvet, L | 2 |
| Nguyen, S | 2 |
| Callens, C | 2 |
| Gentien, D | 2 |
| Rapinat, A | 1 |
| Manduzio, H | 1 |
| Vincent-Salomon, A | 2 |
| Lemonnier, J | 3 |
| Jacobson, A | 1 |
| Lim, JSJ | 1 |
| Wong, ALA | 1 |
| Ow, SGW | 1 |
| Ngoi, NYL | 1 |
| Chan, GHJ | 1 |
| Ang, YLE | 1 |
| Chong, WQ | 1 |
| Lim, SE | 1 |
| Lim, YW | 1 |
| Lee, M | 1 |
| Choo, JRE | 1 |
| Tan, HL | 1 |
| Yong, WP | 1 |
| Soo, RA | 1 |
| Tan, DSP | 1 |
| Chee, CE | 1 |
| Sundar, R | 1 |
| Yadav, K | 1 |
| Jain, S | 1 |
| Wang, L | 4 |
| Tai, BC | 1 |
| Goh, BC | 1 |
| Lee, SC | 2 |
| Gharib, KE | 1 |
| Macaron, W | 1 |
| Kattan, J | 2 |
| Salloum, MA | 1 |
| Farhat, F | 2 |
| Smith, M | 1 |
| Karak, FE | 1 |
| Li, X | 2 |
| Beeghly-Fadiel, A | 1 |
| Bhavnani, SK | 1 |
| Tavana, H | 1 |
| Rubinstein, SM | 1 |
| Gyawali, B | 1 |
| Riaz, IB | 1 |
| Fernandes, HD | 1 |
| Warner, JL | 1 |
| Lu, X | 1 |
| Qian, C | 1 |
| McLaughlin, PMJ | 1 |
| Klar, M | 1 |
| Zwimpfer, TA | 1 |
| Dutilh, G | 1 |
| Vetter, M | 1 |
| Marth, C | 3 |
| du Bois, A | 1 |
| Schade-Brittinger, C | 1 |
| Reuss, A | 1 |
| Bommer, C | 1 |
| Kurzeder, C | 1 |
| Heinzelmann-Schwarz, V | 1 |
| Eser, K | 1 |
| Önder, AH | 1 |
| Sezer, E | 1 |
| Çil, T | 1 |
| İnal, A | 1 |
| Öztürk, B | 1 |
| Erçolak, V | 1 |
| Duman, BB | 1 |
| Çelik, H | 1 |
| Köşeci, T | 1 |
| Kesen, O | 1 |
| Borstnar, S | 2 |
| Palacova, M | 1 |
| Łacko, A | 1 |
| Timcheva, C | 1 |
| Gal-Yam, EN | 1 |
| Papazisis, K | 1 |
| Beniak, J | 1 |
| Kudela, P | 1 |
| Rubovszky, G | 1 |
| Maruthanila, VL | 1 |
| Elancheran, R | 1 |
| Mirunalini, S | 1 |
| Marineau, A | 1 |
| St-Pierre, C | 1 |
| Lessard-Hurtubise, R | 1 |
| David, MÈ | 1 |
| Adam, JP | 1 |
| Chabot, I | 1 |
| Xiang, Y | 1 |
| Liu, H | 3 |
| Hu, H | 2 |
| Li, LW | 1 |
| Zong, QB | 1 |
| Wu, TW | 1 |
| Li, XY | 1 |
| Fang, SQ | 1 |
| Liu, YW | 1 |
| Zhan, Y | 1 |
| Wang, H | 2 |
| Lu, ZX | 1 |
| Knudsen, ES | 1 |
| Schultz, E | 1 |
| Hamilton, D | 1 |
| Attwood, K | 1 |
| Edge, S | 1 |
| O'Connor, T | 1 |
| Levine, E | 1 |
| Witkiewicz, AK | 1 |
| Lalami, I | 1 |
| Labrosse, J | 1 |
| Cedrin-Durnerin, I | 1 |
| Comtet, M | 1 |
| Vinolas, C | 1 |
| Krief, F | 1 |
| Sifer, C | 1 |
| Peigne, M | 1 |
| Grynberg, M | 1 |
| Wu, Y | 2 |
| Gong, X | 1 |
| Wang, K | 1 |
| Yu, C | 2 |
| Qiu, J | 1 |
| Zhang, S | 4 |
| Hu, Y | 1 |
| Hu, K | 1 |
| Khan, MT | 1 |
| Uddin, Z | 1 |
| Javed, MA | 1 |
| Shah, N | 1 |
| Bashir, H | 1 |
| Shaikh, AJ | 1 |
| Rajoka, MSR | 1 |
| Amirzada, MI | 1 |
| Asad, MHHB | 1 |
| Marina, D | 1 |
| Rasmussen, ÅK | 1 |
| Buch-Larsen, K | 1 |
| Gillberg, L | 1 |
| Andersson, M | 1 |
| Schwarz, P | 1 |
| Barberi, V | 1 |
| Renna, D | 1 |
| Annovazzi, A | 1 |
| Ferretti, G | 4 |
| Russillo, M | 1 |
| Balkenende, EME | 2 |
| Dahhan, T | 3 |
| Beerendonk, CCM | 2 |
| Fleischer, K | 2 |
| Stoop, D | 2 |
| Bos, AME | 2 |
| Lambalk, CB | 2 |
| Schats, R | 2 |
| Smeenk, JMJ | 2 |
| Louwé, LA | 2 |
| Cantineau, AEP | 2 |
| de Bruin, JP | 2 |
| Linn, SC | 2 |
| van der Veen, F | 2 |
| van Wely, M | 3 |
| Goddijn, M | 3 |
| Hertz, DL | 4 |
| Douglas, JA | 2 |
| Miller, RM | 1 |
| Kidwell, KM | 7 |
| Gersch, CL | 4 |
| Desta, Z | 10 |
| Storniolo, AM | 15 |
| Stearns, V | 15 |
| Hayes, DF | 14 |
| Henry, NL | 15 |
| Rae, JM | 10 |
| Mo, H | 1 |
| Ma, F | 3 |
| Li, Q | 7 |
| Zhang, P | 8 |
| Yuan, P | 3 |
| Wang, J | 6 |
| Luo, Y | 2 |
| Cai, R | 1 |
| Xu, B | 5 |
| Choong, GM | 1 |
| Liddell, S | 1 |
| Ferre, RAL | 1 |
| O'Sullivan, CC | 1 |
| Ruddy, KJ | 2 |
| Haddad, TC | 1 |
| Hobday, TJ | 1 |
| Peethambaram, PP | 1 |
| Liu, MC | 3 |
| Giridhar, KV | 1 |
| Villacampa, G | 1 |
| Falato, C | 1 |
| Paré, L | 5 |
| Hernando, C | 1 |
| Arumí, M | 1 |
| Saura, C | 3 |
| Gómez, G | 1 |
| Muñoz, M | 6 |
| Izarzugaza, Y | 1 |
| Ferrer, N | 1 |
| Najera-Zuloaga, J | 1 |
| Montaño, A | 1 |
| Ciruelos, E | 5 |
| González-Santiago, S | 2 |
| Villagrasa, P | 4 |
| Prat, A | 10 |
| Pascual, T | 5 |
| Wong, V | 1 |
| de Boer, R | 4 |
| Baron-Hay, S | 1 |
| Blum, R | 1 |
| Chua, S | 1 |
| Clarke, K | 1 |
| Cuff, K | 1 |
| Green, M | 2 |
| Lim, E | 1 |
| Mok, K | 1 |
| Nott, L | 1 |
| Nottage, M | 1 |
| Tafreshi, A | 1 |
| Tsoi, D | 1 |
| Uccellini, A | 1 |
| Hong, W | 1 |
| Gibbs, P | 1 |
| Lok, SW | 1 |
| Caputo, R | 2 |
| Mazza, M | 1 |
| Masetti, R | 1 |
| Ballatore, Z | 1 |
| Torrisi, R | 7 |
| Zambelli, A | 2 |
| Ferro, A | 1 |
| Generali, D | 14 |
| Vici, P | 1 |
| Coltelli, L | 1 |
| Spazzapan, S | 2 |
| Sarobba, MG | 2 |
| Grasso, D | 1 |
| Zamagni, C | 5 |
| Hu, X | 2 |
| Li, W | 3 |
| Sun, T | 3 |
| Shen, K | 1 |
| Wang, S | 4 |
| Cheng, Y | 2 |
| Zhang, Q | 5 |
| Cui, S | 2 |
| Tong, Z | 2 |
| Geng, C | 2 |
| Song, E | 1 |
| Huang, CS | 1 |
| Sriuranpong, V | 1 |
| Ngan, RKC | 1 |
| Chia, YH | 1 |
| Zhao, H | 2 |
| Konstantinopoulos, PA | 1 |
| Lee, EK | 1 |
| Xiong, N | 1 |
| Krasner, C | 1 |
| Campos, S | 1 |
| Kolin, DL | 1 |
| Liu, JF | 1 |
| Horowitz, N | 1 |
| Wright, AA | 1 |
| Bouberhan, S | 1 |
| Penson, RT | 1 |
| Yeku, O | 1 |
| Bowes, B | 1 |
| Needham, H | 1 |
| Hayes, M | 1 |
| Sawyer, H | 1 |
| Polak, M | 1 |
| Shea, M | 1 |
| Cheng, SC | 1 |
| Castro, C | 1 |
| Matulonis, UA | 1 |
| Moreno Anton, F | 1 |
| Rodriguez Sanchez, CA | 1 |
| Galve Calvo, E | 2 |
| Hernando Melia, C | 1 |
| Ciruelos Gil, EM | 1 |
| Vidal, M | 4 |
| Jiménez-Rodriguez, B | 1 |
| De la Cruz Merino, L | 1 |
| Martínez Jañez, N | 1 |
| Villanueva Vazquez, R | 2 |
| de Toro Salas, R | 1 |
| Anton Torres, A | 1 |
| Alvarez Lopez, IM | 1 |
| Gavila Gregori, J | 1 |
| Quiroga Garcia, V | 1 |
| Vicente Rubio, E | 1 |
| De la Haba-Rodriguez, J | 2 |
| Diaz Fernandez, N | 1 |
| Barnadas Molins, A | 1 |
| Cantos Sanchez de Ibargüen, B | 1 |
| Delgado Mingorance, JI | 1 |
| Bellet Ezquerra, M | 1 |
| de Casa, S | 1 |
| Gimeno, A | 1 |
| Acconcia, F | 1 |
| Gil Gil, MJ | 1 |
| Ruiz Borrego, M | 1 |
| Carañana, V | 2 |
| Mina, L | 1 |
| Mukherjee, AG | 1 |
| Wanjari, UR | 1 |
| Nagarajan, D | 1 |
| K K, V | 1 |
| V, A | 1 |
| P, JP | 1 |
| T, TP | 1 |
| Chakraborty, R | 1 |
| Renu, K | 1 |
| Dey, A | 1 |
| Vellingiri, B | 1 |
| Gopalakrishnan, AV | 1 |
| Merola, D | 1 |
| Young, J | 1 |
| Schrag, D | 1 |
| Lin, KJ | 1 |
| Alwardt, S | 1 |
| Schneeweiss, S | 1 |
| Guarneri, V | 7 |
| Bras-Maristany, F | 1 |
| Dieci, MV | 4 |
| Griguolo, G | 4 |
| Par, L | 1 |
| Mar Ín-Aguilera, M | 1 |
| Miglietta, F | 1 |
| Bottosso, M | 1 |
| Giorgi, CA | 2 |
| Blasco, P | 1 |
| Castillo, O | 1 |
| Galv N, P | 1 |
| Vivancos, A | 1 |
| Parker, JS | 2 |
| Perou, CM | 3 |
| Niu, N | 3 |
| Qiu, F | 3 |
| Xu, Q | 3 |
| He, G | 3 |
| Gu, X | 3 |
| Guo, W | 5 |
| Zhang, D | 3 |
| Li, Z | 4 |
| Zhao, Y | 7 |
| Li, K | 5 |
| Zhang, H | 4 |
| Huang, Y | 4 |
| Zhang, G | 3 |
| Han, H | 3 |
| Cai, Z | 3 |
| Li, P | 4 |
| Xu, H | 3 |
| Chen, G | 5 |
| Xue, J | 3 |
| Jiang, X | 5 |
| Jahromi, AH | 3 |
| de Faria Castro Fleury, E | 3 |
| Huo, S | 3 |
| Li, H | 3 |
| Jerusalem, G | 10 |
| Tripodi, D | 3 |
| Liu, T | 3 |
| Liu, C | 4 |
| Ling, AY | 2 |
| Jreich, R | 2 |
| Montez-Rath, ME | 2 |
| Meng, Z | 2 |
| Kapphahn, K | 2 |
| Chandross, KJ | 2 |
| Desai, M | 2 |
| Ahmadi, S | 1 |
| Seraj, M | 1 |
| Chiani, M | 1 |
| Hosseini, S | 1 |
| Bazzazan, S | 1 |
| Akbarzadeh, I | 1 |
| Saffar, S | 1 |
| Mostafavi, E | 1 |
| Silveira, C | 1 |
| Sousa, AC | 1 |
| Corredeira, P | 1 |
| Martins, M | 1 |
| Sousa, AR | 1 |
| Da Cruz Paula, A | 1 |
| Selenica, P | 1 |
| Brown, DN | 1 |
| Golkaram, M | 1 |
| Kaplan, S | 1 |
| Liu, L | 2 |
| Weigelt, B | 1 |
| Reis-Filho, JS | 2 |
| Costa, L | 1 |
| Carmo-Fonseca, M | 1 |
| El-Attar, AA | 1 |
| Ibrahim, OM | 1 |
| Alhassanin, SA | 1 |
| Essa, ES | 1 |
| Mostafa, TM | 1 |
| Kim, CG | 1 |
| Kim, MH | 2 |
| Kim, JH | 2 |
| Kim, SG | 1 |
| Kim, GM | 3 |
| Kim, TY | 3 |
| Ryu, WJ | 1 |
| Kim, JY | 3 |
| Park, HS | 2 |
| Park, S | 3 |
| Cho, YU | 2 |
| Park, BW | 2 |
| Kim, SI | 4 |
| Jeong, J | 3 |
| Sohn, J | 6 |
| Hunt, KK | 2 |
| Suman, VJ | 11 |
| Wingate, HF | 1 |
| Leitch, AM | 1 |
| Unzeitig, G | 3 |
| Boughey, JC | 3 |
| Meric-Bernstam, F | 2 |
| Ellis, MJ | 20 |
| Olson, J | 3 |
| Davis, AA | 1 |
| Luo, J | 7 |
| Zheng, T | 1 |
| Dai, C | 1 |
| Dong, X | 1 |
| Tan, L | 1 |
| Suresh, R | 1 |
| Ademuyiwa, FO | 1 |
| Rigden, C | 1 |
| Rearden, TP | 1 |
| Clifton, K | 1 |
| Weilbaecher, K | 1 |
| Frith, A | 1 |
| Tandra, PK | 1 |
| Summa, T | 1 |
| Haas, B | 1 |
| Thomas, S | 1 |
| Hernandez-Aya, LF | 1 |
| Peterson, LL | 1 |
| Luo, SJ | 1 |
| Zhou, K | 2 |
| Du, P | 1 |
| Jia, S | 1 |
| King, BL | 1 |
| Krishnamurthy, J | 1 |
| Ma, CX | 2 |
| Li, YC | 1 |
| Deng, ZX | 1 |
| Wang, YJ | 1 |
| Xu, T | 1 |
| Sun, Q | 2 |
| Shen, SJ | 1 |
| Hollins, AW | 1 |
| Hein, RE | 1 |
| Atia, AN | 1 |
| Zhang, GX | 1 |
| Sergesketter, AR | 1 |
| Darner, G | 1 |
| Morris, M | 1 |
| Mithani, SK | 1 |
| Satoh, E | 1 |
| Hara, M | 1 |
| Uehira, D | 1 |
| Yonekura, K | 1 |
| Murakata, A | 1 |
| Ohinata, R | 1 |
| Toyofuku, Y | 1 |
| Tanami, H | 1 |
| Osanai, T | 1 |
| Sugano, N | 1 |
| Sakoma, T | 1 |
| Vaklavas, C | 2 |
| Stringer-Reasor, EM | 1 |
| Elkhanany, AM | 1 |
| Ryan, KJ | 1 |
| Theuer, CP | 1 |
| Acosta, EP | 1 |
| Wei, S | 1 |
| Yang, ES | 1 |
| Grizzle, WE | 2 |
| Forero-Torres, A | 3 |
| Heo, JH | 1 |
| Mehta, S | 1 |
| Han, S | 3 |
| Spencer, JC | 1 |
| Louis, DM | 1 |
| Nair, LM | 1 |
| Vijaykumar, DK | 1 |
| Vallonthaiel, AG | 1 |
| Yesodharan, J | 1 |
| Bhaskaran, R | 1 |
| Narmadha, MP | 1 |
| Masurkar, PP | 1 |
| Damgacioglu, H | 1 |
| Deshmukh, AA | 1 |
| Trivedi, MV | 1 |
| Malorni, L | 1 |
| Bianchini, G | 1 |
| Bianchi, GV | 2 |
| Paris, I | 2 |
| Allegrini, G | 1 |
| Colleoni, M | 36 |
| Cazzaniga, ME | 1 |
| Orditura, M | 2 |
| Castelletti, D | 1 |
| Benelli, M | 1 |
| Di Marino, M | 1 |
| Bliss, JM | 3 |
| Tovey, H | 1 |
| Evans, A | 1 |
| Holcombe, C | 2 |
| Horgan, K | 1 |
| Mallon, E | 4 |
| Vidya, R | 1 |
| Skene, A | 1 |
| Dodson, A | 2 |
| Hills, M | 2 |
| Detre, S | 4 |
| Zabaglo, L | 1 |
| Banerji, J | 1 |
| Kilburn, L | 1 |
| Morden, JP | 1 |
| Robertson, JFR | 1 |
| Smith, I | 16 |
| Dowsett, M | 40 |
| Banjara, B | 1 |
| Ohemeng, A | 1 |
| Nozaki, Y | 1 |
| Yamamuro, M | 1 |
| Tanaka, N | 1 |
| Kamo, N | 1 |
| Konishi, J | 1 |
| Rugo, HS | 13 |
| Liu, X | 4 |
| Li, B | 3 |
| McRoy, L | 4 |
| Layman, RM | 3 |
| Brufsky, A | 5 |
| Rostami, N | 1 |
| Gomari, MM | 1 |
| Abdouss, M | 1 |
| Moeinzadeh, A | 1 |
| Choupani, E | 1 |
| Davarnejad, R | 1 |
| Heidari, R | 1 |
| Bencherif, SA | 1 |
| Bayram, D | 1 |
| Aktürk Esen, S | 1 |
| Uçar, G | 1 |
| Köş, FT | 1 |
| Yan, M | 3 |
| Pan, Y | 1 |
| Teng, Y | 1 |
| Yan, X | 1 |
| Wang, Y | 8 |
| Xie, W | 1 |
| Zeng, X | 2 |
| Hu, C | 1 |
| Wu, X | 1 |
| Zhong, J | 2 |
| Xu, J | 2 |
| Shi, Y | 2 |
| Wei, W | 1 |
| Bayaxi, N | 1 |
| Zhu, X | 1 |
| Mamounas, EP | 3 |
| Bandos, H | 2 |
| Rastogi, P | 2 |
| Lembersky, BC | 2 |
| Jeong, JH | 4 |
| Geyer, CE | 2 |
| Fehrenbacher, L | 2 |
| Chia, SK | 4 |
| Brufsky, AM | 5 |
| Walshe, JM | 3 |
| Soori, GS | 2 |
| Dakhil, SR | 5 |
| Wade, JL | 2 |
| McCarron, EC | 2 |
| Swain, SM | 3 |
| Wolmark, N | 5 |
| Baba, O | 1 |
| Kisaoglu, H | 1 |
| Kalyoncu, M | 1 |
| Kapagan, T | 1 |
| Bulut, N | 1 |
| Demirer, S | 1 |
| Erdem, GU | 2 |
| Sun, M | 1 |
| Cai, L | 1 |
| Chen, M | 2 |
| Hu, ZY | 1 |
| Xiong, H | 1 |
| Ran, L | 1 |
| Luo, T | 1 |
| Xie, N | 1 |
| Yang, X | 2 |
| Xiao, H | 1 |
| Liu, B | 1 |
| Carmona-Sarabia, L | 1 |
| Quiñones Vélez, G | 1 |
| Mojica-Vázquez, D | 1 |
| Escalera-Joy, AM | 1 |
| Esteves-Vega, S | 1 |
| Peterson-Peguero, EA | 1 |
| López-Mejías, V | 1 |
| Bezerra, PHA | 1 |
| Amaral, C | 2 |
| Almeida, CF | 2 |
| Correia-da-Silva, G | 2 |
| Torqueti, MR | 1 |
| Teixeira, N | 2 |
| Diaz de Greñu, B | 1 |
| Fernández-Aroca, DM | 1 |
| Organero, JA | 1 |
| Durá, G | 1 |
| Jalón, FA | 1 |
| Sánchez-Prieto, R | 1 |
| Ruiz-Hidalgo, MJ | 1 |
| Rodríguez, AM | 1 |
| Santos, L | 1 |
| Albasanz, JL | 1 |
| Manzano, BR | 1 |
| Symonds, LK | 1 |
| Davidson, NE | 9 |
| Turan, V | 5 |
| Gayete-Lafuente, S | 1 |
| Bang, H | 2 |
| Oktay, KH | 2 |
| Faltinová, M | 2 |
| Vehmanen, L | 2 |
| Lyytinen, H | 2 |
| Haanpää, M | 2 |
| Hämäläinen, E | 2 |
| Tiitinen, A | 2 |
| Blomqvist, C | 2 |
| Mattson, J | 2 |
| Fein, L | 1 |
| Lazaretti, N | 1 |
| Chuken, YL | 1 |
| Benfield, JRGR | 1 |
| Mano, MS | 1 |
| Lobaton, J | 1 |
| Korbenfeld, E | 1 |
| Damian, F | 1 |
| Mori, A | 5 |
| Patyna, SJ | 1 |
| Franco, S | 1 |
| Terasawa, R | 1 |
| Takashima, Y | 1 |
| Hirata, A | 1 |
| Kimura, K | 1 |
| Morita, S | 2 |
| Hayashi, M | 1 |
| Su, F | 3 |
| Solovieff, N | 2 |
| Hortobagyi, G | 3 |
| Chia, S | 2 |
| Neven, P | 28 |
| Bardia, A | 4 |
| Tripathy, D | 6 |
| Lu, YS | 2 |
| Lteif, A | 1 |
| Babbar, N | 1 |
| Slamon, D | 2 |
| Masuda, J | 1 |
| Sakai, H | 1 |
| Tsurutani, J | 1 |
| Tanabe, Y | 1 |
| Masuda, N | 11 |
| Iwasa, T | 1 |
| Futamura, M | 1 |
| Matsumoto, K | 1 |
| Aogi, K | 3 |
| Iwata, H | 10 |
| Hosonaga, M | 1 |
| Mukohara, T | 1 |
| Yoshimura, K | 3 |
| Imamura, CK | 1 |
| Miura, S | 1 |
| Yamochi, T | 1 |
| Kawabata, H | 1 |
| Yasojima, H | 1 |
| Tomioka, N | 1 |
| Takano, T | 1 |
| Anvar, C | 1 |
| Pridko, O | 1 |
| Borikun, T | 1 |
| Rossylna, O | 1 |
| Rusyn, AV | 1 |
| Bidard, FC | 2 |
| Ling, B | 1 |
| Dong, Y | 1 |
| Paux, G | 1 |
| Herold, C | 1 |
| De Giorgi, U | 1 |
| Agostinetto, E | 2 |
| Ignatiadis, M | 2 |
| Jackisch, C | 1 |
| Hlauschek, D | 1 |
| Oliveira, M | 3 |
| Zardavas, D | 1 |
| Jallitsch-Halper, A | 1 |
| de la Peña, L | 1 |
| Nuciforo, P | 2 |
| Dubsky, P | 2 |
| Lombard, JM | 1 |
| Vuylsteke, P | 1 |
| Castaneda, CA | 1 |
| Santos Borges, G | 1 |
| Fornier, M | 2 |
| Boer, K | 4 |
| Wilson, TR | 1 |
| Stout, TJ | 1 |
| Hsu, JY | 1 |
| Piccart, M | 3 |
| Gnant, M | 6 |
| Baselga, J | 3 |
| de Azambuja, E | 5 |
| Giuliano, M | 2 |
| Schettini, F | 3 |
| Rognoni, C | 1 |
| Milani, M | 8 |
| Bachelot, T | 5 |
| Thomas, G | 1 |
| De Placido, P | 2 |
| Cristofanilli, M | 6 |
| Giordano, A | 1 |
| Pistilli, B | 1 |
| Venturini, S | 3 |
| Meynard, L | 1 |
| Grellety, T | 1 |
| Woodford, RG | 1 |
| Becker, GJ | 1 |
| Jain, A | 2 |
| Adamo, B | 4 |
| Pérez Fidalgo, JA | 1 |
| Blanch, S | 1 |
| Martinez, N | 3 |
| Murillo, L | 1 |
| Gómez-Pardo, P | 1 |
| López-González, A | 1 |
| Canes, J | 1 |
| Galván, P | 5 |
| González-Farré, B | 2 |
| González, X | 1 |
| Tarabaih, M | 1 |
| Kanj, A | 1 |
| Aoun, M | 1 |
| Assi, T | 1 |
| Awada, A | 2 |
| Rimawi, MF | 2 |
| Niravath, P | 1 |
| Wang, T | 2 |
| Rexer, BN | 1 |
| Forero, A | 3 |
| Wolff, AC | 4 |
| Nanda, R | 3 |
| Krop, I | 2 |
| Nangia, JR | 1 |
| Jiralerspong, S | 1 |
| Pavlick, A | 1 |
| Veeraraghavan, J | 1 |
| De Angelis, C | 1 |
| Gutierrez, C | 2 |
| Schiff, R | 2 |
| Hilsenbeck, SG | 2 |
| Osborne, CK | 4 |
| Anurag, M | 1 |
| Zhu, M | 1 |
| Huang, C | 1 |
| Vasaikar, S | 1 |
| Hoog, J | 4 |
| Burugu, S | 1 |
| Gao, D | 1 |
| Suman, V | 1 |
| Zhang, XH | 1 |
| Zhang, B | 4 |
| Nielsen, T | 1 |
| Carvalho, MJ | 1 |
| Subtil, S | 1 |
| Rodrigues, Â | 1 |
| Oliveira, J | 1 |
| Figueiredo-Dias, M | 1 |
| Boers, J | 1 |
| Venema, CM | 1 |
| de Vries, EFJ | 1 |
| Glaudemans, AWJM | 1 |
| Kwee, TC | 1 |
| Schuuring, E | 1 |
| Martens, JWM | 1 |
| Elias, SG | 1 |
| Hospers, GAP | 1 |
| Schröder, CP | 1 |
| Yassemi, A | 1 |
| Kashanian, S | 2 |
| Zhaleh, H | 1 |
| He, T | 1 |
| Yang, W | 2 |
| Zhang, X | 3 |
| Yang, D | 1 |
| Fan, Y | 3 |
| Xiang, M | 1 |
| Huang, Q | 1 |
| Chen, J | 4 |
| Zhou, R | 1 |
| Lv, Q | 1 |
| Hack, CC | 4 |
| Häberle, L | 4 |
| Brucker, SY | 6 |
| Volz, B | 2 |
| Loehberg, CR | 2 |
| Hartkopf, AD | 2 |
| Walter, CB | 2 |
| Baake, G | 6 |
| Fridman, A | 2 |
| Malter, W | 2 |
| Wuerstlein, R | 6 |
| Harbeck, N | 15 |
| Hoffmann, O | 2 |
| Kuemmel, S | 3 |
| Martin, B | 2 |
| Thomssen, C | 7 |
| Graf, H | 2 |
| Wolf, C | 7 |
| Lux, MP | 3 |
| Bayer, CM | 5 |
| Rauh, C | 5 |
| Almstedt, K | 2 |
| Gass, P | 2 |
| Heindl, F | 2 |
| Brodkorb, T | 2 |
| Willer, L | 1 |
| Lindner, C | 2 |
| Kolberg, HC | 6 |
| Krabisch, P | 2 |
| Weigel, M | 2 |
| Steinfeld-Birg, D | 2 |
| Kohls, A | 6 |
| Brucker, C | 6 |
| Schulz, V | 2 |
| Fischer, G | 6 |
| Pelzer, V | 2 |
| Rack, B | 2 |
| Beckmann, MW | 8 |
| Fehm, T | 6 |
| Rody, A | 4 |
| Maass, N | 3 |
| Hein, A | 6 |
| Fasching, PA | 8 |
| Nabieva, N | 5 |
| Nicolini, A | 3 |
| Rossi, G | 2 |
| Ferrari, P | 2 |
| Morganti, R | 1 |
| Carpi, A | 3 |
| Rashad, N | 1 |
| Abdelhamid, T | 1 |
| Shouman, SA | 1 |
| Nassar, H | 1 |
| Omran, MA | 1 |
| El Desouky, ED | 1 |
| Khaled, H | 1 |
| Nigro, O | 1 |
| Marrazzo, C | 1 |
| Gallerani, E | 1 |
| Bascialla, L | 1 |
| Gueli, R | 1 |
| Grigioni, E | 1 |
| De Giorgi, A | 1 |
| Giaquinto, A | 1 |
| Vallini, I | 1 |
| Pinotti, G | 1 |
| Roberts, BS | 1 |
| Varley, KE | 1 |
| Lin, NU | 3 |
| Puhalla, S | 2 |
| Carey, LA | 7 |
| Saleh, MN | 2 |
| Delossantos, JF | 1 |
| LoBuglio, AF | 2 |
| Myers, RM | 1 |
| Jain, AL | 1 |
| Mullins, J | 1 |
| Smith, JR | 1 |
| Valasareddy, P | 1 |
| Miller, E | 1 |
| Chaudhry, A | 1 |
| Ryder, J | 1 |
| Hare, F | 1 |
| Ranganath, H | 1 |
| Berry, M | 1 |
| Robins, D | 1 |
| Schwartzberg, L | 1 |
| Vidal, GA | 1 |
| Russell-Goldman, E | 1 |
| Nazarian, RM | 1 |
| Hwang, ES | 3 |
| Hyslop, T | 2 |
| Hendrix, LH | 1 |
| Duong, S | 1 |
| Bedrosian, I | 1 |
| Price, E | 1 |
| Caudle, A | 1 |
| Hieken, T | 1 |
| Guenther, J | 1 |
| Hudis, CA | 4 |
| Winer, E | 6 |
| Lyss, AP | 1 |
| Dickson-Witmer, D | 1 |
| Hoefer, R | 1 |
| Ollila, DW | 1 |
| Hardman, T | 1 |
| Marks, J | 2 |
| Chen, YY | 2 |
| Krings, G | 1 |
| Esserman, L | 3 |
| Hylton, N | 1 |
| Lazzeroni, M | 1 |
| DeCensi, A | 2 |
| Chang, G | 1 |
| Kanaya, N | 2 |
| Park, D | 1 |
| Loeng, M | 1 |
| Takada, K | 1 |
| Kashiwagi, S | 1 |
| Kawajiri, H | 1 |
| Asano, Y | 1 |
| Morisaki, T | 1 |
| Noda, S | 1 |
| Takashima, T | 1 |
| Onoda, N | 1 |
| Hirakawa, K | 1 |
| Ohira, M | 1 |
| Bercaire, LMN | 1 |
| Cavagna, M | 1 |
| Donadio, NF | 1 |
| Rocha, AR | 1 |
| Portela, R | 1 |
| Alves, VR | 1 |
| Santos, TBB | 1 |
| Cavagna, F | 1 |
| Dzik, A | 1 |
| Gebrim, LH | 1 |
| Nahas, EAP | 1 |
| Huang Bartlett, C | 4 |
| Mardekian, J | 2 |
| Cotter, MJ | 2 |
| Huang, X | 8 |
| Zhang, Z | 1 |
| Parrinello, CM | 1 |
| Bourla, AB | 1 |
| Umamaheswaran, G | 2 |
| Kadambari, D | 3 |
| Muthuvel, SK | 2 |
| Kalaivani, S | 1 |
| Devi, J | 1 |
| Damodaran, SE | 1 |
| Pradhan, SC | 1 |
| Dubashi, B | 2 |
| Dkhar, SA | 1 |
| Adithan, C | 2 |
| Giudici, F | 1 |
| De Laurentis, M | 1 |
| Juric, D | 1 |
| Pusztai, L | 1 |
| Di Leo, A | 8 |
| Skriver, SK | 3 |
| Jensen, MB | 6 |
| Knoop, AS | 4 |
| Ejlertsen, B | 19 |
| Laenkholm, AV | 4 |
| Nishimura, R | 4 |
| Inoue, K | 5 |
| Ohno, S | 4 |
| Hashigaki, S | 4 |
| Muramatsu, Y | 4 |
| Umeyama, Y | 4 |
| Jayaraman, S | 1 |
| Hou, X | 2 |
| Kuffel, MJ | 1 |
| Hoskin, TL | 1 |
| Reinicke, KE | 1 |
| Monroe, DG | 1 |
| Kalari, KR | 1 |
| Tang, X | 1 |
| Zeldenrust, MA | 1 |
| Cheng, J | 4 |
| Bruinsma, ES | 1 |
| Buhrow, SA | 1 |
| McGovern, RM | 1 |
| Safgren, SL | 1 |
| Walden, CA | 1 |
| Carter, JM | 1 |
| Reid, JM | 1 |
| Ames, MM | 1 |
| Hawse, JR | 1 |
| Jamal, QMS | 1 |
| Sharma, M | 1 |
| Duan, Z | 1 |
| Giordano, SH | 4 |
| Chavez-MacGregor, M | 1 |
| Wang, Q | 2 |
| Gui, L | 1 |
| Guerreiro, C | 1 |
| Albuquerque, L | 1 |
| Reimão, S | 1 |
| Ham, A | 1 |
| Magbanua, MJM | 1 |
| Savenkov, O | 1 |
| Asmus, EJ | 1 |
| Ballman, KV | 2 |
| Scott, JH | 1 |
| Park, JW | 2 |
| Dickler, M | 1 |
| Partridge, A | 2 |
| Borrie, AE | 2 |
| Rose, FA | 1 |
| Choi, YH | 2 |
| Perera, FE | 2 |
| Read, N | 2 |
| Sexton, T | 2 |
| Lock, M | 2 |
| Vandenberg, TA | 2 |
| Hahn, K | 2 |
| Younus, J | 2 |
| Logan, D | 2 |
| Potvin, K | 2 |
| Yaremko, B | 2 |
| Yu, E | 2 |
| Lenehan, J | 2 |
| Welch, S | 2 |
| Teft, WA | 2 |
| Kim, RB | 2 |
| Wang, C | 3 |
| Lin, Y | 1 |
| Zhou, Y | 2 |
| Mao, F | 1 |
| Zhu, H | 1 |
| Guan, J | 1 |
| Shen, S | 1 |
| Chen, C | 1 |
| Yao, R | 1 |
| Zhao, J | 1 |
| Bondarenko, I | 3 |
| Patel, R | 4 |
| Pinter, T | 3 |
| Schmidt, M | 3 |
| Shparyk, YV | 1 |
| Thummala, A | 1 |
| Voitko, N | 1 |
| Bananis, E | 1 |
| Wilner, K | 1 |
| Slamon, DJ | 7 |
| Ettl, J | 7 |
| Noordhoek, I | 1 |
| Blok, EJ | 4 |
| Meershoek-Klein Kranenbarg, E | 4 |
| Putter, H | 5 |
| Duijm-de Carpentier, M | 3 |
| Rutgers, EJT | 3 |
| Seynaeve, C | 2 |
| Bartlett, JMS | 1 |
| Vannetzel, JM | 1 |
| Rea, DW | 3 |
| Hasenburg, A | 1 |
| Paridaens, R | 11 |
| Markopoulos, CJ | 1 |
| Hozumi, Y | 2 |
| Portielje, JEA | 1 |
| Kroep, JR | 4 |
| van de Velde, CJH | 3 |
| Liefers, GJ | 4 |
| Rose, BI | 1 |
| Brown, SE | 1 |
| Eriksen, JO | 1 |
| Ahlborn, LB | 1 |
| Rossing, M | 1 |
| Mishra, K | 1 |
| Verma, SK | 1 |
| Ratre, P | 1 |
| Banjare, L | 1 |
| Thareja, S | 1 |
| Jain, AK | 1 |
| Cabel, L | 1 |
| Rosenblum, D | 1 |
| Brain, E | 1 |
| Loirat, D | 1 |
| Bergqvist, M | 1 |
| Donnadieu, A | 1 |
| Bethune, A | 1 |
| Kiavue, N | 1 |
| Rodrigues, M | 1 |
| Pierga, JY | 2 |
| Tanguy, ML | 1 |
| Park, JH | 2 |
| Ahn, JH | 3 |
| Kim, JE | 3 |
| Jung, KH | 4 |
| Gong, G | 3 |
| Lee, HJ | 2 |
| Son, BH | 2 |
| Ahn, SH | 4 |
| Kim, HH | 2 |
| Shin, HJ | 2 |
| Moon, DH | 2 |
| Kim, D | 1 |
| Kim, SB | 4 |
| Mukai, H | 2 |
| Rai, Y | 1 |
| Ohtani, S | 3 |
| Shimizu, C | 2 |
| Zhang, Y | 7 |
| Zheng, C | 1 |
| Ren, Q | 1 |
| Gao, X | 1 |
| He, Y | 2 |
| Ma, Z | 2 |
| Rabaglio, M | 14 |
| Sun, Z | 9 |
| Maibach, R | 6 |
| Giobbie-Hurder, A | 17 |
| Harvey, VJ | 3 |
| Láng, I | 18 |
| Bonnefoi, H | 6 |
| Wardley, A | 8 |
| Ruepp, B | 3 |
| Castiglione, M | 7 |
| Coates, AS | 34 |
| Gelber, RD | 37 |
| Goldhirsch, A | 42 |
| Thürlimann, B | 34 |
| Regan, MM | 24 |
| Troussier, I | 1 |
| Canova, C | 1 |
| Klausner, G | 1 |
| Leone, JP | 1 |
| Cole, BF | 4 |
| Vaz-Luis, I | 1 |
| Koh, SJ | 1 |
| Cheon, J | 1 |
| Lee, KS | 5 |
| Sim, SH | 2 |
| Park, IH | 5 |
| Moravek, MB | 1 |
| Confino, R | 1 |
| Lawson, AK | 1 |
| Smith, KN | 1 |
| Kazer, RR | 1 |
| Klock, SC | 1 |
| Gradishar, WJ | 3 |
| Jeruss, JS | 1 |
| Pavone, ME | 1 |
| Shulman, Y | 1 |
| Almog, B | 1 |
| Kalma, Y | 1 |
| Fouks, Y | 1 |
| Azem, F | 1 |
| Cohen, Y | 1 |
| Adachi, K | 4 |
| Suzuki, S | 3 |
| Hirano, T | 4 |
| Sakurai, K | 8 |
| Abdeltawab, AA | 1 |
| Ali, SA | 1 |
| Mostafa, HG | 1 |
| Hassan, MA | 1 |
| Gallegos, KM | 1 |
| Bratton, MR | 2 |
| Lemieux, KP | 1 |
| Zhang, K | 1 |
| Wang, G | 2 |
| Fernandez-Martinez, A | 1 |
| Tanioka, M | 1 |
| Pernas, S | 2 |
| Guarnieri, V | 1 |
| Chic, N | 2 |
| Llombart, A | 6 |
| Conte, B | 1 |
| Debien, V | 1 |
| Marta, GN | 1 |
| Piccart-Gebhart, M | 3 |
| Hae Park, I | 1 |
| Im, SA | 7 |
| Chen, SC | 2 |
| Enatsu, S | 1 |
| Turner, PK | 1 |
| André, VAM | 1 |
| Hardebeck, MC | 1 |
| Sakaguchi, S | 1 |
| Sledge, GW | 1 |
| Yang, HN | 1 |
| Jeon, SY | 1 |
| Egelston, C | 1 |
| Yost, S | 1 |
| Lee, JS | 2 |
| Rose, D | 1 |
| Avalos, C | 1 |
| Ye, J | 5 |
| Frankel, P | 1 |
| Schmolze, D | 2 |
| Waisman, J | 1 |
| Lee, P | 2 |
| Yuan, Y | 2 |
| Kumar, NAN | 1 |
| Aibor Dkhar, S | 1 |
| DeMichele, A | 4 |
| Emir, B | 1 |
| Torres, MA | 1 |
| Vazquez, L | 1 |
| Arnaud, A | 1 |
| Grenier, J | 2 |
| Debourdeau, P | 1 |
| Jung, SU | 1 |
| Jung, M | 1 |
| Choi, JH | 1 |
| Jeon, CW | 1 |
| Gulturk, I | 1 |
| Yilmaz, M | 1 |
| Ozmen, A | 1 |
| Tacar, SY | 1 |
| Erdal, GS | 1 |
| Tural, D | 1 |
| Lee, EY | 1 |
| Freedman, O | 1 |
| Castells, M | 1 |
| Vadas, P | 1 |
| Iida, Y | 1 |
| Hongo, K | 1 |
| Onoda, T | 1 |
| Kita, Y | 1 |
| Ishihara, Y | 1 |
| Takabayashi, N | 1 |
| Kobayashi, R | 1 |
| Kuriki, K | 1 |
| Hiramatsu, T | 1 |
| Mohammadi, E | 1 |
| Tabatabaei, M | 1 |
| Habibi-Anbouhi, M | 1 |
| Tafazzoli-Shadpour, M | 1 |
| Goduni, L | 1 |
| Ashkenazy, N | 1 |
| Hansen, E | 1 |
| Soyano-Muller, A | 1 |
| Correa, ZM | 1 |
| Harbour, JW | 1 |
| Brasó-Maristany, F | 1 |
| Sanfeliu, E | 1 |
| Martínez, D | 1 |
| Martínez-Sáez, O | 1 |
| Soberino, J | 1 |
| Huang, H | 1 |
| Takai, Y | 1 |
| Samejima, K | 1 |
| Gomi, Y | 1 |
| Narita, T | 1 |
| Ichinose, S | 1 |
| Itaya, Y | 1 |
| Ono, Y | 2 |
| Matsunaga, S | 1 |
| Saitoh, M | 1 |
| Seki, H | 1 |
| McGuinness, JE | 1 |
| Altoe, ML | 1 |
| Marone, A | 1 |
| Franks, LE | 1 |
| Lee, SM | 1 |
| Kim, HK | 1 |
| Tejada, M | 1 |
| Trivedi, MS | 1 |
| Accordino, MK | 1 |
| Crew, KD | 1 |
| Hershman, DL | 1 |
| Hielscher, AH | 1 |
| Kalinsky, K | 1 |
| Yost, SE | 1 |
| Frankel, PH | 1 |
| Ruel, C | 1 |
| Egelston, CA | 1 |
| Padam, S | 1 |
| Tang, A | 1 |
| Presant, C | 1 |
| Ebrahimi, B | 1 |
| Yeon, C | 1 |
| Sedrak, M | 1 |
| Patel, N | 1 |
| Portnow, J | 1 |
| Mortimer, J | 1 |
| Malik, AA | 1 |
| Abbas, H | 1 |
| Oo, ZM | 1 |
| Lim, Z | 1 |
| Letourneau, J | 1 |
| Juarez-Hernandez, F | 1 |
| Wald, K | 1 |
| Ribeiro, S | 1 |
| Wang, A | 1 |
| McCulloch, CE | 1 |
| Mok-Lin, E | 1 |
| Dolezal, M | 1 |
| Chien, AJ | 1 |
| Cedars, MI | 1 |
| Rosen, M | 1 |
| Wu, W | 2 |
| Deng, H | 2 |
| Jin, L | 4 |
| He, Z | 3 |
| Rao, N | 2 |
| Nie, Y | 1 |
| Yao, Y | 2 |
| Yang, Y | 3 |
| Reis, J | 1 |
| Thomas, O | 1 |
| Lahooti, M | 1 |
| Lyngra, M | 1 |
| Schandiz, H | 1 |
| Boavida, J | 1 |
| Gjesdal, KI | 1 |
| Geitung, JT | 1 |
| Farah, S | 1 |
| Courtois, A | 1 |
| Chirgwin, J | 7 |
| Aebi, S | 6 |
| Karlsson, P | 3 |
| Hitre, E | 2 |
| Graas, MP | 3 |
| Simoncini, E | 4 |
| Abdi, E | 2 |
| Kamby, C | 3 |
| Thompson, A | 5 |
| Loibl, S | 4 |
| Kuroi, K | 4 |
| Müller, B | 3 |
| O'Reilly, S | 2 |
| Gombos, A | 2 |
| Ruhstaller, T | 7 |
| Burstein, HJ | 3 |
| Ribi, K | 7 |
| Viale, G | 21 |
| Augusto, TV | 1 |
| Warner, E | 2 |
| Bofill, JS | 1 |
| Jacot, W | 2 |
| Dent, S | 1 |
| Lu, J | 2 |
| Azim, HA | 2 |
| Chatterjee, S | 1 |
| Shah, U | 1 |
| Patel, S | 2 |
| Patel, M | 1 |
| Jain, N | 1 |
| Pandey, N | 1 |
| Chauhan, A | 1 |
| Patel, A | 1 |
| Matter-Walstra, K | 2 |
| Schwenkglenks, M | 2 |
| Dedes, KJ | 2 |
| Corona, SP | 1 |
| Ravelli, A | 1 |
| Cretella, D | 1 |
| Cappelletti, MR | 3 |
| Zanotti, L | 2 |
| Dester, M | 1 |
| Gobbi, A | 1 |
| Petronini, PG | 4 |
| Borgquist, S | 1 |
| Ahern, TP | 1 |
| Garber, JE | 1 |
| Debled, M | 6 |
| von Moos, R | 2 |
| Price, KN | 29 |
| Mahadevappa, R | 1 |
| Neves, H | 1 |
| Yuen, SM | 1 |
| Bai, Y | 1 |
| McCrudden, CM | 1 |
| Yuen, HF | 1 |
| Wen, Q | 1 |
| Zhang, SD | 1 |
| Kwok, HF | 1 |
| Mathew, L | 1 |
| Gaikwad, A | 1 |
| Gonzalez, A | 1 |
| Nugent, EK | 1 |
| Smith, JA | 1 |
| Kadakia, KC | 1 |
| Seewald, NJ | 1 |
| Snyder, CF | 1 |
| Otte, JL | 1 |
| Chirila, C | 1 |
| Mitra, D | 3 |
| Colosia, A | 1 |
| Ling, C | 1 |
| Odom, D | 1 |
| Iyer, S | 7 |
| Kaye, JA | 1 |
| Kim, ES | 1 |
| Scott, LJ | 2 |
| Goncalves, R | 2 |
| Reinert, T | 1 |
| Elzoghby, AO | 1 |
| Mostafa, SK | 1 |
| Helmy, MW | 1 |
| ElDemellawy, MA | 1 |
| Sheweita, SA | 1 |
| Wang, XQ | 1 |
| Aka, JA | 1 |
| Li, T | 2 |
| Xu, D | 1 |
| Doillon, CJ | 1 |
| Lin, SX | 1 |
| Hong, N | 1 |
| Yoon, HG | 1 |
| Seo, DH | 1 |
| Sohn, JH | 1 |
| Rhee, Y | 1 |
| Bilgin, B | 1 |
| Sendur, MAN | 1 |
| Şener Dede, D | 1 |
| Akıncı, MB | 2 |
| Yalçın, B | 1 |
| van Golde, RJT | 1 |
| Schipper, I | 1 |
| Reddy, N | 1 |
| Kopeika, Y | 1 |
| Alviggi, C | 1 |
| Marci, R | 1 |
| Vallone, R | 1 |
| Conforti, A | 1 |
| Di Rella, F | 5 |
| Strina, I | 1 |
| Picarelli, S | 1 |
| De Rosa, P | 1 |
| Yding Andersen, C | 1 |
| De Placido, G | 1 |
| Alkner, S | 1 |
| Rasmussen, BB | 9 |
| Bendahl, PO | 1 |
| Fernö, M | 1 |
| Rydén, L | 1 |
| Mouridsen, H | 16 |
| Khan, QJ | 3 |
| Kimler, BF | 4 |
| Reddy, PS | 3 |
| Sharma, P | 2 |
| Klemp, JR | 2 |
| Nydegger, JL | 1 |
| Yeh, HW | 1 |
| Fabian, CJ | 5 |
| Zhang, J | 4 |
| Zheng, S | 1 |
| Wu, K | 1 |
| Liu, XY | 1 |
| Li, S | 3 |
| Zhao, Z | 2 |
| Cui, MK | 2 |
| Wang, EH | 1 |
| van den Bosch, J | 2 |
| Maartense, E | 2 |
| van Leeuwen-Stok, AE | 1 |
| Nortier, JWR | 2 |
| Youngwirth, LM | 1 |
| Raphael, J | 1 |
| Helou, J | 1 |
| Pritchard, KI | 21 |
| Naimark, DM | 1 |
| Messina, C | 1 |
| Messina, M | 1 |
| Zanardi, E | 2 |
| Paluch-Shimon, S | 3 |
| Huober, J | 4 |
| Trédan, O | 1 |
| Manso, L | 1 |
| Freedman, OC | 2 |
| Garnica Jaliffe, G | 1 |
| Forrester, T | 1 |
| Frenzel, M | 1 |
| Barriga, S | 1 |
| Smith, IC | 1 |
| Bourayou, N | 1 |
| Kellner, S | 1 |
| de Waal, J | 4 |
| Rezai, M | 4 |
| Baier, B | 4 |
| Guggenberger, M | 4 |
| Warm, M | 5 |
| Deuker, JU | 4 |
| Dall, P | 4 |
| Richter, B | 4 |
| Wachsmann, G | 5 |
| Siebers, JW | 4 |
| Fersis, N | 3 |
| Kuhn, T | 9 |
| Vollert, HW | 4 |
| Breitbach, GP | 4 |
| Landthaler, R | 4 |
| Rezek, D | 4 |
| Noesselt, T | 3 |
| Henschen, S | 4 |
| Praetz, T | 4 |
| Heyl, V | 4 |
| Krauss, T | 4 |
| Hohn, A | 4 |
| Tesch, H | 4 |
| Mundhenke, C | 5 |
| Jacob, A | 2 |
| Schmidt, K | 4 |
| Belleville, E | 4 |
| Kümmel, S | 5 |
| Wallwiener, D | 7 |
| Hadji, P | 9 |
| Hart, LL | 3 |
| Erdkamp, F | 1 |
| Verma, S | 12 |
| Villanueva, C | 5 |
| Jakobsen, E | 3 |
| Alba, E | 8 |
| Wist, E | 2 |
| Favret, AM | 2 |
| Hegg, R | 1 |
| Wheatley-Price, P | 2 |
| Souami, F | 3 |
| Sutradhar, S | 3 |
| Miller, M | 5 |
| Germa, C | 5 |
| Fujisaki, S | 2 |
| Kubota, H | 2 |
| Hara, Y | 4 |
| Tomita, R | 1 |
| Enomoto, K | 9 |
| Saga, R | 1 |
| Makishima, M | 2 |
| You, N | 1 |
| Cao, M | 1 |
| Alameddine, RM | 1 |
| Ko, AC | 1 |
| Mimura, M | 1 |
| Parker, BA | 2 |
| Lin, JH | 1 |
| Korn, BS | 1 |
| Kikkawa, DO | 1 |
| Safra, T | 2 |
| Kaufman, B | 1 |
| Kadouri, L | 1 |
| Efrat Ben-Baruch, N | 1 |
| Ryvo, L | 2 |
| Nisenbaum, B | 1 |
| Evron, E | 1 |
| Yerushalmi, R | 1 |
| Freedman, RA | 1 |
| Tolaney, SM | 2 |
| Hemati Azandaryani, A | 1 |
| Derakhshandeh, K | 1 |
| Chlebowski, RT | 2 |
| Pan, K | 1 |
| Luo, W | 2 |
| Di Lauro, V | 2 |
| Burstein, H | 1 |
| Bernhard, J | 6 |
| Rabaglio-Poretti, M | 2 |
| Beck, JT | 5 |
| Lindquist, D | 1 |
| Mondal, S | 2 |
| Handler, J | 1 |
| Grundtmann, B | 1 |
| Tvedskov, TF | 1 |
| Christiansen, P | 1 |
| Shien, T | 2 |
| Doihara, H | 1 |
| Sato, N | 2 |
| Anan, K | 1 |
| Komaki, K | 1 |
| Miyauchi, K | 1 |
| Yanagita, Y | 1 |
| Fujisawa, T | 3 |
| Mitsuyama, S | 1 |
| Kanbayashi, C | 1 |
| Kusama, M | 1 |
| Kimura, M | 1 |
| Jinno, H | 1 |
| Sano, M | 4 |
| Ikeda, T | 4 |
| Lykkesfeldt, AE | 9 |
| Iversen, BR | 1 |
| Reiter, BE | 1 |
| Kirkegaard, T | 1 |
| Vohora, D | 1 |
| Kalam, A | 1 |
| Leekha, A | 1 |
| Talegaonkar, S | 1 |
| Verma, AK | 1 |
| Tian, W | 1 |
| Wu, M | 2 |
| Deng, Y | 1 |
| Sugie, T | 2 |
| Suzuki, E | 2 |
| Yamauchi, A | 1 |
| Yamagami, K | 1 |
| Gondo, N | 1 |
| Sumi, E | 2 |
| Tada, H | 2 |
| Uozumi, R | 1 |
| Kanao, S | 1 |
| Tanaka, Y | 3 |
| Hamazaki, Y | 1 |
| Minato, N | 2 |
| Lemieux, J | 1 |
| Brundage, MD | 1 |
| Celano, P | 1 |
| Muss, H | 2 |
| Gralow, J | 2 |
| Strasser-Weippl, K | 3 |
| Whelan, K | 2 |
| Whelan, TJ | 4 |
| Warth, B | 1 |
| Raffeiner, P | 1 |
| Granados, A | 1 |
| Huan, T | 1 |
| Fang, M | 1 |
| Forsberg, EM | 1 |
| Benton, HP | 1 |
| Goetz, L | 1 |
| Johnson, CH | 1 |
| Siuzdak, G | 1 |
| Turner, NC | 3 |
| Diéras, V | 7 |
| Moulder, S | 3 |
| Lipatov, O | 2 |
| Giorgetti, C | 1 |
| Bartlett, CH | 4 |
| Gelmon, KA | 5 |
| Mori, Y | 2 |
| Nagasawa, T | 2 |
| Durairaj, C | 1 |
| Ruiz-Garcia, A | 1 |
| Gauthier, ER | 2 |
| Hoffman, JT | 1 |
| Joy, AA | 5 |
| Zheng, J | 1 |
| Wilner, KD | 1 |
| Wang, DD | 1 |
| Shparyk, Y | 3 |
| Bhattacharyya, H | 2 |
| Bartlett, CHUANG | 1 |
| Johnston, S | 9 |
| Del Pup, L | 1 |
| Peccatori, FA | 1 |
| Huber, KM | 1 |
| Clayman, E | 1 |
| Kumar, A | 1 |
| Smith, P | 1 |
| Diab, S | 1 |
| Beck, TJ | 1 |
| Lopez, R | 1 |
| Tsai, M | 1 |
| Esteva, FJ | 3 |
| Auñón, PZ | 1 |
| Kral, Z | 1 |
| Ward, P | 1 |
| Richards, P | 1 |
| Pluard, TJ | 1 |
| Jordan, VC | 3 |
| Dirix, LY | 1 |
| Gallo, C | 5 |
| Riccardi, F | 2 |
| Russo, A | 1 |
| Cogoni, AA | 1 |
| Foglietta, J | 1 |
| Amoroso, D | 1 |
| Laudadio, L | 1 |
| Moscetti, L | 1 |
| Verusio, C | 1 |
| Bernardo, A | 1 |
| Lorusso, V | 2 |
| Gravina, A | 5 |
| Lauria, R | 2 |
| Lai, A | 1 |
| Mocerino, C | 1 |
| Rizzo, S | 1 |
| Nuzzo, F | 5 |
| Carlini, P | 6 |
| Perrone, F | 6 |
| Fujiwara, A | 1 |
| Waga, E | 1 |
| Gowarty, JL | 1 |
| Herrington, JD | 1 |
| Bozkaya, Y | 1 |
| Demirci, NS | 1 |
| Alemrayat, B | 2 |
| Elhissi, A | 2 |
| Younes, HM | 2 |
| Seynaeve, CM | 1 |
| Chandiwana, D | 1 |
| Dalal, AA | 3 |
| Monaco, M | 1 |
| Popovic, M | 2 |
| Blackwell, KL | 4 |
| Elmeliegy, M | 1 |
| Ueno, T | 1 |
| Kamigaki, S | 2 |
| Morimoto, T | 1 |
| Akiyama, F | 1 |
| Kurosumi, M | 2 |
| Tsuda, H | 2 |
| Mikami, Y | 1 |
| Tanaka, S | 1 |
| Ding, W | 1 |
| Ruan, G | 1 |
| Chen, L | 1 |
| Tu, C | 1 |
| Luo, Z | 1 |
| Cai, Q | 1 |
| Fu, S | 1 |
| Zhai, L | 1 |
| Li, D | 2 |
| McCall, LM | 1 |
| Hahn, OM | 1 |
| Cohen, HJ | 1 |
| Muss, HB | 12 |
| Jatoi, A | 1 |
| Lafky, JM | 4 |
| Schneider, B | 1 |
| Barry, W | 2 |
| Dickler, MN | 5 |
| Hurria, A | 2 |
| Mistry, R | 2 |
| May, JR | 2 |
| Suri, G | 2 |
| Young, K | 2 |
| Brixner, D | 2 |
| Oderda, G | 2 |
| Biskupiak, J | 2 |
| Tang, D | 2 |
| Bhattacharyya, S | 2 |
| Mishra, D | 2 |
| Bhattacharyya, D | 2 |
| Franke, F | 1 |
| Hurvitz, SA | 2 |
| Chow, L | 3 |
| Campos-Gomez, S | 1 |
| Babu, KG | 1 |
| Im, YH | 1 |
| El-Saghir, N | 1 |
| Carlson, G | 1 |
| Hughes, G | 1 |
| Diaz-Padilla, I | 1 |
| Hirawat, S | 2 |
| Luen, SJ | 1 |
| Asher, R | 1 |
| Lee, CK | 1 |
| Savas, P | 1 |
| Kammler, R | 5 |
| Dell'Orto, P | 7 |
| Biasi, OM | 1 |
| Demanse, D | 1 |
| JeBailey, L | 1 |
| Dolan, S | 1 |
| Hackl, W | 3 |
| Thuerlimann, B | 4 |
| Sarradin, V | 1 |
| Sibaud, V | 1 |
| Tournier, E | 1 |
| Roché, H | 2 |
| Xu, YY | 1 |
| Yu, HR | 1 |
| Sun, JY | 1 |
| Zhang, XF | 1 |
| Liao, ZX | 1 |
| Li, C | 1 |
| Schnell, P | 3 |
| Gelmon, K | 4 |
| Gauthier, E | 2 |
| Hettle, R | 1 |
| Elrayess, MA | 1 |
| Alany, RG | 1 |
| Rose, RV | 1 |
| Dinniwell, R | 1 |
| Tyndale, RF | 2 |
| Schickli, MA | 1 |
| Berger, MJ | 2 |
| Lustberg, M | 1 |
| Palettas, M | 1 |
| Vargo, CA | 1 |
| Ye, M | 1 |
| Yang, F | 1 |
| Wu, B | 1 |
| Dequen, F | 1 |
| Schöffski, P | 1 |
| Cresta, S | 1 |
| Mayer, IA | 4 |
| Wildiers, H | 4 |
| Damian, S | 1 |
| Gendreau, S | 1 |
| Rooney, I | 1 |
| Morrissey, KM | 1 |
| Spoerke, JM | 1 |
| Ng, VW | 1 |
| Singel, SM | 1 |
| Darden, C | 1 |
| McSorley, D | 1 |
| Davis, K | 1 |
| Band, J | 1 |
| Yamamoto, Y | 2 |
| Toyama, T | 1 |
| Kashiwaba, M | 1 |
| Taira, N | 2 |
| Sakai, T | 2 |
| Hasegawa, Y | 2 |
| Nakamura, R | 1 |
| Akabane, H | 1 |
| Shibahara, Y | 1 |
| Sasano, H | 6 |
| Yamaguchi, T | 2 |
| Sakamaki, K | 1 |
| Bailey, H | 1 |
| Cherbavaz, DB | 1 |
| Jakubowski, DM | 1 |
| Sugiyama, N | 1 |
| Chao, C | 1 |
| Ohashi, Y | 6 |
| Watson, GA | 1 |
| Deac, O | 1 |
| Aslam, R | 1 |
| O'Dwyer, R | 1 |
| Tierney, A | 1 |
| Sukor, S | 1 |
| Kennedy, J | 1 |
| Ferrero, JM | 1 |
| Canon, JL | 1 |
| Yam, C | 1 |
| Murthy, RK | 1 |
| Rauch, GM | 1 |
| Murray, JL | 2 |
| Walters, RS | 1 |
| Valero, V | 1 |
| Brewster, AM | 1 |
| Bast, RC | 1 |
| Booser, DJ | 1 |
| Moulder, SL | 1 |
| Arun, B | 1 |
| Li, L | 9 |
| Chang, B | 1 |
| Fan, X | 1 |
| Wu, S | 1 |
| Kariminia, S | 1 |
| Plummer, R | 1 |
| Verheul, HM | 1 |
| De Vos, FYFL | 1 |
| Leunen, K | 3 |
| Molife, LR | 1 |
| Rolfo, C | 1 |
| Grundtvig-Sørensen, P | 1 |
| De Grève, J | 3 |
| Rottey, S | 1 |
| Italiano, A | 1 |
| Spicer, J | 1 |
| Dirix, L | 2 |
| Goessl, C | 1 |
| Birkett, J | 1 |
| Spencer, S | 1 |
| Learoyd, M | 1 |
| Bailey, C | 1 |
| Dean, E | 1 |
| Weiss, J | 1 |
| Afghahi, A | 1 |
| Shagisultanova, E | 1 |
| Diamond, JR | 1 |
| Wan, X | 1 |
| Tan, C | 1 |
| Peng, L | 1 |
| Suzuki, Y | 1 |
| Takei, S | 1 |
| Jakobsen, EH | 2 |
| Gladieff, L | 3 |
| Tondini, C | 3 |
| Veyret, C | 1 |
| Gianni, L | 2 |
| Rochlitz, C | 1 |
| Kralidis, E | 1 |
| Zaman, K | 6 |
| Jassem, J | 1 |
| Favretto, D | 1 |
| Snenghi, R | 1 |
| Pertile, R | 1 |
| El Mazloum, R | 1 |
| Tucci, M | 2 |
| Visentin, S | 1 |
| Vogliardi, S | 1 |
| Amir, E | 1 |
| Graham, ML | 1 |
| Seay, TE | 1 |
| Paik, S | 2 |
| Wickerham, DL | 2 |
| Ohsumi, S | 3 |
| Kumar, S | 2 |
| Diamond, T | 1 |
| Barry, P | 1 |
| Boileau, JF | 1 |
| Provencher, L | 2 |
| Robidoux, A | 3 |
| Rimawi, M | 1 |
| McIntosh, SA | 1 |
| Shalaby, I | 1 |
| Stein, RC | 1 |
| Thirlwell, M | 1 |
| Dolling, D | 1 |
| Morden, J | 2 |
| Snowdon, C | 1 |
| Perry, S | 1 |
| Cornman, C | 1 |
| Batten, LM | 1 |
| Jeffs, LK | 1 |
| Martins, V | 1 |
| Modi, A | 2 |
| Pogue-Geile, KL | 1 |
| Cheang, MCU | 1 |
| Julian, TB | 1 |
| Fisher, K | 1 |
| MacKenzie, M | 1 |
| Wilcox, M | 1 |
| Koehler, M | 1 |
| Jacobs, SA | 1 |
| Dellapasqua, S | 6 |
| Gray, KP | 3 |
| Munzone, E | 3 |
| Rubino, D | 1 |
| Johansson, H | 2 |
| Ben-Haroush, A | 2 |
| Wertheimer, A | 1 |
| Klochendler, E | 1 |
| Sapir, O | 2 |
| Shufaro, Y | 1 |
| Oron, G | 1 |
| Goldrat, O | 2 |
| Van Den Steen, G | 1 |
| Gonzalez-Merino, E | 1 |
| Dechène, J | 1 |
| Gervy, C | 2 |
| Delbaere, A | 2 |
| Devreker, F | 1 |
| De Maertelaer, V | 1 |
| Demeestere, I | 2 |
| Selli, C | 1 |
| Turnbull, AK | 3 |
| Pearce, DA | 1 |
| Li, A | 1 |
| Fernando, A | 1 |
| Wills, J | 1 |
| Renshaw, L | 16 |
| Thomas, JS | 5 |
| Dixon, JM | 35 |
| Sims, AH | 4 |
| Castrellon, A | 1 |
| Livi, L | 1 |
| Scotti, V | 1 |
| Desideri, I | 1 |
| Saieva, C | 1 |
| Cecchini, S | 1 |
| Francolini, G | 1 |
| Becherini, C | 1 |
| Delli Paoli, C | 1 |
| Visani, L | 1 |
| Salvestrini, V | 1 |
| De Feo, ML | 1 |
| Nori, J | 1 |
| Bernini, M | 1 |
| Sanchez, L | 1 |
| Orzalesi, L | 1 |
| Bianchi, S | 1 |
| Meattini, I | 1 |
| Zhang, T | 1 |
| Feng, F | 1 |
| Qi, L | 1 |
| Tian, J | 1 |
| Zhou, C | 2 |
| Dong, S | 1 |
| Sun, C | 1 |
| Zhu, L | 2 |
| Zou, J | 2 |
| Chen, B | 2 |
| Kamdem, LK | 2 |
| Xi, J | 1 |
| Clark, BL | 1 |
| Gregory, BJ | 1 |
| De Salvo, GL | 1 |
| Orvieto, E | 1 |
| Urso, L | 1 |
| Ambroggi, M | 1 |
| Vicini, R | 1 |
| Conte, PF | 2 |
| Kensler, KH | 1 |
| Heng, YJ | 1 |
| Baker, GM | 1 |
| Pyle, ME | 1 |
| Schnitt, SJ | 1 |
| Hazra, A | 1 |
| Brown, M | 1 |
| Tamimi, RM | 1 |
| Long, EF | 1 |
| Varella, L | 1 |
| Eziokwu, AS | 1 |
| Jia, X | 3 |
| Kruse, M | 1 |
| Moore, HCF | 1 |
| Budd, GT | 4 |
| Abraham, J | 1 |
| Montero, AJ | 1 |
| Guo, Q | 1 |
| Lin, X | 1 |
| Ye, L | 1 |
| Xu, R | 1 |
| Dai, Y | 1 |
| Chen, Q | 1 |
| Gomez, HL | 2 |
| Biganzoli, L | 1 |
| Barbeaux, A | 1 |
| Francis, PA | 1 |
| Foukakis, T | 1 |
| Pagani, O | 8 |
| Graiff, C | 1 |
| Vorobiof, D | 1 |
| Yu, KD | 2 |
| Shao, ZM | 2 |
| Waller, J | 1 |
| Mycock, K | 1 |
| Taylor-Stokes, G | 1 |
| Milligan, G | 1 |
| Zhan, L | 1 |
| Quintela-Fandino, M | 1 |
| Apala, JV | 1 |
| Malon, D | 1 |
| Mouron, S | 1 |
| Hornedo, J | 1 |
| Gonzalez-Cortijo, L | 1 |
| Colomer, R | 4 |
| Guerra, J | 1 |
| Cinieri, S | 1 |
| Ribecco, AS | 1 |
| Putzu, C | 1 |
| Rossi, E | 4 |
| Tinessa, V | 2 |
| Mosconi, AM | 1 |
| Iodice, G | 1 |
| Landi, G | 4 |
| Pacilio, C | 4 |
| Forestieri, V | 1 |
| Fabbri, A | 1 |
| Ibrahim, T | 1 |
| De Maio, E | 4 |
| Barni, S | 3 |
| Simeon, V | 1 |
| Arenare, L | 1 |
| Daniele, G | 2 |
| Piccirillo, MC | 4 |
| Normanno, N | 2 |
| de Matteis, A | 4 |
| Dempsey, JM | 1 |
| Pesch, AM | 1 |
| Tsai, KS | 1 |
| Lin, TY | 1 |
| Chen, HY | 2 |
| Chen, WC | 1 |
| Chen, YH | 1 |
| Wallwiener, M | 1 |
| Feisst, M | 1 |
| Hartkopf, A | 1 |
| Hwang, CK | 1 |
| Sen, HN | 1 |
| Aktas, B | 2 |
| Cirrincione, CT | 2 |
| Mehta, K | 2 |
| Barry, WT | 2 |
| Morales, S | 2 |
| Garcia-Saenz, JA | 2 |
| Martinez-Jañez, N | 1 |
| Hahn, O | 2 |
| Guerrero-Zotano, A | 2 |
| Hudis, C | 2 |
| Casas, M | 1 |
| Rodriguez-Martin, C | 1 |
| Furlanetto, J | 1 |
| Carrasco, E | 2 |
| Yardley, DA | 1 |
| Aapro, M | 4 |
| van de Velde, CJ | 4 |
| Markopoulos, C | 3 |
| Bartlett, JM | 2 |
| Coleman, RE | 4 |
| Sendur, MA | 2 |
| Aksoy, S | 2 |
| Ozdemir, NY | 1 |
| Zengin, N | 2 |
| Altundag, K | 4 |
| Dantzer, J | 3 |
| Kidwell, K | 1 |
| Gersch, C | 1 |
| Nguyen, AT | 7 |
| Oesterreich, S | 3 |
| Philips, S | 3 |
| Carpenter, JS | 1 |
| Rodriguez, AA | 1 |
| Pavlick, AC | 1 |
| Chang, JC | 1 |
| Akiyoshi, T | 1 |
| Shimomura, Y | 1 |
| Masuda, S | 1 |
| Okamoto, Y | 1 |
| Hiura, S | 1 |
| Kato, H | 1 |
| Asayama, T | 1 |
| Ohtani, H | 1 |
| Allevi, G | 7 |
| Strina, C | 3 |
| Andreis, D | 3 |
| Zanoni, V | 2 |
| Bazzola, L | 2 |
| Bonardi, S | 5 |
| Foroni, C | 2 |
| Gussago, F | 1 |
| Aguggini, S | 7 |
| Giardini, R | 3 |
| Martinotti, M | 2 |
| Fox, SB | 8 |
| Harris, AL | 9 |
| Bottini, A | 10 |
| Berruti, A | 9 |
| Romieu, G | 9 |
| Salvat, J | 1 |
| Chaigneau, L | 2 |
| Merrouche, Y | 1 |
| N'guyen, T | 2 |
| Vuillemin, AT | 1 |
| Demarchi, M | 2 |
| Dobi, E | 1 |
| Pivot, X | 3 |
| Saladores, PH | 1 |
| Precht, JC | 1 |
| Schroth, W | 1 |
| Brauch, H | 1 |
| Schwab, M | 1 |
| Morandi, A | 3 |
| Martin, LA | 8 |
| Gao, Q | 2 |
| Pancholi, S | 3 |
| Mackay, A | 3 |
| Robertson, D | 1 |
| Zvelebil, M | 1 |
| Plaza-Menacho, I | 1 |
| Isacke, CM | 3 |
| Zeng, ZJ | 1 |
| Li, JH | 1 |
| Zhang, YJ | 1 |
| Zhao, ST | 1 |
| Butt, SR | 1 |
| Vatandoust, S | 1 |
| Kleinig, T | 1 |
| Adams, J | 1 |
| Basu, S | 1 |
| Otto, G | 1 |
| Joshi, R | 1 |
| Digklia, A | 1 |
| Tzika, E | 1 |
| Voutsadakis, IA | 1 |
| Townley, I | 1 |
| Zhong, Q | 1 |
| Carriere, PP | 2 |
| Llopis, SD | 2 |
| Preyan, LC | 2 |
| Skripnikova, E | 1 |
| Qu, H | 1 |
| Cao, W | 1 |
| Li, F | 2 |
| Takagi, K | 1 |
| Ishida, T | 1 |
| Miki, Y | 2 |
| Hirakawa, H | 1 |
| Kakugawa, Y | 1 |
| Amano, G | 1 |
| Ebata, A | 1 |
| Mori, N | 1 |
| Nakamura, Y | 3 |
| Watanabe, M | 1 |
| Amari, M | 1 |
| Ohuchi, N | 1 |
| Suzuki, T | 3 |
| Litton, J | 1 |
| Buzdar, A | 8 |
| Mac Gregor, MC | 1 |
| Gonzalez-Angulo, A | 1 |
| Davies, C | 1 |
| Gray, R | 1 |
| Pan, H | 1 |
| Peto, R | 1 |
| Hanamura, T | 1 |
| Niwa, T | 1 |
| Nishikawa, S | 1 |
| Konno, H | 1 |
| Gohno, T | 1 |
| Tazawa, C | 1 |
| Kobayashi, Y | 1 |
| Takei, H | 1 |
| Yamaguchi, Y | 2 |
| Ito, K | 1 |
| Hayashi, S | 2 |
| Kyvernitakis, I | 1 |
| Ziller, V | 1 |
| Hars, O | 1 |
| Bauer, M | 1 |
| Kalder, M | 1 |
| Sgroi, DC | 2 |
| Carney, E | 1 |
| Zarrella, E | 1 |
| Steffel, L | 1 |
| Binns, SN | 1 |
| Finkelstein, DM | 3 |
| Szymonifka, J | 1 |
| Bhan, AK | 1 |
| Shepherd, LE | 14 |
| Schnabel, CA | 1 |
| Erlander, MG | 1 |
| Porter, P | 1 |
| Rimm, DL | 1 |
| Penrod, NM | 2 |
| Moore, JH | 2 |
| Wylie, S | 1 |
| Ravichandran, D | 3 |
| Fatum, M | 1 |
| McVeigh, E | 1 |
| Child, T | 1 |
| Revelli, A | 1 |
| Porcu, E | 1 |
| Levi Setti, PE | 1 |
| Delle Piane, L | 1 |
| Merlo, DF | 1 |
| Anserini, P | 1 |
| Pfeiler, G | 1 |
| Königsberg, R | 1 |
| Fitzal, F | 1 |
| Maroske, M | 1 |
| Dressel-Ban, G | 1 |
| Zellinger, J | 1 |
| Exner, R | 1 |
| Seifert, M | 1 |
| Singer, C | 1 |
| Liu, Y | 4 |
| Hou, G | 1 |
| Bedoschi, G | 3 |
| Moy, F | 4 |
| Oktay, K | 17 |
| Rawat, A | 1 |
| Gopal, G | 1 |
| Selvaluxmy, G | 1 |
| Rajkumar, T | 1 |
| Badovinac-Crnjevic, T | 1 |
| Fan, L | 2 |
| Goodwin, PJ | 2 |
| Chan, HP | 1 |
| Goswami, CP | 1 |
| Khouri, N | 1 |
| Pinsky, R | 1 |
| Hadjiiski, L | 1 |
| Robarge, J | 1 |
| Helvie, MA | 1 |
| Liu, ZH | 1 |
| Mehta, A | 1 |
| Press, MF | 3 |
| Dering, J | 1 |
| O'Rourke, L | 5 |
| Florance, A | 3 |
| Ellis, C | 3 |
| Martin, AM | 1 |
| Balkenende, E | 1 |
| Linn, S | 1 |
| Moy, I | 1 |
| Lin, Z | 1 |
| Rademaker, AW | 1 |
| Reierstad, S | 1 |
| Khan, SA | 1 |
| Bulun, SE | 1 |
| Forbes, JF | 14 |
| Akçay, HT | 1 |
| Bayrak, R | 1 |
| Yoneyama, K | 1 |
| Nakamura, H | 1 |
| Liedke, PE | 3 |
| Isakoff, SJ | 2 |
| St Louis, J | 1 |
| Ryan, PD | 1 |
| Kemp, A | 1 |
| Preen, DB | 1 |
| Saunders, C | 2 |
| Bulsara, M | 1 |
| Holman, CD | 1 |
| Malacova, E | 1 |
| Roughead, EE | 1 |
| Layfield, DM | 1 |
| Mohamud, M | 1 |
| Odofin, O | 1 |
| Walsh, C | 1 |
| Royle, GT | 1 |
| Cutress, RI | 1 |
| Sini, V | 1 |
| Lunardi, G | 2 |
| Cirillo, M | 1 |
| Turazza, M | 1 |
| Giraudi, S | 2 |
| Levaggi, A | 2 |
| Piccioli, P | 2 |
| Gnoni, R | 2 |
| Stridi, G | 1 |
| Porpiglia, M | 3 |
| Picardo, E | 1 |
| Marenco, D | 1 |
| Zhu, ZL | 1 |
| Chen, ML | 1 |
| Siddiqa, AJ | 1 |
| Chaudhury, K | 1 |
| Adhikari, B | 1 |
| Kazi, AA | 3 |
| Gilani, RA | 2 |
| Schech, AJ | 3 |
| Chumsri, S | 4 |
| Sabnis, G | 10 |
| Shah, P | 4 |
| Goloubeva, O | 6 |
| Kronsberg, S | 1 |
| Brodie, AH | 4 |
| Guerrieri-Gonzaga, A | 1 |
| McIntosh, C | 1 |
| Monnier, A | 8 |
| Schönenberger, A | 2 |
| Jud, SM | 1 |
| Hauschild, M | 1 |
| Schütte, M | 1 |
| Hanf, V | 1 |
| Grab, D | 1 |
| Krocker, J | 1 |
| Stickeler, E | 1 |
| Kreienberg, R | 3 |
| Müller, T | 1 |
| Kahlert, S | 1 |
| Paepke, S | 4 |
| Berghorn, M | 1 |
| Muth, M | 1 |
| Baier, M | 1 |
| Wackwitz, B | 2 |
| Schulz-Wendtland, R | 1 |
| Schoenfeld, DA | 2 |
| Nie, D | 1 |
| You, QS | 1 |
| Luan, JW | 1 |
| Li, XL | 1 |
| Guo, RT | 1 |
| Zhang, LP | 1 |
| Haynes, BP | 2 |
| Foster, LM | 1 |
| Mahoney, ME | 1 |
| Harmon, MW | 1 |
| Allen, JW | 1 |
| Luh, JY | 1 |
| Grassadonia, A | 1 |
| Di Nicola, M | 1 |
| Grossi, S | 1 |
| Noccioli, P | 1 |
| Tavoletta, S | 1 |
| Politi, R | 1 |
| Angelucci, D | 1 |
| Marinelli, C | 1 |
| Zilli, M | 1 |
| Ausili Cefaro, G | 1 |
| Tinari, N | 1 |
| De Tursi, M | 1 |
| Iezzi, L | 1 |
| Cioffi, P | 1 |
| Iacobelli, S | 1 |
| Natoli, C | 1 |
| Cianchetti, E | 1 |
| Arnedos, M | 1 |
| Drury, S | 2 |
| Afentakis, M | 1 |
| A'Hern, R | 4 |
| Salter, J | 2 |
| Smith, IE | 16 |
| Carpenter, R | 2 |
| Doughty, JC | 3 |
| Cordiner, C | 1 |
| Moss, N | 1 |
| Gandhi, A | 1 |
| Wilson, C | 1 |
| Andrews, C | 1 |
| Ellis, G | 1 |
| Gui, G | 1 |
| Skene, AI | 1 |
| Generali, DG | 1 |
| Artioli, F | 1 |
| Boni, C | 4 |
| Cavanna, L | 2 |
| Tagliafico, E | 1 |
| Maiorana, A | 1 |
| Cagossi, K | 2 |
| Piacentini, F | 3 |
| Ficarra, G | 2 |
| Bettelli, S | 1 |
| Roncaglia, E | 1 |
| Nuzzo, S | 1 |
| Swaby, R | 1 |
| Holford, C | 1 |
| Kim, J | 3 |
| Lim, W | 1 |
| Kim, EK | 1 |
| Kim, MK | 1 |
| Paik, NS | 1 |
| Jeong, SS | 1 |
| Yoon, JH | 1 |
| Park, CH | 1 |
| Kim, LS | 1 |
| Nam, SJ | 1 |
| Kang, HS | 2 |
| Yoo, YB | 1 |
| Kim, TH | 1 |
| Kang, T | 1 |
| Kim, SW | 2 |
| Jung, Y | 1 |
| Lee, JE | 1 |
| Kim, KS | 1 |
| Yu, JH | 1 |
| Chae, BJ | 1 |
| Jung, SY | 2 |
| Kang, E | 1 |
| Choi, SY | 1 |
| Moon, HG | 2 |
| Noh, DY | 3 |
| Han, W | 2 |
| Abramson, VG | 1 |
| Balko, JM | 3 |
| Kuba, MG | 2 |
| Sanders, ME | 2 |
| Yap, JT | 1 |
| Van den Abbeele, AD | 1 |
| Cantley, LC | 1 |
| Moy, B | 2 |
| Lebrun, F | 1 |
| Sarosiek, T | 1 |
| Goss, P | 2 |
| Zacharchuk, C | 1 |
| Leip, E | 1 |
| Turnbull, K | 1 |
| Bardy-Bouxin, N | 1 |
| Duvillié, L | 1 |
| Tanner, M | 2 |
| Marty, M | 2 |
| Atkins, L | 2 |
| Franquet, A | 2 |
| Neciosup, S | 2 |
| Tesarova, P | 2 |
| Deschamp, V | 2 |
| Higaki, K | 1 |
| Kihara, K | 1 |
| Shimozuma, K | 2 |
| Temin, S | 1 |
| Kirshner, JJ | 1 |
| Chandarlapaty, S | 1 |
| Crews, JR | 1 |
| Gonzalez-Angulo, AM | 2 |
| Levinson, J | 1 |
| Modi, S | 1 |
| Patt, DA | 1 |
| Perez, EA | 23 |
| Perlmutter, J | 1 |
| Ramakrishna, N | 1 |
| Harte, SE | 1 |
| Carpenter, J | 1 |
| Clauw, DJ | 1 |
| Williams, DA | 1 |
| Reddy, J | 1 |
| Yeo, B | 2 |
| Schiavon, G | 1 |
| Aguilar, H | 2 |
| Urruticoechea, A | 4 |
| Halonen, P | 1 |
| Kiyotani, K | 1 |
| Mushiroda, T | 1 |
| Barril, X | 1 |
| Serra-Musach, J | 1 |
| Islam, A | 1 |
| Caizzi, L | 1 |
| Di Croce, L | 1 |
| Nevedomskaya, E | 1 |
| Zwart, W | 1 |
| Bostner, J | 1 |
| Karlsson, E | 1 |
| Pérez Tenorio, G | 1 |
| Fornander, T | 1 |
| Garcia-Mata, R | 1 |
| Jansen, MP | 1 |
| García, N | 1 |
| Bonifaci, N | 1 |
| Climent, F | 1 |
| Soler, MT | 1 |
| Rodríguez-Vida, A | 1 |
| Gil, M | 5 |
| Brunet, J | 1 |
| Martrat, G | 1 |
| Gómez-Baldó, L | 1 |
| Extremera, AI | 1 |
| Figueras, A | 1 |
| Balart, J | 1 |
| Clarke, R | 1 |
| Burnstein, KL | 1 |
| Carlson, KE | 1 |
| Katzenellenbogen, JA | 1 |
| Vizoso, M | 1 |
| Esteller, M | 1 |
| Villanueva, A | 1 |
| Rodríguez-Peña, AB | 1 |
| Bustelo, XR | 1 |
| Zembutsu, H | 1 |
| Stål, O | 1 |
| Beijersbergen, RL | 1 |
| Pujana, MA | 1 |
| Mutlu, H | 1 |
| Coşkun, HŞ | 1 |
| Lee, HS | 1 |
| Lee, JY | 1 |
| Ah, YM | 1 |
| Kim, HS | 1 |
| Lee, BK | 1 |
| Harrow, A | 1 |
| Dryden, R | 1 |
| McCowan, C | 1 |
| Radley, A | 1 |
| Parsons, M | 1 |
| Thompson, AM | 2 |
| Wells, M | 1 |
| Chottanapund, S | 1 |
| Van Duursen, MB | 1 |
| Navasumrit, P | 1 |
| Hunsonti, P | 1 |
| Timtavorn, S | 1 |
| Ruchirawat, M | 1 |
| Van den Berg, M | 1 |
| Segal, RJ | 1 |
| Vallis, M | 1 |
| Ligibel, JA | 2 |
| Pond, GR | 1 |
| Blackburn, GL | 1 |
| Findlay, B | 2 |
| Gralow, JR | 1 |
| Mukherjee, S | 1 |
| Levine, M | 1 |
| Irwin, ML | 1 |
| Pagano, M | 1 |
| Asensio, SN | 1 |
| Zanelli, F | 1 |
| Lococo, F | 1 |
| Cavazza, A | 1 |
| Damiani, S | 1 |
| Rapicetta, C | 1 |
| Dutta, K | 1 |
| Batra, U | 1 |
| Talwar, V | 1 |
| DeSantis, SD | 1 |
| Guo, H | 1 |
| Block, CC | 1 |
| Borges, V | 1 |
| Partridge, AH | 2 |
| Garimella, V | 1 |
| Hussain, T | 1 |
| Agarwal, V | 1 |
| Radhakrishna, S | 1 |
| Fox, JN | 1 |
| Kneeshaw, PJ | 1 |
| Long, ED | 1 |
| Mahapatra, TK | 1 |
| McManus, PL | 1 |
| Lind, MJ | 1 |
| Drew, PJ | 1 |
| Cawkwell, L | 1 |
| Mao, JJ | 2 |
| Farrar, JT | 1 |
| Bruner, D | 1 |
| Zee, J | 1 |
| Bowman, M | 1 |
| Seluzicki, C | 1 |
| Xie, SX | 1 |
| Arthur, LM | 2 |
| Webber, VL | 1 |
| Larionov, AA | 3 |
| Kay, C | 2 |
| Olin, JL | 1 |
| St Pierre, M | 1 |
| Keskin, U | 1 |
| Ercan, CM | 1 |
| Yilmaz, A | 1 |
| Babacan, A | 1 |
| Korkmaz, C | 1 |
| Duru, NK | 1 |
| Ergun, A | 1 |
| Lintermans, A | 2 |
| Vanderschueren, D | 1 |
| Verhaeghe, J | 3 |
| Van Asten, K | 1 |
| Jans, I | 1 |
| Van Herck, E | 1 |
| Laenen, A | 1 |
| Billen, J | 1 |
| Pauwels, S | 1 |
| Vermeersch, P | 1 |
| Christiaens, MR | 4 |
| Kelly, E | 1 |
| Lu, CY | 1 |
| Albertini, S | 1 |
| Vitry, A | 1 |
| Palmieri, C | 1 |
| Cleator, S | 1 |
| Kilburn, LS | 1 |
| Beresford, M | 1 |
| Mansi, J | 1 |
| Reed, S | 1 |
| Mousa, K | 1 |
| Fallowfield, L | 1 |
| Cheang, M | 1 |
| Page, K | 1 |
| Guttery, DS | 1 |
| Rghebi, B | 1 |
| Primrose, L | 1 |
| Shaw, JA | 1 |
| Coombes, RC | 2 |
| Panal, M | 1 |
| Sánchez-Mendez, JI | 1 |
| Revello, R | 1 |
| Abehsera, D | 1 |
| de Santiago, J | 1 |
| Zapardiel, I | 1 |
| Lewis, L | 1 |
| Taylor, M | 1 |
| Suriya Ertugyrovna, Y | 1 |
| Kuanysh Shadybayevich, N | 1 |
| Kaldygul Kabakovna, S | 1 |
| Ramil Zufarovich, A | 1 |
| Teramukai, S | 1 |
| Shimizu, A | 1 |
| García-Arpa, M | 1 |
| Lozano-Martín, E | 1 |
| Rodríguez, CR | 1 |
| Rodríguez-Vázquez, M | 1 |
| R Cappelletti, M | 1 |
| Ferrozzi, F | 1 |
| Bertoni, R | 3 |
| Turley, H | 1 |
| Gatter, K | 1 |
| Reynolds, AR | 1 |
| Crown, JP | 3 |
| Bondarenko, IM | 2 |
| Kulyk, SO | 1 |
| Thummala, AR | 1 |
| Voytko, NL | 1 |
| Fowst, C | 1 |
| Kim, ST | 2 |
| Randolph, S | 4 |
| Vosooghi, M | 1 |
| Firoozpour, L | 1 |
| Rodaki, A | 1 |
| Pordeli, M | 1 |
| Safavi, M | 1 |
| Ardestani, SK | 1 |
| Dadgar, A | 1 |
| Asadipour, A | 1 |
| Moshafi, MH | 1 |
| Foroumadi, A | 1 |
| Moschos, MM | 2 |
| Chatziralli, IP | 2 |
| Sergentanis, T | 1 |
| Zagouri, F | 2 |
| Chrysikos, D | 1 |
| Ladas, I | 1 |
| Zografos, G | 1 |
| Hole, S | 1 |
| Pedersen, AM | 1 |
| Hansen, SK | 1 |
| Lundqvist, J | 1 |
| Yde, CW | 1 |
| Vilquin, P | 1 |
| Donini, CF | 1 |
| Villedieu, M | 1 |
| Grisard, E | 1 |
| Corbo, L | 1 |
| Vendrell, JA | 1 |
| Cohen, PA | 1 |
| von Minckwitz, G | 5 |
| Guerrero, A | 2 |
| Anton, A | 2 |
| Schoenegg, W | 1 |
| Ramos, M | 3 |
| Margeli, M | 1 |
| Liedtke, C | 1 |
| De la Haba-Rodriguez, JR | 1 |
| Derks, MG | 1 |
| van der Hoeven, JJ | 1 |
| Selvakumar, D | 1 |
| Dube, M | 1 |
| Matey, P | 1 |
| Barbie, TU | 1 |
| Ma, C | 3 |
| Margenthaler, JA | 1 |
| Dhillon, S | 1 |
| Mukhopadhyay, KD | 1 |
| Liu, Z | 3 |
| Bandyopadhyay, A | 1 |
| Kirma, NB | 2 |
| Tekmal, RR | 5 |
| Sun, LZ | 1 |
| Hong, Q | 1 |
| Lei, L | 2 |
| Mo, M | 1 |
| Shao, Z | 3 |
| Shen, Z | 2 |
| Liu, G | 3 |
| Wagner-Johnston, ND | 1 |
| Sloan, JA | 3 |
| Kearns, AE | 1 |
| Hines, SL | 4 |
| Puttabasavaiah, S | 1 |
| Loprinzi, CL | 6 |
| Tsuboi, K | 1 |
| Yamamoto, A | 1 |
| Tsuda, S | 1 |
| Tsujii, S | 1 |
| Yagi, K | 1 |
| Kitamura, T | 1 |
| Neuner, JM | 1 |
| Kamaraju, S | 1 |
| Charlson, JA | 1 |
| Wozniak, EM | 1 |
| Smith, EC | 1 |
| Biggers, A | 1 |
| Smallwood, AJ | 1 |
| Laud, PW | 1 |
| Pezzin, LE | 1 |
| Chang, CH | 1 |
| Chen, SJ | 1 |
| Liu, CY | 1 |
| Khatri, R | 1 |
| Guha, R | 1 |
| Rassool, FV | 1 |
| Tomkinson, AE | 1 |
| Brodie, A | 15 |
| Jaiswal, AK | 2 |
| Dunbier, AK | 2 |
| Brugnoli, G | 1 |
| Forti, M | 1 |
| Bedussi, F | 1 |
| Vailati, ME | 1 |
| Ardine, M | 2 |
| Ferrero, G | 1 |
| Morikawa, A | 1 |
| Pacheco, FS | 1 |
| Antolín-Novoa, S | 1 |
| Blanco-Campanario, E | 1 |
| Gallegos-Sancho, MI | 1 |
| Pérez-Carrión, R | 4 |
| Peláez, I | 1 |
| Galán-Brotons, A | 1 |
| de la Cruz-Merino, L | 1 |
| Murías-Rosales, A | 1 |
| Morgan, JL | 1 |
| Collins, K | 1 |
| Robinson, TG | 1 |
| Cheung, KL | 1 |
| Audisio, R | 1 |
| Reed, MW | 1 |
| Wyld, L | 2 |
| Englert, Y | 1 |
| Yu, S | 1 |
| Sabnis, GJ | 5 |
| Rosenblatt, P | 1 |
| Kazi, A | 1 |
| Le Rhun, E | 1 |
| Delbeuck, X | 1 |
| Lefeuvre-Plesse, C | 1 |
| Kramar, A | 1 |
| Skrobala, E | 1 |
| Pasquier, F | 1 |
| Bonneterre, J | 2 |
| Nakayama, I | 1 |
| Muranishi, Y | 1 |
| Fujita, Y | 1 |
| Metzger Filho, O | 1 |
| Gusterson, B | 1 |
| Johnston, SR | 9 |
| Majithia, N | 1 |
| Atherton, PJ | 2 |
| Wagner-Johnston, N | 1 |
| Curley, MD | 1 |
| Wille, L | 1 |
| Adiwijaya, BS | 1 |
| Garcia, G | 1 |
| Moyo, V | 1 |
| MacBeath, G | 1 |
| Ketkaew, C | 1 |
| Kiatying-Angsulee, N | 1 |
| Mangini, NS | 1 |
| Wesolowski, R | 1 |
| Ramaswamy, B | 1 |
| Lustberg, MB | 1 |
| Muehlenberg, K | 1 |
| Dietl, O | 1 |
| Piso, P | 1 |
| Pech, O | 1 |
| Balduzzi, A | 3 |
| Bagnardi, V | 5 |
| Sandri, MT | 1 |
| Cardillo, A | 4 |
| Montagna, E | 3 |
| Cancello, G | 2 |
| Iorfida, M | 3 |
| Ghisini, R | 3 |
| Intra, M | 2 |
| Luini, A | 6 |
| Gusterson, BA | 5 |
| MacGrogan, G | 3 |
| Bibeau, F | 1 |
| Lelkaitis, G | 1 |
| Shankar, A | 1 |
| Roy, S | 1 |
| Rath, GK | 2 |
| Julka, PK | 2 |
| Kamal, VK | 1 |
| Malik, A | 1 |
| Patil, J | 1 |
| Jeyaraj, PA | 1 |
| Mahajan, MK | 1 |
| Pouget, M | 1 |
| Abrial, C | 3 |
| Planchat, E | 1 |
| Van Praagh, I | 2 |
| Arbre, M | 1 |
| Kwiatkowski, F | 2 |
| Dubray-Longeras, P | 1 |
| Devaud, H | 1 |
| Dohou, J | 1 |
| Herviou, P | 1 |
| Mahammedi, H | 1 |
| Durando, X | 4 |
| Chollet, P | 4 |
| Tamura, K | 2 |
| Lazar, AA | 3 |
| Bonetti, M | 3 |
| Yip, WK | 1 |
| Blackwell, K | 1 |
| Burris, H | 2 |
| Gomez, P | 1 |
| Lynn Henry, N | 1 |
| Isakoff, S | 1 |
| Campana, F | 1 |
| Gao, L | 1 |
| Jiang, J | 1 |
| Macé, S | 1 |
| Van Poznak, CH | 1 |
| Hangartner, TN | 1 |
| Peacock, M | 1 |
| Akyol, M | 1 |
| Demir, L | 2 |
| Alacacioglu, A | 1 |
| Ellidokuz, H | 1 |
| Kucukzeybek, Y | 1 |
| Yildiz, Y | 1 |
| Gumus, Z | 1 |
| Bayoglu, V | 1 |
| Yildiz, I | 1 |
| Salman, T | 1 |
| Varol, U | 1 |
| Kucukzeybek, B | 1 |
| Dirican, A | 1 |
| Sutcu, R | 1 |
| Tarhan, MO | 1 |
| Thomsen, KG | 1 |
| Lyng, MB | 2 |
| Elias, D | 1 |
| Vever, H | 1 |
| Lænkholm, AV | 1 |
| Ditzel, HJ | 2 |
| Leyland-Jones, B | 2 |
| Abramovitz, M | 1 |
| Bouzyk, M | 2 |
| Young, B | 1 |
| Long, B | 3 |
| Biasi, MO | 2 |
| Harvey, V | 4 |
| Arnould, L | 2 |
| Bregni, G | 1 |
| de Braud, F | 2 |
| López, AM | 1 |
| Pruthi, S | 1 |
| Perloff, M | 1 |
| Hsu, CH | 1 |
| Lang, JE | 1 |
| Ley, M | 1 |
| Frank, D | 1 |
| Taverna, JA | 1 |
| Chow, HH | 1 |
| Shabana, KM | 1 |
| Abdul Nazeer, KA | 1 |
| Pradhan, M | 1 |
| Palakal, M | 1 |
| Bourgier, C | 1 |
| Kerns, S | 1 |
| Gourgou, S | 3 |
| Lemanski, C | 2 |
| Gutowski, M | 2 |
| Fenoglietto, P | 2 |
| Crompton, N | 1 |
| Lacombe, J | 1 |
| Pèlegrin, A | 2 |
| Ozsahin, M | 4 |
| Rosenstein, B | 2 |
| Azria, D | 4 |
| Naiki, AC | 1 |
| Nguyen, G | 1 |
| Phan, T | 1 |
| Nguyen, MM | 1 |
| Yearby, L | 1 |
| Pratt, J | 1 |
| Burks, H | 1 |
| Davenport, IR | 1 |
| Nguyen, TA | 1 |
| Parker-Lemieux, K | 1 |
| Collins-Burow, B | 1 |
| Hilliard, A | 1 |
| Zhang, M | 1 |
| Lü, H | 1 |
| Niu, L | 1 |
| Zeng, H | 1 |
| Tan, WW | 1 |
| Allred, JB | 1 |
| Moreno-Aspitia, A | 1 |
| Northfelt, DW | 1 |
| Bacci, M | 1 |
| Giannoni, E | 1 |
| Fearns, A | 2 |
| Ribas, R | 2 |
| Taddei, ML | 1 |
| Pintus, G | 1 |
| Chiarugi, P | 2 |
| Saita, C | 1 |
| Goto, R | 1 |
| Aruga, T | 1 |
| Idera, N | 1 |
| Honda, Y | 1 |
| Horiguchi, K | 1 |
| Miyamoto, H | 1 |
| Horiguchi, S | 1 |
| Yamashita, T | 1 |
| Beauchemin, C | 1 |
| Letarte, N | 1 |
| Mathurin, K | 1 |
| Yelle, L | 1 |
| Lachaine, J | 1 |
| Sansone, P | 1 |
| Ceccarelli, C | 1 |
| Berishaj, M | 1 |
| Chang, Q | 1 |
| Rajasekhar, VK | 1 |
| Perna, F | 1 |
| Bowman, RL | 1 |
| Vidone, M | 1 |
| Daly, L | 1 |
| Nnoli, J | 1 |
| Santini, D | 1 |
| Taffurelli, M | 1 |
| Shih, NN | 1 |
| Feldman, M | 1 |
| Colameco, C | 1 |
| Fabbri, N | 1 |
| Healey, JH | 1 |
| Cricca, M | 1 |
| Gasparre, G | 1 |
| Lyden, D | 1 |
| Bonafé, M | 1 |
| Bromberg, J | 1 |
| Zdenkowski, N | 1 |
| Boyle, FM | 1 |
| Kannourakis, G | 1 |
| Gill, PG | 1 |
| Bayliss, E | 1 |
| Della-Fiorentina, S | 1 |
| Kling, N | 1 |
| Campbell, I | 3 |
| Mann, GB | 1 |
| Gebski, V | 1 |
| Davies, L | 1 |
| Thornton, R | 1 |
| Reaby, L | 1 |
| Cuzick, J | 5 |
| Shapiro, AC | 1 |
| Adlis, SA | 1 |
| Robien, K | 1 |
| Kirstein, MN | 1 |
| Liang, S | 1 |
| Richter, SA | 1 |
| Lerner, RE | 1 |
| Shen, YY | 1 |
| Xiong, J | 1 |
| Chai, YX | 1 |
| Dai, TM | 1 |
| Zhang, WJ | 1 |
| Tu, JL | 1 |
| Krekow, LK | 1 |
| Hellerstedt, BA | 1 |
| Collea, RP | 1 |
| Papish, S | 1 |
| Diggikar, SM | 1 |
| Resta, R | 1 |
| Vukelja, SJ | 1 |
| Holmes, FA | 1 |
| Reddy, PK | 1 |
| Asmar, L | 1 |
| Fox, PS | 1 |
| Peck, SR | 1 |
| Bell, T | 1 |
| Zanotti, G | 1 |
| Telford, C | 1 |
| Jones, N | 1 |
| Livings, C | 1 |
| Batson, S | 1 |
| Goodwin, RA | 1 |
| Jamal, R | 1 |
| Booth, CM | 1 |
| Eisenhauer, EA | 1 |
| Bromberg, DJ | 1 |
| Valenzuela, M | 1 |
| Nanjappa, S | 1 |
| Pabbathi, S | 1 |
| Shepherd, L | 6 |
| Chavarri-Guerra, Y | 2 |
| Pereira, N | 1 |
| Hancock, K | 1 |
| Cordeiro, CN | 1 |
| Lekovich, JP | 1 |
| Schattman, GL | 1 |
| Rosenwaks, Z | 2 |
| Moynahan, ME | 1 |
| Innocenti, F | 1 |
| Lake, DE | 1 |
| Schneider, BP | 1 |
| Zhang, CJ | 1 |
| Hu, GZ | 1 |
| Diao, H | 1 |
| Baker, SG | 1 |
| Wang, W | 1 |
| Belosay, A | 2 |
| Hartman, JA | 2 |
| Song, H | 1 |
| Iwaniec, UT | 1 |
| Turner, RT | 1 |
| Churchwell, MI | 1 |
| Doerge, DR | 2 |
| Helferich, WG | 2 |
| Chirgwin, JH | 2 |
| Arul Vijaya Vani, S | 1 |
| Ananthanarayanan, PH | 1 |
| Harichandrakumar, KT | 1 |
| Niranjjan, R | 1 |
| Nandeesha, H | 1 |
| Kang, H | 1 |
| Hai, T | 1 |
| Rong, G | 1 |
| Sun, H | 1 |
| Almajed, MM | 1 |
| Esfahani, K | 1 |
| Pelmus, M | 1 |
| Panasci, L | 2 |
| Robert, NJ | 11 |
| Whelan, T | 2 |
| Rubin, S | 1 |
| Sturtz, K | 1 |
| Stopeck, A | 1 |
| Kaur, JS | 1 |
| Klingbiel, D | 1 |
| Cheang, MC | 1 |
| Viladot, M | 1 |
| Gagnon, R | 1 |
| Lopez-Tarruella, S | 1 |
| Gilarranz, YJ | 1 |
| Curigliano, G | 1 |
| Gómez Pardo, P | 1 |
| Lolkema, MP | 1 |
| Martínez García, M | 1 |
| Penault-Llorca, F | 2 |
| Dhuria, S | 1 |
| Tang, Z | 1 |
| Di Tomaso, E | 1 |
| Flågeng, MH | 1 |
| Larionov, A | 7 |
| Knappskog, S | 1 |
| Prestvik, WS | 1 |
| Bjørkøy, G | 1 |
| Lilleng, PK | 1 |
| Miller, WR | 28 |
| Iuliano, L | 1 |
| Filleron, T | 1 |
| Zerbinati, C | 1 |
| Voisin, M | 1 |
| Arellano, C | 1 |
| Chatelut, E | 1 |
| Marquet, P | 1 |
| Samadi, M | 1 |
| Poirot, M | 1 |
| Silvente-Poirot, S | 1 |
| Nadanaciva, S | 1 |
| Kang, MJ | 1 |
| Beom, SH | 1 |
| Oh, J | 1 |
| Lee, KH | 1 |
| Suh, KJ | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Andreucci, E | 1 |
| Francica, P | 1 |
| O'Leary, CG | 1 |
| Ellis, H | 1 |
| Higgins, M | 1 |
| Noesslet, T | 1 |
| Paepke, D | 1 |
| Niraula, S | 1 |
| Ocana, A | 1 |
| Chan, A | 2 |
| Nusch, A | 1 |
| Burdaeva, O | 1 |
| Grischke, EM | 1 |
| Marschner, N | 1 |
| Yardley, D | 2 |
| Blau, S | 1 |
| Xuan, F | 1 |
| Whitworth, P | 2 |
| Beitsch, P | 1 |
| Mislowsky, A | 1 |
| Pellicane, JV | 1 |
| Nash, C | 1 |
| Murray, M | 1 |
| Lee, LA | 1 |
| Dul, CL | 1 |
| Rotkis, M | 1 |
| Baron, P | 1 |
| Stork-Sloots, L | 1 |
| de Snoo, FA | 1 |
| Beatty, J | 1 |
| Di Maio, M | 3 |
| Simmons, C | 1 |
| McLeod, D | 1 |
| Paterson, A | 1 |
| Rayson, D | 2 |
| Burki, TK | 1 |
| Romero, D | 1 |
| Robarge, JD | 1 |
| Hertz, D | 1 |
| Jones, S | 1 |
| Lipatov, ON | 1 |
| Tocaciu, S | 1 |
| Oliver, LJ | 1 |
| Lowenthal, RM | 1 |
| Peterson, GM | 1 |
| Shastri, M | 1 |
| McGuinness, G | 1 |
| Olesen, I | 1 |
| Fitton, JH | 1 |
| Wright, LE | 1 |
| Harhash, AA | 1 |
| Kozlow, WM | 1 |
| Waning, DL | 1 |
| Regan, JN | 1 |
| She, Y | 1 |
| John, SK | 1 |
| Murthy, S | 1 |
| Niewolna, M | 1 |
| Marks, AR | 1 |
| Mohammad, KS | 1 |
| Guise, TA | 1 |
| Sanati, S | 1 |
| Creighton, CJ | 1 |
| DeSchryver, K | 3 |
| Crouch, E | 1 |
| Brink, A | 1 |
| Watson, M | 2 |
| Tao, Y | 8 |
| Barnes, M | 1 |
| Silverman, P | 1 |
| Carey, L | 1 |
| Pluard, T | 1 |
| Babiera, G | 1 |
| Guenther, JM | 3 |
| Dayao, Z | 1 |
| Ota, D | 2 |
| Leitch, M | 3 |
| Olson, JA | 3 |
| Allred, DC | 3 |
| Hunt, K | 3 |
| Garcia, JR | 1 |
| Pérez, C | 1 |
| Bassa, P | 1 |
| Capdevila, L | 1 |
| Ramos, F | 1 |
| Valenti, V | 1 |
| Amadori, D | 1 |
| McIntyre, K | 1 |
| Jonat, W | 3 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| Yamamoto, D | 1 |
| Yamamoto, C | 1 |
| Yamamoto, M | 1 |
| Hasegawa, K | 1 |
| Higashi, Y | 1 |
| Kamiya, A | 1 |
| Takatsuno, Y | 1 |
| Kondo, I | 1 |
| Kaneko, J | 1 |
| Endo, T | 1 |
| Maejima, S | 1 |
| Brower, V | 1 |
| Muluhngwi, P | 1 |
| Klinge, CM | 1 |
| Rahideh, ST | 1 |
| Keramatipour, M | 1 |
| Nourbakhsh, M | 1 |
| Koohdani, F | 1 |
| Hoseini, M | 1 |
| Talebi, S | 1 |
| Shidfar, F | 1 |
| Glaser, RL | 1 |
| York, AE | 1 |
| Dimitrakakis, C | 1 |
| Khachidze, N | 1 |
| Giorgadze, E | 1 |
| Tsagareli, M | 1 |
| Spolverato, G | 1 |
| Vitale, A | 1 |
| Bagante, F | 1 |
| Connolly, R | 1 |
| Pawlik, TM | 1 |
| Berardi, R | 1 |
| Banna, G | 1 |
| Goubar, A | 1 |
| Brentnall, AR | 1 |
| Sasieni, P | 1 |
| Azim, AA | 2 |
| Costantini-Ferrando, M | 2 |
| Bundred, N | 3 |
| Coleman, R | 3 |
| Lambert-Falls, R | 1 |
| Mena, R | 1 |
| Schenk, N | 3 |
| Ericson, S | 1 |
| Macedo, LF | 4 |
| Schayowitz, A | 3 |
| Brodie, AM | 10 |
| Paydas, S | 1 |
| Vaidya, JS | 1 |
| Veronesi, P | 5 |
| Peruzzotti, G | 1 |
| Rocca, A | 1 |
| Lisztwan, J | 1 |
| Pornon, A | 1 |
| Evans, DB | 24 |
| Chu, QS | 1 |
| Cianfrocca, ME | 1 |
| Goldstein, LJ | 1 |
| Gale, M | 1 |
| Murray, N | 1 |
| Loftiss, J | 1 |
| Arya, N | 1 |
| Koch, KM | 1 |
| Pandite, L | 1 |
| Fleming, RA | 1 |
| Paul, E | 1 |
| Rowinsky, EK | 1 |
| Ju, YH | 1 |
| Woodling, KA | 1 |
| Kwak, J | 1 |
| Nagykálnai, T | 2 |
| Gibson, K | 1 |
| O'Bryant, CL | 1 |
| Lince, SL | 1 |
| Douma, J | 2 |
| Wiersma-Van Tilburg, AJ | 1 |
| Kraayenbrink, AA | 1 |
| Metro, G | 1 |
| Mottolese, M | 2 |
| Bhatnagar, AS | 7 |
| Chaudri Ross, HA | 2 |
| von Kameke, A | 1 |
| Eiermann, W | 3 |
| Helle, H | 1 |
| Ekse, D | 1 |
| Duong, NK | 1 |
| Nordbø, Y | 1 |
| Aas, T | 1 |
| Chander, SK | 1 |
| Newman, SP | 1 |
| Woo, LW | 1 |
| Sutcliffe, OB | 1 |
| Bubert, C | 1 |
| Zhou, D | 1 |
| Reed, MJ | 2 |
| Purohit, A | 2 |
| Bertolini, F | 2 |
| Scarano, E | 4 |
| Orlando, L | 2 |
| Mancuso, P | 2 |
| Calleri, A | 1 |
| Mastropasqua, MG | 4 |
| Maiorano, E | 3 |
| Braye, SG | 1 |
| Ohlschlegel, C | 2 |
| Orosz, Z | 2 |
| Olszewski, WP | 1 |
| Knox, F | 1 |
| Castiglione-Gertsch, M | 9 |
| Nastri, CO | 1 |
| Martins, WP | 1 |
| Ferriani, RA | 1 |
| Filho, FM | 1 |
| Dos Reis, FJ | 1 |
| Forbes, J | 3 |
| Buffa, FM | 1 |
| Brizzi, MP | 4 |
| Campo, L | 3 |
| Bersiga, A | 4 |
| Papotti, M | 1 |
| Dogliotti, L | 6 |
| Jang, RW | 1 |
| Doherty, M | 1 |
| Hopkins, JJ | 1 |
| Cianfrocca, M | 1 |
| Wardley, AM | 4 |
| Fricker, J | 2 |
| Frank, DH | 1 |
| Ranger-Moore, J | 1 |
| Yozwiak, M | 1 |
| Bartels, HG | 2 |
| Alberts, DS | 2 |
| Bartels, PH | 2 |
| Lanitis, S | 1 |
| Sivakumar, S | 1 |
| Behranwala, K | 1 |
| Zacharakis, E | 1 |
| Al Mufti, R | 1 |
| Hadjiminas, DJ | 1 |
| Henriksen, KL | 4 |
| Møller, S | 2 |
| Mouridsen, HT | 11 |
| Bates, G | 1 |
| Banham, AH | 1 |
| Macedo, L | 7 |
| Mincey, B | 1 |
| Dentchev, T | 1 |
| Johnson, DB | 2 |
| Schaefer, PL | 1 |
| Alberts, S | 1 |
| Kahanic, S | 1 |
| Mazurczak, MA | 1 |
| Nikcevich, DA | 1 |
| Anderson, TJ | 9 |
| Walker, JR | 3 |
| Krause, A | 5 |
| Sing, T | 1 |
| McArthur, HL | 1 |
| Olivotto, IA | 2 |
| Speers, CH | 1 |
| Ellard, SL | 1 |
| O'Reilly, SE | 1 |
| Kennecke, HF | 2 |
| Ravaioli, A | 1 |
| Towler, M | 1 |
| Belkacémi, Y | 3 |
| Aliev, DA | 1 |
| Azizov, VA | 1 |
| Sadygova, TA | 1 |
| Zeĭnalov, RS | 1 |
| Musaev, IN | 1 |
| Semiglazov, V | 2 |
| van Dam, P | 1 |
| Manikhas, A | 3 |
| Mayordomo, J | 1 |
| Kubista, E | 2 |
| Greil, R | 1 |
| Bianchi, G | 1 |
| Steinseifer, J | 2 |
| Molloy, B | 1 |
| Tokaji, E | 1 |
| Gardner, H | 1 |
| Phillips, P | 1 |
| Stumm, M | 1 |
| Lane, HA | 4 |
| Morabito, A | 3 |
| Esposito, G | 3 |
| Labonia, V | 3 |
| De Feo, G | 2 |
| D'Aiuto, G | 2 |
| Botti, G | 3 |
| Chiodini, P | 1 |
| Bosserman, LD | 1 |
| Caradonna, RR | 1 |
| Haley, BB | 1 |
| Jones, CM | 1 |
| Moore, HC | 1 |
| Warsi, GM | 1 |
| Ericson, SG | 2 |
| Chao, J | 1 |
| Zvaifler, NJ | 1 |
| Nabholtz, JM | 4 |
| Al-Sukhun, S | 1 |
| Ferriere, JP | 2 |
| Hawle, H | 1 |
| Paridaens, RJ | 4 |
| Pienkowski, T | 3 |
| Nogaret, JM | 3 |
| Harris, LA | 1 |
| Esserman, LJ | 3 |
| Fleming, GF | 1 |
| Marcom, PK | 4 |
| Leight, GS | 1 |
| Giuntoli, T | 1 |
| Commean, P | 1 |
| Bae, K | 2 |
| Smollich, M | 1 |
| Götte, M | 1 |
| Fischgräbe, J | 1 |
| Radke, I | 1 |
| Kiesel, L | 2 |
| Wülfing, P | 1 |
| Rodriguez-Wallberg, K | 1 |
| Schover, L | 1 |
| Wong, AL | 1 |
| Chou, N | 1 |
| Lee, KM | 1 |
| Ang, BW | 1 |
| Cheng, CL | 1 |
| Montironi, R | 1 |
| Scarpelli, M | 1 |
| Baxa, SE | 1 |
| O'Dea, AP | 1 |
| Keating, GM | 1 |
| DeVries, S | 1 |
| Anderson, J | 1 |
| Lessing, J | 1 |
| Swain, R | 1 |
| Chin, K | 1 |
| Shim, V | 1 |
| Waldman, FM | 1 |
| Mauriac, L | 13 |
| Chlebowski, R | 1 |
| Amakye, D | 1 |
| Bauerfeind, I | 1 |
| Cutuli, B | 1 |
| Linforth, R | 1 |
| Noguchi, S | 2 |
| Glück, S | 3 |
| Pippen, J | 1 |
| Lichinitser, M | 1 |
| Sadeghi, S | 1 |
| Kennedy, MJ | 1 |
| Maltzman, J | 4 |
| Oliva, C | 2 |
| Stein, S | 1 |
| Pegram, M | 2 |
| Lazarus, P | 1 |
| Sun, D | 1 |
| Traina, TA | 1 |
| Caravelli, JF | 1 |
| Patil, S | 1 |
| Yeh, B | 1 |
| Melisko, ME | 1 |
| Geneus, S | 1 |
| Paulson, M | 1 |
| Grothusen, J | 1 |
| Seidman, AD | 1 |
| Lake, D | 1 |
| Dang, C | 1 |
| Robson, M | 1 |
| Theodoulou, M | 1 |
| Flombaum, CD | 1 |
| Norton, L | 7 |
| Masri, S | 2 |
| Phung, S | 2 |
| Joerger, M | 1 |
| McCaig, FM | 1 |
| Williams, L | 3 |
| Young, O | 5 |
| Murray, J | 9 |
| Macaskill, EJ | 4 |
| McHugh, M | 3 |
| Hannon, R | 1 |
| Logman, JFS | 1 |
| Heeg, BMS | 1 |
| Botteman, MF | 1 |
| Kaura, S | 1 |
| van Hout, BA | 1 |
| Cigler, T | 1 |
| Yaffe, MJ | 1 |
| Johnston, D | 1 |
| Richardson, H | 1 |
| Qi, S | 1 |
| Barad, D | 1 |
| Babayev, SN | 1 |
| Kiyoto, S | 1 |
| Hara, F | 1 |
| Osumi, S | 1 |
| Takabatake, D | 1 |
| Takashima, S | 5 |
| Wishart, GC | 1 |
| Chetty, U | 1 |
| Ishitobi, M | 1 |
| Komoike, Y | 1 |
| Motomura, K | 1 |
| Koyama, H | 3 |
| Nishiyama, K | 1 |
| Inaji, H | 1 |
| Briot, K | 1 |
| Tubiana-Hulin, M | 1 |
| Bastit, L | 1 |
| Kloos, I | 1 |
| Roux, C | 1 |
| Wang, E | 1 |
| Yuan, YC | 3 |
| Bonelli, MA | 2 |
| Fumarola, C | 2 |
| Alfieri, RR | 2 |
| La Monica, S | 2 |
| Cavazzoni, A | 2 |
| Galetti, M | 2 |
| Gatti, R | 1 |
| Belletti, S | 1 |
| Dalton, RJ | 1 |
| Mattar, BI | 1 |
| Recht, A | 1 |
| Moscardo, CL | 1 |
| Coelho, M | 1 |
| Crompton, NE | 1 |
| Garcia-Casado, Z | 1 |
| Calatrava, A | 1 |
| Fernandez-Serra, A | 1 |
| Ruiz-Simon, A | 1 |
| Climent, MA | 1 |
| Almenar, S | 1 |
| Cervera-Deval, J | 1 |
| Campos, J | 1 |
| Albaladejo, CV | 1 |
| Llombart-Bosch, A | 1 |
| Guillem, V | 1 |
| Lopez-Guerrero, JA | 1 |
| Akli, S | 1 |
| Bui, T | 1 |
| Wingate, H | 1 |
| Biernacka, A | 1 |
| Tucker, SL | 1 |
| Keyomarsi, K | 1 |
| Schwartzberg, LS | 1 |
| Schwarzberg, LS | 1 |
| Franco, SX | 1 |
| Neville-Webbe, HL | 1 |
| Holen, I | 1 |
| Guiu, S | 1 |
| Coudert, B | 1 |
| Favier, L | 1 |
| Fumoleau, P | 2 |
| Shibaki, T | 1 |
| Morimoto, N | 1 |
| Türkçüoğlu, I | 2 |
| Rodriguez-Wallberg, KA | 2 |
| Phillips, KA | 3 |
| Stephens, A | 1 |
| Evans, AH | 1 |
| Farmer, I | 2 |
| Thornhill, A | 1 |
| Ro, J | 2 |
| Kim, EA | 1 |
| Kwon, Y | 1 |
| Nam, BH | 2 |
| Lee, S | 3 |
| Eidtmann, H | 3 |
| Davidson, N | 5 |
| Miller, J | 2 |
| Melichar, B | 1 |
| Plísek, J | 1 |
| Hyspler, R | 1 |
| Kalábová, H | 1 |
| Kasparová, M | 1 |
| Krcmová, L | 1 |
| Studentová, H | 1 |
| Solichová, D | 1 |
| Sedjo, RL | 1 |
| Devine, S | 1 |
| Kijima, I | 3 |
| Evans, D | 3 |
| Riemsma, R | 2 |
| Forbes, CA | 2 |
| Kessels, A | 1 |
| Lykopoulos, K | 2 |
| Amonkar, MM | 4 |
| Kleijnen, J | 2 |
| Peroukides, S | 1 |
| Onyenadum, A | 1 |
| Starakis, I | 1 |
| Koutras, A | 1 |
| Makatsoris, T | 1 |
| Bouboukas, G | 1 |
| Kalofonos, H | 1 |
| Xu, X | 1 |
| Fang, L | 1 |
| Sun, Y | 6 |
| Wang, M | 1 |
| Zhao, N | 2 |
| Curran, MP | 2 |
| Ueda, S | 1 |
| Saeki, T | 1 |
| Omata, J | 1 |
| Osaki, A | 1 |
| Shigekawa, T | 1 |
| Ishida, J | 1 |
| Abe, Y | 1 |
| Moriya, T | 1 |
| Yamamoto, J | 1 |
| Bertolini, E | 1 |
| Letho-Gyselinck, H | 1 |
| Prati, C | 1 |
| Wendling, D | 1 |
| Agrawal, K | 1 |
| Onami, S | 1 |
| Mortimer, JE | 1 |
| Pal, SK | 1 |
| Galleshaw, JA | 1 |
| Jones, CF | 1 |
| Shah, JJ | 1 |
| Percent, IJ | 1 |
| Nabell, LM | 1 |
| Carpenter, JT | 1 |
| Falkson, CI | 1 |
| Krontiras, H | 1 |
| Urist, MM | 1 |
| Bland, KI | 1 |
| De Los Santos, JF | 1 |
| Meredith, RF | 1 |
| Caterinicchia, V | 1 |
| Bernreuter, WK | 1 |
| O'Malley, JP | 1 |
| Beer, B | 1 |
| Schubert, B | 1 |
| Oberguggenberger, A | 1 |
| Meraner, V | 1 |
| Hubalek, M | 1 |
| Oberacher, H | 1 |
| Lipsitz, M | 1 |
| Delea, TE | 4 |
| Guo, A | 1 |
| Jiao, J | 1 |
| Xiang, H | 1 |
| Liao, Q | 1 |
| Sherrill, B | 3 |
| Sherif, B | 2 |
| Langridge, C | 1 |
| Young, OE | 2 |
| McCaig, F | 1 |
| Dixon, OM | 1 |
| Fallowfield, LJ | 1 |
| Yiu, CC | 2 |
| Chanplakorn, N | 2 |
| Chan, MS | 2 |
| Loo, WT | 3 |
| Chow, LW | 5 |
| Zidan, J | 1 |
| Chetver, L | 1 |
| Hussein, O | 1 |
| Zucker, M | 1 |
| Tsoutsou, PG | 1 |
| Kuten, A | 1 |
| Boussen, H | 1 |
| Bese, N | 1 |
| Koukourakis, MI | 1 |
| Aldridge, J | 2 |
| Tang, SC | 1 |
| Harris, CA | 1 |
| Ward, RL | 1 |
| Dobbins, TA | 1 |
| Drew, AK | 1 |
| Pearson, S | 1 |
| Ichinose, Y | 1 |
| Kobayashi, T | 1 |
| Fujimoto, A | 1 |
| Uchida, S | 1 |
| Sasaoki, T | 1 |
| Goto, K | 1 |
| Vallabhaneni, S | 1 |
| Nair, BC | 1 |
| Cortez, V | 1 |
| Challa, R | 1 |
| Chakravarty, D | 1 |
| Vadlamudi, RK | 2 |
| Rotmensz, N | 1 |
| Santoro, A | 1 |
| Amano, S | 2 |
| Van Calster, B | 1 |
| Van Hoydonck, M | 1 |
| Pans, S | 2 |
| Westhovens, R | 2 |
| Dieudonné, AS | 1 |
| Morales, L | 3 |
| Verschueren, K | 1 |
| Timmerman, D | 3 |
| De Smet, L | 2 |
| Vergote, I | 5 |
| Sönmezer, M | 2 |
| Coşkun, U | 1 |
| Koeberle, D | 3 |
| Jost, L | 1 |
| Oehlschlegel, C | 1 |
| Crowe, S | 1 |
| Pilop, C | 1 |
| Miller, TW | 2 |
| Ghazoui, Z | 2 |
| Dunbier, A | 1 |
| Anderson, H | 2 |
| Mills, GB | 1 |
| Wu, H | 1 |
| Shyr, Y | 1 |
| Saboktakin, MR | 1 |
| Tabatabaie, RM | 1 |
| Maharramov, A | 1 |
| Ramazanov, MA | 1 |
| Hong, Y | 1 |
| Rashid, R | 1 |
| Howes, T | 1 |
| Ni, YB | 1 |
| Yang, WJ | 1 |
| Bu, H | 1 |
| Zheng, H | 3 |
| Lee, YS | 1 |
| Kim, SY | 1 |
| Hong, SH | 1 |
| Lee, H | 1 |
| Nair, HB | 1 |
| Ganapathy, M | 1 |
| Yao, S | 1 |
| Lin, L | 2 |
| Snider, J | 2 |
| Unzeitig, GW | 1 |
| Margenthaler, J | 2 |
| Babiera, GV | 2 |
| Watson, MA | 1 |
| Pronzato, P | 1 |
| Ozkavukcu, S | 1 |
| Heytens, E | 1 |
| Alappat, RM | 1 |
| Landherr, L | 1 |
| Mészáros, E | 1 |
| Gallicchio, L | 1 |
| Macdonald, R | 1 |
| Wood, B | 1 |
| Rushovich, E | 1 |
| Helzlsouer, KJ | 1 |
| Abrhale, T | 1 |
| Tian, C | 1 |
| Yue, B | 1 |
| Serrero, G | 1 |
| Buttar, A | 1 |
| Mittal, K | 1 |
| Khan, A | 1 |
| Bathini, V | 1 |
| Chanplakorn, P | 1 |
| Ono, K | 1 |
| Wing, L | 1 |
| Lu, WJ | 1 |
| Xu, C | 1 |
| Pei, Z | 1 |
| Mayhoub, AS | 1 |
| Barsoum, M | 1 |
| Petruzelka, L | 1 |
| Reimer, T | 1 |
| Ragosch, V | 1 |
| Baumgärtner, AK | 1 |
| May, C | 1 |
| Nimmrich, I | 1 |
| Dixon, J | 1 |
| Thomas, J | 2 |
| Ibrahim, NK | 1 |
| Yariz, KO | 1 |
| Alyasova, A | 1 |
| Komisarenko, V | 1 |
| Jones, D | 1 |
| Senderovich, S | 1 |
| Chau, A | 1 |
| Erlandsson, F | 1 |
| Acton, G | 1 |
| Gorouhi, F | 1 |
| Cruz Jurado, J | 1 |
| Richart Aznar, P | 1 |
| García Mata, J | 1 |
| Fernández Martínez, R | 1 |
| Peláez Fernández, I | 1 |
| Sampedro Gimeno, T | 1 |
| Murillo Jaso, L | 1 |
| Polo Marqués, E | 1 |
| García Palomo, A | 1 |
| Osborn, G | 1 |
| Jones, M | 1 |
| Champ, C | 1 |
| Gower-Thomas, K | 1 |
| Vaughan-Williams, E | 1 |
| Toumi, Z | 1 |
| Bullen, C | 1 |
| Tang, AC | 1 |
| Dalal, N | 1 |
| Ellenbogen, S | 1 |
| Novoa Vargas, A | 1 |
| Font López, KC | 1 |
| Amador, DD | 1 |
| Kreutz, Y | 1 |
| Skaar, T | 1 |
| Hoffmann, E | 1 |
| Bedard, PL | 1 |
| Singhal, SK | 2 |
| Bradbury, I | 1 |
| Haibe-Kains, B | 1 |
| Desmedt, C | 1 |
| Michiels, S | 2 |
| Piccart, MJ | 10 |
| Sotiriou, C | 3 |
| Harker, WG | 2 |
| Bosserman, L | 1 |
| Vogel, C | 1 |
| Seidler, C | 2 |
| Warsi, G | 1 |
| Argonza-Aviles, E | 1 |
| Hohneker, J | 2 |
| Mohammadianpanah, M | 1 |
| Ashouri, Y | 1 |
| Hoseini, S | 1 |
| Amadloo, N | 1 |
| Talei, A | 1 |
| Tahmasebi, S | 1 |
| Nasrolahi, H | 1 |
| Mosalaei, A | 1 |
| Omidvari, S | 1 |
| Ansari, M | 1 |
| Mosleh-Shirazi, MA | 1 |
| Lüthi, J | 1 |
| Simcock, M | 1 |
| Berthod, G | 1 |
| Genton, C | 1 |
| Brauchli, P | 1 |
| Zako, M | 1 |
| Takeyama, M | 1 |
| Naito, E | 1 |
| Mizumoto, K | 1 |
| Iwaki, M | 1 |
| Paija, O | 2 |
| Sleeboom, HP | 4 |
| Mebis, J | 1 |
| Deleu, I | 1 |
| Wink, CJ | 1 |
| Woensdregt, K | 1 |
| Nieuwenhuijzen, GA | 1 |
| van der Sangen, MJ | 1 |
| Hutschemaekers, S | 1 |
| Roukema, JA | 1 |
| Tjan-Heijnen, VC | 1 |
| Voogd, AC | 1 |
| Huang, F | 1 |
| Harrington, SC | 1 |
| Reeves, KA | 1 |
| Greer, A | 1 |
| Finckenstein, FG | 1 |
| Gottardis, MM | 1 |
| Carboni, JM | 1 |
| Haluska, P | 1 |
| Jin, H | 1 |
| Metzger-Filho, O | 1 |
| Işçi, H | 1 |
| Güdücü, N | 1 |
| Basgul, AY | 1 |
| Aydinli, K | 1 |
| Calay, Z | 1 |
| Dünder, I | 1 |
| Barnadas, A | 5 |
| Estévez, LG | 2 |
| Lluch-Hernández, A | 1 |
| Rodriguez-Lescure, A | 2 |
| Rodriguez-Sanchez, C | 1 |
| Sanchez-Rovira, P | 2 |
| Balakrishnan, A | 1 |
| Kataoka, M | 1 |
| Moriya, Y | 1 |
| Sawada, N | 1 |
| Yasuno, H | 1 |
| Kondoh, K | 1 |
| Mori, K | 1 |
| Pujol, P | 2 |
| Lasset, C | 1 |
| Berthet, P | 1 |
| Dugast, C | 1 |
| Fricker, JP | 1 |
| Tennevet, I | 1 |
| Chabbert-Buffet, N | 1 |
| This, P | 2 |
| Baudry, K | 1 |
| Roca, L | 1 |
| Mijonnet, S | 1 |
| Gesta, P | 1 |
| Chiesa, J | 1 |
| Dreyfus, H | 1 |
| Vennin, P | 1 |
| Delnatte, C | 1 |
| Bignon, YJ | 1 |
| Lortholary, A | 1 |
| Prieur, F | 1 |
| Lesur, A | 1 |
| Clough, KB | 1 |
| Nogues, C | 1 |
| Martin, AL | 1 |
| Steiner, AZ | 1 |
| Fritz, M | 1 |
| Mersereau, JE | 1 |
| Cohen, MH | 2 |
| Johnson, JR | 3 |
| Justice, R | 1 |
| Pazdur, R | 3 |
| Chimge, NO | 1 |
| Baniwal, SK | 1 |
| Coetzee, S | 1 |
| Khalid, O | 1 |
| Berman, BP | 1 |
| Frenkel, B | 1 |
| Fleeman, N | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Dickson, R | 1 |
| Dundar, Y | 1 |
| Moonan, M | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Davis, H | 1 |
| Armstrong, A | 1 |
| Thorp, N | 1 |
| Bernstein-Molho, R | 1 |
| Greenberg, J | 1 |
| Pelles-Avraham, S | 1 |
| Stephansky, I | 1 |
| Sarid, D | 1 |
| Inbar, MJ | 1 |
| Geffen, DB | 1 |
| Fontein, DB | 1 |
| Nortier, JW | 3 |
| Rutgers, EJ | 1 |
| Bell, LN | 1 |
| Arai, T | 1 |
| Ooshiro, C | 1 |
| Miwa, H | 1 |
| Yoneda, G | 1 |
| Harada, H | 2 |
| Furukawa, H | 1 |
| Nagashima, S | 1 |
| Shibata, M | 1 |
| Maeda, T | 1 |
| Ueda, Y | 1 |
| Kuwayama, T | 1 |
| Sato, T | 1 |
| Nakagawa, T | 1 |
| Sugimoto, H | 1 |
| Ishiba, T | 1 |
| Kubota, K | 1 |
| Sugihara, K | 1 |
| Diniz da Costa, AT | 1 |
| Coelho, AM | 1 |
| Lourenço, AV | 1 |
| Bernardino, M | 1 |
| Ribeirinho, AL | 1 |
| Jorge, CC | 1 |
| Canpolat, U | 1 |
| Sunman, H | 1 |
| Kaya, EB | 1 |
| Aytemir, K | 1 |
| Oto, A | 1 |
| Griggs, JJ | 1 |
| Galán, A | 1 |
| Buch, E | 1 |
| Ruiz, A | 1 |
| Fuster Diana, C | 1 |
| Guillem Porta, V | 1 |
| Takahashi, S | 1 |
| Iwase, T | 1 |
| Kohno, N | 1 |
| Ishikawa, T | 1 |
| Taguchi, T | 1 |
| Horiguchi, J | 1 |
| Nakamura, S | 1 |
| Fukunaga, M | 1 |
| Azzouz, F | 1 |
| Lemler, S | 1 |
| Hayden, J | 1 |
| Tarpinian, K | 1 |
| Yakim, E | 1 |
| Farhi, J | 1 |
| Ben-Aharon, I | 1 |
| Pinkas, H | 1 |
| Fisch, B | 1 |
| Hata, K | 1 |
| Hirai, I | 1 |
| Tanaka, T | 1 |
| Tanino, H | 1 |
| Kelly, CM | 1 |
| Tang, W | 1 |
| Lastoria, S | 1 |
| Bartiromo, A | 1 |
| Buonfanti, G | 1 |
| D'Aniello, R | 1 |
| Maiolino, P | 1 |
| Signoriello, S | 1 |
| Colantuoni, G | 1 |
| D'Aiuto, M | 2 |
| Di Bonito, M | 1 |
| Giordano, P | 1 |
| Alkaied, H | 1 |
| Harris, K | 1 |
| Brenner, A | 1 |
| Awasum, M | 1 |
| Varma, S | 1 |
| Airoud, K | 1 |
| Tramonti, S | 1 |
| Galvani, E | 1 |
| Smith, J | 1 |
| Dilawari, A | 1 |
| Ursin, G | 1 |
| Andreopoulou, E | 1 |
| Checka, C | 1 |
| Axelrod, D | 1 |
| Guth, A | 1 |
| Toth, H | 1 |
| Utate, M | 1 |
| Carapetyan, K | 1 |
| Reich, E | 1 |
| Diflo, T | 1 |
| Muggia, F | 1 |
| Fu, J | 1 |
| Shen, ZH | 1 |
| Cheng, FX | 1 |
| Liu, GX | 1 |
| Li, WH | 1 |
| Tang, Y | 1 |
| Checa Vizcaíno, MA | 1 |
| Corchado, AR | 1 |
| Cuadri, ME | 1 |
| Comadran, MG | 1 |
| Brassesco, M | 1 |
| Carreras, R | 1 |
| Liu, GY | 1 |
| He, PQ | 1 |
| Zhang, HW | 1 |
| Lou, LH | 1 |
| Wang, XJ | 1 |
| Tang, JH | 1 |
| Liu, YH | 1 |
| Jiang, ZF | 2 |
| Ma, LW | 1 |
| Gu, L | 1 |
| Cao, MZ | 1 |
| Zhang, QY | 1 |
| Wang, SM | 1 |
| Su, FX | 1 |
| Li, HY | 1 |
| Tang, LL | 1 |
| Sun, SR | 1 |
| Liu, JP | 1 |
| Shen, ZZ | 1 |
| O'Hara, J | 1 |
| Vareslija, D | 1 |
| McBryan, J | 1 |
| Bane, F | 1 |
| Tibbitts, P | 1 |
| Byrne, C | 1 |
| Conroy, RM | 1 |
| Hao, Y | 1 |
| Gaora, PÓ | 1 |
| Hill, AD | 1 |
| McIlroy, M | 1 |
| Young, LS | 1 |
| Kubo, M | 2 |
| Onishi, H | 1 |
| Kuroki, S | 1 |
| Okido, M | 2 |
| Shimada, K | 2 |
| Yokohata, K | 1 |
| Umeda, S | 1 |
| Ogawa, T | 1 |
| Tanaka, M | 1 |
| Katano, M | 1 |
| Ito, Y | 1 |
| Rajan, S | 1 |
| Munot, K | 1 |
| Haselden, J | 1 |
| Sasaki, Y | 2 |
| Okuyama, M | 1 |
| Hibino, M | 1 |
| Tenma, K | 1 |
| Nakamura, M | 1 |
| Wong, C | 1 |
| Smith, D | 2 |
| Reddy, K | 1 |
| Ding, L | 1 |
| Shen, D | 1 |
| Wallis, JW | 1 |
| Van Tine, BA | 1 |
| Goiffon, RJ | 1 |
| Goldstein, TC | 1 |
| Ng, S | 1 |
| Crowder, R | 1 |
| Ballman, K | 1 |
| Weber, J | 1 |
| Chen, K | 1 |
| Koboldt, DC | 1 |
| Kandoth, C | 1 |
| Schierding, WS | 1 |
| McMichael, JF | 1 |
| Miller, CA | 1 |
| Lu, C | 1 |
| Harris, CC | 1 |
| McLellan, MD | 1 |
| Wendl, MC | 1 |
| Maher, CA | 1 |
| Fulton, LL | 1 |
| Fulton, RS | 1 |
| Harrison, M | 1 |
| Oberkfell, B | 1 |
| Du, F | 1 |
| Demeter, R | 1 |
| Vickery, TL | 1 |
| Elhammali, A | 1 |
| Piwnica-Worms, H | 1 |
| McDonald, S | 1 |
| Dooling, DJ | 1 |
| Chang, LW | 1 |
| Bose, R | 1 |
| Ley, TJ | 1 |
| Piwnica-Worms, D | 1 |
| Stuart, JM | 1 |
| Wilson, RK | 1 |
| Mardis, ER | 1 |
| Singh, SK | 1 |
| Bansal, VK | 1 |
| Wiley, EL | 1 |
| Valyi-Nagy, T | 1 |
| Villano, JL | 1 |
| La Verde, N | 1 |
| Bramati, A | 1 |
| Girelli, S | 1 |
| Piva, S | 1 |
| Moretti, A | 1 |
| Sburlati, P | 1 |
| Mihali, D | 1 |
| Farina, G | 1 |
| Correa, PD | 1 |
| Shrimali, RK | 1 |
| Rizwanullah, M | 1 |
| Diaz, JR | 1 |
| King, V | 1 |
| Goldfarb, SB | 1 |
| Brooks, JD | 1 |
| Sung, JS | 1 |
| Nulsen, BF | 1 |
| Jozefara, JE | 1 |
| Pike, MC | 1 |
| Morris, EA | 1 |
| Folkerd, EJ | 1 |
| A'Hern, RP | 2 |
| Riedmann, EM | 1 |
| Nakamura, K | 1 |
| Shibata, T | 1 |
| Kinoshita, T | 1 |
| Fukuda, H | 1 |
| Larsen, MS | 1 |
| Bjerre, K | 1 |
| Meszoely, IM | 1 |
| Wagle, N | 1 |
| Garraway, LA | 1 |
| Zografos, GC | 1 |
| Xu, BH | 1 |
| Wang, JY | 1 |
| Cai, RG | 1 |
| Mehta, R | 1 |
| Alimirah, F | 1 |
| Peng, X | 1 |
| Murillo, G | 1 |
| Wiehle, R | 1 |
| Mehta, RG | 1 |
| Turaka, K | 1 |
| Nottage, JM | 1 |
| Hammersmith, KM | 1 |
| Nagra, PK | 1 |
| Rapuano, CJ | 1 |
| Castonguay, A | 1 |
| Doucet, C | 1 |
| Juhas, M | 1 |
| Maysinger, D | 1 |
| Martino, S | 10 |
| Livingston, RB | 7 |
| Ewertz, M | 1 |
| Barrios, C | 1 |
| Martin, N | 1 |
| Guest, S | 1 |
| Weigel, MT | 1 |
| Thornhill, AM | 1 |
| Wasan, KM | 2 |
| Pritchard, PH | 2 |
| Higgins, MJ | 1 |
| Notaro, R | 1 |
| Lastraioli, S | 1 |
| Serra, M | 1 |
| Marroni, P | 1 |
| Cavazzini, G | 1 |
| Clavarezza, M | 1 |
| Davis, SR | 1 |
| Bell, RJ | 1 |
| Hanna, F | 1 |
| Davies-Tuck, M | 1 |
| Bell, R | 1 |
| Cicuttini, F | 1 |
| Xie, J | 1 |
| Diener, M | 1 |
| De, G | 1 |
| Yang, H | 1 |
| Wu, EQ | 1 |
| Namjoshi, M | 1 |
| Petrossian, K | 1 |
| Warden, C | 1 |
| Osako, T | 1 |
| Chu, P | 1 |
| Gildea, JJ | 1 |
| Yue, W | 6 |
| Lee, RJ | 1 |
| Armstrong, AC | 1 |
| Garin, AM | 1 |
| Brincat, S | 1 |
| Neskovic-Konstantinovic, Z | 1 |
| Guimaraes, RC | 1 |
| Hachemi, S | 1 |
| Strahs, A | 1 |
| Cincotta, M | 1 |
| Berkenblit, A | 1 |
| Krygowski, M | 1 |
| Kang, LL | 1 |
| Moore, L | 1 |
| Chow, S | 1 |
| Cheung, WH | 1 |
| Chan, FL | 1 |
| Leung, LK | 1 |
| Komeda, S | 1 |
| Furukawa, N | 1 |
| Kasai, T | 1 |
| Washida, A | 1 |
| Kobayashi, H | 1 |
| Rodríguez, J | 1 |
| Castañeda, G | 1 |
| Muñoz, L | 1 |
| Sabine, VS | 1 |
| Sahmoud, T | 1 |
| Untch, M | 1 |
| Tung, N | 1 |
| Schaverien, MV | 1 |
| Raine, C | 1 |
| Majdak-Paredes, E | 1 |
| Pan, L | 1 |
| Smith, RE | 2 |
| Assikis, VJ | 1 |
| Sperone, P | 1 |
| Gorzegno, G | 1 |
| Familiari, U | 1 |
| Buzdar, AU | 14 |
| Mokbel, K | 2 |
| Robertson, JF | 3 |
| Atalay, G | 1 |
| Tominaga, T | 5 |
| Adachi, I | 1 |
| Tabei, T | 1 |
| Takatsuka, Y | 1 |
| Suwa, T | 1 |
| Mitropoulou, TN | 1 |
| Tzanakakis, GN | 1 |
| Kletsas, D | 1 |
| Kalofonos, HP | 1 |
| Karamanos, NK | 1 |
| Zapatero, A | 1 |
| Martín de Vidales, C | 1 |
| Pérez-Torrubia, A | 1 |
| Karnon, J | 8 |
| Jones, T | 2 |
| Lipton, A | 6 |
| Ali, SM | 4 |
| Leitzel, K | 4 |
| Demers, L | 5 |
| Harvey, HA | 7 |
| Chaudri-Ross, HA | 11 |
| Brady, C | 5 |
| Wyld, P | 2 |
| Carney, W | 4 |
| Macfarlane, L | 1 |
| Cameron, D | 2 |
| Gershanovich, M | 7 |
| Apffelstaedt, J | 2 |
| Smith, R | 4 |
| Jaenicke, F | 1 |
| Pluzanska, A | 3 |
| Dank, M | 2 |
| Becquart, D | 3 |
| Bapsy, PP | 2 |
| Salminen, E | 2 |
| Snyder, R | 2 |
| Chaudri-Ross, H | 1 |
| Lang, R | 4 |
| Bhatnagar, A | 1 |
| Berstein, LM | 2 |
| Wang, JP | 2 |
| Naftolin, F | 2 |
| Shanabrough, M | 1 |
| Santen, RJ | 8 |
| Dranitsaris, G | 2 |
| Trudeau, M | 2 |
| Kleeberg, U | 1 |
| Burton, G | 1 |
| Ozdogan, M | 1 |
| Samur, M | 1 |
| Bozcuk, HS | 1 |
| Sagtas, E | 1 |
| Yildiz, M | 1 |
| Artac, M | 1 |
| Savas, B | 1 |
| Sayer, HG | 1 |
| Höffken, K | 1 |
| Baum, M | 2 |
| Rocchi, A | 1 |
| Bhatnager, A | 1 |
| Rose, C | 4 |
| Thomas, R | 4 |
| Jackson, J | 2 |
| Eckhardt, S | 1 |
| Lønning, P | 1 |
| Pfister, C | 3 |
| Martoni, A | 2 |
| Bryant, J | 1 |
| Abrams, JS | 6 |
| Therasse, P | 1 |
| Palmer, MJ | 9 |
| Pater, JL | 9 |
| Vtoraya, O | 1 |
| Johnson, S | 1 |
| Caicedo, JJ | 1 |
| Gervasio, H | 1 |
| Manikhas, G | 1 |
| Ben Ayed, F | 1 |
| Burdette-Radoux, S | 1 |
| Coop, A | 2 |
| Singh, B | 2 |
| Jänicke, F | 5 |
| Quebe-Fehling, E | 2 |
| Glendenning, A | 1 |
| Papaldo, P | 4 |
| Ruggeri, EM | 4 |
| Milella, M | 3 |
| Hobson, K | 1 |
| Rosen, E | 1 |
| Dressman, H | 1 |
| Wong, JL | 1 |
| Twombly, R | 1 |
| Runowicz, CD | 1 |
| DeGrendele, H | 1 |
| Hietanen, P | 1 |
| Mäkelä, M | 1 |
| Shahab, N | 1 |
| Harris, SR | 1 |
| Hellman, S | 1 |
| Hellman, D | 1 |
| Domont, J | 1 |
| Namer, M | 1 |
| Khayat, D | 2 |
| Spano, JP | 2 |
| Kawakami, M | 1 |
| Saji, S | 2 |
| Long, BJ | 5 |
| Jelovac, D | 8 |
| Handratta, V | 3 |
| Thiantanawat, A | 2 |
| MacPherson, N | 2 |
| Ragaz, J | 1 |
| Goloubeva, OG | 4 |
| Campos, SM | 1 |
| Smyczek-Gargya, B | 1 |
| Armeanu, S | 1 |
| Gagulic, E | 1 |
| Pantic, L | 1 |
| Relakis, K | 1 |
| Friedrich, M | 1 |
| Oyan, B | 1 |
| Ozisik, Y | 1 |
| Arora, A | 1 |
| Potter, JF | 1 |
| Clemons, M | 1 |
| Sainsbury, R | 1 |
| Simpson, D | 1 |
| Perry, CM | 1 |
| Ellis, M | 4 |
| Russo, F | 1 |
| Martincich, L | 1 |
| Cirillo, S | 1 |
| Gatti, M | 1 |
| Aglietta, M | 1 |
| Regge, D | 1 |
| Gerken, P | 1 |
| Baumann, ChK | 1 |
| Guan, XY | 1 |
| Tobias, JS | 2 |
| Howell, A | 2 |
| Núñez, NP | 1 |
| Berrigan, D | 1 |
| Perkins, SN | 1 |
| Hursting, SD | 1 |
| Barrett, JC | 1 |
| Morandi, P | 1 |
| Rouzier, R | 1 |
| Theriault, RL | 1 |
| Choueiri, TK | 1 |
| Alemany, CA | 1 |
| Abou-Jawde, RM | 1 |
| Godward, S | 1 |
| Makris, A | 2 |
| Bloomfield, D | 1 |
| Moody, AM | 1 |
| Williams, M | 2 |
| Van Limbergen, E | 2 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Ravdin, PM | 1 |
| Davis, GJ | 1 |
| Marchetti, M | 1 |
| Caruggi, M | 1 |
| de Cremoux, P | 1 |
| Poupon, MF | 1 |
| Magdelénat, H | 1 |
| Sigal-Zafrani, B | 2 |
| Fourquet, A | 1 |
| Harwood, KV | 1 |
| Larbouret, C | 1 |
| Cunat, S | 1 |
| Martineau, P | 1 |
| Fentiman, IS | 1 |
| Clemons, MJ | 1 |
| Henderson, IC | 1 |
| Sonne-Hansen, K | 1 |
| Okubo, I | 1 |
| Kondo, M | 1 |
| Ochiai, T | 1 |
| Miki, S | 1 |
| Kahán, Z | 1 |
| Liu, S | 3 |
| Heath, M | 1 |
| Deangelis, D | 1 |
| Buyuk, E | 1 |
| Libertella, N | 1 |
| Akar, M | 1 |
| Itoh, T | 2 |
| Karlsberg, K | 1 |
| Baron, AT | 1 |
| Cora, EM | 1 |
| Hillman, DW | 1 |
| Maihle, NJ | 1 |
| Ansari, TN | 1 |
| Mahmood, A | 1 |
| Hussain, I | 1 |
| Samad, A | 1 |
| Delozier, T | 1 |
| Dodwell, D | 2 |
| Kaufmann, M | 2 |
| Bobilev, D | 1 |
| Shelef, I | 1 |
| Lavrenkov, K | 1 |
| Tokar, M | 1 |
| Man, S | 1 |
| Baumgarten, A | 1 |
| Ariad, S | 1 |
| Irish, W | 1 |
| Cole, B | 1 |
| Gard, C | 1 |
| Glendenning, GA | 1 |
| Hamer, P | 3 |
| Senn, HJ | 1 |
| Nordman, IC | 1 |
| Spillane, AJ | 1 |
| Hamilton, AL | 1 |
| Klause, A | 1 |
| Vickers, A | 1 |
| White, S | 6 |
| Bertelli, G | 2 |
| Bertolotti, L | 2 |
| Occelli, M | 2 |
| Conforti, S | 1 |
| Marzano, N | 1 |
| Febbraro, A | 1 |
| Liossi, C | 1 |
| Leonard, RC | 4 |
| Boulay, A | 1 |
| Rudloff, J | 1 |
| Zumstein-Mecker, S | 1 |
| O'Reilly, T | 1 |
| Bria, E | 2 |
| Giannarelli, D | 2 |
| Felici, A | 1 |
| Nisticò, C | 1 |
| Terzoli, E | 2 |
| Mann, BS | 1 |
| Kelly, R | 1 |
| Sridhara, R | 1 |
| Williams, G | 1 |
| Noonan, D | 1 |
| Chowdhury, S | 1 |
| Ellis, PA | 1 |
| Pritchard, K | 1 |
| Palmer, M | 2 |
| Madhup, R | 1 |
| Kirti, S | 1 |
| Bhatt, ML | 1 |
| Srivastava, PK | 1 |
| Srivastava, M | 1 |
| Song, ST | 1 |
| Keshaviah, A | 4 |
| Wardly, A | 1 |
| Merlano, M | 1 |
| Castiglione, F | 1 |
| Pepi, F | 1 |
| Fusco, O | 1 |
| Tuma, RS | 1 |
| Chia, WK | 1 |
| Lim, YL | 1 |
| Greaves, MW | 1 |
| Ang, P | 1 |
| Shin, I | 1 |
| Miller, T | 1 |
| Fodor, J | 1 |
| Delea, T | 3 |
| Brandman, J | 3 |
| Sung, J | 1 |
| Gltick, S | 1 |
| Michaud, LB | 1 |
| Keam, SJ | 2 |
| Higa, GM | 1 |
| Hargis, JB | 1 |
| Nakajima, ST | 1 |
| Leheurteur, M | 2 |
| Cabrespine, A | 1 |
| Cure, H | 2 |
| Erban, JK | 1 |
| Ribelles, N | 1 |
| Fernández, R | 2 |
| Mayordomo, JI | 2 |
| Tusquets, I | 3 |
| Carabante, F | 1 |
| Ruiz, M | 1 |
| Vera, R | 1 |
| Palomero, I | 1 |
| Soriano, V | 1 |
| González, J | 1 |
| Grana, G | 1 |
| Dunn, C | 1 |
| Lebwohl, D | 1 |
| Walsh, G | 1 |
| Hayes, D | 1 |
| Proia, AD | 1 |
| Faratian, D | 1 |
| Gil, JM | 1 |
| Rubio-Terrés, C | 1 |
| Del Castillo, A | 1 |
| González, P | 1 |
| Canorea, F | 1 |
| Maciá Escalante, S | 1 |
| Pons Sanz, V | 1 |
| Rodríguez Lescure, A | 1 |
| Ballester Navarro, I | 1 |
| Carrato Mena, A | 1 |
| Duffy, MJ | 1 |
| Tsukagoshi, S | 1 |
| Manquez, ME | 1 |
| Brown, MM | 1 |
| Shields, CL | 1 |
| Shields, JA | 1 |
| El Ouagari, K | 1 |
| Talbot, W | 1 |
| Josse, RG | 1 |
| Findlay, BP | 1 |
| Shenkier, TN | 1 |
| Tozer, RG | 1 |
| Sung, JC | 1 |
| Gross, PE | 1 |
| Bodini, G | 1 |
| Dionisio, R | 2 |
| Bernardi, C | 1 |
| Montruccoli, A | 1 |
| Hourvitz, A | 1 |
| Sahin, G | 1 |
| Oktem, O | 1 |
| Safro, B | 1 |
| Cil, A | 1 |
| Guo, Z | 1 |
| Qiu, Y | 1 |
| Isaacs, C | 1 |
| Harris, L | 1 |
| Wong, ZW | 1 |
| Kommarreddy, A | 1 |
| Novielli, N | 1 |
| Mann, G | 1 |
| Vakaet, L | 1 |
| de la Rochefordière, A | 1 |
| Bredart, A | 1 |
| Asselain, B | 1 |
| Poinsot, R | 1 |
| Dolbeault, S | 1 |
| Venturini, M | 1 |
| Stebbing, J | 1 |
| Crane, J | 1 |
| Gaya, A | 1 |
| Mauri, D | 1 |
| Pavlidis, N | 1 |
| Polyzos, NP | 1 |
| Ioannidis, JP | 1 |
| Speers, C | 1 |
| Norris, B | 1 |
| Bryce, C | 1 |
| Goodwin, GM | 1 |
| Souder, C | 1 |
| Amant, F | 1 |
| Berteloot, P | 1 |
| Smeets, A | 1 |
| Weltens, C | 1 |
| Van den Bogaert, W | 1 |
| Tacca, O | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Beresford, MJ | 1 |
| Vachon, CM | 1 |
| Scott, CG | 1 |
| Gottardt, H | 1 |
| Olson, JE | 1 |
| Njar, VC | 2 |
| Carroll, R | 1 |
| Tan-Chiu, E | 1 |
| Lacerna, L | 1 |
| Petrone, S | 1 |
| Ivanov, VG | 1 |
| Tsyrlina, EV | 1 |
| Kovalenko, IG | 1 |
| Poroshina, TE | 1 |
| Gamaiunova, VB | 1 |
| Malysheva, SA | 1 |
| Zhil'tsova, EK | 1 |
| Barash, NIu | 1 |
| Shcherbakova, EB | 1 |
| Semiglazov, VF | 2 |
| Bershteĭn, LM | 1 |
| Skedgel, C | 1 |
| Dewar, R | 1 |
| Younis, T | 1 |
| Zalles, CM | 1 |
| Mayo, MS | 1 |
| Phillips, TA | 1 |
| Simonsen, M | 1 |
| Metheny, T | 1 |
| Petroff, BK | 1 |
| Lembersky, B | 1 |
| Cronin, W | 1 |
| Harkins, B | 1 |
| Geyer, C | 1 |
| Costantino, J | 1 |
| Imai, H | 1 |
| Ono, M | 1 |
| Zabaznyi, N | 1 |
| van Nes, JG | 1 |
| Lostritto, K | 2 |
| Marshall, E | 1 |
| Mosca, A | 1 |
| Vana, F | 1 |
| Angeli, A | 1 |
| Bertoldo, F | 1 |
| Yang, MT | 1 |
| Lian, ZQ | 1 |
| Wengström, Y | 1 |
| Leto di Priolo, S | 1 |
| Cannon, H | 1 |
| Georgiou, V | 1 |
| Ricci, S | 1 |
| Pellegrini, M | 1 |
| Cresti, N | 1 |
| Alimonti, A | 1 |
| Salesi, N | 1 |
| Pater, J | 1 |
| Monnier, AM | 1 |
| Demirtas, E | 1 |
| Son, WY | 1 |
| Chian, RC | 1 |
| Tan, SL | 1 |
| Dexter, T | 2 |
| Fenwick, K | 1 |
| Ashworth, A | 2 |
| Ohorodnik, S | 1 |
| Settlage, J | 1 |
| Langecker, P | 2 |
| Blanchett, D | 2 |
| Kaiser, J | 1 |
| Sofrygin, O | 2 |
| Thomas, SK | 1 |
| Papo, NL | 1 |
| Barghout, V | 2 |
| Hind, D | 1 |
| Ward, S | 1 |
| De Nigris, E | 1 |
| Simpson, E | 1 |
| Carroll, C | 1 |
| Walker, G | 1 |
| MacLeod, K | 1 |
| Williams, AR | 1 |
| Smyth, JF | 1 |
| Langdon, SP | 1 |
| Solé, X | 1 |
| Capellà, G | 1 |
| Germà-Lluch, JR | 1 |
| Julian, HS | 1 |
| Green, RV | 1 |
| Dixon, MJ | 1 |
| Venkatesh, P | 1 |
| Garg, S | 1 |
| El-Ouagari, K | 1 |
| Raffoul, J | 1 |
| Braye, S | 2 |
| Subar, M | 1 |
| Abreu, P | 1 |
| Thomsen, T | 1 |
| Banke-Bochita, J | 1 |
| Beeram, M | 1 |
| Tan, QT | 1 |
| Russell, D | 1 |
| Middleton, A | 1 |
| DeGraffenried, LA | 1 |
| Amar, S | 1 |
| Roy, V | 1 |
| Pruneri, G | 1 |
| Bottiglieri, L | 1 |
| Magni, E | 1 |
| D'Alessandro, C | 1 |
| Wadman, M | 1 |
| Manikhas, GM | 1 |
| Spaeth, D | 1 |
| Dodwell, DJ | 1 |
| Bessems, A | 1 |
| Park, YC | 1 |
| De Porre, PM | 1 |
| Perez Ruixo, JJ | 1 |
| Howes, AJ | 1 |
| Lindberg, H | 1 |
| Nielsen, DL | 1 |
| Tuxen, M | 1 |
| Murray, E | 1 |
| Hampton, G | 1 |
| Ho, S | 1 |
| Cufer, T | 1 |
| Haidinger, R | 1 |
| Jahanzeb, M | 1 |
| Atabekoglu, C | 1 |
| Lloveras, B | 2 |
| Constenla, M | 1 |
| Gilabert, M | 2 |
| Bondarenko, IN | 1 |
| Manikhas, GN | 1 |
| Pendergrass, KB | 1 |
| Miller, WH | 1 |
| Dutta, U | 1 |
| Pant, K | 1 |
| Williamson, D | 1 |
| Fontaine, C | 2 |
| Wouters, C | 1 |
| Tanaka, C | 1 |
| Zoellner, U | 1 |
| Tang, P | 1 |
| Del Curto, B | 1 |
| Méry, E | 1 |
| Lacroix-Triki, M | 1 |
| Altermatt, HJ | 1 |
| Rinaldo, M | 1 |
| Russell, CA | 1 |
| Eisen, A | 1 |
| Shelley, W | 1 |
| Messersmith, H | 1 |
| Collingridge, D | 1 |
| Bundred, NJ | 1 |
| Campbell, ID | 1 |
| DeBoer, RH | 1 |
| Miller, JC | 1 |
| Schenk, NL | 1 |
| Shin, A | 1 |
| Matthews, CE | 1 |
| Shu, XO | 1 |
| Gao, YT | 1 |
| Lu, W | 1 |
| Gu, K | 1 |
| Zheng, W | 1 |
| Monzo, M | 1 |
| Rifa, J | 1 |
| Baena, JM | 1 |
| Calvo, L | 2 |
| Carabantes, F | 1 |
| Crespo, C | 1 |
| Plazaola, A | 1 |
| Artells, R | 1 |
| Yip, AY | 1 |
| Kerr, GR | 1 |
| Chapman, JA | 1 |
| Meng, D | 1 |
| Parulekar, W | 1 |
| Herold, CI | 2 |
| Krainick-Strobel, UE | 1 |
| Lichtenegger, W | 1 |
| Tulusan, AH | 1 |
| Bastert, G | 1 |
| Thiery-Vuillemin, A | 1 |
| Meaux-Ruault, N | 1 |
| Maurina, T | 1 |
| Stein, U | 1 |
| Lorgis, V | 1 |
| Crivellari, D | 1 |
| Pennery, E | 1 |
| Folkerd, E | 1 |
| Marshall, C | 1 |
| Walker, L | 1 |
| Kendall, A | 1 |
| Harper-Wynne, C | 3 |
| Kihara, M | 1 |
| Miyauchi, A | 1 |
| Brown-Shimer, S | 1 |
| Pierce, K | 1 |
| Gaur, V | 1 |
| Vergoni, F | 1 |
| Adrover, E | 1 |
| de la Haba, J | 1 |
| Meulemans, A | 1 |
| Huizing, M | 1 |
| Collen, C | 1 |
| Kaufman, L | 1 |
| De Mey, J | 1 |
| Bourgain, C | 1 |
| Verfaillie, G | 1 |
| Lamote, J | 1 |
| Sacre, R | 1 |
| Schallier, D | 1 |
| Neyns, B | 1 |
| Vermorken, J | 1 |
| Mellington, TE | 1 |
| Fields, MM | 1 |
| Goyal, S | 1 |
| Puri, T | 1 |
| Jovic, G | 1 |
| Giovannelli, S | 1 |
| Lee, K | 2 |
| Macaulay, VM | 2 |
| Nicholls, JE | 1 |
| Klein, KO | 1 |
| Demers, LM | 4 |
| Santner, SJ | 1 |
| Baron, J | 1 |
| Cutler, GB | 1 |
| Kambic, KB | 2 |
| Grossberg, H | 2 |
| Adlercruetz, H | 1 |
| Trunet, PF | 7 |
| Manni, A | 1 |
| Pfister, CU | 2 |
| Duval, M | 2 |
| Godbillon, J | 1 |
| Gosset, G | 1 |
| Gygax, D | 1 |
| Marfil, F | 1 |
| Sioufi, A | 2 |
| Winkler, B | 1 |
| Iveson, TJ | 1 |
| Ahern, J | 1 |
| Smithers, DA | 1 |
| Rowlands, M | 2 |
| Grimshaw, R | 2 |
| Cocconi, G | 2 |
| Scaglione, F | 1 |
| Fraschini, F | 1 |
| Chaudri, HA | 5 |
| Hornberger, U | 3 |
| Johnson, PA | 2 |
| Gerstner, JB | 1 |
| Mailliard, JA | 2 |
| Camoriano, JK | 1 |
| Gesme, DH | 1 |
| Hatfield, AK | 1 |
| Hartmann, LC | 1 |
| Mullen, P | 1 |
| Sourdaine, P | 1 |
| Watson, C | 1 |
| Telford, J | 1 |
| Roseman, BJ | 1 |
| Singletary, SE | 1 |
| Dombernowsky, P | 1 |
| Falkson, G | 1 |
| Leonard, R | 1 |
| Bellmunt, J | 1 |
| Bezwoda, W | 1 |
| Gardin, G | 1 |
| Gudgeon, A | 1 |
| Morgan, M | 2 |
| Fornasiero, A | 1 |
| Hoffmann, W | 1 |
| Michel, J | 1 |
| Hatschek, T | 1 |
| Tjabbes, T | 1 |
| McLeskey, SW | 1 |
| Zhang, L | 1 |
| El-Ashry, D | 1 |
| Trock, BJ | 1 |
| Lopez, CA | 1 |
| Kharbanda, S | 1 |
| Tobias, CA | 1 |
| Lorant, LA | 1 |
| Hannum, RS | 1 |
| Dickson, RB | 1 |
| Kern, FG | 1 |
| Lu, Q | 3 |
| Campos, D | 2 |
| Lurie, H | 2 |
| Bonaventura, A | 2 |
| Jeffrey, M | 2 |
| Buzzi, F | 2 |
| Bodrogi, I | 2 |
| Ludwig, H | 2 |
| Reichardt, P | 1 |
| O'Higgins, N | 1 |
| Friederich, P | 1 |
| Lassus, M | 4 |
| Hoctin-Boes, G | 1 |
| Yates, R | 1 |
| Steinberg, M | 1 |
| Norton, A | 1 |
| Jones, A | 1 |
| Jacobs, S | 1 |
| Trunet, P | 1 |
| Lamb, HM | 1 |
| Adkins, JC | 1 |
| Grigoryev, DN | 1 |
| Mor, G | 1 |
| Gutierrez, L | 1 |
| Eliza, M | 1 |
| Harada, N | 1 |
| Lysiak, J | 1 |
| Diano, S | 1 |
| Hamilton, A | 2 |
| Krook, JE | 1 |
| Wheeler, RH | 1 |
| Bajetta, E | 4 |
| Zilembo, N | 4 |
| Guillevin, L | 1 |
| Celio, L | 2 |
| Martinetti, A | 2 |
| Marchianò, A | 1 |
| Pozzi, P | 3 |
| Stani, S | 1 |
| Bichisao, E | 3 |
| de Jong, PC | 1 |
| Blijham, GH | 2 |
| Miles, DW | 1 |
| Houston, SJ | 1 |
| Verbeek, JA | 2 |
| Gundacker, H | 1 |
| Chaudri, Kh | 1 |
| Reichard, P | 1 |
| O'Higgins, NO | 1 |
| Friedrich, P | 1 |
| Feutrie, ML | 1 |
| Nuijten, M | 1 |
| Meester, L | 1 |
| Waibel, F | 1 |
| Wait, S | 1 |
| Love, CD | 2 |
| Bellamy, C | 1 |
| Kirma, N | 1 |
| Gill, K | 1 |
| Fowler, K | 1 |
| Toffolatti, L | 1 |
| Casali, A | 2 |
| Sega, FM | 1 |
| Casali, M | 1 |
| Giuntini, T | 1 |
| Cappellini, GC | 1 |
| Perey, L | 1 |
| Sonoo, H | 1 |
| Crucitta, E | 1 |
| Attolico, M | 1 |
| Sambiasi, D | 1 |
| Mazzei, A | 1 |
| De Lena, M | 1 |
| Leung, P | 1 |
| Mather, J | 1 |
| Oza, A | 1 |
| Messori, A | 1 |
| Cattel, F | 1 |
| Trippoli, S | 1 |
| Vaiani, M | 1 |
| Schwetz, BA | 1 |
| Kerbrat, P | 1 |
| Lefeuvre, C | 1 |
| Staffler, B | 1 |
| Dugan, M | 3 |
| Elledge, R | 1 |
| Porter, L | 1 |
| Nabholtz, J | 1 |
| Xiang, X | 1 |
| Elisaf, MS | 1 |
| Bairaktari, ET | 1 |
| Nicolaides, C | 1 |
| Kakaidi, B | 1 |
| Tzallas, CS | 1 |
| Katsaraki, A | 1 |
| Pavlidis, NA | 1 |
| Bellamy, CO | 1 |
| Smith, H | 1 |
| Volm, M | 1 |
| Llombert-Cussac, A | 1 |
| Borgs, M | 2 |
| Panasci, LC | 1 |
| Murray, R | 1 |
| Mackey, JR | 1 |
| Lelli, G | 1 |
| Souppart, C | 1 |
| Reese, DM | 1 |
| Bando, H | 1 |
| Brink, S | 1 |
| Haynes, B | 1 |
| Anker, G | 1 |
| Fenaroli, P | 1 |
| Labianca, R | 1 |
| De Marco, S | 1 |
| Nardi, M | 1 |
| Paoloni, F | 1 |
| Appfelstaedt, J | 1 |
| Eremin, J | 1 |
| Vinholes, J | 1 |
| Fulton, A | 1 |
| Chen, T | 1 |
| DeJong, PC | 1 |
| Blankenstein, MA | 1 |
| Slee, PH | 1 |
| van de Ven, J | 1 |
| van Gorp, JM | 1 |
| Elbers, JR | 1 |
| Schipper, ME | 1 |
| Thijssen, JH | 1 |
| Junker, A | 1 |
| Wiedemann, GJ | 1 |
| Possinger, K | 1 |
| Li, N | 1 |
| Timms, B | 1 |
| Johnson, PE | 1 |
| Illiger, HJ | 1 |
| Nomura, Y | 3 |
| Aoyama, H | 1 |
| Abe, R | 2 |
| Nomizu, T | 3 |
| Tohge, T | 3 |
| Ferrari, L | 1 |
| Buzzoni, R | 1 |
| La Torre, I | 1 |
| Gattinoni, L | 1 |
| Catena, L | 1 |
| Vitali, M | 1 |
| Seregni, E | 1 |
| Bombardieri, E | 1 |
| Shaw, HS | 1 |
| Jones, SE | 1 |
| Genta, F | 1 |
| Vicelli, R | 1 |
| De Nicola, B | 1 |
| Ferraris, F | 1 |
| Piccinno, R | 1 |
| Benedetto, C | 1 |
| Ueo, H | 2 |
| Ikeda, S | 2 |
| Kimijima, I | 1 |
| Ragonesi, G | 1 |
| Colla, F | 1 |
| Mazzoleni, A | 1 |
| Farina, C | 1 |
| Ross, G | 1 |
| Sacks, N | 1 |
| Nasiri, N | 1 |
| Iqbal, J | 1 |
| Pérez, N | 1 |
| Borja, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Letrozole Adjuvant Therapy Duration (LEAD) Study: Standard Versus Long Treatment. A Phase III Trial in Post-Menopausal Women With Early Breast Cancer.[NCT01064635] | Phase 3 | 2,056 participants (Actual) | Interventional | 2005-08-31 | Active, not recruiting | ||
| A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer[NCT02491983] | Phase 2 | 486 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregional[NCT02246621] | Phase 3 | 493 participants (Actual) | Interventional | 2014-11-06 | Active, not recruiting | ||
| A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in The MA.17 Study)[NCT00754845] | Phase 3 | 1,918 participants (Actual) | Interventional | 2004-11-23 | Completed | ||
| A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast Cancer[NCT03900884] | Phase 1 | 36 participants (Anticipated) | Interventional | 2019-09-25 | Recruiting | ||
| A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease[NCT01958021] | Phase 3 | 668 participants (Actual) | Interventional | 2013-12-17 | Completed | ||
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).[NCT04111978] | Phase 3 | 540 participants (Anticipated) | Interventional | 2020-11-05 | Recruiting | ||
| CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.[NCT03248427] | Phase 2 | 106 participants (Actual) | Interventional | 2017-07-13 | Completed | ||
| COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HE[NCT02941926] | Phase 3 | 3,246 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCER[NCT02297438] | Phase 3 | 340 participants (Actual) | Interventional | 2015-03-23 | Active, not recruiting | ||
| A Phase 2 Study of Abemaciclib in Combination With Letrozole or in Combination With Letrozole and Metformin in Recurrent or Persistent Endometrial Cancer[NCT03675893] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-12-24 | Recruiting | ||
| A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer[NCT02273973] | Phase 2 | 334 participants (Actual) | Interventional | 2014-11-12 | Completed | ||
| Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer[NCT02802748] | Early Phase 1 | 60 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| TBCRC 023: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib Pus Trastuzumab, With or Without Endocrine Therapy for 12 Weeks vs. 24 Weeks in Patients With HER2 Overexpressing Breast Cancer[NCT00999804] | Phase 2 | 128 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | ||
| Early Identification of Patients Who Benefit From Palbociclib in Addition to Letrozole[NCT02806050] | Phase 2 | 30 participants (Actual) | Interventional | 2016-09-16 | Completed | ||
| A Phase II Open Label Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination With Bevacizumab in Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer[NCT00161291] | Phase 2 | 28 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)[NCT01439711] | Phase 2 | 108 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMI[NCT01740427] | Phase 3 | 666 participants (Actual) | Interventional | 2013-02-22 | Completed | ||
| Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.[NCT00908531] | Phase 3 | 123 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Poor recruitement) | ||
| A PHASE 1/2 STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ORAL PD-0332991, A CYCLIN-DEPENDENT KINASE 4 AND 6 (CDK4/6) INHIBITOR, AS SINGLE AGENT IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS OR IN COMBINATION WITH LETROZOLE FOR THE FIRST-LINE T[NCT01684215] | Phase 2 | 61 participants (Actual) | Interventional | 2012-10-19 | Completed | ||
| A Randomized, Open-label Study of First Line Pyrotinib, Trastuzumab With an Aromatase Inhibitors, in the Treatment of HER2 Positive and HR Positive Metastatic or Inoperable Locally Advanced Breast Cancer[NCT03910712] | Phase 2 | 250 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMENT OF ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER IN POS[NCT00721409] | Phase 2 | 177 participants (Actual) | Interventional | 2008-09-15 | Completed | ||
| Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Can[NCT00036270] | Phase 3 | 9,779 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Analysis of Circulating Tumor Markers in the Blood[NCT02866149] | 682 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | |||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer[NCT02778685] | Phase 2 | 40 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | ||
| Real-world Treatment Patterns and Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as Initial Endocrine Based Therapy in Metastatic/Advanced Breast Cancer[NCT04176354] | 1 participants (Actual) | Observational | 2019-01-25 | Active, not recruiting | |||
| Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients[NCT06076772] | 54 participants (Anticipated) | Observational [Patient Registry] | 2023-11-30 | Not yet recruiting | |||
| Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial[NCT03011684] | Phase 3 | 144 participants (Anticipated) | Interventional | 2016-07-21 | Recruiting | ||
| A Randomised Pilot Study of Neoadjuvant Everolimus Plus Letrozole Compared With FEC in Postmenopausal Patients With ER-positive, HER2-negative Breast Cancer[NCT02742051] | Phase 2 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Phase II Randomized Trial of Lenvatinib Combined With Letrozole Versus Fulvestrant in Metastatic Estrogen Receptor (ER) Positive, HER2 Negative Breast Cancer, Who Have Progressed on First-line Aromatase Inhibitor + a CDK4/6 Inhibitor.[NCT05181033] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-12-27 | Recruiting | ||
| Phase II, Multicenter, Single Arm Trial to Assess the Feasibility of First Line Ribociclib in Combination With a Non Steroidal Aromatase Inhibitor in Elderly Patients With Hormone Receptor Positive/HER2 Negative Advanced Breast Cancer[NCT03944434] | Phase 2 | 116 participants (Actual) | Interventional | 2018-12-27 | Active, not recruiting | ||
| Trial of Tucidinostat in Combination With Fulvestrant in Patients With Hormone-receptor Positive Advanced Breast Cancer[NCT04999540] | Phase 2 | 73 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positi[NCT00553410] | Phase 3 | 4,884 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE D[NCT01942135] | Phase 3 | 521 participants (Actual) | Interventional | 2013-09-26 | Completed | ||
| An Open-label, Prospective Study of Tumor Response Time of Palbociclib in Combination With AI in Real-world First-line Treatment of Postmenopausal Chinese Patients With ER (+) HER2 (-) Metastatic Breast Cancer[NCT04858997] | Phase 2 | 150 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| A Phase III Study Comparing Anastrozole, Letrozole and Exemestane, Upfront (for 5 Years) or Sequentially (for 3 Years After 2 Years of Tamoxifen), as Adjuvant Treatment of Postmenopausal Patients With Endocrine-responsive Breast Cancer[NCT00541086] | Phase 3 | 3,697 participants (Actual) | Interventional | 2007-03-31 | Active, not recruiting | ||
| Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.[NCT05163106] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| Endocrine Therapy With or Without Anti-VEGF Therapy: A Randomized, Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865) for Women With Hormone Receptor-Positive Advanced Breast Cancer[NCT00601900] | Phase 3 | 394 participants (Actual) | Interventional | 2008-05-15 | Active, not recruiting | ||
| A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Posi[NCT02278120] | Phase 3 | 672 participants (Actual) | Interventional | 2014-11-20 | Completed | ||
| PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 [NCT02513394] | Phase 3 | 5,796 participants (Actual) | Interventional | 2015-08-31 | Active, not recruiting | ||
| A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of PI3-Kinase Inhibitor GDC-0941 (Pictilisib) in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole in Patients With Locally Recurrent O[NCT00960960] | Phase 1 | 71 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk [NCT02400567] | Phase 2 | 125 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect [NCT02093351] | Phase 1 | 79 participants (Actual) | Interventional | 2014-09-01 | Completed | ||
| A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in[NCT00382070] | Phase 3 | 3,966 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer[NCT02005887] | Phase 2 | 51 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Efficiency and Safety Study of Ovarian Stimulation With Letrozole for Fertility Preservation in Breast Cancer Patients[NCT02661932] | Phase 4 | 65 participants (Actual) | Interventional | 2012-11-30 | Active, not recruiting | ||
| A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial[NCT02616744] | Phase 2 | 171 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study[NCT02411344] | Phase 2 | 64 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM)[NCT00651456] | Phase 2/Phase 3 | 448 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING PALBOCICLIB COMBINATIONS FOR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER IN REAL WORLD SETTINGS[NCT03159195] | 652 participants (Actual) | Observational | 2017-06-12 | Completed | |||
| Nintedanib Plus Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Phase 0/1 Safety and Pharmacodynamics[NCT02619162] | Phase 1 | 25 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole,[NCT00412022] | Phase 3 | 1,294 participants (Actual) | Interventional | 2004-03-31 | Active, not recruiting | ||
| Multicenter, Randomized Trial to Evaluate Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment vs Endocrine Alone, in Postmenopausal With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line[NCT00545077] | Phase 3 | 380 participants (Actual) | Interventional | 2007-11-06 | Completed | ||
| A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line[NCT02422615] | Phase 3 | 726 participants (Actual) | Interventional | 2015-06-09 | Completed | ||
| PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer[NCT01973660] | Phase 2 | 151 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Phase II Trial of Lapatinib and Trastuzumab With or Without Endocrine Therapy in Locally Advanced HER2 Overexpressing Breast Cancer Patients[NCT00548184] | Phase 2 | 65 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer[NCT03168074] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-03-28 | Recruiting | ||
| Light Emitting Diode for the Treatment of Genitourinary Syndrome of Menopause Associated With Hormonal Therapy for Treating Breast Cancer: Randomized Controlled Clinical Trial[NCT03833726] | 77 participants (Actual) | Interventional | 2019-01-30 | Completed | |||
| Breast Cancer Index (BCI) Registry[NCT04875351] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2021-04-14 | Recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor- Positive Advanced or Metastatic Breast Cancer[NCT00073528] | Phase 3 | 1,286 participants (Actual) | Interventional | 2003-12-09 | Completed | ||
| Investigating Bone Density and Bone Loss Without Baseline Information[NCT00369850] | Phase 3 | 458 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Neoadjuvant Hormone Therapy for Postmenopausal Women With HR+ Primary Breast Cancer: A Multi-center Study to Determine the Optimum Length of Treatment With Letrozole on Tumour Regression to Permit Breast Conserving Surgery.[NCT00330317] | Phase 3 | 300 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation.[NCT00429299] | Phase 2 | 121 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF BOSUTINIB ADMINISTERED IN COMBINATION WITH LETROZOLE VS. LETROZOLE ALONE AS FIRST LINE THERAPY IN POST-MENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/PR+/HER2- BREAST CANCER.[NCT00880009] | Phase 2 | 16 participants (Actual) | Interventional | 2009-07-30 | Terminated (stopped due to See termination reason in detailed description.) | ||
| A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer[NCT02514681] | Phase 3 | 370 participants (Anticipated) | Interventional | 2015-08-01 | Active, not recruiting | ||
| A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response With Aromatase Polymorphism[NCT00228956] | 500 participants (Anticipated) | Observational | 2005-01-31 | Recruiting | |||
| Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study[NCT00504699] | 120 participants (Actual) | Interventional | 2002-01-31 | Terminated (stopped due to The PI left the Institution.) | |||
| Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer[NCT00463489] | 338 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breas[NCT03220178] | Phase 4 | 532 participants (Actual) | Interventional | 2017-07-24 | Terminated (stopped due to Due to COVID-19 pandemic, study cannot be finished in planned timeframe.) | ||
| A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer[NCT02536742] | Phase 2 | 124 participants (Actual) | Interventional | 2016-08-30 | Active, not recruiting | ||
| Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer[NCT02692755] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Meta[NCT02947685] | Phase 3 | 496 participants (Anticipated) | Interventional | 2017-06-21 | Active, not recruiting | ||
| PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer[NCT04360941] | Phase 1 | 45 participants (Anticipated) | Interventional | 2020-08-11 | Recruiting | ||
| A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Bre[NCT03820830] | Phase 3 | 400 participants (Anticipated) | Interventional | 2019-08-27 | Recruiting | ||
| Impact of Routine Assessment of Health-Related Quality of Life Coupled With Therapeutic Information on Compliance With Endocrine Therapy in Patients With Non-metastatic Breast Cancer[NCT04176809] | 342 participants (Anticipated) | Interventional | 2021-05-14 | Recruiting | |||
| Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer[NCT02955394] | Phase 2 | 61 participants (Actual) | Interventional | 2017-09-21 | Active, not recruiting | ||
| Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer[NCT01077453] | Phase 1 | 112 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Phase II Randomized Study to Compare Skin Late Toxicities of Concomitant Letrozole-Radiotherapy and Radiotherapy Followed by Letrozole as Adjuvant Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00208273] | Phase 2 | 150 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer[NCT01105312] | Phase 1/Phase 2 | 28 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Phase 2 Study Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors[NCT01509079] | Phase 2 | 116 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A Trial of Abbreviated Hormone Therapy for Low Risk Hormone Receptor Positive, HER2 Negative Early Breast Cancer[NCT03917082] | Phase 2 | 290 participants (Anticipated) | Interventional | 2019-09-23 | Active, not recruiting | ||
| A Phase III Randomized Double Blind Study of Letrozole Versus Placebo in Women With Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen[NCT00003140] | Phase 3 | 5,187 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| A Multicenter, Open, Single Arm Dose-escalation and Dose-expansion Study: to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of FCN-437c Alone or in Combination With Letrozole in ER+/ HER2- Advanced Breast Cancer[NCT04488107] | Phase 1/Phase 2 | 78 participants (Anticipated) | Interventional | 2019-02-14 | Recruiting | ||
| A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer[NCT01919229] | Phase 2 | 14 participants (Actual) | Interventional | 2013-10-31 | Terminated (stopped due to Due to low recruitment, it was decided to terminate the study.) | ||
| A Phase II Study of Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation[NCT03879174] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-08-01 | Not yet recruiting | ||
| Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positi[NCT03644186] | Phase 2 | 144 participants (Actual) | Interventional | 2019-04-16 | Completed | ||
| A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer[NCT04985266] | Phase 2 | 1,100 participants (Anticipated) | Interventional | 2022-03-30 | Recruiting | ||
| A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg Daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer[NCT00265759] | Phase 3 | 622 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study[NCT01953588] | Phase 3 | 1,473 participants (Actual) | Interventional | 2013-12-13 | Active, not recruiting | ||
| Phase Ib Study of Neoadjuvant DPX-Survivac, Aromatase Inhibition, and With/Without Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer[NCT04895761] | Phase 1 | 6 participants (Actual) | Interventional | 2021-09-10 | Active, not recruiting | ||
| Vitrification of Oocytes From Female Cancer Patients to Preserve Their Fertility Potential[NCT01268592] | 16 participants (Actual) | Interventional | 2010-10-31 | Terminated (stopped due to Study technique has been declared part of standard care) | |||
| Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study[NCT01016665] | 71 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy[NCT00291135] | Phase 2 | 42 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Controlled, Open-Label Trial of Empiric Prophylactic vs. Delayed Use of Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women With Breast Cancer Initiating Therapy With Letrozole After Tamoxifen[NCT00107263] | Phase 3 | 558 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| A Phase 2, Double-blind, Randomized, Placebo-controlled, Multi-center Study Assessing the Value of Adding Everolimus to Letrozole as Preoperative Therapy of Primary Breast Cancer in Postmenopausal Women[NCT00107016] | Phase 2 | 267 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A PHASE II Multicentric Trial Evaluating a High Dose Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer Treated by Adjuvant Chemotherapy[NCT04091178] | Phase 2 | 57 participants (Actual) | Interventional | 2013-10-10 | Completed | ||
| An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS[NCT02936999] | Early Phase 1 | 8 participants (Actual) | Interventional | 2016-08-31 | Terminated (stopped due to Terminated for lack of patient samples and funding) | ||
| Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer[NCT00290745] | Phase 1/Phase 2 | 79 participants (Actual) | Interventional | 2002-02-19 | Completed | ||
| A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies[NCT02238509] | Phase 2 | 154 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Phase II Study of Pyrotinib in Combination With Fulvestrant in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive，Hormone Receptor（HR）-Positive Metastatic Breast Cancer[NCT04034589] | Phase 2 | 46 participants (Anticipated) | Interventional | 2019-07-17 | Recruiting | ||
| A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer[NCT00305825] | Phase 2 | 43 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer[NCT05247268] | Phase 2 | 104 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density[NCT00238316] | Phase 2 | 68 participants (Actual) | Interventional | 2000-12-05 | Completed | ||
| Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy[NCT00436917] | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Feasibility Clinical Trial of Intraoperative Radiotherapy (IORT) and Second Breast-conserving-surgery After Local Recurrence of Breast Carcinoma[NCT02386371] | 66 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| Dual Versus Single Trigger in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome: a Randomized, Double-blinded, Controlled Trial.[NCT05638529] | Phase 4 | 80 participants (Actual) | Interventional | 2019-05-01 | Active, not recruiting | ||
| Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer[NCT03192293] | Phase 2 | 28 participants (Anticipated) | Interventional | 2017-01-20 | Recruiting | ||
| Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation[NCT01645241] | 15 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Double Ovarian Stimulation in Cases of Preimplantation Genetic Testing: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore[NCT03291821] | 136 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial[NCT00238290] | Phase 2 | 13 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Comparison of Neoadjuvant Aromatase Inhibitors With Ovarian Suppression Versus Chemotherapy in Premenopausal Patients With Hormone Receptor-positive Breast Cancer (COMPETE): a Randomized Phase 3 Trial[NCT02532400] | Phase 3 | 21 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Hard to enroll expected number of eligible patients.) | ||
| FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma[NCT05627960] | Phase 1 | 77 participants (Anticipated) | Interventional | 2022-02-14 | Recruiting | ||
| Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen in Premenopausal Women With Breast Cancer[NCT03582865] | 100 participants (Anticipated) | Observational | 2019-09-01 | Not yet recruiting | |||
| A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer[NCT00770354] | Phase 2 | 110 participants (Anticipated) | Interventional | 2008-09-30 | Terminated | ||
| Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation[NCT00673335] | Phase 3 | 170 participants (Actual) | Interventional | 2008-05-31 | Active, not recruiting | ||
| Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation[NCT03667417] | 5,000 participants (Anticipated) | Observational | 1999-10-15 | Recruiting | |||
| Phase 3 Study of the Effect of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving the Aromatase Inhibitor, Letrozole, in the Adjuvant Setting[NCT00376740] | Phase 3 | 90 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormo[NCT06164119] | 600 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| Development and Evaluation of a Therapeutic Education Intervention Focused on the Accession of Patients Treated With Hormonal Therapy in the Management of Breast Cancer: PEPs Hormonotherapy[NCT02300675] | 352 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| A Prospective, Multicentre, Controlled, Observational Study to Evaluate the Performance of Patient Support Programme (PSP) in Improving Patient Adherence With Adjuvant Aromatase Inhibitors (AI) Medication for Postmenopausal, Early Stage Breast Cancer[NCT00769080] | 524 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients: A Multicenter Retrospective Study[NCT03924609] | 1,500 participants (Actual) | Observational | 2018-03-01 | Completed | |||
| An Open-Label, Randomized, MultiCenter Study to Evaluate the Use of Zolendronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women With Estrogen Positive and/or Progesterone Positive Breast Cancer Receiving Letrozole as A[NCT00171340] | Phase 3 | 1,065 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.[NCT03784651] | 120 participants (Anticipated) | Observational | 2018-12-17 | Recruiting | |||
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer[NCT00083993] | Phase 3 | 1,236 participants | Interventional | 2004-05-31 | Terminated | ||
| A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors.[NCT00851110] | Phase 2 | 50 participants (Anticipated) | Interventional | 2004-10-31 | Terminated | ||
| Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms[NCT00603967] | 151 participants (Actual) | Interventional | 2006-03-31 | Completed | |||
| Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)[NCT00712985] | Phase 3 | 18 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy[NCT02394496] | Phase 3 | 396 participants (Anticipated) | Interventional | 2007-11-30 | Recruiting | ||
| PHASE III RANDOMIZED CONTROL CASE STUDY OF LETROZOLE IN WOMEN WITH HEAVILY PRETREATED OVARIAN CANCER (MITO 32)[NCT04421547] | Phase 3 | 236 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | ||
| Placebo-controlled Evaluation of the Homeopathic Drug BRN01 for the Treatment of Hot Flashes in Women With Non Metastatic Breast Cancer Treated by Adjuvant Hormonal Therapy[NCT01246427] | Phase 3 | 138 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer[NCT02263846] | 1,183 participants (Actual) | Observational | 2011-11-30 | Completed | |||
| Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients[NCT00954135] | Phase 2 | 190 participants (Anticipated) | Interventional | 2007-09-30 | Active, not recruiting | ||
| Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer[NCT00134680] | Phase 2 | 33 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| A Randomised, Blinded, Phase 2 Study of Letrozole Plus the Farnesyl Transferase Inhibitor ZARNESTRA TM (R115777) and Letrozole Plus Placebo in the Treatment of Advanced Breast Cancer After Antiestrogen Therapy.[NCT00050141] | Phase 2 | 121 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study[NCT03358017] | Phase 2 | 54 participants (Actual) | Interventional | 2018-03-05 | Completed | ||
| A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level[NCT02347163] | Phase 2 | 22 participants (Actual) | Interventional | 2015-02-03 | Terminated (stopped due to The study stopped prematurely due to the low accrual rate) | ||
| Pre-operative Hormone Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer: An Uncontrolled Phase IIb/III Trial to Assess Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate [NCT00535418] | Phase 2/Phase 3 | 35 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| Prospective Study of UDP-gluconoryltransferase (UGT) 2B17 Genotype as a Predictive Marker of Exemestane Pharmacokinetics and Pharmacodynamics in Asian Women With Hormone Receptor-positive Advanced Breast Cancer[NCT01655004] | 110 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Minimally important differences in the EQ-5D VAS score are 7 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline. (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | millimeter (mm) (Least Squares Mean) |
|---|---|
| Abemaciclib + NSAI | 0.49 |
| Placebo + NSAI | 1.51 |
The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts.The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a five level scale (no problem, slight problem, moderate problem, severe problem and extreme problem) with higher levels indicating greater severity/ impairment. Published weights are available that allow for the creation of a single summary score called the EQ-5D index that ranges from 0 to 1, with low scores representing a higher level of dysfunction and 1 as perfect health. Minimally important differences in the EQ-5D index score are 0.06 or greater in cancer patients. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline. (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Abemaciclib + NSAI | 0.01 |
| Placebo + NSAI | 0.01 |
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. (NCT02246621)
Timeframe: CR or PR to Disease Progression or Death Due to Any Cause (Up to 32 Months)
| Intervention | Months (Median) |
|---|---|
| Abemaciclib + NSAI | 27.39 |
| Placebo + NSAI | 17.46 |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Abemaciclib + NSAI | 49.7 |
| Placebo + NSAI | 37 |
DCR was the percentage of participants with a best overall response of CR, PR, or SD as per response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Abemaciclib + NSAI | 88.7 |
| Placebo + NSAI | 86.7 |
CBR defined as percentage of participants with best overall response of CR, PR, or SD with a duration of at least 6 months. CR, PR, or SD were defined using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Percentage of participants = (participants with CR+PR+SD with a duration of at least 6 months / number of participants enrolled) * 100. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Abemaciclib + NSAI | 78.0 |
| Placebo + NSAI | 71.5 |
PFS defined as the time from the first day of therapy to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. (NCT02246621)
Timeframe: Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)
| Intervention | Months (Median) |
|---|---|
| Abemaciclib + NSAI | 28.18 |
| Placebo + NSAI | 14.76 |
"The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from: 1, Not at all; 2, A little; 3, Quite a bit; to 4, Very much. All scores are converted to a 0 to 100 scale. A higher score representing a higher (better) level of functioning (BR23: body image, sexual functioning, future perspective), or a higher (worse) level of symptoms. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline." (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | score on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Body image | Sexual functioning | Future perspective | Systemic therapy side effects | Breast symptoms | Arm symptoms | |
| Abemaciclib + NSAI | -4.5 | -0.2 | 12.7 | 8.15 | -6.12 | -1.14 |
| Placebo + NSAI | 0.6 | -0.1 | 11.9 | 3.68 | -6.23 | -2.23 |
"EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. Symptom scale ranges from: 1, Not at all; 2, A little; 3, Quite a bit; to 4, Very much. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For symptoms scales, higher scores indicated greater symptom burden. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline. Small changes are generally defined as at least a 3, 4 or 5 point change from baseline." (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | score on a scale (Least Squares Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Nausea and Vomiting | Pain | Dyspnea | Insomnia | Appetite loss | Constipation | Diarrhea | Financial difficulties | |
| Abemaciclib + NSAI | 2.4 | 2.4 | -4.8 | 0.9 | -1.7 | 0.2 | -0.8 | 18.2 | -0.7 |
| Placebo + NSAI | -2.6 | -0.4 | -5.7 | -1.6 | -4.1 | -3.9 | 1.6 | -0.5 | -1.2 |
"EORTC QLQ-C30 v3.0 is a self-administered questionnaire with multidimensional scales that measures 5 functional domains(physical,role,cognitive,emotional, and social),global health status, and symptom scales of fatigue, pain, nausea and vomiting,dyspnea,loss of appetite,insomnia,constipation and diarrhea, and financial difficulties.Functional scale options are defined on a 7-point scale ranging from 1, Very poor to 7, Excellent. A linear transformation is applied to standardize the raw scores to range between 0 and 100 with higher score indicating better functioning. For functional domains and global health status, higher scores represent a better level of functioning. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, Visit, Treatment*Visit and Baseline." (NCT02246621)
Timeframe: Baseline, End of Study (Up to 32 Months)
| Intervention | score on a scale (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Physical | Role | Emotional | Cognitive | Social | |
| Abemaciclib + NSAI | -1.0 | -1.4 | 4.7 | -4.0 | -0.1 |
| Placebo + NSAI | 1.7 | 2.9 | 4.0 | -4.0 | 3.3 |
Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve From Time 0 Hour to Infinity [AUC(0-∞)] of Abemaciclib and Its Metabolites M2 and M20 (NCT02246621)
Timeframe: Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
| Intervention | nanogram*hours/milliliter (ng*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| Abemaciclib | M2 | M20 | |
| Abemaciclib + NSAI | 3360 | 1290 | 2300 |
PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20 (NCT02246621)
Timeframe: Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
| Intervention | liters/hour (L/h) (Geometric Mean) | ||
|---|---|---|---|
| Abemaciclib | M2 | M20 | |
| Abemaciclib + NSAI | 23.0 | 21.6 | 26.0 |
Difference between post baseline scores and baseline score of role function-physical scale on SF-36 Health Survey (scale range between 0 and 100 with higher score indicating better quality of life). (NCT00754845)
Timeframe: 8 years
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Letrozole | -7.74 |
| Placebo | -6.28 |
It is defined as the months from the day of randomization to the earliest date when a recurrence of the primary disease (recurrence in the breast, chest wall and nodal sites or the development of metastatic disease) or a contralateral breast cancer was observed. Subjects who died without recurrence of the primary disease or the development of the contralateral breast cancer were censored at their death date. If a patient has not recurred, developed a contralateral breast cancer, or died, disease-free survival was censored on the date of the last day the patient was known to be alive. Probability of disease free survival at 5 years is estimated and reported. (NCT00754845)
Timeframe: Unitil the end of study with a median follow up of 75 months
| Intervention | probability of DFS at 5 years (Number) |
|---|---|
| Letrozole | 0.95 |
| Placebo | 0.91 |
The annual incidence rate was estimated based on the time to the development of contralateral breast cancer, which was calculated in months from the day of randomization to the diagnosis date of contralateral breast cancer for subjects who had developed the contralateral breast cancer, to the time of death for the patient who died, or to the last day the patient was known alive for subjects without contralateral breast cancer (NCT00754845)
Timeframe: 10 years
| Intervention | Number of new case per 1000 person years (Number) |
|---|---|
| Letrozole | 2.1 |
| Placebo | 4.9 |
For subjects who died, overall survival was calculated in months from the day of randomization to the date of death. Otherwise, survival was censored at the last day the patient was known to be alive. Probability of overall survival at 5 years is estimated and reported. (NCT00754845)
Timeframe: Until the end of study with a median follow-up of 75 months
| Intervention | probability of OS at 5 years (Number) |
|---|---|
| Arm I | 0.93 |
| Arm II | 0.94 |
Overall response rate (ORR) is defined as the proportion of patients with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. (NCT01958021)
Timeframe: Up to approximately 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| LEE011 + Letrozole | 40.7 |
| Placebo + Letrozole | 27.5 |
PFS, defined as the time from the date of randomization to the date of the first documented progression or death due to any cause. PFS was assessed via a local radiology assessment according to RECIST 1.1 (NCT01958021)
Timeframe: Up to approximately 20 months
| Intervention | months (Median) |
|---|---|
| LEE011 + Letrozole | NA |
| Placebo + Letrozole | 14.7 |
"Clinical benefit rate (CBR) is defined as the percentage of participants with a best overall response of complete response (CR), or partial response (PR) or an overall lesion response of stable disease (SD), lasting as per local review, for a duration of at least 24 weeks. CR, PR and SD are defined according to RECIST 1.1 based on investigator's assessment.~CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.~SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease.~95% CI was calculated using the exact binomial method." (NCT02941926)
Timeframe: Up to approximately 33 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ribociclib + Letrozole + Goserelin/Leuprolide | 70.7 |
"Overall response rate (ORR) is defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 based on investigator's assessment.~CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.~95% CI was calculated using the exact binomial method." (NCT02941926)
Timeframe: Up to approximately 33 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ribociclib + Letrozole + Goserelin/Leuprolide | 29.3 |
"Time to progression (TTP) is defined as time from date of start of treatment to the date of first documented progression or death due to underlying cancer. Participants with symptoms of rapidly progressing disease without radiologic evidence were classified as progression only when clear evidence of clinical deterioration was documented and/or patient discontinued due to 'Disease progression' or death due to study indication. When there was no documentation of radiologic evidence of progression, and the patient discontinued for 'Disease progression' due to documented clinical deterioration of disease, the date of discontinuation was used as date of progression.~TTP was estimated using the Kaplan-Meier method. 95% CI of median was calculated according to Brookmeyer and Crowley method." (NCT02941926)
Timeframe: Up to approximately 33 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Letrozole + Goserelin/Leuprolide | 27.1 |
"On-treatment- Core phase: from first treatment in the Core phase up to 30 days post-treatment (for participants who did not enter the Extension phase) or up to last treatment in the Core phase (for participants who entered the Extension phase). Extension phase: from first dose of treatment in the Extension phase up to 30 days after last dose of treatment.~Post-treatment survival follow-up- Core phase: from 31 days post-treatment in the core phase up to end of study; Extension phase: from 31 days post-treatment in the Extension phase up to end of study." (NCT02941926)
Timeframe: On-treatment Core Phase: up to 33 months; Post-treatment survival Follow-up Core Phase: Up to 33 months; On-treatment Extension Phase: up to approximately 37.6 months; Post-treatment survival Follow-up Extension Phase: Up to approximately 37.6 months.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| On-treatment Core Phase | Post-treatment survival follow-up Core Phase | All deaths Core Phase | On-treatment Extension Phase | Post-treatment survival follow-up Extension Phase | All deaths Extension Phase | |
| Ribociclib + Letrozole + Goserelin/Leuprolide | 74 | 90 | 164 | 5 | 3 | 8 |
Exploratory analysis performed in archival tumor samples collected during screening in the main study. Protein expression levels of the ribociclib plus letrozole cohort that did not achieve clinical benefit (progression within 3 months of treatment) and the cohort sensitive to ribociclib and letrozole (cohort with a time to progression of 22 months or more) were determined using using Single-Pot, Solid-Phase-enhanced, Sample Preparation-Clinical Tissue Proteomics (SP3-CTP). For normalization purposes a pooled internal standard sample, comprised of aliquots of every sample included in the study, was included in each experimental batch. Protein abundances were calculated as the log2 transformed abundances relative to the pooled internal standard. Positive values represent higher protein expression levels compared to the pooled internal standard. Expression levels of proteins that showed association to predicting response to study treatment are presented. (NCT02941926)
Timeframe: Screening (up to 28 days before first dose of study treatment)
| Intervention | log2 transformed relative ratio (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) | Retinal dehydrogenase 1 (ALDH1A1) | Coagulation factor XIII A chain (F13A1) | Argininosuccinate synthase (ASS1) | Heat shock protein beta-1 (HSPB1) | Aldehyde dehydrogenase, mitochondrial (ALDH2) | Decorin (DCN) | Cathepsin G (CTSG) | Pyruvate carboxylase, mitochondrial (PC) | C-1-tetrahydrofolate synthase, cytoplasmic (MTHFD1) | Collagen alpha-3(VI) chain (COL6A3) | Versican core protein (VCAN) | Fibulin-1 (FBLN1) | Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) | Long-chain-fatty-acid--CoA ligase 1 (ACSL1) | Pigment epithelium-derived factor (SERPINF1) | 3-ketoacyl-CoA thiolase, mitochondrial (ACAA2) | Fatty acid synthase (FASN) | Lumican (LUM) | Fibulin-2 (FBLN2) | Prolow-density lipoprotein receptor-related protein 1 (LRP1) | Galectin-3-binding protein (LGALS3BP) | Inactive tyrosine-protein kinase 7 (PTK7) | Ras GTPase-activating-like protein IQGAP2 (IQGAP2) | Spectrin alpha chain, non-erythrocytic 1 (SPTAN1) | Periostin (POSTN) | Procollagen C-endopeptidase enhancer 1 (PCOLCE) | CD109 antigen (CD109) | Palladin (PALLD) | Collagen triple helix repeat-containing protein 1 (CTHRC1) | Collagen alpha-1(XII) chain (COL12A1) | Matrix-remodeling-associated protein 5 (MXRA5) | C-type mannose receptor 2 (MRC2) | |
| Primary Resistance Cohort | 0.112 | 0.022 | -0.378 | 0.104 | -0.546 | 0.319 | -0.456 | -0.634 | 0.413 | 0.033 | -0.186 | -0.301 | -0.245 | 0.135 | 0.296 | -0.378 | 0.258 | -0.198 | -0.355 | -0.208 | -0.148 | -0.491 | -0.251 | 0.318 | 0.085 | -0.419 | -0.217 | -0.213 | -0.207 | -0.514 | -0.302 | -0.221 | -0.201 |
| Sensitive Cohort | -0.218 | -0.325 | -0.010 | -0.466 | -0.151 | -0.077 | -0.033 | -0.175 | -0.004 | -0.129 | -0.015 | 0.141 | 0.128 | -0.074 | -0.144 | 0.169 | -0.080 | 0.038 | 0.010 | 0.075 | 0.094 | -0.126 | 0.070 | -0.036 | -0.082 | 0.051 | 0.184 | 0.043 | 0.050 | 0.176 | 0.230 | 0.205 | 0.170 |
"Change from baseline in FACT-B scores was assessed. FACT-B is a self-report instrument that measures multidimensional quality of life (QOL) in patients with breast cancer. The FACT-B consists of 37 questions that address physical, social, emotional, and functional well-being, with specific questions relevant to women with breast cancer. Each item has a score range of 0 (Not at all) to 4 (Very much), with a total score ranging from 0-148. The higher the score, the better the QOL reported by the participant. A positive change from baseline indicates improvement in QoL.~Due to the nature of the questionnaire, only females were asked to complete this questionnaire." (NCT02941926)
Timeframe: On Day 1 of Cycle 1, 2, 3, 4 ,5, 6, 8, 10, 12 and after that every 3 cycles, and End of treatment, assessed up to 33 months. Cycle=28 days
| Intervention | Score on a scale (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 8 Day 1 | Cycle 10 Day 1 | Cycle 12 Day 1 | Cycle 15 Day 1 | Cycle 18 Day 1 | Cycle 21 Day 1 | Cycle 24 Day 1 | Cycle 27 Day 1 | Cycle 30 Day 1 | Cycle 33 Day 1 | End of Treatment | |
| Ribociclib + Letrozole + Goserelin/Leuprolide | 0.2 | 0.1 | -0.3 | 0.0 | -0.8 | -0.9 | -1.2 | -1.6 | -2.0 | -2.0 | -2.0 | -3.0 | -2.7 | -2.0 | 12.1 | -4.1 |
"AEs were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s).~SAEs were defined as meeting at least 1 of the following criteria: is fatal or life-threatening, Results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, is medically significant, requires inpatient hospitalization or prolongation of existing hospitalization. A SAE which caused death of the participant was considered as fatal SAE.~AEs were assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 to 5 were used to characterize the severity of the Adverse Event. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening and Grade 5: death related to AE.~A participant with multiple severity grades for an AE is only counted under the maximum grade." (NCT02941926)
Timeframe: From start of treatment up to 30 days after last treatment (for participants who did not enter to the Extension phase) or up to last treatment in the Core phase (for participants who entered the Extension phase), assessed up to approximately 33 months.
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs- All grades | AEs- Grade ≥ 3 | Treatment-related AEs- All grades | Treatment-related AEs- Grade ≥ 3 | SAEs- All grades | SAEs- Grade ≥ 3 | Treatment-related SAEs- All grades | Treatment-related SAEs- Grade ≥ 3 | Fatal SAEs- All grades | Treatment-related Fatal SAEs- All grades | AEs leading to discontinuation- All grades | AEs leading to discontinuation- Grade ≥ 3 | Treatment-related AEs leading to discontinuation- All grades | Treatment-related AEs leading to discontinuation-Grade ≥ 3 | AEs leading to dose adjustment/interruption- All grades | AEs leading to dose adjustment/interruption- Grade ≥ 3 | Treatment-related AEs leading to dose adjustment/interruption- All grades | Treatment-related AEs leading to dose adjustment/interruption- Grade ≥ 3 | AEs requiring additional therapy- All grades | AEs requiring additional therapy- Grade ≥ 3 | Treatment-related AEs requiring additional therapy- All grades | Treatment-related AEs requiring additional therapy- Grade ≥ 3 | |
| Ribociclib + Letrozole + Goserelin/Leuprolide | 3203 | 2461 | 3091 | 2192 | 702 | 590 | 203 | 178 | 62 | 14 | 528 | 310 | 418 | 237 | 2434 | 2095 | 2235 | 1964 | 2624 | 844 | 1613 | 392 |
"AEs were defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s).~SAEs were defined as meeting at least 1 of the following criteria: is fatal or life-threatening, Results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, is medically significant, requires inpatient hospitalization or prolongation of existing hospitalization.~AEs were assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 to 5 were used to characterize the severity of the Adverse Event. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening and Grade 5: death related to AE.~A participant with multiple severity grades for an AE is only counted under the maximum grade." (NCT02941926)
Timeframe: From first dose of treatment in the Extension phase up to 30 days after last dose of treatment, assessed up approximately 37.6 months
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AEs- All grades | AEs- Grade ≥ 3 | Treatment-related AEs- All grades | Treatment-related AEs- Grade ≥ 3 | SAEs- All grades | SAEs- Grade ≥ 3 | Treatment-related SAEs- All grades | Treatment-related SAEs- Grade ≥ 3 | Fatal SAEs- All grades | Treatment-related Fatal SAEs- All grades | AEs leading to discontinuation- All grades | AEs leading to discontinuation- Grade ≥ 3 | Treatment-related AEs leading to discontinuation- All grades | Treatment-related AEs leading to discontinuation-Grade ≥ 3 | AEs leading to dose adjustment/interruption- All grades | AEs leading to dose adjustment/interruption- Grade ≥ 3 | Treatment-related AEs leading to dose adjustment/interruption- All grades | Treatment-related AEs leading to dose adjustment/interruption- Grade ≥ 3 | AEs requiring additional therapy- All grades | AEs requiring additional therapy- Grade ≥ 3 | Treatment-related AEs requiring additional therapy- All grades | Treatment-related AEs requiring additional therapy- Grade ≥ 3 | |
| Ribociclib + Letrozole + Goserelin/Leuprolide | 297 | 159 | 221 | 123 | 54 | 45 | 7 | 6 | 5 | 0 | 17 | 9 | 7 | 4 | 185 | 132 | 134 | 113 | 186 | 56 | 47 | 12 |
Clinical benefit as assessed by the Investigator during Extension phase (NCT02941926)
Timeframe: On Day 1 of every 3 cycles, starting from Cycle 1 of the Extension phase until end of treatment, assessed up to 37.4 months. Cycle= 28 days
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | Cycle 4 Day 1 | Cycle 7 Day 1 | Cycle 10 Day 1 | Cycle 13 Day 1 | Cycle 16 Day 1 | Cycle 19 Day 1 | Cycle 22 Day 1 | Cycle 25 Day 1 | Cycle 28 Day 1 | Cycle 31 Day 1 | Cycle 34 Day 1 | Cycle 37 Day 1 | Cycle 40 Day 1 | |
| Ribociclib + Letrozole + Goserelin/Leuprolide | 413 | 386 | 353 | 323 | 245 | 200 | 183 | 118 | 55 | 51 | 44 | 32 | 24 | 5 |
DOR was defined as the time from the first documentation of objective tumor response (complete response [CR] or partial response [PR]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on BICR. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Letrozole | 30.3 |
| Placebo + Letrozole | 24.9 |
DOR was defined as the time from the first documentation of objective tumor response (complete response [CR] or partial response [PR]) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. DOR data was censored on the date of the last tumor assessment on study for participants who did not have objective tumor progression and who did not die due to any cause while on study. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, DOR was based on investigator assessment. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Letrozole | 22.4 |
| Placebo + Letrozole | 19.4 |
Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of Ki67 associated with sensitivity and/or resistance to Palbociclib. (NCT02297438)
Timeframe: Baseline
| Intervention | Percentage of Ki67 positive cells (Median) |
|---|---|
| Palbociclib + Letrozole | 30.0 |
| Placebo + Letrozole | 27.5 |
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was assessed using Kaplan-Meier methods. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Letrozole | 51.7 |
| Placebo + Letrozole | 51.5 |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 37.3 |
| Placebo + Letrozole | 31.6 |
DC/CBR was defined as CR, PR, or stable disease (SD) >=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 76.9 |
| Placebo + Letrozole | 73.1 |
DC/CBR was defined as CR, PR, or stable disease (SD) >=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on BICR. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 78.1 |
| Placebo + Letrozole | 71.8 |
DC/CBR was defined as CR, PR, or stable disease (SD) >=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as >=30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 79.3 |
| Placebo + Letrozole | 80.1 |
DC/CBR was defined as CR, PR, or stable disease (SD) >=24 weeks according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) recorded in the time period between randomization and disease progression or death to any cause. CR was defined as complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. SD was defined as not qualifying for CR, PR, PD. PD is defined using RECIST v1.1 as a 20% increase in the sum of of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 mm. In this outcome measure, DC/CBR was based on investigator assessment. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 77.9 |
| Placebo + Letrozole | 79.6 |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 40.2 |
| Placebo + Letrozole | 33.9 |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on BICR. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 52.3 |
| Placebo + Letrozole | 43.5 |
OR was defined as a complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 recorded from randomization until disease progression or death due to any cause. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). No new lesions. The PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No new lesions. In this outcome measure, OR was based on investigator assessment. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Letrozole | 43.4 |
| Placebo + Letrozole | 38.0 |
PFS was based on Kaplan-Meier estimates. PFS was defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause in the absence of documented progressive disease, whichever occurs first. In this outcome measure, PFS was based on BICR. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Letrozole | 21.6 |
| Placebo + Letrozole | 16.4 |
PFS was based on Kaplan-Meier estimates. PFS was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm. In this outcome measure, PFS was based on investigator's assessment. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Letrozole | 21.5 |
| Placebo + Letrozole | 13.9 |
OS was defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. The 1-year survival probability was estimated using the Kaplan-Meier method and a 2-sided 95% confidence interval (CI) for the log [-log(1 year survival probability)] was be calculated using a normal approximation, and then back transformed to give a CI for the 1-year survival probability itself. The 2-year, and 3-year survival probabilities were estimated similarly. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| 1-year survival probability | 2-year survival probability | 3-year survival probability | |
| Palbociclib + Letrozole | 92.8 | 80.3 | 67.1 |
| Placebo + Letrozole | 90.5 | 78.0 | 60.6 |
The EQ VAS recorded the participant's self rated questionnaire to assess generic health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). Published weights were available that allow for the creation of a single summary score. (NCT02297438)
Timeframe: Baseline up to Cycle 65 Day 1
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 5 Day 1 | Cycle 7 Day 1 | Cycle 9 Day 1 | Cycle 11 Day 1 | Cycle 13 Day 1 | Cycle 15 Day 1 | Cycle 17 Day 1 | Cycle 19 Day 1 | Cycle 21 Day 1 | Cycle 23 Day 1 | Cycle 25 Day 1 | Cycle 27 Day 1 | Cycle 29 Day 1 | Cycle 31 Day 1 | Cycle 33 Day 1 | Cycle 35 Day 1 | Cycle 37 Day 1 | Cycle 39 Day 1 | Cycle 41 Day 1 | Cycle 43 Day 1 | Cycle 45 Day 1 | Cycle 47 Day 1 | Cycle 49 Day 1 | Cycle 51 Day 1 | Cycle 53 Day 1 | Cycle 55 Day 1 | Cycle 57 Day 1 | Cycle 59 Day 1 | Cycle 61 Day 1 | Cycle 63 Day 1 | Cycle 65 Day 1 | |
| Palbociclib + Letrozole | 3.047 | 3.125 | 3.279 | 3.434 | 3.589 | 3.743 | 3.898 | 4.052 | 4.207 | 4.362 | 4.516 | 4.671 | 4.826 | 4.980 | 5.135 | 5.289 | 5.444 | 5.599 | 5.753 | 5.908 | 6.063 | 6.217 | 6.372 | 6.526 | 6.681 | 6.836 | 6.990 | 7.145 | 7.300 | 7.454 | 7.609 | 7.763 | 7.918 |
| Placebo + Letrozole | 1.861 | 1.815 | 1.724 | 1.634 | 1.543 | 1.452 | 1.361 | 1.271 | 1.180 | 1.089 | 0.998 | 0.908 | 0.817 | 0.726 | 0.635 | 0.545 | 0.454 | 0.363 | 0.272 | 0.182 | 0.091 | 0.000 | -0.091 | -0.181 | -0.272 | -0.363 | -0.454 | -0.544 | -0.635 | -0.726 | -0.817 | -0.907 | -0.998 |
The EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/depression); a participant was asked to rate each state on a 3 level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/impairment. (NCT02297438)
Timeframe: Baseline up to Cycle 65 Day 1
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 5 Day 1 | Cycle 7 Day 1 | Cycle 9 Day 1 | Cycle 11 Day 1 | Cycle 13 Day 1 | Cycle 15 Day 1 | Cycle 17 Day 1 | Cycle 19 Day 1 | Cycle 21 Day 1 | Cycle 23 Day 1 | Cycle 25 Day 1 | Cycle 27 Day 1 | Cycle 29 Day 1 | Cycle 31 Day 1 | Cycle 33 Day 1 | Cycle 35 Day 1 | Cycle 37 Day 1 | Cycle 39 Day 1 | Cycle 41 Day 1 | Cycle 43 Day 1 | Cycle 45 Day 1 | Cycle 47 Day 1 | Cycle 49 Day 1 | Cycle 51 Day 1 | Cycle 53 Day 1 | Cycle 55 Day 1 | Cycle 57 Day 1 | Cycle 59 Day 1 | Cycle 61 Day 1 | Cycle 63 Day 1 | Cycle 65 Day 1 | |
| Palbociclib + Letrozole | 0.013 | 0.012 | 0.010 | 0.008 | 0.006 | 0.004 | 0.02 | 0.000 | -0.002 | -0.004 | -0.006 | -0.008 | -0.010 | -0.012 | -0.014 | -0.016 | -0.018 | -0.020 | -0.022 | -0.024 | -0.027 | -0.029 | -0.031 | -0.033 | -0.035 | -0.037 | -0.039 | -0.041 | -0.043 | -0.045 | -0.047 | -0.049 | -0.051 |
| Placebo + Letrozole | 0.014 | 0.011 | 0.005 | 0.000 | -0.006 | -0.012 | -0.017 | -0.023 | -0.029 | -0.034 | -0.040 | -0.045 | -0.051 | -0.057 | -0.062 | -0.068 | -0.074 | -0.079 | -0.085 | -0.090 | -0.096 | -0.102 | -0.107 | -0.113 | -0.119 | -0.124 | -0.130 | -0.136 | -0.141 | -0.147 | -0.152 | -0.158 | -0.164 |
"The Functional Assessment of Cancer Therapy (FACT) is a modular approach to assess participant health related quality of life using a core set of questions (FACT-G) as well as a cancer site specific module. The FACT-G was a 27-item compilation of general questions divided into 4 domains: Physical Well Being, Social/Family Well Being, Emotional Well Being, and Functional Well Being. The FACT-B consists of the FACT-G (27 items) and a breast specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a 5-level scale ranging from 0=Not at all to 4=Very much. FACT-B total score = FACT-G + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-148, with 0 being the worst possible score and 148 the best. A positive change of the total score indicated improvement from baseline and a negative change indicated deterioration." (NCT02297438)
Timeframe: Baseline up to Cycle 65 Day 1
| Intervention | Units on a scale (Mean) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 5 Day 1 | Cycle 7 Day 1 | Cycle 9 Day 1 | Cycle 11 Day 1 | Cycle 13 Day 1 | Cycle 15 Day 1 | Cycle 17 Day 1 | Cycle 19 Day 1 | Cycle 21 Day 1 | Cycle 23 Day 1 | Cycle 25 Day 1 | Cycle 27 Day 1 | Cycle 29 Day 1 | Cycle 31 Day 1 | Cycle 33 Day 1 | Cycle 35 Day 1 | Cycle 37 Day 1 | Cycle 39 Day 1 | Cycle 41 Day 1 | Cycle 43 Day 1 | Cycle 45 Day 1 | Cycle 47 Day 1 | Cycle 49 Day 1 | Cycle 51 Day 1 | Cycle 53 Day 1 | Cycle 55 Day 1 | Cycle 57 Day 1 | Cycle 59 Day 1 | Cycle 61 Day 1 | Cycle 63 Day 1 | Cycle 65 Day 1 | |
| Palbociclib + Letrozole | 1.618 | 1.441 | 1.087 | 0.732 | 0.378 | 0.024 | -0.331 | -0.685 | -1.039 | -1.393 | -1.748 | -2.102 | -2.456 | -2.810 | -3.165 | -3.519 | -3.873 | -4.227 | -4.582 | -4.936 | -5.290 | -5.644 | -5.999 | -6.353 | -6.707 | -7.061 | -7.416 | -7.770 | -8.124 | -8.478 | -8.833 | -9.187 | -9.541 |
| Placebo + Letrozole | 1.021 | 0.850 | 0.510 | 0.169 | -0.171 | -0.512 | -0.852 | -1.193 | -1.534 | -1.874 | -2.215 | -2.555 | -2.896 | -3.326 | -3.577 | -3.918 | -4.258 | -4.599 | -4.939 | -5.280 | -5.620 | -5.961 | -6.301 | -6.642 | -6.983 | -7.323 | -7.664 | -8.004 | -8.345 | -8.685 | -9.026 | -9.367 | -9.707 |
Archived formalin-fixed paraffin embedded (FFPE) specimen from the original diagnostic tumor tissue was collected and sent to the sponsor-designated central laboratories for assessment of ER associated with sensitivity and/or resistance to Palbociclib. (NCT02297438)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Positive | Negative | Unknown | |
| Palbociclib + Letrozole | 152 | 2 | 14 |
| Placebo + Letrozole | 162 | 1 | 8 |
The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following hematology parameters had met the criteria of CTCAE grade shift change from Grade <=2 at baseline to Grade 3 or 4 post baseline: neutrophils (absolute), white blood cells, platelets, anemia and hemoglobin increased. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Neutrophils (absolute) | White blood cells | Platelets | Anemia | Hemoglobin increased | |
| Palbociclib + Letrozole | 143 | 77 | 13 | 10 | 3 |
| Placebo + Letrozole | 2 | 1 | 1 | 3 | 0 |
The laboratory results were graded according to the National Cancer Institute (NCI) CTCAE v4.0 severity grade. Shift tables were provided to examine the distribution of laboratory toxicities. The following chemistry parameters had met the criteria of CTCAE grade shift change from Grade <=2 at baseline to Grade 3 or 4 post baseline: alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, and hyponatremia. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT | Alkaline phosphatase | AST | Bilirubin (total) | Creatinine | Hypercalcemia | Hyperglycemia | Hyperkalemia | Hypermagnesemia | Hypernatremia | Hypoalbuminemia | Hypocalcemia | Hypoglycemia | Hypokalemia | Hypomagnesemia | Hyponatremia | |
| Palbociclib + Letrozole | 9 | 0 | 9 | 2 | 1 | 1 | 1 | 1 | 10 | 2 | 0 | 1 | 0 | 3 | 3 | 11 |
| Placebo + Letrozole | 1 | 2 | 6 | 2 | 0 | 2 | 1 | 0 | 8 | 1 | 0 | 1 | 1 | 6 | 1 | 2 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Participants were counted only once per treatment in each row. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | Participants discontinued study due to AEs | Participants discontinued Palbociclib/Placebo or Letrozole due to AEs | Participants discontinued Palbociclib/Placebo due to AEs | Participants discontinued Letrozole due to AEs | Participants temporarily discontinued Palbociclib/Placebo due to AEs | Participants temporarily discontinued Letrozole due to AEs | Participants with dose reduction of Palbociclib/Placebo due to AEs | Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs | |
| Palbociclib + Letrozole | 168 | 26 | 152 | 4 | 13 | 11 | 11 | 10 | 136 | 11 | 16 | 38 |
| Placebo + Letrozole | 155 | 16 | 38 | 2 | 5 | 4 | 4 | 3 | 17 | 9 | 2 | 2 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to treatment was assessed by the investigator (Yes/No). Participants were counted only once per treatment in each row. (NCT02297438)
Timeframe: Randomization up to 65 months
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | Participants discontinued study due to AEs | Participants discontinued Palbociclib/Placebo or Letrozole due to AEs | Participants discontinued due to AEs related to Palbociclib/Placebo | Participants discontinued due to AEs related to Letrozole | Participants temporarily discontinued Palbociclib/Placebo due to AEs | Participants temporarily discontinued Letrozole due to AEs | Participants with dose reduction of Palbociclib/Placebo due to AEs | Participants with dose reduction and temporary discontinuations of Palbociclib/Placebo due to AEs | |
| Palbociclib + Letrozole | 167 | 8 | 149 | 1 | 6 | 5 | 5 | 1 | 132 | 7 | 15 | 37 |
| Placebo + Letrozole | 123 | 3 | 18 | 0 | 2 | 2 | 2 | 0 | 11 | 5 | 2 | 2 |
Summary of palbociclib trough concentrations (NCT02297438)
Timeframe: Pre-dose on Day 14 of Cycle 1 and Cycle 2
| Intervention | ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Cycle 1 | Cycle 2 | Average trough concentration | |
| Palbociclib + Letrozole | 81.1 | 77.4 | 80.2 |
(NCT02273973)
Timeframe: From Baseline to Surgery (Weeks 17-18)
| Intervention | percent change (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | -70.60 |
| Placebo Comparator: Placebo + Letrozole | -57.28 |
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. (NCT02273973)
Timeframe: Baseline up to 22 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 91.0 |
| Placebo Comparator: Placebo + Letrozole | 83.2 |
Objective response rate (ORR) was defined as proportion of participants achieving complete response (CR) or partial response (PR). As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 50.0 |
| Placebo Comparator: Placebo + Letrozole | 39.3 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 61.6 |
| Placebo Comparator: Placebo + Letrozole | 40.5 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 54.3 |
| Placebo Comparator: Placebo + Letrozole | 51.7 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 56.2 |
| Placebo Comparator: Placebo + Letrozole | 38.0 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 45.7 |
| Placebo Comparator: Placebo + Letrozole | 40.4 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 74.0 |
| Placebo Comparator: Placebo + Letrozole | 63.3 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 62.0 |
| Placebo Comparator: Placebo + Letrozole | 59.6 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 41.1 |
| Placebo Comparator: Placebo + Letrozole | 31.6 |
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 40.2 |
| Placebo Comparator: Placebo + Letrozole | 32.6 |
Total pCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( i.e., ypT0/Tis, ypN0 in the AJCC staging system, 7th edition). (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 1.8 |
| Placebo Comparator: Placebo + Letrozole | 0.6 |
Total pCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes (i.e., ypT0/Tis, ypN0 in the AJCC staging system, 7th edition). (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 1.4 |
| Placebo Comparator: Placebo + Letrozole | 0 |
Total pCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes (i.e., ypT0/Tis, ypN0 in the AJCC staging system, 7th edition). (NCT02273973)
Timeframe: From Baseline to 16 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Experimental: Taselisib + Letrozole | 2.2 |
| Placebo Comparator: Placebo + Letrozole | 1.1 |
Ki67 is a prognostic marker and is used to evaluate the proliferative activity of breast cancer. (NCT02273973)
Timeframe: From Baseline to Week 3 and Surgery (Weeks 17-18); and Week 3 to Surgery (Weeks 17-18)
| Intervention | percentage (Number) | |
|---|---|---|
| From Baseline to Week 3 | From Baseline to Surgery | |
| Experimental: Taselisib + Letrozole | -83.81 | -75.58 |
| Placebo Comparator: Placebo + Letrozole | -80.44 | -80.51 |
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. The first 28 questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting [N/V], constipation, and pain) and a single item (financial difficulties). The last 2 questions represented the participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement. Here, Post surgery= PS. (NCT02273973)
Timeframe: Weeks 1, 5, 9, 13, 16, 4-week Post-Surgery
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appetite Loss: Baseline | Appetite Loss: Change at Week 5 | Appetite Loss: Change at Week 9 | Appetite Loss: Change at Week 13 | Appetite Loss: Change at Week 16 | Appetite Loss: Change at PS Visit | Cognitive functioning: Baseline | Cognitive functioning: Change at Week 5 | Cognitive functioning: Change at Week 9 | Cognitive functioning: Change at Week 13 | Cognitive functioning: Change at Week 16 | Cognitive functioning: Change at PS Visit | Constipation: Baseline | Constipation: Change at Week 5 | Constipation: Change at Week 9 | Constipation: Change at Week 13 | Constipation: Change at Week 16 | Constipation: Change at PS Visit | Diarrhoea: Baseline | Diarrhoea: Change at Week 5 | Diarrhoea: Change at Week 9 | Diarrhoea: Change at Week 13 | Diarrhoea: Change at Week 16 | Diarrhoea: Change at PS Visit | Dyspnoea: Baseline | Dyspnoea: Change at Week 5 | Dyspnoea: Change at Week 9 | Dyspnoea: Change at Week 13 | Dyspnoea: Change at Week 16 | Dyspnoea: Change at PS Visit | Emotional functioning: Baseline | Emotional functioning: Change at Week 5 | Emotional functioning: Change at Week 9 | Emotional functioning: Change at Week 13 | Emotional functioning: Change at Week 16 | Emotional functioning: Change at PS Visit | Fatigue: Baseline | Fatigue: Change at Week 5 | Fatigue: Change at Week 9 | Fatigue: Change at Week 13 | Fatigue: Change at Week 16 | Fatigue: Change at PS Visit | Financial difficulties: Baseline | Financial difficulties: Change at Week 5 | Financial difficulties: Change at Week 9 | Financial difficulties: Change at Week 13 | Financial difficulties: Change at Week 16 | Financial difficulties: Change at PS Visit | Global health status / QoL: Baseline | Global health status / QoL: Change at Week 5 | Global health status / QoL: Change at Week 9 | Global health status / QoL: Change at Week 13 | Global health status / QoL: Change at Week 16 | Global health status / QoL: Change at PS Visit | Insomnia: Baseline | Insomnia: Change at Week 5 | Insomnia: Change at Week 9 | Insomnia: Change at Week 13 | Insomnia: Change at Week 16 | Insomnia: Change at PS Visit | Nausea and vomiting: Baseline | Nausea and vomiting: Change at Week 5 | Nausea and vomiting: Change at Week 9 | Nausea and vomiting: Change at Week 13 | Nausea and vomiting: Change at Week 16 | Nausea and vomiting: Change at PS Visit | Pain: Baseline | Pain: Change at Week 5 | Pain: Change at Week 9 | Pain: Change at Week 13 | Pain: Change at Week 16 | Pain: Change at PS Visit | Physical functioning: Baseline | Physical functioning: Change at Week 5 | Physical functioning: Change at Week 9 | Physical functioning: Change at Week 13 | Physical functioning: Change at Week 16 | Physical functioning: Change at PS Visit | Role functioning: Baseline | Role functioning:Change at Week 5 | Role functioning:Change at Week 9 | Role functioning:Change at Week 13 | Role functioning:Change at Week 16 | Role functioning:Change at PS Visit | Social functioning: Baseline | Social functioning: Change at Week 5 | Social functioning: Change at Week 9 | Social functioning: Change at Week 13 | Social functioning: Change at Week 16 | Social functioning: Change at PS Visit | |
| Experimental: Taselisib + Letrozole | 6.2 | 3.0 | 5.3 | 5.5 | 6.8 | 5.0 | 90.8 | 0.4 | -1.1 | -3.4 | -4.2 | -3.1 | 6.8 | 0.0 | 0.2 | -0.4 | -1.1 | 4.8 | 5.9 | 6.7 | 6.4 | 7.9 | 8.4 | 0.2 | 7.4 | -0.2 | 2.0 | 3.5 | 3.4 | 3.1 | 77.0 | 4.2 | 3.8 | 2.5 | 1.0 | -0.8 | 14.8 | 4.7 | 5.0 | 7.9 | 6.8 | 12.3 | 9.0 | -2.6 | -2.6 | -1.1 | -1.1 | 1.9 | 75.3 | 1.5 | -1.1 | -2.4 | -2.2 | -5.9 | 23.0 | -2.4 | -1.8 | -1.1 | -0.7 | -1.4 | 1.9 | 3.7 | 3.4 | 3.7 | 2.5 | 2.1 | 13.1 | -0.6 | -1.8 | -1.4 | -0.9 | 11.1 | 89.6 | 0.5 | 0.2 | -0.3 | -0.5 | -5.2 | 90.7 | 1.3 | -0.2 | -2.3 | -4.6 | -15.1 | 91.2 | 3.1 | 2.0 | 0.0 | -0.5 | -6.4 |
| Placebo Comparator: Placebo + Letrozole | 5.9 | 1.9 | 3.0 | 2.1 | 0.9 | 5.0 | 90.9 | -2.5 | -4.2 | -5.1 | -4.1 | -5.4 | 8.3 | 3.1 | 0.2 | -0.6 | 1.6 | 1.1 | 4.3 | -0.2 | 0.8 | -0.4 | 0.2 | -0.9 | 8.5 | 0.6 | 1.9 | 1.7 | 2.6 | 2.1 | 78.2 | 2.4 | 1.3 | -1.4 | -3.5 | -3.6 | 15.6 | 4.9 | 7.5 | 8.8 | 8.0 | 12.4 | 10.0 | -0.4 | 0.7 | 0.0 | 2.1 | 3.8 | 74.6 | -1.1 | -3.2 | -3.7 | -2.9 | -7.0 | 22.4 | -0.4 | -0.6 | 2.1 | -2.2 | 3.2 | 1.6 | 1.9 | 1.7 | 0.7 | 0.6 | 1.0 | 12.3 | 2.6 | 3.8 | 4.7 | 1.8 | 13.8 | 90.8 | -1.2 | -2.0 | -1.9 | -3.4 | -7.5 | 93.1 | -2.5 | -4.9 | -5.6 | -4.4 | -20.1 | 94.9 | -2.0 | -4.0 | -4.0 | -3.1 | -10.1 |
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective [FP]) and four symptom scales (systemic side effects [SE], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL. Here, Post surgery= PS. (NCT02273973)
Timeframe: Weeks 1, 5, 9, 13, 16, 4-week Post-Surgery
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Body image: Baseline | Body image: Change at Week 5 | Body image: Change at Week 9 | Body image: Change at Week 13 | Body image: Change at Week 16 | Body image: Change at PS Visit | Breast symptoms: Baseline | Breast symptoms: Change at Week 5 | Breast symptoms: Change at Week 9 | Breast symptoms: Change at Week 13 | Breast symptoms: Change at Week 16 | Breast symptoms: Change at PS Visit | Future perspective: Baseline | Future perspective: Change at Week 5 | Future perspective: Change at Week 9 | Future perspective: Change at Week 13 | Future perspective: Change at Week 16 | Future perspective: Change at PS Visit | Sexual enjoyment: Baseline | Sexual enjoyment: Change at Week 5 | Sexual enjoyment: Change at Week 9 | Sexual enjoyment: Change at Week 13 | Sexual enjoyment: Change at Week 16 | Sexual enjoyment: Change at PS Visit | Sexual functioning: Baseline | Sexual functioning: Change at Week 5 | Sexual functioning: Change at Week 9 | Sexual functioning: Change at Week 13 | Sexual functioning: Change at Week 16 | Sexual functioning: Change at PS Visit | Systematic therapy side effects: Baseline | Systematic therapy side effects: Change at Week 5 | Systematic therapy side effects: Change at Week 9 | Systematic therapy side effects: Change at Week 13 | Systematic therapy side effects: Change at Week 16 | Systematic therapy side effects:Change at PS Visit | Upset by hair loss: Baseline | Upset by hair loss: Change at Week 5 | Upset by hair loss: Change at Week 9 | Upset by hair loss: Change at Week 13 | Upset by hair loss: Change at Week 16 | Upset by hair loss: Change at PS Visit | |
| Experimental: Taselisib + Letrozole | 91.8 | 2.8 | 1.2 | 1.2 | 0.1 | -6.5 | 5.3 | 2.3 | 4.5 | 5.8 | 7.9 | 6.6 | 57.7 | 6.5 | 10.2 | 7.7 | 10.2 | 6.5 | 41.7 | 3.3 | 8.3 | 6.1 | 9.8 | 14.3 | 81.2 | 1.2 | 1.3 | 4.1 | 4.8 | 9.6 | 8.7 | 4.3 | 6.7 | 7.3 | 7.5 | 7.0 | 24.6 | 11.1 | 9.1 | 16.7 | 21.2 | 30.8 |
| Placebo Comparator: Placebo + Letrozole | 94.0 | 0.6 | -0.2 | -1.6 | -1.2 | -8.3 | 6.9 | 1.0 | 1.8 | 2.3 | 3.9 | 4.3 | 58.7 | 9.3 | 9.7 | 4.4 | 5.1 | 3.4 | 47.1 | 11.1 | 10.6 | 1.6 | 7.6 | 2.2 | 85.1 | 1.0 | 0.3 | 1.6 | 1.1 | 4.1 | 9.5 | 3.9 | 5.9 | 6.2 | 7.1 | 5.9 | 35.2 | -3.3 | -9.1 | -3.0 | -7.1 | -2.6 |
the safety and tolerability of an extended regimen of lapatinib + trastuzumab, with or without endocrine therapy (NCT00999804)
Timeframe: 12 week or 24 weeks depending on arm assignment
| Intervention | participants (Number) |
|---|---|
| 24-week Arm | 61 |
| 12-week Arm | 26 |
(NCT00999804)
Timeframe: 12 weeks or 24 weeks depending on arm assignment
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | Unknown | |
| 12-week Arm | 21 | 13 | 3 | 4 | 2 |
| 24-week Arm | 46 | 10 | 2 | 13 | 10 |
"Pathologic complete response was defined as no residual invasive cancer in the breast, after 12 or 24 weeks of lapatinib/trastuzumab with or without endocrine therapy.~This outcome is based on patient's pathological report. We are not measuring the clinical response.~Participants who have received at least one cycle of therapy (defined as one dose of trastuzumab and 21 days of lapatinib), and have had their response classified were evaluable." (NCT00999804)
Timeframe: 12 or 24 week depending the arm assignment
| Intervention | participants (Number) | |
|---|---|---|
| pathologic complete response | non-complete pathologic response | |
| 12-week Arm | 5 | 38 |
| 24-week Arm | 20 | 61 |
pathologic complete response was defined as no residual invasive cancer in the breast and the axillary lymph nodes. (NCT00999804)
Timeframe: 12 weeks or 24 weeks depending on arm assignment
| Intervention | participants (Number) | |
|---|---|---|
| total complete pathologic response | not total complete pathologic response | |
| 12-week Arm | 2 | 41 |
| 24-week Arm | 8 | 72 |
Change in maximum diameter at 6-months based on mammographic measurement (MD6) will be estimated using the methods in Primary Outcome #1, but using the mammographic measurements instead. (NCT01439711)
Timeframe: 6-months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -3.31 |
Mean total MRI FTV change from baseline to month 3 (V3): For patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. V3 was calculated by subtracting the total MRI FTV measured (i.e. the sum over all lesions present with MRI FTV measurements) at 3 months from the total MRI FTV measured at baseline. For V3 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests. (NCT01439711)
Timeframe: up to 3 months from start of treatment
| Intervention | cubic centimeters (Mean) |
|---|---|
| Letrozole + MRI | -1.93 |
Mean total MRI FTV change from baseline to month 6 (V6): For patients with more than one measureable lesion on the MRI, the sum over all measureable lesions on the MRI was calculated at each time point. V6 was calculated by subtracting the total MRI FTV measured at 6 months from the total MRI FTV measured at baseline. For V6 the raw change in the volume will be calculated for each patient and a mean and 95% confidence interval will be constructed using two-sided t-tests. (NCT01439711)
Timeframe: up to 6 months from start of treatment
| Intervention | cubic centimeters (Mean) |
|---|---|
| Letrozole + MRI | -1.82 |
To ascertain the change in maximum tumor diameter from baseline to 3 months (D3) the same methods as in Primary outcome #1 will be used but on diameter instead of volume. For patients with more than one lesion longest diameter measurement, the sum of all lesion longest diameter measurements was calculated. (NCT01439711)
Timeframe: 3-months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -10.3 |
Mean total MRI tumor diameter change from baseline to month 6: To ascertain the change in maximum tumor diameter from baseline to 6 months (D6) the same methods as in Primary Outcome #2 will be used but on diameter instead of volume. (NCT01439711)
Timeframe: 6 months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -16.66 |
To ascertain the change in maximum tumor diameter from baseline to 6 months (D6) the same methods as in Primary outcome #2 will be used but on diameter instead of volume. For patients with more than one lesion longest diameter measurement, the sum of all lesion longest diameter measurements was calculated. (NCT01439711)
Timeframe: 6 months
| Intervention | millimeters (Mean) |
|---|---|
| Letrozole + MRI | -16.66 |
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. The percentage of patients with a maximum grade 3 or higher adverse event at least possibly related to the study treatment are reported below. (NCT01439711)
Timeframe: Up to 6 months post surgery
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Allergic reaction | Cholesterol high | Gastrointestinal disorder | Hot flashes | |
| Letrozole + MRI | 31 | 7 | 2 | 1 |
Rate of Mastectomy will be estimated as the number of mastectomies divided by the number of surgeries. A 95% confidence interval will be constructed using exact binomial methods. Rate of Lumpectomy will be estimated as the number of lumpectomies divided by the number of surgeries. A 95% confidence interval will be constructed using exact binomial methods. (NCT01439711)
Timeframe: up to 6 months
| Intervention | percentage of surgeries (Number) | |
|---|---|---|
| Rate of Mastectomy | Rate of Lumpectomy | |
| Letrozole + MRI | 7 | 93 |
The EuroQol EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (1=no problem, 2=some problem, and 3=extreme problem). The scores on the 5 descriptors are summarized to create a single summary score. An overall utility score is calculated based on these domains, with a range score from 0 (worse health scenario) to a maximum of 1.0 (best health scenario). (NCT01740427)
Timeframe: From Baseline up to 2.5 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Palbociclib Plus Letrozole | 0.014 |
| Placebo Plus Letrozole | -0.010 |
FACT is a modular approach to assess participant health-related quality of life using a 'core' set of questions (FACT-G) as well as a cancer site-specific module. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. The FACT-B consisted of the FACT-G (27-item) and a breast-specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a five-level scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. FACT-B total score = Physical Well-Being + Social/Family Well-Being + Emotional Well-Being + Functional Well-Being + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-144, with 0 being the worst possible score and 144 the best. (NCT01740427)
Timeframe: From Baseline up to 2.5 years
| Intervention | Units on a scale (Mean) |
|---|---|
| Palbociclib Plus Letrozole | -0.106 |
| Placebo Plus Letrozole | 0.219 |
DC is defined as the overall CR, PR, or stable disease (SD) ≥24 weeks according to the RECIST version 1.1. Disease Control Rate (DCR) is defined as the patients with CR, PR, or SD ≥24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD≥24 weeks, or who died, progressed,or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD≥24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression (NCT01740427)
Timeframe: From randomization until end of treatment (up to approximately 2.5 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib Plus Letrozole | 85.8 |
| Placebo Plus Letrozole | 71.2 |
DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as [the date response ended (i.e. date of PD or death) - first CR or PR date + 1)]/30.4. DR would only be calculated for the subgroup of patients with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: ≥30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression. (NCT01740427)
Timeframe: From randomization until end of treatment (up to approximately 2.5 years)
| Intervention | Months (Median) |
|---|---|
| Palbociclib Plus Letrozole | 20.1 |
| Placebo Plus Letrozole | 16.7 |
Objective Response (OR) defined as the overall complete response (CR) or partial response (PR) according to the RECIST v1.1. Objective Response Rate (ORR) is defined as proportion of patients with CR or PR relative to all randomized patients with measurable disease at baseline. Patients who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression. (NCT01740427)
Timeframe: From randomization until end of treatment (up to approximately 2.5 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib Plus Letrozole | 46.4 |
| Placebo Plus Letrozole | 38.3 |
The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of patients with CR or PR relative to all randomized patients with measurable disease at baseline. Patients who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: ≥30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression. (NCT01740427)
Timeframe: From randomization until end of treatment (up to approximately 2.5 years)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib Plus Letrozole | 60.7 |
| Placebo Plus Letrozole | 49.1 |
OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive. (NCT01740427)
Timeframe: From date of randomization until death due to any cause or censored, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
| Intervention | Months (Median) |
|---|---|
| Palbociclib Plus Letrozole | 53.9 |
| Placebo Plus Letrozole | 51.2 |
PFS is defined as the time from the date of randomization to the date of the first documentation of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death due to any cause in the absence of documented PD, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date - randomization date +1)/30.4. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions, or the appearance of new lesions. (NCT01740427)
Timeframe: From randomization date to date of first documentation of progression OR death (up to approximately 2.5 years)
| Intervention | Months (Median) |
|---|---|
| Palbociclib Plus Letrozole | 24.8 |
| Placebo Plus Letrozole | 14.5 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Time-matched change from baseline values were reported for QTc analysis population. (NCT01740427)
Timeframe: Time-matched triplicate ECGs were collected at 0 (predose), 2, 4, 6 and 8 hours on Day 0 and on Cycle1 Day14
| Intervention | msec (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QTcS at 0 hour | QTcS at 2 hour | QTcS at 4 hour | QTcS at 6 hour | QTcS at 8 hour | QTcF at 0 hour | QTcF at 2 hour | QTcF at 4 hour | QTcF at 6 hour | QTcF at 8 hour | QTcB at 0 hour | QTcB at 2 hour | QTcB at 4 hour | QTcB at 6 hour | QTcB at 8 hour | |
| Palbociclib Plus Letrozole | 0.80 | 3.32 | 2.76 | 4.49 | 0.94 | 1.10 | 3.68 | 2.86 | 4.57 | 1.21 | -0.11 | 1.46 | 2.58 | 4.03 | -0.17 |
| Placebo Plus Letrozole | 2.95 | 1.65 | 1.74 | 0.72 | 3.14 | 3.06 | 1.73 | 1.54 | 0.71 | 2.84 | 2.78 | 0.83 | 2.47 | 0.53 | 4.14 |
Laboratory abnormalities included anemia, hemoglobin increased, neutrophils (absolute), platelets, white blood cells, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia and hyponatremia. Laboratory abnormalities were graded by CTCAE version (v) 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life-threatening. Categories with at least 1 non-zero data values are reported. (NCT01740427)
Timeframe: From randomization up to 28 days after last dose of study drug (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia: Grade 1-2 | Anemia: Grade 3 | Hemoglobin Increased: Grade 1-2 | Hemoglobin Increased: Grade 3 | Neutrophils (Absolute): Grade 1-2 | Neutrophils (Absolute): Grade 3 | Neutrophils (Absolute): Grade 4 | Platelets: Grade 1-2 | Platelets: Grade 3 | Platelets: Grade 4 | White Blood Cells: Grade 1-2 | White Blood Cells: Grade 3 | White Blood Cells: Grade 4 | ALT: Grade 1-2 | ALT: Grade 3 | ALT: Grade 4 | Alkaline Phosphatase: Grade 1-2 | Alkaline Phosphatase: Grade 3 | AST: Grade 1-2 | AST: Grade 3 | Bilirubin (Total): Grade 1-2 | Bilirubin (Total): Grade 3 | Creatinine: Grade 1-2 | Creatinine: Grade 3 | Creatinine: Grade 4 | Hypercalcemia: Grade 1-2 | Hypercalcemia: Grade 3 | Hyperkalemia: Grade 1-2 | Hyperkalemia: Grade 3 | Hyperkalemia: Grade 4 | Hypermagnesemia: Grade 1-2 | Hypermagnesemia: Grade 3 | Hypermagnesemia: Grade 4 | Hypernatremia: Grade 1-2 | Hypernatremia: Grade 3 | Hypoalbuminemia: Grade 1-2 | Hypoalbuminemia: Grade 3 | Hypocalcemia: Grade 1-2 | Hypocalcemia: Grade 3 | Hypocalcemia: Grade 4 | Hypokalemia: Grade 1-2 | Hypokalemia: Grade 3 | Hypomagnesemia: Grade 1-2 | Hypomagnesemia: Grade 3 | Hypomagnesemia: Grade 4 | Hyponatremia: Grade 1-2 | Hyponatremia: Grade 3 | |
| Palbociclib Plus Letrozole | 328 | 30 | 14 | 1 | 109 | 254 | 60 | 289 | 6 | 1 | 248 | 177 | 6 | 222 | 16 | 1 | 174 | 7 | 260 | 23 | 33 | 3 | 418 | 8 | 2 | 111 | 1 | 118 | 6 | 2 | 71 | 9 | 2 | 94 | 8 | 118 | 2 | 158 | 4 | 3 | 105 | 11 | 127 | 1 | 2 | 107 | 11 |
| Placebo Plus Letrozole | 90 | 6 | 25 | 0 | 42 | 2 | 1 | 32 | 0 | 0 | 57 | 0 | 0 | 76 | 0 | 0 | 95 | 0 | 82 | 2 | 11 | 0 | 201 | 0 | 0 | 54 | 2 | 51 | 1 | 0 | 26 | 6 | 0 | 35 | 1 | 42 | 0 | 48 | 1 | 0 | 32 | 2 | 41 | 0 | 0 | 44 | 4 |
Summary of Plasma Palbociclib Within-Patient Mean Steady-State Trough Concentrations. (NCT01740427)
Timeframe: 0 hour (predose) on Day 14 of cycles 1 and 2
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1 Day 14 | Cycle 2 Day 14 | |
| Palbociclib Plus Letrozole | 70.1 | 64.2 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Percentage of participants with post-baseline maximum absolute values and maximum increase from baseline were summarized for the safety analysis population. (NCT01740427)
Timeframe: For safety monitoring triplicate ECGs were obtained at 0 hour (pre-dose) on Day 1 of Cycle 1, Day 14 of Cycles 1 and Cycle 2, then on Day 1 of Cycles 4, 7, and 10. ECGs beyond Cycle 10 were performed as clinically indicated
| Intervention | Percentage of participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum QTcS <450 msec | Maximum QTcS 450-<480 msec | Maximum QTcS 480-<500 msec | Maximum QTcS ≥500 msec | Maximum QTcF <450 msec | Maximum QTcF 450-<480 msec | Maximum QTcF 480-<500 msec | Maximum QTcF ≥500 msec | Maximum QTcB <450 msec | Maximum QTcB 450-<480 msec | Maximum QTcB 480-<500 msec | Maximum QTcB ≥500 msec | Maximum QTcS Change <30 msec | Maximum QTcS 30≤Change <60 msec | Maximum QTcS Change≥60 msec | Maximum QTcF Change <30 msec | Maximum QTcF 30≤Change <60 msec | Maximum QTcF Change≥60 msec | Maximum QTcB Change <30 msec | Maximum QTcB 30≤Change <60 msec | Maximum QTcB Change≥60 msec | |
| Palbociclib Plus Letrozole | 80.5 | 17.9 | 1.1 | 0.5 | 85.9 | 12.2 | 1.6 | 0.2 | 64.9 | 32.2 | 2.3 | 0.7 | 92.7 | 6.6 | 0.7 | 91.6 | 7.9 | 0.5 | 88.9 | 10.2 | 0.9 |
| Placebo Plus Letrozole | 85.9 | 11.8 | 2.3 | 0 | 89.5 | 9.5 | 0.9 | 0 | 69.1 | 27.3 | 3.2 | 0.5 | 94.5 | 5.5 | 0 | 93.6 | 6.4 | 0 | 91.4 | 8.2 | 0.5 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization; resulted in persistent or significant disability or in congenital anomaly/birth defect. TEAE were events that occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Severity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening and Grade 5 = death related to AE. (NCT01740427)
Timeframe: From date of randomization up to 28 days after last dose of study drug, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
| Intervention | Percentage of Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | Permanently discontinued study due to AEs | Permanently disc. palbociclib/placebo due to AEs | Permanently discontinued letrozole due to AEs | Temporarily disc. palbociclib/placebo due to AEs | Temporarily discontinued letrozole due to AEs | With palbociclib/placebo dose reduction due to AEs | |
| Palbociclib Plus Letrozole | 99.1 | 27.5 | 82.7 | 3.6 | 4.1 | 14.2 | 9.0 | 79.5 | 22.7 | 40.8 |
| Placebo Plus Letrozole | 96.4 | 17.1 | 30.2 | 2.3 | 2.3 | 5.9 | 5.4 | 17.1 | 11.3 | 2.3 |
"PFS by biomarker status by Investigator assessment. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.~Positive is defined as H-Score ≥1 and negative as H-Score <1. H-Score is calculated as the sum of the % of cells at each level of staining intensity (0, 1+, 2+, and 3+) multiplied by the staining intensity value: H-Score = (% at 0)*0 + (% at 1+)*1 + (% at 2+)*2 + (% at 3+)*3. H-Score values range from 0 to 300.~ER stands for estrogen receptor and Rb stands for retinoblastoma susceptibility gene product." (NCT01740427)
Timeframe: From randomization until end of treatment (up to approximately 24 Months)
| Intervention | Months (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ER Positive | ER Negative | Rb Positive | Rb Negative | Cyclin D1 Positive | Cyclin D1 Negative | p16 Positive | p16 Negative | p16 H-Score<175 | p16 H-Score≥175 | Ki67 ≤20% | Ki67 >20% | |
| Palbociclib Plus Letrozole | 24.9 | 15.6 | 24.2 | NA | 24.8 | 11.1 | 24.8 | 16.8 | 23.7 | 24.2 | 27.6 | 17.5 |
| Placebo Plus Letrozole | 16.3 | 5.4 | 13.7 | 18.5 | 13.8 | 8.1 | 13.8 | 13.8 | 13.8 | 5.6 | 16.8 | 8.4 |
One, two or three-year survival probability was defined as the probability of survival 1 year, 2 or 3 years after the date of randomization. The survival probability was estimated using the Kaplan-Meier method and 2-sided 95% confidence interval (CI) was calculated using the product limit method. (NCT01740427)
Timeframe: 1, 2 and 3 years after randomization
| Intervention | Percent probability (Number) | ||
|---|---|---|---|
| 1 year survival probability | 2 year survival probability | 3 year survival probability | |
| Palbociclib Plus Letrozole | 92.7 | 78.4 | 69.8 |
| Placebo Plus Letrozole | 94.9 | 82.5 | 65.0 |
Rac is the ratio of AUCtau (after multiple doses) to AUCtau (after single dose). AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | ratio (Median) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 2.060 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1.855 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by AUCtau. AUCtau is the area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
| Intervention | L/hr (Geometric Mean) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 63.21 |
AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | nanogram*hour per milliliter (ng*hr/mL) (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1276 |
| PD-0332991 125 mg: Dose Escalation Cohort | 2838 |
AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 1979 |
AUC24 is area under the plasma concentration-time curve from 0 to time 24 hours which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12 and 24 hours post-dose in Lead-in period (Day -7)
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 547.5 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1322 |
AUClast is area under the plasma concentration-time curve from 0 to time of last measurable concentration which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 971.7 |
| PD-0332991 125 mg: Dose Escalation Cohort | 2396 |
AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1039 |
| PD-0332991 125 mg: Dose Escalation Cohort | 2483 |
AUC24 Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to time 24 hours dose normalized to 125 mg which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12 and 24 hours post-dose in Lead-in period (Day -7)
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 684.5 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1322 |
AUCinf Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to infinity dose normalized to 125 mg which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1296 |
| PD-0332991 125 mg: Dose Escalation Cohort | 2483 |
AUClast Dose Normalized to 125 mg is area under the plasma concentration-time curve from 0 to time of last measurable concentration dose normalized to 125 mg which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1215 |
| PD-0332991 125 mg: Dose Escalation Cohort | 2396 |
AUCtau Dose Normalized to 125 mg is area under the plasma concentration-time curve over dosing interval dose normalized to 125 mg which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | ng*hr/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1595 |
| PD-0332991 125 mg: Dose Escalation Cohort | 2838 |
Duration of response was defined as the interval from the first documentation of objective tumor response in participants with CR (disappearance of all target lesions with the exception of nodal disease, all target nodes reduced to normal size (short axis <10 mm) or PR (a >=30 % decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to RECIST version 1.1 to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PD was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01684215)
Timeframe: From initiation of treatment up to disease progression (up to 1526 days)
| Intervention | months (Median) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 41.4 |
Rss is the ratio of AUCtau (after multiple doses) to AUCinf (after single dose). AUCtau is area under the plasma concentration-time curve over dosing interval which is calculated by log-linear trapezoidal method. AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | ratio (Median) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1.130 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1.105 |
Cmax is maximum plasma concentration which is observed directly from the actual time-concentration data. (NCT01684215)
Timeframe: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 124.7 |
Abnormality criteria: hemoglobin: <0.8*lower limit of normal [LLN], platelets: <0.5*LLN or >1.75*upper limit of normal [ULN], leukocytes: <0.6*LLN or >1.5*ULN, lymphocytes, total neutrophils: <0.8*LLN or >1.2*ULN, basophils, eosinophil,monocytes: >1.2*ULN); aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase (GT): >0.3*ULN, total protein, albumin: <0.8*LLN or >1.2*ULN, total bilirubin, direct bilirubin: >1.5*ULN; blood urea nitrogen, creatinine: >1.3*ULN, uric acid: >1.2*ULN; sodium: <0.95*LLN or >1.05*ULN, potassium, chloride, calcium, magnesium: <0.9*LLN or >1.1*ULN, phosphate: <0.8*LLN or >1.2*ULN; creatine kinase: >2.0*ULN, glucose fasting: <0.6*LLN or >1.5*ULN, glycosylated haemoglobin: >1.3*ULN;urinalysis dipstick (urine protein, urine blood >=1); urine protein 24 hour: >1.1*ULN; coagulation Activated partial thromboplastin time [APTT], Prothrombin, prothrombin international ratio: >1.1*ULN. (NCT01684215)
Timeframe: Part 1 Phase 1: Lead-in period (Day -7) up to 308 days; Part 2 Phase 1: Baseline (Day 1) up to 1673 days; Phase 2: Baseline (Day 1) up to 1526 days
| Intervention | Participants (Count of Participants) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 6 |
| PD-0332991 125 mg: Dose Escalation Cohort | 6 |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | 6 |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 40 |
DLT was classified as per common terminology criteria for adverse events (CTCAE) version 4.0 as any of the events occurring during 28 days of Cycle 1,attributed to study drug:grade 4 neutropenia(for a duration of greater than [>]7 days); febrile neutropenia (grade greater than or equal to [>=]3 neutropenia,body temperature >=38.5 degree Celsius);grade >=3 thrombocytopenia with bleeding episode;grade 4 thrombocytopenia;grade >=3 non-hematologic toxicity except grade 3 or more nausea, vomiting,electrolyte abnormality(if controllable by therapy);grade 3 QTc prolongation(>500 millisecond [msec])persist after correction of reversible cause such as electrolyte abnormalities or hypoxia. Lack of hematologic recovery (platelets less than [<]50,000/microliter [mcL],absolute neutrophil count <1,000/mcL,hemoglobin <8.0 gram/deciliter [g/dL]) or prolonged non hematologic toxicities that delays initiation of next dose by >7 days;receipt of <75 percent of planned dose in first cycle due to toxicity. (NCT01684215)
Timeframe: Lead-in period (Day -7) up to Day 28 (Cycle 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 1 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1 |
Overall survival was defined as the time from first dose of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. OS was estimated with Kaplan-Meier method. (NCT01684215)
Timeframe: From initiation of treatment up to follow-up period (up to 1526 days)
| Intervention | months (Median) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | NA |
PFS was defined as the time from first dose of study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurred first. PD was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.1-year PFS was defined as the percentage of participants without PFS events (PD or death due to any cause) at 12 months based on the Kaplan-Meier estimate. Percentage of participants with 1-year PFS with 90% confidence interval (CI) were reported. (NCT01684215)
Timeframe: From initiation of treatment up to 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 75.6 |
DC: CR, PR or stable disease (SD) for >=24 weeks according to RECIST version (v)1.1 recorded in time period between first dose of study treatment and disease progression or death to any cause. CR: disappearance of all target lesions with exception of nodal disease. All target nodes reduced to normal size (short axis <10 mm). PR: >=30% decrease in sum of longest dimensions of target lesions taking as a reference baseline sum longest dimensions. SD was defined as not achieving an OR with confirmed CR or PR according to RECIST v1.1, as determined by investigators, relative to response evaluable population, but remained stable for at least 24 weeks after first dose, then best overall response for such a participant was considered as stable disease. PD was defined using RECIST v1.1 as a 20% increase in sum of longest diameter of target lesions, or a measurable increase in a non-target lesion, or appearance of new lesions. (NCT01684215)
Timeframe: From initiation of treatment up to disease progression (up to 1526 days)
| Intervention | percentage of participants (Number) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 85.7 |
Objective response was defined as a complete response (CR) or partial response (PR) according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression or death due to any cause. PD was defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. CR was defined as disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis <10 mm). PR was defined as a >=30% decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Percentage of participants with objective response (who achieved CR or PR) were reported. (NCT01684215)
Timeframe: From initiation of treatment up to disease progression (up to 1526 days)
| Intervention | percentage of participants (Number) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 47.6 |
Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data. (NCT01684215)
Timeframe: Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 35.51 |
| PD-0332991 125 mg: Dose Escalation Cohort | 72.76 |
Ctrough is pre-dose concentration during multiple dosing which is observed directly from the actual time-concentration data. (NCT01684215)
Timeframe: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 59.75 |
Tmax is time at which maximum plasma concentration (Cmax) was observed. It was observed directly from data as time of first occurrence. (NCT01684215)
Timeframe: 0 (pre-dose), 1, 2, 4, 6, 8, 10, 24 hours post dose on Cycle 1 Day 15
| Intervention | hour (Median) |
|---|---|
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 4.90 |
Vz/F is apparent volume of distribution estimated from terminal phase, which is calculated as CL/F/kel. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method (AUCinf). kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7)
| Intervention | liter (Geometric Mean) |
|---|---|
| PD-0332991 100 mg: Dose Escalation Cohort | 3514 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1730 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. It was calculated by dividing the given oral dose by AUCinf. AUCinf is area under the plasma concentration-time curve from 0 to infinity which is calculated by log-linear trapezoidal method. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | liter per hour (L/hr) (Geometric Mean) | |
|---|---|---|
| Single dose | Multiple dose | |
| PD-0332991 100 mg: Dose Escalation Cohort | 96.43 | 78.43 |
| PD-0332991 125 mg: Dose Escalation Cohort | 50.29 | 44.03 |
The functional assessment of cancer therapy (FACT) is a modular approach to assess participant's health-related quality of life. FACT-B total score was derived from the sum of these 5 sub-scale scores: physical well-being, social/family well-being and functional well-being (all 3 sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life), emotional well-being (consists of 6 items and ranging from 0 to 24, where higher scores indicating better quality of life, and a breast cancer subscale (consists of 9 items and ranging from 0 to 36, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. FACT-B total score range was of 0 (not at all good) to 144 (very well), where higher scores indicating better quality of life. (NCT01684215)
Timeframe: Baseline (Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, End of treatment (up to 1526 days)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 2: Day 1 | Change at Cycle 3: Day 1 | Change at Cycle 5: Day 1 | Change at Cycle 7: Day 1 | Change at Cycle 9: Day 1 | Change at Cycle 11: Day 1 | Change at Cycle 13: Day 1 | Change at Cycle 15: Day 1 | Change at Cycle 17: Day 1 | Change at Cycle 19: Day 1 | Change at Cycle 21: Day 1 | Change at Cycle 23: Day 1 | Change at Cycle 25: Day 1 | Change at Cycle 27: Day 1 | Change at Cycle 29: Day 1 | Change at Cycle 31: Day 1 | Change at Cycle 33: Day 1 | Change at Cycle 35: Day 1 | Change at Cycle 37: Day 1 | Change at Cycle 39: Day 1 | Change at Cycle 41: Day 1 | Change at Cycle 43: Day 1 | Change at Cycle 45: Day 1 | Change at Cycle 47: Day 1 | Change at Cycle 49: Day 1 | End of Treatment | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 106.46 | -1.20 | -2.22 | -2.38 | -4.62 | -4.45 | -4.48 | -6.32 | -4.06 | -6.07 | -7.39 | -5.85 | -5.89 | -4.22 | -4.76 | -6.26 | -5.13 | -7.12 | -7.68 | -8.07 | -6.87 | -5.70 | -10.42 | -7.94 | -8.56 | -10.58 | -9.17 |
FACT is a modular approach to assess participant's health-related quality of life. FACT-G total score was derived from the sum of these 4 sub-scale scores: physical well-being, social/family well-being and functional well-being (all 3 sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life), emotional well-being (consists of 6 items and ranging from 0 to 24, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. FACT-G total score range was of 0 (not at all good) to 108 (very well), where higher scores indicating better quality of life. (NCT01684215)
Timeframe: Baseline (Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, End of treatment (up to 1526 days)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 2: Day 1 | Change at Cycle 3: Day 1 | Change at Cycle 5: Day 1 | Change at Cycle 7: Day 1 | Change at Cycle 9: Day 1 | Change at Cycle 11: Day 1 | Change at Cycle 13: Day 1 | Change at Cycle 15: Day 1 | Change at Cycle 17: Day 1 | Change at Cycle 19: Day 1 | Change at Cycle 21: Day 1 | Change at Cycle 23: Day 1 | Change at Cycle 25: Day 1 | Change at Cycle 27: Day 1 | Change at Cycle 29: Day 1 | Change at Cycle 31: Day 1 | Change at Cycle 33: Day 1 | Change at Cycle 35: Day 1 | Change at Cycle 37: Day 1 | Change at Cycle 39: Day 1 | Change at Cycle 41: Day 1 | Change at Cycle 43: Day 1 | Change at Cycle 45: Day 1 | Change at Cycle 47: Day 1 | Change at Cycle 49: Day 1 | End of Treatment | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 80.22 | -1.15 | -1.34 | -0.36 | -3.56 | -2.39 | -3.94 | -4.74 | -2.98 | -4.64 | -5.48 | -4.34 | -4.39 | -3.22 | -3.80 | -4.52 | -4.55 | -6.67 | -6.63 | -6.49 | -5.07 | -5.06 | -7.08 | -5.94 | -6.22 | -8.58 | -7.09 |
FACT is a modular approach to assess participant's health-related quality of life. TOI total score was derived from the sum of the 3 sub-scale scores: physical well-being, functional well-being (both sub-scales consisting of 7 items ranging from 0 to 28, where higher scores indicating better quality of life) and breast cancer subscale (consists of 9 items and ranging from 0 to 36, where higher scores indicating better quality of life). Each individual item was rated on a 5-point Likert scale, ranging from 0 (not at all good) to 4 (very well), where higher scores indicating better quality of life. TOI total score range was of 0 (not at all good) to 92 (very well), where higher scores indicating better quality of life. (NCT01684215)
Timeframe: Baseline (Day 1 of Cycle 1), Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, End of treatment (up to 1526 days)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 2: Day 1 | Change at Cycle 3: Day 1 | Change at Cycle 5: Day 1 | Change at Cycle 7: Day 1 | Change at Cycle 9: Day 1 | Change at Cycle 11: Day 1 | Change at Cycle 13: Day 1 | Change at Cycle 15: Day 1 | Change at Cycle 17: Day 1 | Change at Cycle 19: Day 1 | Change at Cycle 21: Day 1 | Change at Cycle 23: Day 1 | Change at Cycle 25: Day 1 | Change at Cycle 27: Day 1 | Change at Cycle 29: Day 1 | Change at Cycle 31: Day 1 | Change at Cycle 33: Day 1 | Change at Cycle 35: Day 1 | Change at Cycle 37: Day 1 | Change at Cycle 39: Day 1 | Change at Cycle 41: Day 1 | Change at Cycle 43: Day 1 | Change at Cycle 45: Day 1 | Change at Cycle 47: Day 1 | Change at Cycle 49: Day 1 | End of Treatment | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 71.52 | -1.17 | -2.20 | -2.54 | -3.63 | -3.31 | -2.30 | -3.93 | -2.49 | -3.18 | -4.32 | -3.56 | -3.19 | -2.13 | -2.50 | -3.70 | -1.95 | -4.30 | -4.65 | -4.84 | -3.47 | -2.27 | -7.00 | -3.00 | -4.00 | -2.00 | -6.03 |
Cmax Dose Normalized to 125 mg is maximum plasma concentration dose normalized to 125 mg which is observed directly from the actual time-concentration data. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Single dose | Multiple dose | |
| PD-0332991 100 mg: Dose Escalation Cohort | 51.74 | 96.72 |
| PD-0332991 125 mg: Dose Escalation Cohort | 104.1 | 185.5 |
Duration of response was defined as the interval from the first documentation of objective tumor response in participants with CR (disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis <10 millimeter [mm]) or PR (a >=30 percent decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to RECIST version 1.1 to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. (NCT01684215)
Timeframe: baseline up to 1673 days
| Intervention | days (Number) | |
|---|---|---|
| Participant 1 | Participant 2 | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | 1509 | 1428 |
Cmax is maximum plasma concentration which is observed directly from the actual time-concentration data. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | nanogram per milliliter (ng/mL) (Geometric Mean) | |
|---|---|---|
| Single dose | Multiple dose | |
| PD-0332991 100 mg: Dose Escalation Cohort | 41.37 | 77.36 |
| PD-0332991 125 mg: Dose Escalation Cohort | 104.1 | 185.5 |
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if occurred for the first time after the start of study treatment or occurred prior to the start of treatment but increased in NCI CTCAE version 4.0 grade during study treatment period. AE severity was defined to be the maximum toxicity grade of the TEAEs experienced by the participants during the study. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE). (NCT01684215)
Timeframe: Part 1 Phase 1: Lead-in period (Day -7) up to 28 days after last dose of study drug (up to 308 days), Phase 2: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1526 days)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| PD-0332991 100 mg: Dose Escalation Cohort | 0 | 0 | 4 | 2 | 0 |
| PD-0332991 125 mg: Dose Escalation Cohort | 1 | 1 | 3 | 1 | 0 |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 0 | 2 | 29 | 10 | 1 |
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE was considered treatment emergent if occurred for the first time after the start of study treatment or occurred prior to the start of treatment but increased in National Cancer Institute (NCI) CTCAE grade during study treatment period. AE severity was defined to be the maximum toxicity grade of the TEAEs experienced by the participants during the study. AE was assessed according to severity as: Grade 1 (mild AE), Grade 2 (moderate AE), Grade 3 (severe AE), Grade 4 (life-threatening consequences) and Grade 5 (death related to AE). (NCT01684215)
Timeframe: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1673 days)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | 0 | 0 | 4 | 2 | 0 |
"A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.~Relatedness was judged by investigator. AEs included both serious and non-serious adverse events." (NCT01684215)
Timeframe: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1673 days)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | 6 | 2 |
"A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.~Relatedness was judged by investigator. AEs included both serious and non-serious adverse events." (NCT01684215)
Timeframe: Part 1 Phase 1: Lead-in period (Day -7) up to 28 days after last dose of study drug (up to 308 days), Phase 2: Baseline (Day 1) up to 28 days after last dose of study drug (up to 1526 days)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AEs | SAEs | |
| PD-0332991 100 mg: Dose Escalation Cohort | 6 | 0 |
| PD-0332991 125 mg: Dose Escalation Cohort | 5 | 0 |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 42 | 2 |
Objective response (OR) was defined as a complete response (CR) or partial response (PR) according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all target lesions with the exception of nodal disease. All target nodes reduced to normal size (short axis <10 millimeter [mm]). PR was defined as a >=30 percent decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Percentage of participants with objective response (who achieved CR or PR) were reported. (NCT01684215)
Timeframe: From initiation of treatment up to disease progression (up to 30 months)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| With Complete Response | With Partial Response | |
| PD-0332991 100 mg: Dose Escalation Cohort | 0 | 0 |
| PD-0332991 125 mg: Dose Escalation Cohort | 0 | 0 |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | 0 | 33.3 |
Tumor tissue biomarker, Ki67 was analyzed to investigate possible associations with resistance or sensitivity to treatment with study drugs and was selected based on its known relevance to mechanisms involved in cell cycle regulation. Number of participants with less than or equal to and greater than 20 percent of Ki67 tumor tissue biomarker were reported. (NCT01684215)
Timeframe: Baseline (Day 1)
| Intervention | participants (Number) | |
|---|---|---|
| <=20 percent | >20 percent | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 19 | 23 |
Tumor tissue biomarkers ER, Rb, BCL-1 and P16 were analyzed to investigate possible associations with resistance or sensitivity to treatment with study drugs and were selected based on their known relevance to mechanisms involved in cell cycle regulation. Number of participants with positive ER (H-Score), Rb (H-Score), BCL-1 (H-Score) and P16 (H-Score) tumor tissue biomarkers were reported. The H-score is a method of assessing the extent of nuclear immunoreactivity, applicable to steroid receptors. (NCT01684215)
Timeframe: Baseline (Day 1)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ER (H-Score) | Rb (H-Score) | BCL-1 (H-Score) | P16 (H-Score) | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort | 41 | 41 | 42 | 41 |
PFS was defined as the time from first dose of study treatment to the date of the first documentation of objective progression of disease (PD) or death due to any cause in the absence of documented PD, whichever occurs first. PD was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01684215)
Timeframe: baseline up to 1673 days
| Intervention | days (Number) | |||||
|---|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 3 | Participant 4 | Participant 5 | Participant 6 | |
| PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort | 1590 | 1593 | 1602 | 36 | 31 | 1512 |
t1/2 is terminal elimination half-life which is calculated by loge(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | hour (Mean) | |
|---|---|---|
| Single dose | Multiple dose | |
| PD-0332991 100 mg: Dose Escalation Cohort | 25.72 | 23.75 |
| PD-0332991 125 mg: Dose Escalation Cohort | 23.93 | 23.15 |
Tmax is time at which maximum plasma concentration (Cmax) was observed. It was observed directly from data as time of first occurrence. (NCT01684215)
Timeframe: Single dose: 0 hour (pre-dose),1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose in Lead-in period (Day -7), Multiple dose: 0 hour (pre-dose), 1, 2, 4, 6, 8, 12, 24 hours post-dose on Cycle 1 Day 8
| Intervention | hour (Median) | |
|---|---|---|
| Single dose | Multiple dose | |
| PD-0332991 100 mg: Dose Escalation Cohort | 5.02 | 4.02 |
| PD-0332991 125 mg: Dose Escalation Cohort | 4.00 | 4.02 |
Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST). (NCT00721409)
Timeframe: From randomization up to the end of treatment (approximately 41 months)
| Intervention | Months (Median) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 20.3 |
| Phase 2 (Letrozole) | 11.1 |
| Ph2P1 (Palbociclib + Letrozole) | 20.9 |
| Ph2P1 (Letrozole) | 10.8 |
| Ph2P2 (Palbociclib + Letrozole) | 20.2 |
| Ph2P2 (Letrozole) | 14.8 |
CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST. (NCT00721409)
Timeframe: From randomization up to the end of treatment (approximately 41 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 81.0 |
| Phase 2 (Letrozole) | 58.0 |
| Ph2P1 (Palbociclib + Letrozole) | 76.5 |
| Ph2P1 (Letrozole) | 43.8 |
| Ph2P2 (Palbociclib + Letrozole) | 84.0 |
| Ph2P2 (Letrozole) | 67.3 |
Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. (NCT00721409)
Timeframe: From randomization up to the end of treatment (approximately 41 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 42.9 |
| Phase 2 (Letrozole) | 33.3 |
| Ph2P1 (Palbociclib + Letrozole) | 44.1 |
| Ph2P1 (Letrozole) | 25.0 |
| Ph2P2 (Palbociclib + Letrozole) | 42.0 |
| Ph2P2 (Letrozole) | 38.8 |
Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes). (NCT00721409)
Timeframe: From randomization up to the end of treatment (approximately 41 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 55.4 |
| Phase 2 (Letrozole) | 39.4 |
| Ph2P1 (Palbociclib + Letrozole) | 55.6 |
| Ph2P1 (Letrozole) | 34.8 |
| Ph2P2 (Palbociclib + Letrozole) | 55.3 |
| Ph2P2 (Letrozole) | 41.9 |
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. (NCT00721409)
Timeframe: From Baseline up to end of study (assessed up to 55 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 1 (Palbociclib + Letrozole) | 33.3 |
Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months. (NCT00721409)
Timeframe: From randomization until death (assessed up to 86 months)
| Intervention | Months (Median) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 37.5 |
| Phase 2 (Letrozole) | 34.5 |
| Ph2P1 (Palbociclib + Letrozole) | 37.5 |
| Ph2P1 (Letrozole) | 33.3 |
| Ph2P2 (Palbociclib + Letrozole) | 35.1 |
| Ph2P2 (Letrozole) | 35.7 |
CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging >= 4 weeks after initial response. (NCT00721409)
Timeframe: From Baseline up to end of study (assessed up to 55 months)
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 1 (Palbociclib + Letrozole) | 83.3 |
PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs). (NCT00721409)
Timeframe: From randomization date to date of first documentation of progression or death (assessed up to 41 months)
| Intervention | Months (Median) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 20.2 |
| Phase 2 (Letrozole) | 10.2 |
| Ph2P1 (Palbociclib + Letrozole) | 26.1 |
| Ph2P1 (Letrozole) | 5.7 |
| Ph2P2 (Palbociclib + Letrozole) | 18.1 |
| Ph2P2 (Letrozole) | 11.1 |
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing. (NCT00721409)
Timeframe: Cycle 2 Day 14, Cycle 2 Day 28
| Intervention | ng·hr/mL (Geometric Mean) |
|---|---|
| Palbociclib + Letrozole (Cycle 2 Day 14) | 1739 |
| Letrozole Alone (Cycle 2 Day 28) | 1936 |
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing. (NCT00721409)
Timeframe: Cycle 2 Day 14, and Cycle 2 Day 28
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Palbociclib + Letrozole (Cycle 2 Day 14) | 94.95 |
| Letrozole Alone (Cycle 2 Day 28) | 104.0 |
On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing. (NCT00721409)
Timeframe: Cycle 2 Day 14, and Cycle 2 Day 28
| Intervention | Hour (Median) |
|---|---|
| Palbociclib + Letrozole (Cycle 2 Day 14) | 2.00 |
| Letrozole Alone (Cycle 2 Day 28) | 1.04 |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. (NCT00721409)
Timeframe: Cycle 1 Day 14, and Cycle 2 Day 14
| Intervention | L/hr (Geometric Mean) |
|---|---|
| Palbociclib Alone (Cycle 1 Day 14) | 63.08 |
| Palbociclib + Letrozole (Cycle 2 Day 14) | NA |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. (NCT00721409)
Timeframe: Cycle 1 Day 14, and Cycle 2 Day 14
| Intervention | L (Geometric Mean) |
|---|---|
| Palbociclib Alone (Cycle 1 Day 14) | 2583 |
| Palbociclib + Letrozole (Cycle 2 Day 14) | NA |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. (NCT00721409)
Timeframe: Cycle 1 Day 14, and Cycle 2 Day 14
| Intervention | ng·hr/mL (Geometric Mean) |
|---|---|
| Palbociclib Alone (Cycle 1 Day 14) | 1982 |
| Palbociclib + Letrozole (Cycle 2 Day 14) | 1933 |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. (NCT00721409)
Timeframe: Cycle 1 Day 14, and Cycle 2 Day 14
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Palbociclib Alone (Cycle 1 Day 14) | 115.8 |
| Palbociclib + Letrozole (Cycle 2 Day 14) | 108.4 |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. (NCT00721409)
Timeframe: Cycle 1 Day 14, and Cycle 2 Day 14
| Intervention | Hour (Mean) |
|---|---|
| Palbociclib Alone (Cycle 1 Day 14) | 28.81 |
| Palbociclib + Letrozole (Cycle 2 Day 14) | NA |
On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. (NCT00721409)
Timeframe: Cycle 1 Day 14, and Cycle 2 Day 14
| Intervention | Hour (Median) |
|---|---|
| Palbociclib Alone (Cycle 1 Day 14) | 7.92 |
| Palbociclib + Letrozole (Cycle 2 Day 14) | 7.92 |
Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST). (NCT00721409)
Timeframe: From randomization up to the end of treatment (approximately 41 months)
| Intervention | Months (Median) |
|---|---|
| Phase 2 (Palbociclib + Letrozole) | 20.2 |
| Phase 2 (Letrozole) | 10.2 |
| Ph2P1 (Palbociclib + Letrozole) | 26.1 |
| Ph2P1 (Letrozole) | 5.7 |
| Ph2P2 (Palbociclib + Letrozole) | 18.8 |
| Ph2P2 (Letrozole) | 11.1 |
"The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (no pain or does not interfere) to 10 (pain as bad as you can imagine or completely interferes)." (NCT00721409)
Timeframe: Baseline, End of treatment (approximately 41 months)
| Intervention | Units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| General Activity | Mood | Walking ability | Normal work | Relations | Sleep | Enjoyment of life | Pain Interference Scale | |
| Ph2P1 (Letrozole) | 0.2 | -0.2 | 0.3 | 0.2 | 0.6 | 0.5 | 0.2 | 0.3 |
| Ph2P1 (Palbociclib + Letrozole) | 1.0 | 0.6 | 1.0 | 1.0 | 0.6 | 0.1 | 0.4 | 0.7 |
| Ph2P2 (Letrozole) | 0.3 | 0.4 | 0.0 | 0.4 | 0.8 | 0.1 | 0.8 | 0.4 |
| Ph2P2 (Palbociclib + Letrozole) | 1.2 | 1.0 | 0.7 | 0.5 | 0.9 | 0.9 | 1.1 | 0.9 |
| Phase 2 (Letrozole) | 0.2 | 0.2 | 0.1 | 0.3 | 0.8 | 0.3 | 0.6 | 0.4 |
| Phase 2 (Palbociclib + Letrozole) | 1.1 | 0.8 | 0.8 | 0.7 | 0.8 | 0.6 | 0.8 | 0.8 |
"The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (no pain or does not interfere) to 10 (pain as bad as you can imagine or completely interferes)." (NCT00721409)
Timeframe: Baseline, End of treatment (approximately 41 months)
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Pain at its worst in the last 24 hours | Pain at its least in the last 24 hours | Pain on the average | Pain right now | Pain Severity Scale | |
| Ph2P1 (Letrozole) | 0.0 | 0.7 | 0.2 | 0.3 | 0.3 |
| Ph2P1 (Palbociclib + Letrozole) | 0.2 | 0.3 | -0.1 | 0.1 | 0.0 |
| Ph2P2 (Letrozole) | 0.1 | 0.2 | 0.3 | 0.0 | 0.1 |
| Ph2P2 (Palbociclib + Letrozole) | 1.2 | 0.5 | 0.4 | 0.3 | 0.6 |
| Phase 2 (Letrozole) | 0.1 | 0.4 | 0.2 | 0.1 | 0.2 |
| Phase 2 (Palbociclib + Letrozole) | 0.6 | 0.4 | 0.2 | 0.3 | 0.4 |
Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets <25,000/μL, ANC <500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count <50,000/μL; ANC <1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment. (NCT00721409)
Timeframe: Cycle 2 (4 weeks)
| Intervention | Participants (Number) | |
|---|---|---|
| Grade 4 Neutropenia | <80% of doses due to elevated creatinine | |
| Phase 1 (Palbociclib + Letrozole) | 2 | 1 |
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (<) 60 msec(borderline) and greater than or equal to (>=) 60 msec (prolonged) were summarized. (NCT00721409)
Timeframe: Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| QTcB - Change <30 | QTcB - 30 ≤ change <60 | QTcB - Change ≥60 | QTcF - Change <30 | QTcF - 30 ≤ change <60 | QTcF - Change ≥60 | QTcS - Change <30 | QTcS - 30 ≤ change <60 | QTcS - Change ≥60 | |
| Phase 1 (Palbociclib + Letrozole) | 9 | 3 | 0 | 11 | 1 | 0 | 8 | 4 | 0 |
AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE. (NCT00721409)
Timeframe: Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | |
| Ph2P1 (Letrozole) | 25 | 2 | 5 | 0 |
| Ph2P1 (Palbociclib + Letrozole) | 33 | 10 | 29 | 0 |
| Ph2P2 (Letrozole) | 41 | 4 | 14 | 0 |
| Ph2P2 (Palbociclib + Letrozole) | 50 | 12 | 41 | 1 |
| Phase 2 (Letrozole) | 66 | 6 | 19 | 0 |
| Phase 2 (Palbociclib + Letrozole) | 83 | 22 | 70 | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00721409)
Timeframe: Maximum treatment duration (approximately 55 months)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | |
| Phase 1 (Palbociclib + Letrozole) | 12 | 2 | 11 | 0 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00721409)
Timeframe: Maximum treatment duration (approximately 55 months)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | |
| Phase 1 (Palbociclib + Letrozole) | 12 | 0 | 11 | 0 |
AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE. (NCT00721409)
Timeframe: Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Participants with AEs | Participants with SAEs | Participants with Grade 3 or 4 AEs | Participants with Grade 5 AEs | |
| Ph2P1 (Letrozole) | 13 | 0 | 0 | 0 |
| Ph2P1 (Palbociclib + Letrozole) | 32 | 0 | 25 | 0 |
| Ph2P2 (Letrozole) | 20 | 0 | 2 | 0 |
| Ph2P2 (Palbociclib + Letrozole) | 46 | 1 | 32 | 0 |
| Phase 2 (Letrozole) | 33 | 0 | 2 | 0 |
| Phase 2 (Palbociclib + Letrozole) | 78 | 1 | 57 | 0 |
One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed. (NCT00721409)
Timeframe: Screening visit (≤ 28 Days prior to dosing)
| Intervention | Percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| CYP19A1 - A/A Genotype | CYP19A1 - C/A Genotype | CYP19A1 - C/C Genotype | CCND1 - A/A Genotype | CCND1 - G/A Genotype | CCND1 - G/G Genotype | |
| Ph2P1 (Letrozole) | 10.7 | 42.9 | 46.4 | 39.3 | 42.9 | 17.9 |
| Ph2P1 (Palbociclib + Letrozole) | 10.0 | 33.3 | 56.7 | 33.3 | 43.3 | 23.3 |
| Ph2P2 (Letrozole) | 2.2 | 32.6 | 65.2 | 21.7 | 50.0 | 28.3 |
| Ph2P2 (Palbociclib + Letrozole) | 6.5 | 34.8 | 58.7 | 21.7 | 50.0 | 28.3 |
| Phase 2 (Letrozole) | 5.4 | 36.5 | 58.1 | 28.4 | 47.3 | 24.3 |
| Phase 2 (Palbociclib + Letrozole) | 7.9 | 34.2 | 57.9 | 26.3 | 47.4 | 26.3 |
Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups. (NCT00721409)
Timeframe: Screening visit (≤ 28 Days prior to dosing)
| Intervention | Participants (Number) | |
|---|---|---|
| <=20% | >20% | |
| Ph2P1 (Letrozole) | 16 | 10 |
| Ph2P1 (Palbociclib + Letrozole) | 7 | 17 |
| Ph2P2 (Letrozole) | 15 | 30 |
| Ph2P2 (Palbociclib + Letrozole) | 19 | 31 |
| Phase 2 (Letrozole) | 31 | 40 |
| Phase 2 (Palbociclib + Letrozole) | 26 | 48 |
Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples. (NCT00721409)
Timeframe: Screening visit (≤ 28 Days prior to dosing)
| Intervention | Participants (Number) | ||
|---|---|---|---|
| CCND1>=1.5 | p16/INK4A<0.8 | CCND1>=1.5 and p16/INK4A<0.8 | |
| Ph2P1 (Letrozole) | 9 | 2 | 2 |
| Ph2P1 (Palbociclib + Letrozole) | 12 | 0 | 0 |
| Ph2P2 (Letrozole) | 44 | 12 | 8 |
| Ph2P2 (Palbociclib + Letrozole) | 39 | 19 | 8 |
Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression >0 and Negative: any expression=0. (NCT00721409)
Timeframe: Screening visit (≤ 28 Days prior to dosing)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| CyclinD1 - Positive | CyclinD1 - Negative | RB - Positive | RB - Negative | |
| Ph2P1 (Letrozole) | 16 | 0 | 16 | 0 |
| Ph2P1 (Palbociclib + Letrozole) | 10 | 2 | 10 | 2 |
| Ph2P2 (Letrozole) | 16 | 3 | 16 | 2 |
| Ph2P2 (Palbociclib + Letrozole) | 31 | 1 | 31 | 0 |
| Phase 2 (Letrozole) | 32 | 3 | 32 | 2 |
| Phase 2 (Palbociclib + Letrozole) | 41 | 3 | 41 | 2 |
Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group. (NCT00721409)
Timeframe: Screening visit (≤ 28 Days prior to dosing)
| Intervention | Copy number (Mean) | |
|---|---|---|
| CCND1 | p16/INK4A | |
| Phase 2 (Letrozole) | 2.73 | 0.87 |
| Phase 2 (Palbociclib + Letrozole) | 2.76 | 0.83 |
Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse. (NCT00036270)
Timeframe: Baseline (Month 0) up to 2.75 years
| Intervention | Events (disease relapse or death) (Number) |
|---|---|
| Exemestane | 352 |
| Tamoxifen Followed by Exemestane | 388 |
Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 5 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse. (NCT00036270)
Timeframe: Baseline (Month 0) up to 5 years
| Intervention | Events (disease relapse or death) (Number) |
|---|---|
| Exemestane | 712 |
| Tamoxifen Followed by Exemestane | 714 |
Number of events (death) to time of observation for OS. OS is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact. (NCT00036270)
Timeframe: Baseline (Month 0) up to 5 years
| Intervention | Events (death) (Number) |
|---|---|
| Exemestane | 485 |
| Tamoxifen Followed by Exemestane | 476 |
Number of events to time of observation for relapse. Relapse is defined as all recurrences of the primary tumor (loco-regional and distant recurrence), second primary breast cancer, contralateral breast cancer. (NCT00036270)
Timeframe: Baseline (Month 0) up to 5 years
| Intervention | Events (disease relapse) (Number) |
|---|---|
| Exemestane | 499 |
| Tamoxifen Followed by Exemestane | 521 |
Number of participants with new primary non-breast cancers which included colorectal cancer, lung cancer, endometrial cancer, ductal carcinoma in situ (DCIS) and other primary cancer types. (NCT00036270)
Timeframe: Baseline (Month 0) up to 5 years
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Colorectal cancer | Lung cancer | Endometrial cancer | DCIS | Other primary cancer types | |
| Exemestane | 43 | 24 | 7 | 3 | 110 |
| Tamoxifen Followed by Exemestane | 32 | 17 | 17 | 4 | 106 |
Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event. (NCT00553410)
Timeframe: 5-year estimates, reported at a median follow-up of 60 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Continuous Letrozole | 91.2 |
| Arm B: Intermittent Letrozole | 90.9 |
Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit. (NCT00553410)
Timeframe: 5-year estimates, reported at a median follow-up of 60 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Continuous Letrozole | 87.5 |
| Arm B: Intermittent Letrozole | 85.8 |
"Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.*~*This endpoint replaced DDFS, which was specified in the protocol" (NCT00553410)
Timeframe: 5-year estimates, reported at a median follow-up of 60 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Continuous Letrozole | 92.5 |
| Arm B: Intermittent Letrozole | 93.2 |
Duration of time from randomization to death from any cause, or was censored at the date last known alive. (Note, for patients who withdrew consent or were lost to follow-up but follow-up for survival was possible through hospital or registry records, OS was censored at the date last known alive rather than date of last follow-up/withdrawn consent). (NCT00553410)
Timeframe: 5-year estimates, reported at a median follow-up of 60 months
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Continuous Letrozole | 93.7 |
| Arm B: Intermittent Letrozole | 94.3 |
The EuroQol-5D (version 3L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) |
|---|---|
| Palbociclib + Fulvestrant | -1.8 |
| Placebo + Fulvestrant | -2.6 |
The EuroQol-5D (version 3L) is a brief self-administered, validated instrument consisting of 2 parts. The first part consists of 5 descriptors of current health state (mobility, self care, usual activities, pain/discomfort, and anxiety/ depression); a participant is asked to rate each state on a three level scale (1=no problem, 2=some problem, and 3=extreme problem) with higher levels indicating greater severity/ impairment Published weights are available that allow for the creation of a single summary score called the EQ-5D index, which basically ranges from 0 to 1 with low scores representing a higher level of dysfunction and 1 as perfect health. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) |
|---|---|
| Palbociclib + Fulvestrant | 0.006 |
| Placebo + Fulvestrant | -0.031 |
CBR is defined as the overall complete response (CR), partial response (PR) , or stable disease (SD) ≥24 weeks according to the RECIST version 1.1. Clinical Benefit Response Rate (CBRR) is defined as the proportion of participants with CR, PR, or SD ≥24 weeks relative to all randomized participants and randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received antitumor treatment other than the study medication prior to reaching a CR or PR, a best response of SD ≥24 weeks, or who died, progressed, or dropped out for any reason prior to reaching a CR or PR and a best response of SD ≥24 weeks was counted as non-responders in the assessment of CBR. Per RECIST v1.1 for target lesions and assessed by MRI: CR, disappearance of all target lesions; PR, ≥30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR. (NCT01942135)
Timeframe: From randomization until end of treatment (assessed up to 12 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Palbociclib + Fulvestrant | 34.0 |
| Placebo + Fulvestrant | 19.0 |
DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date was used. DR was calculated as [the date response ended (ie, date of PD or death) - first CR or PR date + 1)]/30.4. Kaplan-Meier estimate of median of the DR is provided below. No inferential statistical analysis were done for DR. The DR was only calculated for the participants with a CR or PR. (NCT01942135)
Timeframe: From randomization until end of treatment (assessed up to 12 months)
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Fulvestrant | 9.3 |
| Placebo + Fulvestrant | 5.7 |
OR is defined as the overall complete response (CR) or partial response (PR) according to the RECIST version 1.1 Objective Response Rate (ORR) is defined as the proportion of participants with CR or PR relative to all randomized participants and randomized participants with measurable disease at baseline. Participants who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment other than the study medication prior to reaching a CR or PR, or who died, progressed, or dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per response evaluation criteria in solid tumors criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), ≥30% decrease in the sum of the longest diameter of target lesions (longest for non-nodal and short axis for nodal target lesions); Overall Response (OR) = CR + PR. (NCT01942135)
Timeframe: From randomization until end of treatment (assessed up to 12 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Palbociclib + Fulvestrant | 10.4 |
| Placebo + Fulvestrant | 6.3 |
OS is defined as the time from date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time was censored to last date the participant was known to be alive. For participants lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Participants lacking survival data beyond randomization were to have their OS times be censored at randomization. The length of OS was calculated as OS time (months) = [death date (censor date) - randomization date + 1]/30.4. No inferential statistical analysis were done because of the immaturity of the OS data. (NCT01942135)
Timeframe: From randomization until death (up to approximately 36 months)
| Intervention | deaths (Number) |
|---|---|
| Palbociclib + Fulvestrant | 19 |
| Placebo + Fulvestrant | 9 |
PFS is the time from the date of randomization to the date of the first documentation of objective progression of disease (PD)or death due to any cause in absence of documented PD. Participants lacking an evaluation of tumor response after randomization had their PFS time censored on the date of randomization with the duration of a day. Participants with documentation of PD or death after a long interval (2 or more incomplete or non-evaluable assessments) since the last tumor assessment were censored at the time of last objective assessment that did not show PD. The length of PFS was calculated as PFS time (months) =[progression/death date(censor date) - randomization date + 1]/30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors(RECIST v1.1) a 20% increase in the sum of diameters of target lesions and the sum must also demonstrate an absolute increase of at least 5mm or unequivocal progression of existing non-target lesions or the appearance of new lesions. (NCT01942135)
Timeframe: From randomization date to date of first documentation of progression or death (assessed up to 12 months)
| Intervention | Months (Median) |
|---|---|
| Palbociclib + Fulvestrant | 9.2 |
| Placebo + Fulvestrant | 3.8 |
The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from 'not at all' to 'very much'. All scores are converted to a 0 to 100 scale. For symptom-oriented scales, a higher score represent more severe symptoms. (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Systemic therapy side effects | Breast symptoms | Arm symptoms | Upset by hair loss | |
| Palbociclib + Fulvestrant | 3.8 | -2.2 | -2.2 | 2.9 |
| Placebo + Fulvestrant | 3.4 | -1.3 | -2.0 | -6.0 |
"The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from not at all to very much and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant." (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Nausea and vomiting | Pain | Dyspnoea | Insomnia | Appetite loss | Constipation | Diarrhoea | Financial difficulties | |
| Palbociclib + Fulvestrant | 1.8 | 1.7 | -3.3 | 2.8 | -2.4 | 1.1 | 3.5 | 1.9 | -3.7 |
| Placebo + Fulvestrant | 3.3 | 4.2 | 2.0 | 3.3 | -0.4 | 1.7 | 2.8 | 2.4 | -4.0 |
The EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side effects, breast symptoms, arm symptoms, upset by hair loss). QLQ-BR23 questionnaire employs 4-point scales with responses from 'not at all' to 'very much'. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Body image | Sexual functioning | Sexual enjoyment | Future perspective | |
| Palbociclib + Fulvestrant | 1.9 | -1.1 | -5.2 | 8.1 |
| Placebo + Fulvestrant | -0.3 | -0.4 | -6.6 | 4.5 |
"The EORTC-QLQ-C30 is a 30-item questionnaire composed of five multi-item functional subscales (physical, role, emotional, cognitive , and social functioning), three multi-item symptom scales (fatigue, nausea/vomiting, and pain), a global quality of life (QOL) subscale, and six single item symptom scales assessing other cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and the financial impact of cancer). The questionnaire employs 28 4-point Likert scales with responses from not at all to very much and two 7-point Likert scales for global health and overall QOL. Responses to all items are then converted to a 0 to 100 scale. For functional and global QOL scales, higher scores represent a better level of functioning/QOL. For symptom-oriented scales, a higher score represents more severe symptoms. A 10-point or higher change in scores from baseline is considered clinically significant." (NCT01942135)
Timeframe: From Cycle 1 to 14, as of 05 December 2014.
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Global health status / QoL | Physical functioning | Role functioning | Emotional functioning | Cognitive functioning | Social functioning | |
| Palbociclib + Fulvestrant | -0.9 | -0.7 | -1.8 | 2.7 | -1.7 | -0.5 |
| Placebo + Fulvestrant | -4.0 | -1.7 | -3.7 | -1.9 | -2.9 | -0.6 |
"Ctrough for Fulvestrant (if applicable). The method of dispersion applied here is percent coefficient of variation (%CV)." (NCT01942135)
Timeframe: Cycles 2/Day 1 and Cycle 3/Day 1
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 2/Day 1 (N= 35, 19) | Cycle 3/Day 1 (N= 29, 14) | |
| Palbociclib + Fulvestrant | 11.75 | 9.90 |
| Placebo + Fulvestrant | 9.31 | 7.60 |
"Cmin for goserelin (if applicable). The method of dispersion applied here is percent coefficient of variation (%CV)." (NCT01942135)
Timeframe: Cycles 2/ Day 1 and Cycle 3/ Day 1
| Intervention | pg/mL (Geometric Mean) | |
|---|---|---|
| Cycle 2/Day 1 (N= 9, 5) | Cycle 3/Day 1 (N= 7, 3) | |
| Palbociclib + Fulvestrant | 295.1 | 344.8 |
| Placebo + Fulvestrant | 302.5 | 288.5 |
"Ctrough for palbociclib (if applicable). The method of dispersion applied here is percent coefficient of variation (%CV)." (NCT01942135)
Timeframe: Cycle 1/Day 15 and Cycle 2/Day 15
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| Cycle 1/Day 15 (N= 165) | Cycle 2/Day 15 (N= 160) | |
| Palbociclib + Fulvestrant | 70.70 | 75.29 |
An AE is any untoward medical occurrence in a clinical investigation patient administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening; requires hospitalization; results in persistent or significant disability or in congenital anomaly/birth defect. Severity will be graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0. (NCT01942135)
Timeframe: From the signing of the informed consent until 28 days after the last dose of study medication up to 14 months
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| With AEs | With SAEs | With Grade 3 or 4 AEs | With Grade 5 AEs | Discontinued palbociclib/placebo due to AEs | |
| Palbociclib + Fulvestrant | 97.7 | 9.6 | 70.1 | 0.9 | 3.8 |
| Placebo + Fulvestrant | 89.0 | 14.0 | 18.0 | 1.2 | 4.1 |
One-, Two- or Three-year Survival Probability is defined as the probability of survival 1 year, 2 or 3 years after the date of randomization based on the Kaplan-Meier estimate. Survival time was censored to last date the participant is known to be alive. (NCT01942135)
Timeframe: From randomization until death (assessed up to 36 months)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Survival Probability at Month 12 | Survival Probability at Month 24 | Survival Probability at Month 36 | |
| Palbociclib + Fulvestrant | 89.3 | NA | NA |
| Placebo + Fulvestrant | 89.3 | NA | NA |
A time to event analysis was pre-specified for pain. An analysis of TTD in pain defined as time between baseline and first occurrence of increase of ≥10 points in pain. Deterioration will be defined increase in score of 10 points or greater from baseline. The Kaplan-Meier estimates of quartiles (time to deterioration) with 95% CI is mentioned below. (NCT01942135)
Timeframe: Baseline, Day 1 of Cycles 2 to 4, Day 1 of every alternate cycle after that until the end of treatment
| Intervention | Months (Median) | |
|---|---|---|
| 25% quartile | 50% quartile | |
| Palbociclib + Fulvestrant | 1.9 | 8.0 |
| Placebo + Fulvestrant | 1.0 | 2.8 |
The 12 month progression-free survival rate was defined as the proportion of patients who were alive progression-free 12 months after registration into the study. (NCT00601900)
Timeframe: At 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Endocrine Therapy With Monoclonal Antibody) | 73 |
| Arm II (Endocrine Therapy) | 61 |
The 6 month progression-free survival rate was defined as the proportion of patients who were alive progression-free 6 months after registration into the study. (NCT00601900)
Timeframe: At 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I (Endocrine Therapy With Monoclonal Antibody) | 87 |
| Arm II (Endocrine Therapy) | 77 |
OS is defined as the time from study entry to death from any cause. The median OS was estimated using the Kaplan-Meier method. (NCT00601900)
Timeframe: Assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Endocrine Therapy With Monoclonal Antibody) | 47.2 |
| Arm II (Endocrine Therapy) | 43.9 |
The Primary Endpoint for this study was to compare the progression-free survival of letrozole therapy alone with the combination of letrozole therapy plus bevacizumab as first-line treatment in women with estrogen- and/or progesterone-receptor-positive advanced breast cancer. Progression-free survival (PFS) was defined as the time from randomization until disease progression or death, whichever occurs first. The median PFS was estimated using the Kaplan-Meier method. Progression was assessed per RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions from baseline or the appearance of new lesions. (NCT00601900)
Timeframe: From randomization until disease progression or death whichever occurs first, assessed up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm I (Endocrine Therapy With Monoclonal Antibody) | 20.2 |
| Arm II (Endocrine Therapy) | 15.6 |
Response was defined using RECIST criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions. (NCT00601900)
Timeframe: Assessed up to 5 years
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | |
| Arm I (Endocrine Therapy With Monoclonal Antibody) | 4 | 65 | 22 |
| Arm II (Endocrine Therapy) | 7 | 42 | 34 |
Percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1.CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters; SD = Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease: PD = At least a 20% increase in the sum of diameter of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition to the relative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02278120)
Timeframe: Up to approximately 25 months
| Intervention | Percentage of participants (Number) |
|---|---|
| LEE011 + NSAI/Tamoxifen + Goserelin | 79.1 |
| LEE011 Placebo + NSAI/Tamoxifen+ Goserelin | 69.7 |
Time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer (NCT02278120)
Timeframe: Up to approximately 25 months
| Intervention | Months (Median) |
|---|---|
| LEE011 + NSAI/Tamoxifen + Goserelin | 21.3 |
| LEE011 Placebo + NSAI/Tamoxifen+ Goserelin | 17.5 |
ORR is the percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1. CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. (NCT02278120)
Timeframe: Up to approximately 25 months
| Intervention | Percentage of participants (Number) |
|---|---|
| LEE011 + NSAI/Tamoxifen + Goserelin | 40.9 |
| LEE011 Placebo + NSAI/Tamoxifen+ Goserelin | 29.7 |
PFS, defined as the time from the date of randomization to the date of the first documented progression or death due to any cause and assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1]. PFS was assessed via a local radiology assessment according to RECIST 1.1 (NCT02278120)
Timeframe: Up to approximatley 25 months
| Intervention | Months (Median) |
|---|---|
| LEE011 + NSAI/Tamoxifen + Goserelin | 23.8 |
| LEE011 Placebo + NSAI/Tamoxifen+ Goserelin | 13.0 |
Time to response is the time from the date of randomization to the first documented response (CR or PR, which must be confirmed subsequently) according to RECIST 1.1. All patients will be included in time to response calculations. Patients who do not achieve a confirmed response will be censored at the maximum follow-up time (i.e. first patient first visit to last patient last visit used for the analysis) for patients who had a PFS event (i.e. either progressed or died due to any cause) or at the date of last adequate tumor assessment otherwise. (NCT02278120)
Timeframe: Up to approximately 25 months
| Intervention | months (Median) |
|---|---|
| LEE011 + NSAI/Tamoxifen + Goserelin | NA |
| LEE011 Placebo + NSAI/Tamoxifen+ Goserelin | NA |
Compare time to distant recurrence-free survival (DRFS). Distant recurrence is defined according to STEEP criteria as the time from randomization to the date of the first event: distant recurrence or death from any cause. Patients with a locoregional recurrence will continue to be followed for DRFS. Surviving patients who are event-free will be censored at: the date of last disease assessment, or withdrawal of consent to be followed, or death whichever came first. Direct comparison between arms used time to DRFS events and Kaplan-Meier Log-rank analysis. Due to the medians not yet achieved, the percentage of patients considered DRFS at 4 years is reported. (NCT02513394)
Timeframe: 4 years
| Intervention | percentage of patients (Number) |
|---|---|
| Palbociclib Plus Endocrine Therapy (Arm A) | 86.2 |
| Endocrine Therapy Alone (Arm B) | 87.8 |
Invasive disease-free survival (iDFS) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer (EBC) at 4 years. iDFS is defined as the time from randomization to the date of the first event: local/regional invasive ipsilateral recurrence, contralateral invasive breast cancer, distant recurrence, second primary invasive cancer of non-breast origin or death from any cause. Direct comparison between arms used time to iDFS events and Kaplan-Meier Log-rank analysis. Due to the medians not yet achieved, the percentage of patients considered iDFS at 4 years is reported. (NCT02513394)
Timeframe: 4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Palbociclib Plus Endocrine Therapy (Arm A) | 84.2 |
| Endocrine Therapy Alone (Arm B) | 84.5 |
Invasive disease-free survival (iDFS, excluding second primary invasive cancers of non-breast origin) for the combination of at least 5 years endocrine therapy and 2-year palbociclib treatment versus at least 5 years endocrine therapy alone in patients with histologically confirmed HR+/HER2- invasive early breast cancer (EBC) at 4 years. iDFS excluding second primary invasive cancers of non-breast origin is defined as the time from randomization to the date of the first event: local/regional invasive ipsilateral recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause. Second primary invasive cancers of non-breast origin will not be considered as events for this endpoint. Direct comparison between arms used time to iDFS events and Kaplan-Meier Log-rank analysis. Due to the medians not yet achieved, the percentage of patients considered iDFS at 4 years is reported. (NCT02513394)
Timeframe: 4 years
| Intervention | percentage of patients (Number) |
|---|---|
| Palbociclib Plus Endocrine Therapy (Arm A) | 85.4 |
| Endocrine Therapy Alone (Arm B) | 86.0 |
Compare locoregional recurrence-free survival (LRRFS). LRRFS is defined as the time from randomization to the date of the first event: local/regional invasive ipsilateral recurrence, contralateral invasive breast cancer, or death from any cause. Patients with second primary invasive cancers of non-breast origin or distant recurrence will be censored at the date of diagnosis. Surviving patients who are event-free will be censored at: the date of last disease assessment, or withdrawal of consent to be followed, whichever occurs first. (NCT02513394)
Timeframe: 4 years
| Intervention | percentage of patients (Number) |
|---|---|
| Palbociclib Plus Endocrine Therapy (Arm A) | 96.8 |
| Endocrine Therapy Alone (Arm B) | 95.4 |
Compare overall survival (OS). Overall survival is defined as the time period between randomization and death. Surviving patients classified as lost-to-follow up or having withdrawn consent to be followed will be censored at their date of last contact or withdrawal of consent to be followed, whichever occurs first. (NCT02513394)
Timeframe: 4 years
| Intervention | percentage of patients (Number) |
|---|---|
| Palbociclib Plus Endocrine Therapy (Arm A) | 93.8 |
| Endocrine Therapy Alone (Arm B) | 95.2 |
Olaparib AUC0-τ, in the presence and absence of co-administered anastrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 55.49 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 44.33 |
Olaparib Cmax ss in the presence and absence of co-administered anastrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 24
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Olaparib (Treatment Period 1) | 9.490 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 8.256 |
Olaparib AUC0-τ, in the presence and absence of co-administered letrozole, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 61.77 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 67.82 |
Olaparib Cmax ss in the presence and absence of co-administered letrozole, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Olaparib (Treatment Period 1) | 10.05 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 10.48 |
Anastrozole Area under plasma concentration-time curve over the dosing interval at steady state (AUC0-τ), in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 696.8 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 582.5 |
Anastrozole maximum plasma concentration at steady state (Cmax ss) in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 19 and Day 24
| Intervention | micrograms per millilitre (mcg/mL) (Geometric Mean) |
|---|---|
| Cohort 2 - Anastrozole Alone (Treatment Period 2) | 40.98 |
| Cohort 2 - Olaparib + Anastrozole (Treatment Period 3) | 35.83 |
Letrozole AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 2292 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 2167 |
Letrozole Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post-dose on Day 38 and Day 43
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 3 - Letrozole Alone (Treatment Period 2) | 118.9 |
| Cohort 3 - Olaparib + Letrozole (Treatment Period 3) | 111.8 |
Olaparib AUC0-τ, in the presence and absence of co-administered tamoxifen, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 62.12 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 42.27 |
Olaparib Cmax ss in the presence and absence of co-administered tamoxifen, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 hours post morning dose on Day 5 and Day 31
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Cohort 1 - Olaparib (Treatment Period 1) | 9.456 |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 7.216 |
Tamoxifen, N-DMT and endoxifen AUC0-τ, in the presence and absence of co-administered olaparib, and associated AUC0-τ treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | microgram x hour/millilitre (mcg*h/mL) (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 2751 | 2955 | 115.8 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 2233 | 3189 | 119.3 |
Tamoxifen, N-desmethyl tamoxifen (N-DMT) and endoxifen Cmax ss in the presence and absence of co-administered olaparib, and associated Cmax ss treatment ratios (NCT02093351)
Timeframe: Pre-dose and at 1, 2, 4, 5, 6, 8, 12 and 24 hours post-dose on Day 26 and Day 31
| Intervention | mcg/mL (Geometric Mean) | ||
|---|---|---|---|
| PK analysis of tamoxifen | PK analysis of N-DMT | PK analysis of endoxifen | |
| Cohort 1 - Olaparib + Tamoxifen (Treatment Period 3) | 154.2 | 149.1 | 5.727 |
| Cohort 1 - Tamoxifen Alone (Treatment Period 2) | 130.3 | 162.9 | 5.923 |
Cumulative incidence of arterial thrombotic events, as defined by CTCAE version 4.0 (grade ≥1 stroke or transient ischaemic attack; grade ≥2 acute coronary syndrome or cerebrovascular ischaemia; grade ≥3 myocardial infarction, peripheral ischaemia, or visceral arterial ischaemia; and grade ≥4 selected thromboembolic events [cerebrovascular event, arterial insufficiency]). (NCT00382070)
Timeframe: 7 years
| Intervention | percentage of patients (Number) |
|---|---|
| Group 2 Letrozole | 4.0 |
| Group 1 Placebo | 3.4 |
Cumulative incidence of breast-cancer-free interval events. BCFI events include local-regional recurrence, distant recurrence or contralateral breast cancer as a first event. (NCT00382070)
Timeframe: 7 years
| Intervention | percentage of patients (Number) |
|---|---|
| Group 2 Letrozole | 6.7 |
| Group 1 Placebo | 10 |
Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer. (NCT00382070)
Timeframe: 7 years.
| Intervention | percentage of patients free of disease (Number) |
|---|---|
| Group 2 Letrozole | 84.7 |
| Group 1 Placebo | 81.3 |
Cumulative incidence of distant recurrences. (NCT00382070)
Timeframe: 7 years
| Intervention | percentage of patients (Number) |
|---|---|
| Group 2 Letrozole | 3.9 |
| Group 1 Placebo | 5.8 |
Cumulative incidence of osteoporotic-related fractures defined as Colles', hip or spinal fractures (NCT00382070)
Timeframe: 7 years
| Intervention | percentage of patients (Number) |
|---|---|
| Group 2 Letrozole | 5.4 |
| Group 1 Placebo | 4.8 |
Percentage of patients alive (NCT00382070)
Timeframe: 7 years
| Intervention | percentage of patients alive (Number) |
|---|---|
| Group 2 Letrozole | 91.8 |
| Group 1 Placebo | 92.3 |
Based on WHO tumor measurement and response criteria [1], measured from the start of treatment across all time points until disease progression or the end of 6 cycles of neoadjuvant therapies, whichever comes first. Response was determined by the IBCSG Head of Medical Affairs. An internal review (IR) form was created to record the final determination on best overall response. Confirmation of partial or complete response by an additional scan was not required in this trial. Best overall response was assessed based on changes in tumor size from baseline to the assessments after 3 and after 6 cycles (denoted as day 1 of cycle 4 and prior to surgery respectively) as measured physically by caliper or ruler and as measured by breast tumor imaging (i.e., bilateral mammography and breast ultrasound). (NCT02005887)
Timeframe: From day 1 of cycle 1 across all time points until disease progression
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 46.2 |
| Arm B: Degarelix + Letrozol | 44.0 |
The percent change in Ki67 expression from pre-treatment diagnostic (baseline) biopsy to surgery, calculated as (surgery-baseline)/baseline*100. (NCT02005887)
Timeframe: Before day1 of cycle 1 and surgery
| Intervention | percentage change (Median) |
|---|---|
| Arm A: Triptorelin + Letrozol | -10.0 |
| Arm B: Degarelix + Letrozol | -8.0 |
The patient-reported symptoms (PRS) will be assessed using the Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-ES) comprising 18 items (each has score range from 0 to 4) with a possible minimum total score of 0 and maximum total score of 72 (72 is best). Functional Assessment of Chronic Illness Therapy (FACIT) guidelines will be used for scoring and interpretation of the FACT-ES total score. (NCT02005887)
Timeframe: At baseline, day 1 of cycle 2 and cycle 4 and prior to surgery; cycle 4 reported
| Intervention | units on a scale (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 64 |
| Arm B: Degarelix + Letrozol | 62 |
Whether or not patient undergoes BCS (per Surgery form). (NCT02005887)
Timeframe: During surgery, an average of 2 hours
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 42.3 |
| Arm B: Degarelix + Letrozol | 52.2 |
The number of lymph nodes assessed at surgery minus the number of positives nodes identified, equal to zero. (NCT02005887)
Timeframe: During surgery, an average of 2 hours
| Intervention | percentage of patients (Number) |
|---|---|
| Arm A: Triptorelin + Letrozol | 34.6 |
| Arm B: Degarelix + Letrozol | 43.5 |
Preoperative Endocrine Prognostic Index (PEPI) is the sum of the risk points (tumor size, nodal status, Ki67 level, ER status) with a 0-12 score representing the best prognostic feature (0 being the best score; 12 being the worst score), as previously determined to be associated with recurrence-free survival. (NCT02005887)
Timeframe: After 24 weeks or the time of surgery
| Intervention | scores on a scale (Median) |
|---|---|
| Arm A: Triptorelin + Letrozol | 6.5 |
| Arm B: Degarelix + Letrozol | 6.0 |
Time from the first injection of degarelix or triptorelin to the first assessment of centrally assessed 17-β-estradiol (E2) level in the range of optimal ovarian function suppression (≤2.72 pg/mL or ≤10 pmol/L) during the 6 cycles of neoadjuvant treatments. (NCT02005887)
Timeframe: up to 24 weeks
| Intervention | days (Median) |
|---|---|
| Arm A: Triptorelin + Letrozol | 14 |
| Arm B: Degarelix + Letrozol | 3 |
Percentage of participants alive from date of initiation of palbociclib treatment through up to 2 or above progression-based lines of therapy were recorded and reported in this outcome measure. Percentage of participants who alive after 1 year post Palbociclib treatment initiation were based on the Kaplan-Meier estimate. (NCT03159195)
Timeframe: 1 Year (Month 12) post Palbociclib treatment initiation (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Aromatase Inhibitor (P+AI) | 95.1 |
| Palbociclib + Fulvestrant (P+FV) | 87.9 |
Percentage of participants alive from date of initiation of palbociclib treatment through up to 2 or above progression-based lines of therapy were recorded and reported in this outcome measure. Percentage of participants who alive after 2 years post Palbociclib treatment initiation were based on the Kaplan-Meier estimate. (NCT03159195)
Timeframe: 2 years (Month 24) post Palbociclib treatment initiation (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Aromatase Inhibitor (P+AI) | 90.1 |
CBR was defined as the percentage of participants who achieved complete (where 'complete response' was recorded at any time on treatment) or partial response (where 'partial response' was recorded at any time on treatment), or stable disease at greater than equal to (>=) 24 weeks on palbociclib combination therapy. Stable disease was defined as no evidence of complete or partial response, and no progression on palbociclib therapy for 24 weeks or greater. Complete response - Complete resolution of all visible disease. Partial response - Partial reduction in size of visible disease in some or all areas without any areas of increase in visible disease. (NCT03159195)
Timeframe: From initiation of treatment up to disease progression (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Aromatase Inhibitor (P+AI) | 93.8 |
| Palbociclib + Fulvestrant (P+FV) | 93.2 |
ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) on palbociclib combination therapy according to the RECIST version 1.1 recorded from first dose of study treatment until disease progression due to any cause. Complete response: complete resolution of all visible disease. Partial response: partial reduction in size of visible disease in some or all areas without any areas of increase in visible disease. (NCT03159195)
Timeframe: From initiation of treatment up to disease progression (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Aromatase Inhibitor (P+AI) | 79.5 |
| Palbociclib + Fulvestrant (P+FV) | 74.0 |
PFS was defined as the time from palbociclib combination treatment initiation until 1) clinician documented disease progression (PD) while on palbociclib, 2) death, 3) start of a new therapy line after final palbociclib dose, if the reason for discontinuation of palbociclib was disease progression, or 4) last available follow-up, whichever occurred first. Participants who did not experience a progression event (items 1, 2 and 3) were censored at date of last available follow-up. PFS (in months) was calculated as (first event date - palbociclib initiation date + 1)/30.4. Progressive disease - An increase in visible disease and/or presence of any new lesions; included cases where the clinician indicated progressive disease. Percentage of participants with PFS events at 12 months based on the Kaplan-Meier estimate were reported. (NCT03159195)
Timeframe: Day 1 of palbociclib combination treatment up to Month 12 (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Aromatase Inhibitor (P+AI) | 84.1 |
| Palbociclib + Fulvestrant (P+FV) | 79.8 |
PFS was defined as the time from palbociclib combination treatment initiation until 1) clinician documented disease progression (PD) while on palbociclib, 2) death, 3) start of a new therapy line after final palbociclib dose, if the reason for discontinuation of palbociclib was disease progression, or 4) last available follow-up, whichever occurred first. Participants who did not experience a progression event (items 1, 2 and 3) were censored at date of last available follow-up. PFS (in months) was calculated as (first event date - palbociclib initiation date + 1)/30.4. Progressive disease - An increase in visible disease and/or presence of any new lesions; included cases where the clinician indicated progressive disease. Percentage of participants with PFS events at 24 months based on the Kaplan-Meier estimate were reported. (NCT03159195)
Timeframe: Day 1 of palbociclib combination treatment up to Month 24 (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) |
|---|---|
| Palbociclib + Aromatase Inhibitor (P+AI) | 64.3 |
Best overall response was defined as the percentage of participants who achieved complete (where 'complete response' was recorded at any time on treatment), partial response (where 'partial response' was recorded at any time on treatment) and stable disease at greater than equal to (>=) 24 weeks on palbociclib combination therapy. Stable disease was defined as no evidence of complete or partial response, and no progression on palbociclib therapy for 24 weeks or greater. (NCT03159195)
Timeframe: From initiation of treatment up to disease progression (data recorded during 4 years of retrospective observation period)
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease >=24 Weeks | Stable Disease <24 Weeks | |
| Palbociclib + Aromatase Inhibitor (P+AI) | 11.0 | 68.5 | 14.3 | 1.4 |
| Palbociclib + Fulvestrant (P+FV) | 8.5 | 65.5 | 11.0 | 3.2 |
CBR was defined as the percentage of patients achieving a Complete Response (CR), a Partial Response (PR) or a stabilization of the disease (SD) > 6 months: the response will be evaluated according to the RECIST criteria. In the patients without measurable disease at the baseline time, the clinical benefit will be defined as the absence of progression > 6 months. (NCT00545077)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: Endocrine Therapy (ET) | 124 |
| Arm B: ET With Bevacizumab (ET-B) | 146 |
ORR to treatment is reflected by a frequency table containing the data of the best overall response (Complete Response, Partial Response,Stable Disease or Progressive Disease) experienced for each patient during treatment (recorded from the start of the treatment until disease progression) per arm. (NCT00545077)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: Endocrine Therapy (ET) | 32 |
| Arm B: ET With Bevacizumab (ET-B) | 58 |
OS was defined as the time elapsed since randomization, until the time in which death occurs for any reason. The patients lost in the follow-up will be censured at the date of the last follow-up. (NCT00545077)
Timeframe: Up to 2 years
| Intervention | Months (Median) |
|---|---|
| Arm A: Endocrine Therapy (ET) | 51.8 |
| Arm B: ET With Bevacizumab (ET-B) | 52.1 |
PFS was defined as the time elapsed from randomization until the date in which the progression of the disease or the death for any reason (whichever occurs first) is documented. (NCT00545077)
Timeframe: Up to 2 years
| Intervention | Months (Median) |
|---|---|
| Arm A: Endocrine Therapy (ET) | 14.4 |
| Arm B: ET With Bevacizumab (ET-B) | 19.3 |
RD was defined as the time elapsed from when a partial or complete response is verified until the time in which progression or death occurs. (NCT00545077)
Timeframe: Up to 2 years
| Intervention | Months (Median) |
|---|---|
| Arm A: Endocrine Therapy (ET) | 13.32 |
| Arm B: ET With Bevacizumab (ET-B) | 17.59 |
TTF was defined as the time elapsed since randomization until the date the treatment is discontinued for any reason (progression disease, treatment toxicity or death). (NCT00545077)
Timeframe: Up to 2 years
| Intervention | Months (Median) |
|---|---|
| Arm A: Endocrine Therapy (ET) | 14.4 |
| Arm B: ET With Bevacizumab (ET-B) | 15.1 |
"CBR was defined as the percentage of participants with a best overall response of CR or PR or stable disease (SD) lasting 24 weeks or longer as defined in RECIST 1.1 as per investigator assessment.~CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.~SD: Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progressive disease." (NCT02422615)
Timeframe: Up to approximately 26 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ribociclib + Fulvestrant | 70.2 |
| Placebo + Fulvestrant | 62.8 |
"DOR was defined as the time from the first documented response (CR or PR) to the first documented progression or death due to underlying cancer as defined in RECIST 1.1 per investigator assessment. The Kaplan-Meier method was used to estimate DOR, and the median DOR, along with 95% confidence intervals, was reported for each treatment group. If a participant had not had an event, duration was censored at the date of last adequate tumor assessment.~CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters." (NCT02422615)
Timeframe: From first documented response to progression or death, assessed up to approximately 26 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | NA |
| Placebo + Fulvestrant | NA |
"ORR was defined as the percentage of participants with the best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 as per investigator assessment.~CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters." (NCT02422615)
Timeframe: Up to approximately 26 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Ribociclib + Fulvestrant | 32.4 |
| Placebo + Fulvestrant | 21.5 |
"OS was defined as the time from the date of randomization to the date of death from any cause. In cases where the patient's death was not recorded, the OS value was censored at the date of the last known patient's survival status. As per protocol, the final OS analysis was conducted after approximately 351 deaths were documented.~OS was estimated using the Kaplan-Meier method. The median OS, along with 95% confidence intervals (CIs), was reported for each treatment group.~The distribution of OS between the two treatment arms was compared using a log-rank test at one-sided cumulative 2.5% level of significance. A stratified Cox regression was used to estimate the OS hazard ratio and the associated 95% CI." (NCT02422615)
Timeframe: From randomization to death, assessed up to approximately 46 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | NA |
| Placebo + Fulvestrant | 40.0 |
"PFS was defined as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason. In cases where patients did not experience an event, the PFS was censored at the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered as documented disease progression.~PFS was assessed via BIRC assessment according to RECIST 1.1. The Kaplan-Meier method was used to estimate PFS, and the median PFS, along with 95% confidence intervals, was reported for each treatment group." (NCT02422615)
Timeframe: From randomization to first documented progression or death, assessed up to approximately 26 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | NA |
| Placebo + Fulvestrant | 10.9 |
"PFS was defined as the period starting from the date of randomization to the date of the first documented progression or death caused by any reason. In cases where patients did not experience an event, the PFS was censored at the date of the last adequate tumor assessment. Clinical deterioration without objective radiological evidence was not considered as documented disease progression.~PFS was assessed via local radiology assessment according to RECIST 1.1. The Kaplan-Meier method was used to estimate PFS, and the median PFS, along with 95% confidence intervals, was reported for each treatment group.~The distribution of PFS between the two arms was compared using a stratified log-rank test at a one-sided 2.5% level of significance. The PFS hazard ratio with two-sided 95% confidence interval was derived from the stratified Cox proportional hazards model." (NCT02422615)
Timeframe: From randomization to first documented progression or death, assessed up to approximately 26 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | 20.5 |
| Placebo + Fulvestrant | 12.8 |
"The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, a GHS/QoL scale, and 6 single items. GHS/QoL scale scores range between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.~The time to definitive 10% deterioration is defined as the time from the date of randomization to the date of event, which is defined as at least 10% relative to baseline worsening of the QoL score (without further improvement above the threshold) or death due to any cause. The Kaplan-Meier method was used to estimate the distribution, and the median time to definitive 10% deterioration, along with 95% confidence intervals, was reported for each treatment group. If a patient had not had an event, time to deterioration was censored at the date of the last adequate QoL evaluation." (NCT02422615)
Timeframe: Up to approximately 26 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | NA |
| Placebo + Fulvestrant | 19.4 |
ECOG PS categorized patients based on their ability to perform daily activities and self-care, with scores ranging from 0 to 5. A score of 0 indicated no restrictions in activity, while higher scores indicated increasing limitations. Time to definitive deterioration was defined as the time from the date of randomization to the date of the event, defined as experiencing an increase in ECOG PS by at least one category from the baseline or death. A deterioration was considered definitive if no improvements in the ECOG PS were observed at a subsequent time. The Kaplan-Meier method was used to estimate the distribution, and the median time to definitive deterioration, along with 95% confidence intervals, was reported for each treatment group. Patients receiving any further therapy prior to definitive worsening were censored at their date of last assessment prior to start of therapy. Patients that had not worsened at the data cutoff point were censored at the date of last assessment. (NCT02422615)
Timeframe: Up to approximately 26 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | NA |
| Placebo + Fulvestrant | NA |
"TTR was defined as the time from randomization to the first documented and confirmed response (CR or PR) as defined by RECIST 1.1 per investigator assessment. The Kaplan-Meier method was used to estimate TTR, and the median TTR, along with 95% confidence intervals, was reported for each treatment group. Participants who did not achieve a confirmed response were censored at the maximum follow-up time for patients who had a PFS event (i.e. either progressed or died due to any cause) or at the date of last adequate tumor assessment otherwise.~CR: Disappearance of all lesions with lymph nodes measuring < 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters." (NCT02422615)
Timeframe: From randomization to first response, assessed up to approximately 26 months
| Intervention | Months (Median) |
|---|---|
| Ribociclib + Fulvestrant | NA |
| Placebo + Fulvestrant | NA |
"Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication.~On-treatment deaths were collected from start of treatment to 30 days after last dose of treatment or one day before first administration of crossover treatment (for crossover participants), whichever came first Crossover on-treatment deaths were collected from start of crossover treatment up to 30 days after last dose of crossover treatment.~Post-treatment efficacy/survival follow-up deaths were collected from day 31 after last dose of study treatment to end of study.~Crossover post-treatment efficacy/survival follow-up deaths were collected from day 31 after last dose of crossover treatment to end of study." (NCT02422615)
Timeframe: Pre-treatment: Up to 28 days prior to treatment. On-treatment: Up to 82 months. Crossover on-treatment: Up to 3.5 months. Post-treatment efficacy/survival follow-up: Up to 82 months. Crossover post-treatment efficacy/survival follow-up: Up to 1 year
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Pre-treatment deaths | On-treatment deaths | Post-treatment efficacy/survival deaths | All deaths | |
| Ribociclib + Fulvestrant | 0 | 13 | 264 | 277 |
"Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication.~On-treatment deaths were collected from start of treatment to 30 days after last dose of treatment or one day before first administration of crossover treatment (for crossover participants), whichever came first Crossover on-treatment deaths were collected from start of crossover treatment up to 30 days after last dose of crossover treatment.~Post-treatment efficacy/survival follow-up deaths were collected from day 31 after last dose of study treatment to end of study.~Crossover post-treatment efficacy/survival follow-up deaths were collected from day 31 after last dose of crossover treatment to end of study." (NCT02422615)
Timeframe: Pre-treatment: Up to 28 days prior to treatment. On-treatment: Up to 82 months. Crossover on-treatment: Up to 3.5 months. Post-treatment efficacy/survival follow-up: Up to 82 months. Crossover post-treatment efficacy/survival follow-up: Up to 1 year
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Pre-treatment deaths | On-treatment deaths | Crossover on-treatment deaths | Post-treatment efficacy/survival deaths | Crossover post-treatment efficacy/survival deaths | All deaths | |
| Placebo + Fulvestrant | 0 | 8 | 0 | 153 | 1 | 162 |
"The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, a GHS/QoL scale, and 6 single items. GHS/QoL scale scores range between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.~The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicates improvement. For subjects who discontinued treatment without disease progression, post-treatment efficacy visits occurred every 8 weeks during the initial 18 months since start of treatment, followed by visits every 12 weeks until disease progression." (NCT02422615)
Timeframe: Baseline, every 8 weeks after randomization during 18 months, then every 12 weeks up to end of treatment; end of treatment; and every 8 or 12 weeks post-treatment until progression (post-treatment efficacy visits), assessed up to approximately 26 months
| Intervention | Score on a Scale (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 3 Day 1 (Cycle= 28 days) | Cycle 5 Day 1 (Cycle= 28 days) | Cycle 7 Day 1 (Cycle= 28 days) | Cycle 9 Day 1 (Cycle= 28 days) | Cycle 11 Day 1 (Cycle= 28 days) | Cycle 13 Day 1 (Cycle= 28 days) | Cycle 15 Day 1 (Cycle= 28 days) | Cycle 17 Day 1 (Cycle= 28 days) | Cycle 19 Day 1 (Cycle= 28 days) | Cycle 22 Day 1 (Cycle= 28 days) | Cycle 25 Day 1 (Cycle= 28 days) | Cycle 28 Day 1 (Cycle= 28 days) | End of treatment (EOT) | Post EOT1 | Post EOT2 | Post EOT3 | Post EOT4 | |
| Placebo + Fulvestrant | 2.7 | 3.2 | 4.3 | 3.3 | 2.3 | 1.3 | 3.6 | 3.4 | 3.7 | 4.7 | 8.3 | 19.4 | -5.5 | -33.3 | -16.7 | -16.7 | -25.0 |
"The EORTC QLQ-C30 is a questionnaire that includes 5 functional scales, 3 symptom scales, a GHS/QoL scale, and 6 single items. GHS/QoL scale scores range between 0 and 100. A high score for GHS/QoL represents better functioning or QoL.~The change from baseline in the GHS/QoL score was assessed. A positive change from baseline indicates improvement. For subjects who discontinued treatment without disease progression, post-treatment efficacy visits occurred every 8 weeks during the initial 18 months since start of treatment, followed by visits every 12 weeks until disease progression." (NCT02422615)
Timeframe: Baseline, every 8 weeks after randomization during 18 months, then every 12 weeks up to end of treatment; end of treatment; and every 8 or 12 weeks post-treatment until progression (post-treatment efficacy visits), assessed up to approximately 26 months
| Intervention | Score on a Scale (Mean) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 3 Day 1 (Cycle= 28 days) | Cycle 5 Day 1 (Cycle= 28 days) | Cycle 7 Day 1 (Cycle= 28 days) | Cycle 9 Day 1 (Cycle= 28 days) | Cycle 11 Day 1 (Cycle= 28 days) | Cycle 13 Day 1 (Cycle= 28 days) | Cycle 15 Day 1 (Cycle= 28 days) | Cycle 17 Day 1 (Cycle= 28 days) | Cycle 19 Day 1 (Cycle= 28 days) | Cycle 22 Day 1 (Cycle= 28 days) | Cycle 25 Day 1 (Cycle= 28 days) | Cycle 28 Day 1 (Cycle= 28 days) | End of treatment (EOT) | Post EOT1 | Post EOT2 | Post EOT3 | Post EOT4 | Post EOT5 | Post EOT6 | Post EOT7 | Post EOT8 | Post EOT9 | Post EOT10 | |
| Ribociclib + Fulvestrant | 4.5 | 4.2 | 4.9 | 4.1 | 4.9 | 4.4 | 3.6 | 3.9 | 3.8 | 6.6 | 5.7 | 12.5 | -5.2 | 4.5 | -4.8 | 14.6 | 10.0 | 13.9 | 22.2 | 19.4 | 37.5 | 8.3 | -8.3 |
Blood samples were collected to assess the concentration by time point for LEQ803, a metabolite of ribociclib. Participants were classified into the following dose groups at each timepoint: 1) ribociclib 600 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 600 mg immediately prior to the blood collection without a dose change or interruption. 2) ribociclib 400 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 400 mg immediately prior to the blood collection without a dose change or interruption. 3) ribociclib 200 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 200 mg immediately prior to the blood collection without a dose change or interruption. (NCT02422615)
Timeframe: Cycle 1 and Cycle 2 at Day 15 pre-dose and at 2, 4, and 6 hours post-dose. Cycle = 28 days
| Intervention | ng/mL (Geometric Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 predose (ribociclib 600 mg) | Cycle 1 Day 15 2 hours post-dose (ribociclib 600 mg) | Cycle 1 Day 15 4 hours post-dose (ribociclib 600 mg) | Cycle 1 Day 15 6 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 predose (ribociclib 600 mg) | Cycle 2 Day 15 predose (ribociclib 400 mg) | Cycle 2 Day 15 2 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 2 hours post-dose (ribociclib 400 mg) | Cycle 2 Day 15 2 hours post-dose (ribociclib 200 mg) | Cycle 2 Day 15 4 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 4 hours post-dose (ribociclib 400 mg) | Cycle 2 Day 15 4 hours post-dose (ribociclib 200 mg) | Cycle 2 Day 15 6 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 6 hours post-dose (ribociclib 400 mg) | Cycle 2 Day 15 6 hours post-dose (ribociclib 200 mg) | |
| Ribociclib + Fulvestrant | 75.6 | 134 | 137 | 128 | 72.7 | 46.2 | 126 | 70.8 | 36.0 | 134 | 79.3 | 41.9 | 122 | 72.3 | 38.3 |
Blood samples were collected to assess the concentration by time point for ribociclib. Participants were classified into the following dose groups at each timepoint: 1) ribociclib 600 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 600 mg immediately prior to the blood collection without a dose change or interruption. 2) ribociclib 400 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 400 mg immediately prior to the blood collection without a dose change or interruption. 3) ribociclib 200 mg: consisted of all participants who provided evaluable concentrations after receiving at least 10 consecutive daily ribociclib doses of 200 mg immediately prior to the blood collection without a dose change or interruption. (NCT02422615)
Timeframe: Cycle 1 and Cycle 2 at Day 15 pre-dose and at 2, 4, and 6 hours post-dose. Cycle=28 days
| Intervention | nanogram (ng) / miliLiter (mL) (Geometric Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 predose (ribociclib 600 mg) | Cycle 1 Day 15 2 hours post-dose (ribociclib 600 mg) | Cycle 1 Day 15 4 hours post-dose (ribociclib 600 mg) | Cycle 1 Day 15 6 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 predose (ribociclib 600 mg) | Cycle 2 Day 15 predose (ribociclib 400 mg) | Cycle 2 Day 15 2 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 2 hours post-dose (ribociclib 400 mg) | Cycle 2 Day 15 2 hours post-dose (ribociclib 200 mg) | Cycle 2 Day 15 4 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 4 hours post-dose (ribociclib 400 mg) | Cycle 2 Day 15 4 hours post-dose (ribociclib 200 mg) | Cycle 2 Day 15 6 hours post-dose (ribociclib 600 mg) | Cycle 2 Day 15 6 hours post-dose (ribociclib 400 mg) | Cycle 2 Day 15 6 hours post-dose (ribociclib 200 mg) | |
| Ribociclib + Fulvestrant | 627 | 1670 | 1690 | 1420 | 553 | 220 | 1470 | 794 | 104 | 1610 | 913 | 112 | 1280 | 710 | 104 |
Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy. Pathologic complete response: no invasive cancer in the residual breast. Near pathologic complete response: residual disease of less than 1 cm in breast. (NCT00548184)
Timeframe: 12 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Pathologic Response | Near Complete Pathologic Response | Not Pathologic response | |
| Lapatinib + Trastuzumab | 18 | 16 | 30 |
CB is defined as the percentage of participants with evidence of confirmed CR, PR, or stable disease (SD) for at least 6 months. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the baseline measurement. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Months (Number) |
|---|---|
| Placebo + Letrozole 2.5 mg | 28.7 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 47.7 |
CB is defined as the percentage of participants with evidence of confirmed CR, PR, or stable disease (SD) for at least 6 months. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the baseline measurement. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Letrozole 2.5 mg | 50.6 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 55.8 |
Duration of response is defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD) until the first documented sign of disease progression or death due to any cause. The assessments of CR or PR required confirmation using bone scans. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 84.4 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 47.4 |
Duration of response is defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD) until the first documented sign of disease progression or death due to any cause. The assessments of CR or PR required confirmation using bone scans. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 72.6 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 60.1 |
The confirmation criteria for the evidence of brain metastases was the incidence of lesions occurring within any part of the central nervous system (CNS) as evidenced by radiological scans. Metastases are defined as the spread of cancer from one part of the body to another. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | participants (Number) |
|---|---|
| Placebo + Letrozole 2.5 mg | 4 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 6 |
The confirmation criteria for the evidence of brain metastases was the incidence of lesions occurring within any part of the central nervous system (CNS) as evidenced by radiological scans. Metastases are defined as the spread of cancer from one part of the body to another. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | participants (Number) |
|---|---|
| Placebo + Letrozole 2.5 mg | 2 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 1 |
PFS is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. The date of documented disease progression is defined as the date of radiological disease progression as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per RECIST 1.0, disease progression is defined as a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions. (NCT00073528)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Letrozole 2.5 mg | 476 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 413 |
PFS is defined as the time from randomization until the earliest date of disease progression (PD) or death due to any cause, if sooner. The date of documented PD is defined as the date of radiological PD as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per Response Evaluation Criteria in Solid Tumors (RECIST 1.0), PD is defined as a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions. (NCT00073528)
Timeframe: From the date of randomization until the date of the first documented progression or date of death from any cause, whichever came first, assessed for up to 46 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Letrozole 2.5 mg | 89 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 88 |
Overall survival was defined as the time from randomization until death due to any cause. (NCT00073528)
Timeframe: From date of randomization until date of death due to any cause, assessed up to 46 months
| Intervention | Weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 140.3 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 144.7 |
Overall survival was defined as the time from randomization until death due to any cause. (NCT00073528)
Timeframe: From date of randomization until date of death due to any cause, assessed up to 46 months
| Intervention | weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 176.3 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 170.9 |
OR is defined as the percentage of participants achieving either a confirmed complete response (CR) or partial response (PR). Response was assessed via Response Evaluation criteria in Solid Tumors (RECIST). The percentage of participants with response was calculated by using the formula: 100 * (number of participants with CR + number of participants with PR)/total number of participants. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Percent response rate (Number) |
|---|---|
| Placebo + Letrozole 2.5 mg | 14.8 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 27.9 |
OR is defined as the percentage of participants achieving either a confirmed complete response (CR) or partial response (PR). Response was assessed via Response Evaluation criteria in Solid Tumors (RECIST). The percentage of participants with response was calculated by using the formula: 100 * (number of participants with CR + number of participants with PR)/total number of participants. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo + Letrozole 2.5 mg | 27.8 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 30.5 |
PFS is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. The date of documented disease progression is defined as the date of radiological disease progression as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per RECIST 1.0, disease progression is defined as a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions. (NCT00073528)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
| Intervention | Weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 47.0 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 51.7 |
PFS is defined as the time from randomization until the earliest date of disease progression or death due to any cause, if sooner. The date of documented disease progression is defined as the date of radiological disease progression as assessed by the investigator based on imaging data and also by the clinical assessment of symptomatic progression. Per RECIST 1.0, disease progression is defined as a 20% increase in the sum of the LD of target lesions, taking as a reference the smallest sum LD recorded since the treatment started, or the appearance of 1 or more new lesions. (NCT00073528)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
| Intervention | Weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 13.0 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 35.4 |
TTP is defined as the interval between the date of randomization and the earliest date of disease progression or death due to breast cancer. Disease progression was based on the assessments by the Investigator. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 13.0 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 35.4 |
Time to seroconversion was defined as the time from the date of randomization until the first instance of serum HER2 (>15 ng/mL) on two consecutive occasions. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | NA |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 36.1 |
TTP is defined as the interval between the date of randomization and the earliest date of disease progression or death due to breast cancer. Disease progression was based on the assessments by the Investigator. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | weeks (Median) |
|---|---|
| Placebo + Letrozole 2.5 mg | 47.0 |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 51.7 |
Quality of Life (QOL) was assessed using the FACT-B questionnaire, which is a 37-item (27 general and 10 breast cancer-specific questions) self-reporting instrument consisting of 5 dimensions: physical-, social/family-, emotional-, functional-well being, and a breast cancer subscale. Higher scores on the FACT-B scales indicate a higher QOL; each ranging from 0 (not at all) to 4 (very much). The score is transformed for FACT-B and results in a total score ranging from 0 to 144. The FACT-B is designed to measure multidimensional QOL in participants with breast cancer. (NCT00073528)
Timeframe: Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
| Intervention | Adjusted mean change (Number) | ||||
|---|---|---|---|---|---|
| Week 12 | Week 24 | Week 36 | Week 48 | Conclusion/WD | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 3.3 | 1.9 | 1.4 | 0.3 | -9.0 |
| Placebo + Letrozole 2.5 mg | 1.5 | 3.8 | 3.3 | 2.9 | -9.4 |
FACT-G is a subscale of the FACT-B QOL questionnaire and consists of 27 questions grouped into 4 domains that measure a participant's physical, functional, social and family, and emotional well-being. FACT-G is assessed on a five-point Likert-type scale, with scores ranging from 0 to 4 (0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, 4=very much). The total score is calculated as the sum of the item scores on the subscale; the total ranges from 0 to 108, with higher score indicating a better quality of life. (NCT00073528)
Timeframe: Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
| Intervention | Adjusted mean change (Number) | ||||
|---|---|---|---|---|---|
| Week 12 | Week 24 | Week 36 | Week 48 | Conclusion/WD | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 1.5 | 0.6 | 0.9 | -0.9 | -8.5 |
| Placebo + Letrozole 2.5 mg | 1.6 | 2.2 | 2.6 | 2.0 | -7.8 |
The TOI score is the sum of the physical well-being, functional well-being, and breast cancer unweighted subscale scores. The total TOI score ranges from 0 to 92, with higher scores representing a better quality of life. (NCT00073528)
Timeframe: Week 12, 24, 36, and 48 visits; conclusion/withdrawal visit
| Intervention | Adjusted mean change (Number) | ||||
|---|---|---|---|---|---|
| Week 12 | Week 24 | Week 36 | Week 48 | Conclusion/WD | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 2.7 | 2.0 | 0.8 | -0.7 | -6.4 |
| Placebo + Letrozole 2.5 mg | -0.3 | 3.9 | 3.3 | 2.2 | -6.2 |
"On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 663.9 weeks (treatment duration ranged from 0.1 to 659.9 weeks).~Deaths post treatment survival follow up were collected after the on- treatment period, up to approximately 14 years. Patients who didn't die during the on-treatment period and had not stopped study participation at the time of data cut-off (end of study) were censored." (NCT00073528)
Timeframe: up to 663 weeks (on-treatment), up to approximately 14 years (study duration)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| On-treatment deaths | All deaths | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 18 | 488 |
| Placebo + Letrozole 2.5 mg | 23 | 484 |
Participants who had a HER2-negative tumor status based on baseline tissue with baseline serum HER2 ECD values =<15 ng/mL but later had at least two consecutive serum HER2 ECD values >15 ng/mL experienced seroconversion. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Seroconversion, No | Seroconversion, Yes | Missing | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 140 | 219 | 119 |
| Placebo + Letrozole 2.5 mg | 323 | 52 | 99 |
A minimally important difference (MID) is the smallest difference in a score for a measure of QOL that corresponds to a difference in function or clinical course. Responders are defined as participants with an MID => 8 for the FACT-B score, and an MID =>6 for the FACT-G and TOI scores. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| FACT-B total, =>8 (MID upper bound) | FACT-G, =>6 (MID upper bound) | TOI, =>6 (MID upper bound) | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 33 | 38 | 33 |
| Placebo + Letrozole 2.5 mg | 29 | 29 | 29 |
Quality of Life (QOL) was assessed using the FACT-B questionnaire, which was a 37-item (27 general and 10 breast cancer-specific questions) self-reporting instrument consisting of 5 dimensions: physical-, social/family-, emotional-, functional-well being, and a breast cancer subscale. Higher scores on the FACT-B scales (each ranging from 0 [not at all] to 4 [very much]) indicate a higher QOL. The score is transformed for FACT-B and results in a total score ranging from 0 to 144. Complete: completing at least 1 question from FACT-B. (NCT00073528)
Timeframe: Day 1 (baseline) visit; Week 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192 visits; conclusion/withdrawal visit
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, baseline | Week 12 | Week 24 | Week 36 | Week 48 | Week 60 | Week 72 | Week 84 | Week 96 | Week 108 | Week 120 | Week 132 | Week 144 | Week 156 | Week 168 | Week 180 | Week 192 | Conclusion/withdrawal | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 605 | 476 | 382 | 294 | 243 | 183 | 153 | 119 | 98 | 62 | 56 | 43 | 33 | 21 | 11 | 5 | 1 | 359 |
| Placebo + Letrozole 2.5 mg | 605 | 460 | 350 | 291 | 254 | 199 | 181 | 144 | 117 | 80 | 59 | 43 | 33 | 22 | 15 | 11 | 6 | 327 |
Clinical benefit: participants with CR, PR, or SD for =>6-month period. FISH testing measures the amount of the HER2 gene in each cell. This gene is responsible for the overproduction of the HER2 protein. FISH-positive: excessive amounts of the gene are present; FISH-negative: normal levels of the gene are present. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| FISH status, Positive | FISH status, Negative | FISH status, missing | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 49 | 245 | 64 |
| Placebo + Letrozole 2.5 mg | 28 | 237 | 61 |
IHC is a commonly used test to assess the amount of the HER2 receptor protein on the surface of the cancer cells. The IHC test results in a score of 0 to 3+, which indicates the amount of HER2 receptor protein on the cells in a sample of breast cancer tissue. Tissue scores of 0 to 1+ indicate HER2 negativity; scores of 2+ and 3+ indicate HER2 positivity. Clinical benefit is defined as participants with CR, PR, or SD for =>6-month period. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| IHC Intensity 0 | IHC Intensity 1 | IHC Intensity 2 | IHC Intensity 3 | IHC Intensity Missing | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 106 | 106 | 85 | 26 | 35 |
| Placebo + Letrozole 2.5 mg | 74 | 108 | 94 | 16 | 34 |
Participants were stratified based on site of disease at screening (SDS) (soft tissue or visceral or bone-only disease) and prior adjuvant endocrine therapy (PAET) (discontinuation interval [DI] =>6 months or DI <6 months). OR is defined as the number of participants achieving either a confirmed CR or PR. Response was assessed via RECIST. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. DI is defined as the time period from stopping the PEAT to the randomization date. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| SDS, Soft tissue or visceral | SDS, Bone-only disease | PAET, DI =>6 months | PAET, DI <6 months | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 31 | 0 | 24 | 7 |
| Placebo + Letrozole 2.5 mg | 14 | 0 | 12 | 2 |
Participants were stratified based on site of disease at screening (SDS) (soft tissue or visceral or bone-only disease) and prior adjuvant endocrine therapy (PAET) (discontinuation interval [DI] =>6 months or DI <6 months). OR is defined as the number of participants achieving either a confirmed CR or PR. Response was assessed via RECIST. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as a reference the baseline sum LD. DI is defined as the time period from stopping the PEAT and the randomization date. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| SDS, Soft tissue or visceral | PAET, DI =>6 months | PAET, DI <6 months | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 190 | 168 | 22 |
| Placebo + Letrozole 2.5 mg | 170 | 151 | 19 |
The HER2 ECD is a glycoprotein that can be shed from the cell surface into the blood of normal individuals and can be elevated in different pathologic conditions. The serum HER2 ECD level generally reflects the tissue HER2 status. The HER2 ECD is quantified in serum with an enzyme-linked immunosorbent assay (ELISA). Non-Evaluable (NE): any participant who could not be classified as CR, PR, SD, or PD. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| >15 ng/mL, CR/PR | >15 ng/mL, SD | >15 ng/mL, PD/NE | =<15 ng/mL, CR/PR | =<15 ng/mL, SD | =<15 ng/mL, PD/NE | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 9 | 13 | 12 | 17 | 30 | 23 |
| Placebo + Letrozole 2.5 mg | 3 | 11 | 39 | 12 | 23 | 16 |
CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum LD since the baseline measurement. The best overall response is defined as the best response recorded from the start of treatment until disease progression/recurrence. PD: presence of target lesions, non-target lesions, and/or new lesions. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| CR | PR | SD | PD | Unknown | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 5 | 26 | 44 | 30 | 6 |
| Placebo + Letrozole 2.5 mg | 4 | 12 | 35 | 49 | 8 |
CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum LD since the baseline measurement. The best overall response is defined as the best response recorded from the start of treatment until disease progression/recurrence. PD: presence of target lesions, non-target lesions, and/or new lesions. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| CR | PR | SD | PD | Unknown | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 28 | 168 | 280 | 113 | 53 |
| Placebo + Letrozole 2.5 mg | 26 | 153 | 243 | 174 | 48 |
EGFR is a cell surface receptor tyrosine kinase expressed in certain types of tumors. Depending upon the staining intensity, EGFR was graded as follows: 0=absence of membrane staining above background in all tumor cells; EGFR-positive=staining is defined as any IHC staining of tumor cell membranes above background level, whether it is complete or incomplete circumferential staining (1+, 2+, 3+). (NCT00073528)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| EGFR, 0 | EGFR, 1+ | EGFR, 2+ | EGFR, 3+ | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 522 | 45 | 12 | 1 |
| Placebo + Letrozole 2.5 mg | 513 | 43 | 17 | 3 |
Time to response is defined as the time from randomization until the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sume of the LD of target lesions, taking as reference the baseline sum LD) (whichever status was recorded first). The assessments of CR or PR required confirmation using bone scans. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Week 12 | Week 16 | Week 24 or longer | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 23 | 3 | 5 |
| Placebo + Letrozole 2.5 mg | 11 | 1 | 4 |
Time to response is defined as the time from randomization until the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sume of the LD of target lesions, taking as reference the baseline sum LD) (whichever status was recorded first). The assessments of CR or PR required confirmation using bone scans. (NCT00073528)
Timeframe: Up to 46 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 12 | Week 16 | Week 24 | Week 28 | Week 36 or longer | |
| Lapatinib 1500 mg + Letrozole 2.5 mg | 94 | 18 | 28 | 14 | 42 |
| Placebo + Letrozole 2.5 mg | 76 | 21 | 28 | 17 | 37 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment had been exercised in deciding whether reporting was appropriate in other situations. (NCT00429299)
Timeframe: From the first dose of randomized therapy to 30 days after the last dose of randomized therapy (assessed up to Study Week 29)
| Intervention | Participants (Number) |
|---|---|
| CT Plus Trastuzumab | 35 |
| CT Plus Lapatinib 1500 mg | 38 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 46 |
Treatment failure is defined as the occurrence of local tumor progression (including ipsilateral and controlateral breast), distant tumor progression, permanent treatment discontinuation (either for the experimental or conventional arm), or death due to any cause. (NCT00429299)
Timeframe: From randomization up to 29 weeks
| Intervention | Participants (Number) |
|---|---|
| CT Plus Trastuzumab | 7 |
| CT Plus Lapatinib 1500 mg | 9 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 7 |
Pathological Complete Response (pCR) is defined by the complete absence of infiltrating tumor cells in the breast and in the lymph nodes. The pathological response in the breast was evaluated according to the criteria of Miller and Payne as follows: Grade 1, no change or some alteration to individual malignant cells, but no reduction in overall cellularity; Grade 2, a minor loss in tumor cells (up to 30%); Grade 3, between an estimated 30% and 90% reduction in tumor cells; Grade 4, marked disappearance of tumor cells, with only a small cluster or a dispersed cell remaining (more than 90% loss); Grade 5, no identifiable malignant cells. Ductal carcinoma in situ (DCIS) may be present. Grades were interpreted as follows: Grade 1-2=no response; Grade 3-4=partial response; Grade 5=complete response. pCR was defined by comparing specimens obtained at Baseline (biopsy) to those obtained upon surgery. (NCT00429299)
Timeframe: At Baseline and surgery (within 5 weeks after the last chemotherapy administration) (assessed up to Study Week 29)
| Intervention | Percentage of participants (Number) |
|---|---|
| CT Plus Trastuzumab | 25 |
| CT Plus Lapatinib 1500 mg | 26.3 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 46.7 |
Time to treatment failure (TTF) is defined as the interval of time between the date of randomization and the earliest date of disease progression, premature treatment discontinuation and death due to any cause. The overall disease progression date is the earlier of the two disease progression dates from ultrasonography and mammography assessments. For ultrasonography, disease progression is defined as at least 20% increase in the longest diameter of the primary lesion at pre-surgery comparing to Baseline. For mammography, disease progression is defined as at least 20% increase in the larger nodule dimension at pre-surgery comparing to Baseline. For participants who has neither progressed, pre-maturely withdrawn or died, time to treatment failure will be censored at the latest date of ultrasonography and mammography tumor assessments. (NCT00429299)
Timeframe: From randomization up to Study Week 307
| Intervention | Months (Median) |
|---|---|
| CT Plus Trastuzumab | 28.2 |
| CT Plus Lapatinib 1500 mg | 39.6 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 39.6 |
Analysis of mutations in the PI3KCA gene was performed from RNA extracted from frozen tumor tissue samples (sections). A gene is either a wild-type (no mutation) or mutated (presence of a mutation). Exons 9 and 20 of the PI3KCA gene were accessed (high frequency mutation at these two spots). (NCT00429299)
Timeframe: Baseline
| Intervention | Variations/Somatic mutations (Number) | |||
|---|---|---|---|---|
| PIK3CA Exon 9 Wild-Type | PIK3CA Exon 9 Mutation | PIK3CA Exon 20 Wild-type | PIK3CA Exon 20 Mutation | |
| CT Plus Lapatinib 1500 mg | 35 | 2 | 31 | 6 |
| CT Plus Trastuzumab | 29 | 1 | 25 | 5 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 39 | 3 | 37 | 5 |
The percentage of inhibition of intermediate (EGFR, HER2, pMAPK, pAKT, PTEN, and PI3KCA) and final (TUNEL and Ki67) biomarkers of the proliferation and apoptosis pathways was calculated as the difference between the staining scores before (Baseline [biopsy]) and after treatment (withdrawal). (NCT00429299)
Timeframe: At Baseline and Withdrawal (assessed up to Study Week 29)
| Intervention | Percentage of inhibition (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ki67, Baseline, n=34, 37, 42 | Ki67, Post-treatment, n=22, 21, 18 | pAKT, Baseline, n=34, 37, 42 | pAKT, Post-treatment, 18, 20, 17 | pMAPK, Baseline, n=9, 5, 7 | pMAPK, Post-treatment, n=0, 1, 2 | Tunel test, Baseline, n=25, 27, 31 | Tunel test, Post-treatment, n=7, 12, 11 | PTEN, Baseline, n=27, 35, 37 | PTEN, Post-treatment, n=14, 17, 15 | pEGFR, Baseline, n=21, 24, 28 | pEGFR, Post-treatment, n=5, 10, 11 | |
| CT Plus Lapatinib 1500 mg | 25 | 15 | 10 | 0 | 10 | 70 | 0.58 | 0.1 | 80 | 80 | 0 | 0 |
| CT Plus Trastuzumab | 25 | 19 | 2.5 | 0 | 0 | NA | 0.4 | 0.1 | 80 | 100 | 0 | 0 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 30 | 10 | 0 | 0 | 0 | 5 | 0.8 | 0.05 | 90 | 80 | 0 | 0 |
The percentage of participants who had BCS and mastectomy and who were initiallycandidates for mastectomy and who actually had BCS was measured. At Baseline, the surgeon stated, within 4 weeks before starting the primary treatment, which type of surgical treatment he would perform in the absence of primary therapy and in the case of primary therapy (if the tumor size was reduced by the primary treatment to less than 3 centimeters), and the reasons for these choices. The rules for choosing the type of surgical treatment are reported in the Consensus Conference on Primary Treatment of Early Breast Cancer. The surgeon was to have re-evaluated the participant after primary treatment. In cases in which the type of surgical procedure was different from that originally programmed, the reason for this chance was to have been reported. (NCT00429299)
Timeframe: At Baseline and at surgery (up to Study Week 29)
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| BCS | Mastectomy | Conversion from mastectomy to BCS | |
| CT Plus Lapatinib 1500 mg | 57.9 | 39.5 | 42.8 |
| CT Plus Trastuzumab | 66.7 | 33.3 | 61.9 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 68.9 | 31.1 | 60 |
The clinical response was evaluated by comparing the tumor size (largest tumor diameter) before (at Baseline [biopsy]) and after treatment (before surgery), as assessed by ultrasonography examination. The clinical response was scored by Response Evaluation Criteria in Solid Tumors (RECIST) as follows: complete clinical response: the nodule is not detectable and all the ultrasound abnormality detected at diagnosis disappeared (margins circumscribed, round oval shape, parallel orientation, isoechoic echo pattern, no posterior acoustic features, echogenic lesion boundary, and tumor vascularity not present); partial clinical response: the longest diameter of the tumor has been reduced by >50%, and the ultrasound characteristics of the tumor persist; no response (stable disease): the longest diameter of the tumor has been reduced by <50% or has increased by no more than 20% from the starting value; progressive disease: tumor longest diameter has increased >20% from the starting value. (NCT00429299)
Timeframe: At Baseline and after primary treatment (within 2 weeks before surgery; up to Study Week 27)
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease | Progressive Disease | Not Evaluable | |
| CT Plus Lapatinib 1500 mg | 15.8 | 44.7 | 13.1 | 2.6 | 23.7 |
| CT Plus Trastuzumab | 30.5 | 41.7 | 5.5 | 2.8 | 19.4 |
| CT Plus Trastuzumab and Lapatinib 1000 mg | 42.2 | 28.9 | 0 | 0 | 28.9 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. (NCT00880009)
Timeframe: Part 1 Baseline up to 28 days after the last dose
| Intervention | percentage of participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Bosutinib + Letrozole (Part 1) | 100 | 31.3 |
Clinical Benefit Rate (CBR), for those with evaluable disease, defined as the percentage of patients who achieved complete response, partial response and stable disease. RECIST 1.1 was used as the standard way to measure response to treatment. The mean (SD) of specific metabolites were calculated at each time point and graphically assess these measures over time with clinical response and hematological toxicity. The mean change in these variables from baseline to each follow-up point was be calculated. Generalized linear model was utilized for the correlative analysis of clinical response and hematologic events. (NCT02692755)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Single ARM | 23 |
Number of patients who required dose delays in palbociclib attributed to neutropenia. (NCT02692755)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Single ARM | 17 |
Number of patients who required dose reductions in palbociclib therapy (NCT02692755)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Single ARM | 13 |
"For study purpose febrile neutropenia will be defined according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0: ANC less than 1000/mm3 with a single temperature of >38.3 degrees Celsius (101 degrees Fahrenheit) or a sustained temperature of 38 degrees Celsius (100.4 degrees Fahrenheit) for more than one hour.~Planned oncology therapy is defined as completion of one year of therapy for advanced breast cancer in the absence of disease progression or cessation of study drug due to progressive disease or non-hematological toxicity." (NCT02692755)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Palbociclib + Letrozole or Fulvestrant | 35 |
The strength of AR signaling was measured by the percentage of downstream AR-regulated genes that were expressed. (NCT02955394)
Timeframe: 16 Weeks
| Intervention | percentage of genes expressed (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 85 |
| Fulvestrant With Enzalutamide | 80 |
Disease-free survival is defined as the time in months from the start of fulvestrant until documented disease progression or death. Complete and partial response for the single drug arm and combination of enzalutamide/fulvestrant arm separately. (NCT02955394)
Timeframe: 15 months
| Intervention | months (Median) |
|---|---|
| Fulvestrant Without Enzalutamide | 3.6 |
| Fulvestrant With Enzalutamide | 3.7 |
"The preoperative endocrine prognostic index (PEPI) is a validated measure of pathologic response to endocrine therapy. It is a model that combines estrogen receptor (ER) level, pathologic tumor site, nodal status, and Ki67 score at the time of surgery to predict subsequent risk of cancer recurrence.~PEPI scoring is typically discretized into three risk groups: 0 (low risk of recurrence and best outcome), 1-3 (intermediate risk), and >= 4 (high risk). This study was concerned only with the distinction between zero and non-zero PEPI scores. Zero is the minimum score, and there is no maximum score. Lower scores are better." (NCT02955394)
Timeframe: 16 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Fulvestrant Without Enzalutamide | 2 |
| Fulvestrant With Enzalutamide | 8 |
Clinical benefit rate will be estimated by the total number of patients with an objective status of CR, PR, or SD for duration of at least 6 months divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculated. (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 0 |
A confirmed response is defined to be a CR or PR (as determined by RECIST criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response. The number of confirmed responses will be reported here. (NCT01105312)
Timeframe: from baseline up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level One | 0 |
| Phase I: Dose Level Two | 2 |
Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | NA |
MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6> new patients). If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT are seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. The number of DLT's will be reported here. (NCT01105312)
Timeframe: Up to 2.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level One | 1 |
| Phase I: Dose Level Two | 3 |
Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. PFS at 6 months will be estimated. The distribution of PFS will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | months (Median) |
|---|---|
| Phase II | 2.1 |
"A confirmed response is defined to be a CR or PR (as determined by RECIST (version 1.1 criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.~A CR is defined as:~All of the following must be true:~Disappearance of all non-nodal target lesions~Each target lymph node must have reduction in short axis to <1.0 cm~A PR is defined as:~At least a 30% decrease in the sum of the longest diameters of the non-nodal target lesions and the short axes of the target lymph nodes taking as reference the BSD (Section 11.41)" (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 0 |
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | 16.1 |
Time to treatment failure (TTF) is defined as the time from the date of registration to the date at which the patient is removed from treatment due to progression, unacceptable adverse events, or refusal. The distribution of TTF will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | 2 |
"Time-to-disease progression (TTP) is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of TTP will be estimated using the method of Kaplan-Meier. Progression is defined as at least one of the following:~At least one new malignant lesion or a lymph node whose short axis has increased to >1.5 cm~At least a 20% increase in the sum of diameters of target lesions taking as reference the MSD. In addition, the sum must also demonstrate an absolute increase of at least 0.5 cm" (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | months (Median) |
|---|---|
| Phase II | 2.1 |
adherence measured with pill counts for the vitamin D at predesignated study timepoints: baseline (after run-in), 3 months and 6 months (NCT01509079)
Timeframe: average for all study ppts for: screening to baseline; baseline to 3 months; 3 month to 6 months
| Intervention | % of adherence for each treatment arm (Number) |
|---|---|
| Vitamin D3 4000 IU | 95 |
| Vitamin D3 600 IU | 95 |
(NCT01509079)
Timeframe: baseline to 6 months
| Intervention | pounds (Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.8 |
| Vitamin D3 600 IU | 1.0 |
The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | -0.2 |
| Vitamin D3 600 IU | -0.5 |
PROMIS measures physical functioning on the short form and higher scores reflect better physical functioning with 10 questions on daily activities of life on a Likert scale ranging from 5 (no problem performing activity) to 1 (cannot do activity). Range on this measure is from 50 (best)-10 (worst). (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Vitamin D3 4000 IU | 0.6 |
| Vitamin D3 600 IU | 1.7 |
GLM Mean and standard deviation of Whole Body Bone Mineral Density (grams/cm2) of Trial Participants by Treatment Arm after controlling for bisphosphonate use (NCT01509079)
Timeframe: From Baseline and 6 months of D3 supplementation
| Intervention | gm/cm2 (Geometric Least Squares Mean) |
|---|---|
| Vitamin D3 4000 IU | 1.1 |
| Vitamin D3 600 IU | 1.12 |
Difference in steady state concentrations in plasma from baseline to 6 months (NCT01509079)
Timeframe: baseline to 6 months
| Intervention | mg/L (Mean) | |
|---|---|---|
| anastrozole | letrozole | |
| Vitamin D3 4000 IU | -1.31 | 2.16 |
| Vitamin D3 600 IU | 2.4 | -0.83 |
(NCT01509079)
Timeframe: baseline and 6 months
| Intervention | pg/ml (Geometric Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Vitamin D3 4000 IU | 2.83 | 2.94 |
| Vitamin D3 600 IU | 2.77 | 3.0 |
Occurrence, frequency and severity of adverse events (AEs), laboratory abnormalities (NCT01919229)
Timeframe: Up to 30 days after the last dose
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Adverse Events | Serious Adverse Events | Deaths | Other Adverse Events | |
| LEE011 400mg + Letrozole | 0 | 0 | 0 | 5 |
| LEE011 600mg + Letrozole | 0 | 0 | 0 | 4 |
| Letrozole | 0 | 0 | 0 | 2 |
The primary aim is to assess the anti-tumor effect in terms of pathologic CR rates of neo-adjuvant chemotherapy in patients with T2-T4c, any N, M0 breast cancer (by clinical staging) who are endocrine therapy resistant (that is, their Ki-67 level is >10 after 2-4 week of neo-adjuvant endocrine therapy alone). The pCR rate (percentage) for neo-adjuvant chemotherapy is defined as 100 times the number of eligible patients with no histologic evidence of invasive tumor cells in the surgical breast specimen and the axillary or sentinel lymph nodes divided by the total number of eligible patients who received neo-adjuvant chemotherapy. (NCT00265759)
Timeframe: Up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort B Arm II: Week 2 Ki67 > 10% | 5.7 |
The clinical response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose disease meets the WHO criteria for complete or partial response prior to surgery divided by the total number of eligible patients randomized to that treatment. For each treatment arm, a 95% binomial confidence interval will be constructed for the true clinical response rate. Complete Response (CR): The disappearance of all known disease based on a comparison between the measurements at baseline and the Week 16 visit. Partial Response (PR): A 50% or greater decrease in the product of the bi-dimensional measurements of the lesion (total tumor size) based on a comparison between the measurements at baseline and the Week 16 visit. In addition there can be no appearance of new lesions or progression of any lesion. (NCT00265759)
Timeframe: Up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 62.9 |
| Cohort A Arm II: Letrozole | 74.8 |
| Cohort A Arm III: Anastrozole | 69.1 |
The rate (percentage) of improved surgical outcome for patients considered marginal for breast conservation surgery prior to therapy for Cohort A is reported below for each treatment arm. Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of improved surgical outcome (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 85.2 |
| Cohort A Arm II: Letrozole | 77.4 |
| Cohort A Arm III: Anastrozole | 86.4 |
Rate (percentage) of Improved surgical outcome for patients designated as candidates for mastectomy prior to therapy (Cohort A). Breast conservation surgery (not mastectomy) as the most extensive surgery performed for a patient is considered an improvement in surgical outcome. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 48.1 |
| Cohort A Arm II: Letrozole | 42.1 |
| Cohort A Arm III: Anastrozole | 60.0 |
For those patients who undergo a sentinel lymph node dissection or an axillary lymph node dissection (at least 6 nodes examined with Hematoxylin & Eosin Staining), the LNI rate (percentage) is defined as 100 times the proportion of eligible patients randomized to that treatment with at least one positive node. For each neo-adjuvant endocrine treatment, a 95% binomial confidence interval will be constructed for its true LNI rate. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 41.1 |
| Cohort A Arm II: Letrozole | 48.2 |
| Cohort A Arm III: Anastrozole | 44.1 |
The pathologic complete response is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes. The pathologic complete response rate (percentage) of a given treatment is defined as 100 times the number of eligible patients randomized to that treatment whose surgical specimen is such that there is no histologic evidence of invasive tumor cells in the surgical breast specimen and axillary or sentinel lymph nodes divided by the total number of eligible patients randomized to that treatment. For each neo-adjuvant endocrine treatment pair, a 95% binomial confidence interval will be constructed for the true difference in the pCR between these 2 treatments. (NCT00265759)
Timeframe: At time of surgery up to 18 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Cohort A Arm I: Exemestane | 1.7 |
| Cohort A Arm II: Letrozole | 0.0 |
| Cohort A Arm III: Anastrozole | 0.0 |
Incidence of the most common grade 3+ toxicities reported to be probably, possibly, or definitely related to treatment as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (Cohort A) At each treatment evaluation, the type, severity, and attribution of each adverse event reported will be assessed using the NCI-CTCAE definitions. For each treatment, the percentage of patients who developed a severe (grade 3+) toxicity considered possibly, probably or definitively related to treatment will be determined. (NCT00265759)
Timeframe: Up to 30 days after drug therapy
| Intervention | percentage of patients (Number) | ||
|---|---|---|---|
| Fatigue | Hot flashes/flushes | Joint pain | |
| Cohort A Arm I: Exemestane | 2 | 2 | 2 |
| Cohort A Arm II: Letrozole | 2 | 4 | 3 |
| Cohort A Arm III: Anastrozole | 3 | 2 | 2 |
Proliferation assessment by immunocytochemistry using Ki-67. Expressed as percent of cells staining positive for Ki-67. (NCT00291135)
Timeframe: Baseline, 6 months
| Intervention | Change in % of cells positive for Ki-67 (Median) |
|---|---|
| Letrozole | -2.3 |
Correlations between pathologic tumor size and maximum diameters of baseline and pre-surgical mammographic extent of disease were evaluated using Spearman correlation coefficient measure of association. The Spearman's rank-order correlation (rs) measures the strength and direction of association between two variables. The Spearman correlation coefficient, rs, can take values from +1 to -1 where a value of +1 indicates a perfect association, an rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association. (NCT00290745)
Timeframe: 6 months
| Intervention | Spearman correlation coefficient (rs) (Number) |
|---|---|
| Tamoxifen or Letrozole | 0.02 |
Correlations between pathologic tumor size and maximum diameters of baseline and 6-month MRI extent of disease were evaluated using Spearman correlation coefficient measure of association. The Spearman's rank-order correlation (rs) measures the strength and direction of association between two variables. The Spearman correlation coefficient, rs, can take values from +1 to -1 where a value of +1 indicates a perfect association, an rs of 0 indicates no association and an rs of -1 indicates a perfect negative association. The closer rs is to 0, the weaker the association. (NCT00290745)
Timeframe: 6 months
| Intervention | Spearman correlation coefficient (rs) (Number) |
|---|---|
| Tamoxifen or Letrozole | 0.46 |
Change in size of Ductal Carcinoma in situ (DCIS) on hormonal therapy, as determined by MRI are determined by (1) largest diameter of tumor, as visualized on MRI (2) extent of disease on MRI (3) quantification of MR-detected change from baseline to 6-month and used to generate the change in tumor volume of MRI extent of disease from baseline. Since values were not normally distributed, the median change was calculated, and Wilcoxon sign rank tests were used to evaluate the significance of these changes. (NCT00290745)
Timeframe: Baseline and 6 months
| Intervention | change in tumor volume (cm3) (Median) |
|---|---|
| Tamoxifen or Letrozole | -0.8 |
Change in size of Ductal Carcinoma in situ (DCIS) for participants on hormonal therapy, as determined by mammography are determined by (1) largest diameter of tumor, as visualized on mammography (2) extent of disease on mammography (3) quantification of mammographically-detected change from baseline to 6-month and used to generate the change in tumor volume of mammographic extent of disease from baseline. Since values were not normally distributed, the median change was calculated, and Wilcoxon sign rank tests were used to evaluate the significance of these changes (NCT00290745)
Timeframe: Baseline and 6 months
| Intervention | change in tumor volume (mm) (Median) |
|---|---|
| Tamoxifen or Letrozole | -5.0 |
Tumor volume changes between baseline and surgery were calculated at month 6 and compared across baseline ER Hormone (H-) Score quartile. The ER H- scores are a percentage that tells you how many cells out of 100 stain positive for hormone receptors. Each participant is assigned an ER H- score at baseline with the full score range between 0 (none have receptors) and 100 (all have receptors). The participants were grouped into quartiles (four equal groups) based on their baseline ER H- score. ER H- score and the reduction in tumor volume from baseline to month 6 was measured for each quartile group. (NCT00290745)
Timeframe: Baseline and 6 months
| Intervention | decrease in tumor volume (cm^3) (Median) | |||
|---|---|---|---|---|
| Baseline ER Score quartile = 0-25 | Baseline ER Score quartile = 26-50 | Baseline ER Score quartile = 51-75 | Baseline ER Score quartile = 76-100 | |
| Tamoxifen or Letrozole | -58.8 | -70.3 | -80.3 | -71.1 |
"Tumor volume changes between baseline and surgery were calculated at month 6 by Baseline Ki-67 Average Score which is divided into 2 groups: (1) <=10% or (2) >10% to 100%. In est results, the Ki-67 findings expressed as a percentage with less than 10% considered low Ki-67 expression and > than 10% or higher considered high. A high score means that the breast tumor is more likely to be aggressive and spread quickly. A wilcoxon sign rank tests were used to evaluate the significance of these changes" (NCT00290745)
Timeframe: Baseline and 6 months
| Intervention | reduction in tumor volume (cm^3) (Median) | |
|---|---|---|
| Baseline Ki67 Average <=10% | Baseline Ki67 Average > 10% | |
| Tamoxifen or Letrozole | -73.0 | -70.3 |
"Tumor volume changes between baseline and surgery were calculated at month 6 and compared across baseline PgR Hormone (H-) Score quartile. The PgR H-scores are a percentage that tells you how many cells out of 100 stain positive for hormone receptors. Each participant is assigned a PgR H- score at baseline with the full PgR H score ranges between 0 (none have receptors) and 100 (all have receptors). The participants were grouped into quartiles (four equal groups) based on their baseline PgR H- score and the reduction in tumor volume from baseline to month 6 was measured for each quartile group.~A wilcoxon sign rank tests were used to evaluate the significance of these changes" (NCT00290745)
Timeframe: Baseline and 6 months
| Intervention | reduction in tumor volume (cm^3) (Median) | |||
|---|---|---|---|---|
| Baseline PgR Score Quartile = 0-25 | Baseline PgR Score Quartile = 26-50 | Baseline PgR Score Quartile = 51-75 | Baseline PgR Score Quartile = 76-100 | |
| Tamoxifen or Letrozole | -69.1 | -45.8 | -69.6 | -96.2 |
MRI volume response at each time point was classified as follows: 90% image-complete response (ICR90) is defined as a >90% reduction in tumor volume, 80% image-complete response (ICR80) is defined as an 81-90% reduction in tumor volume , partial response (PR) is defined as a 20-80% reduction in tumor volume, and sustained disease or progressive disease (SD/PD) defined as a <20% reduction or increase in volume. (NCT00290745)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ICR90 | ICR80 | PR | SD/PD | |
| Tamoxifen or Letrozole | 13 | 10 | 27 | 17 |
MRI volume response at each time point was classified as follows: 90% image-complete response (ICR90) is defined as a >90% reduction in tumor volume, 80% image-complete response (ICR80) is defined as an 81-90% reduction in tumor volume , partial response (PR) is defined as a 20-80% reduction in tumor volume, and sustained disease or progressive disease (SD/PD) defined as a <20% reduction or increase in volume. (NCT00290745)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ICR90 | ICR80 | PR | SD/PD | |
| Tamoxifen or Letrozole | 22 | 7 | 26 | 12 |
Change: BMD values at year 1 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 1 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 5.66 |
Change: BMD values at year 2 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 2 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 10.47 |
Change: BMD values at year 3 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 3 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 8.44 |
Change: BMD values at year 4 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 4 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.49 |
Change: BMD values at year 5 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 5 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.54 |
Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 1 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 2.66 |
Change: BMD values at year 2 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 2 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.94 |
Change: BMD values at year 3 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 3 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 6.20 |
Change: BMD values at year 4 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 4 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 6.99 |
Change: BMD values at year 5 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 5 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 11.71 |
Adverse events were assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Grade 1=Mild, Grade 2=Moderate. (NCT00436917)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 Arthralgia | Grade 2 Arthralgia | Grade 3 Arthralgia | Grade 1 Creatinine Increase | Grade 2 Creatinite increase | Grade 2 Desquamating Rash | Grade 2 Headache | Grade 2 Hot flashes | Grade 1 Nausea | Grade 3 Pain in extremity | Grade 1 Fever | Grade 1 Vomiting | Grade 1 Musculoskeletal disorder | Grade 2 Urogenital disorder | |
| Zoledronic Acid | 7 | 4 | 1 | 7 | 2 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 1 | 1 |
Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA). (NCT00171340)
Timeframe: Baseline, 12 months
| Intervention | Percentage change in BMD (Mean) |
|---|---|
| Zoledronic Acid 4 mg Upfront | 2.208 |
| Zoledronic Acid 4 mg Delayed | -3.617 |
At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan. (NCT00171340)
Timeframe: Baseline,3 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Zoledronic Acid 4 mg Upfront | 0.6 |
| Zoledronic Acid 4 mg Delayed | 1.5 |
Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA) (NCT00171340)
Timeframe: Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.
| Intervention | Percentage change in BMD (Mean) | |||
|---|---|---|---|---|
| At 2 years (n=339,343) | At 3 years (n=313,311) | At 4 years (n=290,294) | At 5 years (n=264,264) | |
| Zolendronic Acid 4 mg Delayed | -4.601 | -4.871 | -5.154 | -5.414 |
| Zolendronic Acid 4 mg Upfront | 3.463 | 3.730 | 3.782 | 4.308 |
Bone Mineral Density (g/cm^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA) (NCT00171340)
Timeframe: Baseline, 12 months. Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.
| Intervention | Percentage change in BMD (Mean) | ||||
|---|---|---|---|---|---|
| At 12 months (n=419,434) | At 2 years (n=394,393) | At 3 years (n=376,365) | At 4 years (n=336,349) | At 5 years (n=306,314) | |
| Zolendronic Acid 4 mg Delayed | -2.239 | -2.990 | -3.302 | -3.922 | -4.162 |
| Zolendronic Acid 4 mg Upfront | 1.222 | 1.649 | 1.754 | 1.716 | 1.615 |
Bone Mineral Density (g/cm^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA) (NCT00171340)
Timeframe: Baseline, 5 years.
| Intervention | Percentage change in BMD (Mean) | ||||
|---|---|---|---|---|---|
| At 12 months (n=360,369) | At 2 years (n=339,343) | At 3 years (n=313,311) | At 4 years (n=290,294) | At 5 years (n=264,264) | |
| Zolendronic Acid 4 mg Delayed | -3603 | -4.521 | -4.869 | -5.148 | -5.427 |
| Zolendronic Acid 4 mg Upfront | 2.128 | 3.300 | 3.521 | 3.529 | 3.898 |
17 women with early breast cancer receiving adjuvant Aromatase Inhibitor (AI) therapy were treated with a single 5 mg IV dose of zoledronic acid. Urine and serum NTx and serum CTx were measured at baseline and month 12. (NCT00712985)
Timeframe: One year
| Intervention | participants (Number) |
|---|---|
| Zoledronic Acid 5 mg IV | 13 |
250 reviews available for letrozole and Breast Cancer
| Article | Year |
|---|---|
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antit | 2021 |
An overview on Estrogen receptors signaling and its ligands in breast cancer.
Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Hum | 2022 |
Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Quality | 2022 |
Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Cryopreservation; Female; Fertility Preservation; Humans; Letrozole; Oocytes; Ovul | 2022 |
[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2022 |
PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged Bicyclo Compounds, Heteroc | 2022 |
Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Network Meta-Analysis; Randomized | 2022 |
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Est | 2023 |
Letrozole: Pharmacology, toxicity and potential therapeutic effects.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Infertility, Female; Letrozole; N | 2022 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2019 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2020 |
Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review.
Topics: Aged; Antibodies, Antinuclear; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; F | 2020 |
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic | 2020 |
A review of the physiology behind letrozole applications in infertility: are current protocols optimal?
Topics: Androgens; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Follicle Stimulating Hormone; | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2021 |
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyc | 2021 |
CDK4/6 inhibitor-induced colitis: a case report and review of the literature.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colitis; Cyc | 2021 |
CDK4/6 inhibitors in HER2-positive breast cancer.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Fulvestrant; Huma | 2017 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Dis | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cy | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradi | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cy | 2017 |
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2018 |
In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Halluc | 2019 |
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doubl | 2018 |
Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; F | 2019 |
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; B | 2019 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Pharmacological; | 2013 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2013 |
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemothera | 2013 |
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Awards and Prizes; Breast Neoplasms; Chemotherapy, Adj | 2013 |
Obesity and endocrine therapy: host factors and breast cancer outcome.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Topics: Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Humans; Letrozole; Nitriles; Oocytes; | 2013 |
Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinic | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Ho | 2014 |
The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dru | 2014 |
Neoadjuvant chemotherapy in breast cancer: review of literature.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemothe | 2013 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female | 2014 |
Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fertility Preservation; H | 2014 |
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2015 |
Palbociclib: first global approval.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors | 2015 |
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2015 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; | 2015 |
Development of cell-cycle checkpoint therapy for solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Aurora Kinase A; Biomarkers, T | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, N | 2015 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2016 |
Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Ant | 2016 |
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Res | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adj | 2017 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Never too late: reducing late breast cancer relapse risk.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Eur | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2008 |
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Human | 2008 |
[Problems and future direction of preoperative systemic therapy for patients with operable breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast | 2008 |
Aromatase inhibitors and breast cancer.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitor | 2009 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Huma | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cance | 2009 |
Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitril | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoadjuva | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; La | 2010 |
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromones; Coumarins; Fema | 2010 |
Fertility preservation in women with breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Counseling; Cryopreservation; Embryo, Mammalian; Female; Fer | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; L | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Adm | 2011 |
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; C | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2011 |
[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Brea | 2011 |
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Double-Blind Method; | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Metaplastic breast carcinoma: a case report and systematic review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; H | 2011 |
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2011 |
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2011 |
Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2012 |
[Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
Topics: Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Catalysis | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates | 2012 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Desi | 2012 |
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzoquinones; Breast Neoplasms; Cell Line, | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Fe | 2012 |
Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dru | 2013 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2013 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tol | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2002 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Human | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2002 |
Anti-tumor effects of letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clin | 2002 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochro | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tri | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2003 |
Development of aromatase inhibitors and their pharmacologic profile.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonis | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2003 |
Emerging role of aromatase inhibitors in the adjuvant setting.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuva | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; E | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2003 |
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme | 2003 |
The pharmacology of letrozole.
Topics: Adrenocorticotropic Hormone; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzy | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as T | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2004 |
Letrozole: a review of its use in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents; Area Under Curve; Aromatase Inhibitors; Biological Availability; Breast Neopl | 2004 |
Overcoming endocrine therapy resistance by signal transduction inhibition.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Res | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antag | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; De | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2004 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2005 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; | 2004 |
Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistan | 2004 |
Aromatase inhibitors in early breast cancer therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Hum | 2004 |
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuva | 2004 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clin | 2004 |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2005 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 2004 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2005 |
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fem | 2005 |
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Clinical | 2005 |
Letrozole in the treatment of breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Female; Humans; Letroz | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2005 |
Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival | 2006 |
Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Fema | 2006 |
The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human | 2006 |
The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; | 2006 |
Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; | 2006 |
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adju | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemo | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Surviv | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Surviv | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Surviv | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Surviv | 2006 |
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Topics: Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neo | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit | 2006 |
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; H | 2006 |
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cli | 2006 |
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2006 |
Breast cancer (metastatic).
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Hum | 2006 |
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2006 |
Neoadjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; | 2007 |
Continuing with letrozole offers greater benefits.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cli | 2007 |
Prescribing extended adjuvant letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Femal | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Letrozole: present and future role in the treatment of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Premeno | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Human | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemot | 2007 |
The early days of letrozole.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Design | 2007 |
The discovery and mechanism of action of letrozole.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
The patient experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2007 |
Femara and the future: tailoring treatment and combination therapies with Femara.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2007 |
Assisted reproduction and breast cancer.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cryopreservation; Embr | 2007 |
Update on the use of letrozole in breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Le | 2007 |
Aromatase inhibitors: past, present and future in breast cancer therapy.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2008 |
Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Fem | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
A review of the BIG results: the Breast International Group 1-98 trial analyses.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cli | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoa | 2008 |
Clinical use of aromatase inhibitors in the treatment of breast cancers.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letro | 1993 |
The control and biological importance of intratumoural aromatase in breast cancer.
Topics: Adenocarcinoma; Androgens; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aro | 1996 |
Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhi | 1996 |
New aromatase inhibitors for breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 1997 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Br | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormo | 1997 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 1998 |
Pivotal trials of letrozole: a new aromatase inhibitor.
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 1998 |
Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; E | 1998 |
Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Aromatase Inhibitors; Biolog | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplast | 1999 |
Aromatase inhibitors and their application in breast cancer treatment*.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; | 2000 |
Drug and hormone interactions of aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; E | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 1999 |
Aromatase inhibitors and their use in the sequential setting.
Topics: Androstenedione; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 1999 |
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhib | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormo | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2000 |
Aromatase regulation and breast cancer.
Topics: 2-Methoxyestradiol; Adult; Animals; Aromatase; Aromatase Inhibitors; Aryl Hydrocarbon Hydroxylases; | 2001 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; C | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibit | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast N | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined C | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Toleran | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; B | 2001 |
Letrozole in the treatment of breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Clinical Tri | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinica | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; F | 1992 |
354 trials available for letrozole and Breast Cancer
| Article | Year |
|---|---|
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Adm | 2021 |
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
Topics: Adipokines; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Leptin; Letrozol | 2021 |
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letro | 2021 |
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Female; H | 2022 |
Predicting the clinical outcomes and benefit from letrozole after 5 years of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nomograms | 2022 |
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; | 2022 |
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Huma | 2022 |
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Neoadju | 2022 |
Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; | 2022 |
Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as | 2022 |
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Le | 2022 |
Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Topics: Breast Neoplasms; Female; Fertility Preservation; Fertilization in Vitro; Gonadotropin-Releasing Hor | 2022 |
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Genome-Wide Association Study; Humans; Letrozole; Ta | 2022 |
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
Topics: Aminopyridines; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors | 2022 |
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Quality | 2022 |
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; | 2022 |
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Endometrial Neo | 2023 |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplas | 2022 |
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letro | 2023 |
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Genomic | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2022 |
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical
Topics: Anastrozole; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Mastectomy; Neoadjuvant The | 2023 |
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Ne | 2023 |
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Br | 2023 |
Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015).
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Receptor, ErbB-2; | 2023 |
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-con
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2023 |
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind | 2023 |
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Recepto | 2023 |
Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen measurem
Topics: Breast Neoplasms; Chromatography, Liquid; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; | 2023 |
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
Topics: Aminopyridines; Antibodies; Benzimidazoles; Breast Neoplasms; Female; Humans; Letrozole; Nivolumab | 2023 |
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Let | 2023 |
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I P | 2019 |
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic | 2019 |
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2020 |
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2020 |
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2020 |
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2020 |
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2020 |
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients.
Topics: Aged; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Complementary Therapies; Female; Germany; | 2020 |
Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
Topics: Abdominal Pain; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplas | 2020 |
Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor-positive/HER2-negative advanced breast cancer women with or without visceral disease: time to turn page?
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2020 |
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; | 2020 |
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brea | 2020 |
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Electronic Health Re | 2020 |
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2020 |
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2020 |
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Topics: Acrylamides; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Anastrozole; Androstadiene | 2020 |
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Es | 2020 |
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Topics: Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Letrozo | 2020 |
Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Topics: Aged; Biomarkers, Tumor; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA-Bindi | 2020 |
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2021 |
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Ch | 2021 |
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow- | 2021 |
Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kin | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Doubl | 2021 |
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Brea | 2021 |
Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, Liquid; Estradiol; F | 2021 |
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 CYP2A6; Female; Genome-Wide Association Stu | 2021 |
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; MCF | 2021 |
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom | 2021 |
Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cryopreservatio | 2021 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neopl | 2021 |
Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial.
Topics: Breast Neoplasms; Female; Humans; Letrozole; Magnetic Resonance Imaging; Neoadjuvant Therapy; Treatm | 2021 |
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogens; Fe | 2021 |
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Le | 2021 |
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Topics: Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ch | 2017 |
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy | 2017 |
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Estrogens; | 2017 |
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Gene Expres | 2017 |
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Topics: Administration, Oral; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Dietary; Chemothe | 2017 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcin | 2018 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Pr | 2017 |
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2018 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, A | 2017 |
Everolimus Plus Letrozole for Treatment of Patients With HR
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che | 2018 |
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy | 2018 |
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2018 |
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Denmark; | 2018 |
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Bone and Bones; Breast Neoplasms; Chemo | 2018 |
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms | 2018 |
Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diph | 2018 |
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle A | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2018 |
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2018 |
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Human | 2018 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2018 |
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2018 |
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neop | 2018 |
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast N | 2018 |
Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplas | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2018 |
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidyli | 2018 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2019 |
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cohort S | 2018 |
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; | 2019 |
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Dose-Respo | 2019 |
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2018 |
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2018 |
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2018 |
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2018 |
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Kaplan-Meier Es | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relations | 2018 |
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2019 |
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2019 |
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast | 2019 |
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2019 |
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2019 |
Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers.
Topics: Adolescent; Adult; Breast Neoplasms; Cellular Microenvironment; Estradiol; Female; Fertility Preserv | 2019 |
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Human | 2019 |
Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
Topics: Absorptiometry, Photon; Adult; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density | 2019 |
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neopl | 2019 |
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
Topics: Aged; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Mu | 2019 |
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Sc | 2019 |
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breas | 2019 |
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density Conservati | 2019 |
Effects of
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogens; Female; | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Ne | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Ne | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Ne | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Ne | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2019 |
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Rec | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2013 |
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy | 2013 |
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors | 2013 |
Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2013 |
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; | 2014 |
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neop | 2013 |
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Breast | 2014 |
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphospho | 2014 |
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Huma | 2014 |
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast N | 2014 |
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Female; Humans | 2014 |
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2014 |
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemothe | 2014 |
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letr | 2014 |
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitr | 2014 |
Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Topics: Adult; Anti-Mullerian Hormone; Breast Neoplasms; Chorionic Gonadotropin; Female; Fertility Preservat | 2014 |
Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Exercise; Female; Follow-Up Studies; Humans; Letrozole; Lif | 2014 |
Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depr | 2014 |
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 2014 |
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Protocols; Diphosphonates; Female; Human | 2014 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bi | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2015 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Pot | 2016 |
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breas | 2015 |
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2015 |
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 2015 |
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal | 2015 |
Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Data In | 2016 |
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2015 |
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Early Detectio | 2015 |
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Double-Blind Method; | 2016 |
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Combined Modality Thera | 2016 |
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2016 |
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Combined M | 2016 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone De | 2016 |
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; | 2016 |
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Pain; Disease-Free Survival; Drug Therapy, Com | 2016 |
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Breast Neoplasms; Chemotherapy, Adju | 2016 |
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medic | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medic | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medic | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medic | 2016 |
Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole.
Topics: Arthralgia; Breast Neoplasms; Calcium; Cholecalciferol; Dietary Supplements; Female; Humans; Letrozo | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double- | 2016 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; C | 2016 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; C | 2016 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; C | 2016 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; C | 2016 |
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2016 |
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarker | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromata | 2017 |
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estrogens; Female; | 2017 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2017 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counse | 2008 |
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Fem | 2008 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High | 2008 |
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase; Biomarkers, Tumor; Breast Neoplasms; Disease-Free | 2009 |
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Co | 2008 |
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neopla | 2009 |
Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Topics: Aromatase Inhibitors; Biopsy, Fine-Needle; Breast Neoplasms; Cell Nucleus; Clinical Trials, Phase II | 2009 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agent | 2009 |
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Humans; Letrozole; Mi | 2009 |
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipide | 2009 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2009 |
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuv | 2009 |
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents | 2009 |
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Fractures, Bone; Humans; | 2009 |
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinom | 2009 |
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemothe | 2009 |
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Sit | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene | 2009 |
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2009 |
Update of the BIG 1-98 Trial: where do we stand?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; | 2010 |
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Topics: Antineoplastic Agents; Bone Density; Breast; Breast Neoplasms; Double-Blind Method; Female; Humans; | 2010 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2010 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Brea | 2010 |
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Dermatit | 2010 |
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Dermatit | 2010 |
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Dermatit | 2010 |
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Dermatit | 2010 |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-F | 2010 |
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2010 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; B | 2010 |
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Feas | 2011 |
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance | 2010 |
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blin | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2011 |
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; | 2011 |
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Co | 2011 |
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2011 |
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Bre | 2011 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplas | 2011 |
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neo | 2012 |
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans | 2011 |
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Di | 2012 |
[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modalit | 2011 |
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Ag | 2011 |
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone and Bones; Bone Density; Bon | 2012 |
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Fre | 2011 |
The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Topics: Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents | 2012 |
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Biomarkers, Tumor; | 2011 |
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Topics: Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administrat | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Met | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase In | 2011 |
High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence I | 2012 |
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast | 2012 |
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Female; Follow-Up Studies; Humans; | 2012 |
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Bone Density; Bone Density Conservatio | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; | 2012 |
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 CYP2 | 2012 |
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone D | 2012 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2012 |
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cognition; Estrogen Antagonists; Female; Humans; Letrozole; | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Br | 2012 |
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; | 2012 |
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease | 2013 |
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Dens | 2013 |
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholest | 2012 |
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2013 |
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Class I | 2013 |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progres | 2003 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disea | 2003 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
Topics: Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Met | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aroma | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2003 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzy | 2003 |
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Double-Blind Method; ErbB Receptor | 2003 |
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over | 2003 |
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase In | 2003 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Topics: Androstadienes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibi | 2003 |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplas | 2004 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studi | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2004 |
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neopl | 2004 |
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2004 |
Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Topics: Aged; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Chole | 2005 |
Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Topics: Adult; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility; Humans; Letrozole; | 2005 |
Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuva | 2005 |
Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Topics: Administration, Oral; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Disease Progression; Fema | 2005 |
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Topics: Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Fe | 2005 |
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Huma | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase I | 2005 |
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2005 |
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Topics: Aged; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Coho | 2006 |
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Female; Humans; Ki-67 Antigen; Let | 2006 |
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease | 2006 |
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2006 |
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2006 |
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, | 2006 |
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic | 2006 |
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic | 2006 |
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic | 2006 |
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic | 2006 |
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 2006 |
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Double-Blind Met | 2006 |
Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule | 2007 |
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Breast Neoplasms; Collagen Type I; Diphosphonates; | 2007 |
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neopla | 2007 |
Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Topics: Adult; Aged; Anticarcinogenic Agents; Aromatase Inhibitors; Biomarkers; Biopsy, Fine-Needle; Breast | 2007 |
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Ad | 2006 |
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitor | 2007 |
Letrozole in advanced breast cancer: the PO25 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis | 2007 |
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cryopreservation; Estradiol; | 2007 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozo | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, | 2007 |
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modal | 2007 |
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Topics: Androstenedione; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Estradiol; Female; Gas Ch | 2007 |
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen | 2007 |
Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cicat | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Anal | 2008 |
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Topics: Adult; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochem | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers | 2007 |
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; ErbB Re | 2007 |
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Do | 2008 |
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cluster Analysis; Databases, Nucleic Acid; Female; Gene Expr | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Do | 2007 |
Letrozole in the extended adjuvant setting: MA.17.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2007 |
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Ch | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Me | 2007 |
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; | 2007 |
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2008 |
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2008 |
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Fem | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; | 2008 |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neopl | 2008 |
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Disease Progr | 2009 |
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Cardiovascular Disease | 2008 |
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, D | 2008 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2008 |
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2008 |
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast | 2008 |
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Coh | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, | 2008 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Ne | 2008 |
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2009 |
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme-Linked Immunosorbent | 2008 |
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brea | 2008 |
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatin | 2008 |
Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole.
Topics: Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Estradiol; Female; Humans; Letrozole; Nitr | 1995 |
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Fe | 1995 |
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Fadrozole; Female; Humans; Le | 1994 |
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Humans; Letrozole; Microsomes; Middle Ag | 1993 |
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cosynt | 1993 |
Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
Topics: Adult; Aged; Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhi | 1996 |
A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedul | 1997 |
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease P | 1998 |
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Topics: Administration, Oral; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Co | 1998 |
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme | 1995 |
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherap | 1999 |
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Rel | 1999 |
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplast | 1999 |
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
Topics: Aged; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitor | 1999 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female | 2001 |
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inh | 2001 |
Letrozole as primary medical therapy for locally advanced and large operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; | 2001 |
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; ErbB Receptors; E | 2001 |
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; | 2001 |
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhi | 2002 |
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind | 2001 |
[Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Double-Blind Meth | 2002 |
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Sche | 2002 |
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estro | 2002 |
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Sche | 2002 |
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Topics: Administration, Oral; Aged; Biomarkers; Biopsy, Needle; Breast Diseases; Breast Neoplasms; Cell Divi | 2002 |
633 other studies available for letrozole and Breast Cancer
| Article | Year |
|---|---|
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
Topics: Aromatase; Biological Products; Breast Neoplasms; Fatty Acids; Female; Humans; Microsomes; Placenta; | 2006 |
Synthesis of 6- or 4-functionalized indoles via a reductive cyclization approach and evaluation as aromatase inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Gene Expression Regulation, Neoplastic | 2008 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Si | 2010 |
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Models, Mo | 2012 |
Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cytochrome P-450 CYP11B2; Female; H | 2013 |
Investigation of fluorinated and bifunctionalized 3-phenylchroman-4-one (isoflavanone) aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Isoflavones | 2014 |
Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Sy | 2015 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosi | 2015 |
Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules.
Topics: Antineoplastic Agents; Apoptosis; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Li | 2017 |
Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.
Topics: Allosteric Regulation; Antineoplastic Agents; Aromatase; Breast Neoplasms; Cell Line, Tumor; Cell Pr | 2019 |
Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Femal | 2021 |
Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Molecular Docking Simulation; Molecular Stru | 2021 |
4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Triazoles | 2022 |
Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Femal | 2021 |
Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling.
Topics: Amphiregulin; Aromatase Inhibitors; Breast Neoplasms; Calcium; Drug Resistance, Neoplasm; Female; Hu | 2021 |
Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
Topics: Acrylamides; Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fema | 2021 |
A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chromatography, Liquid; Dried Blood Spot Te | 2021 |
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australi
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Female; Humans; Letrozo | 2022 |
Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Femal | 2022 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Prolifera | 2022 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans | 2022 |
Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Cohort Studies; Databases, Factual; Elec | 2022 |
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
Topics: Apoptosis; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neo | 2022 |
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letro | 2022 |
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Letrozole; Th | 2022 |
Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Liver N | 2022 |
Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma.
Topics: Breast Neoplasms; Cholesterol, HDL; Female; Humans; Letrozole; Postmenopause; Prognosis; Retrospecti | 2022 |
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Hum | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catec | 2022 |
Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; | 2023 |
LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway.
Topics: Aromatase; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulatio | 2022 |
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; | 2022 |
Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
Topics: Breast Neoplasms; Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Letrozole; | 2022 |
Neoadjuvant Endocrine Therapy: A Potential Way to Make Cold Hormone Receptor-Rich Breast Cancer Hot.
Topics: Breast Neoplasms; Female; Hormones; Humans; Letrozole; Neoadjuvant Therapy; Tumor Microenvironment | 2023 |
PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines.
Topics: Breast Neoplasms; Drug Carriers; Female; Humans; Letrozole; MCF-7 Cells; Nanoparticles; Particle Siz | 2022 |
Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Middle | 2022 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; F | 2022 |
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin- | 2022 |
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; F | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac | 2022 |
Effectiveness research in oncology with electronic health record data: A retrospective cohort study emulating the PALOMA-2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Electronic Health | 2023 |
Transporting observational study results to a target population of interest using inverse odds of participation weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Piperaz | 2022 |
Transporting observational study results to a target population of interest using inverse odds of participation weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Piperaz | 2022 |
Transporting observational study results to a target population of interest using inverse odds of participation weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Piperaz | 2022 |
Transporting observational study results to a target population of interest using inverse odds of participation weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Piperaz | 2022 |
In vitro Development of Controlled-Release Nanoniosomes for Improved Delivery and Anticancer Activity of Letrozole for Breast Cancer Treatment.
Topics: Breast Neoplasms; Delayed-Action Preparations; Female; Humans; Letrozole; Liposomes; MCF-7 Cells | 2022 |
Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Female; Genomics; | 2022 |
Effect of metformin as an adjuvant therapy to letrozole on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women: a pilot study.
Topics: Biomarkers; Blood Glucose; Breast Neoplasms; Estradiol; Female; Humans; Insulin; Leptin; Letrozole; | 2023 |
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Lymphoc | 2023 |
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependen | 2023 |
[A real-world study of the effects of endocrine therapy on liver function in breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bilirubin; Breast Neoplasms; Fema | 2023 |
Variations in Incidence of Trigger Finger and Response to Corticosteroid Injection after Aromatase Inhibitor Therapy for Breast Cancer.
Topics: Adrenal Cortex Hormones; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incide | 2023 |
[A Case of Recurrent Breast Cancer with Multiple Bone Metastasis Effectively Treated by CDK4/6 Inhibitor in Addition to Aromatase Inhibitor].
Topics: Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Humans; Letrozole; Lymph | 2022 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitr | 2023 |
Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers.
Topics: Breast Neoplasms; Estrogens; Female; Humans; Ki-67 Antigen; Letrozole; Tamoxifen | 2023 |
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Effectiveness Analysis; | 2023 |
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Estr | 2023 |
[Chemotherapy-Resistant Breast Cancer and Carcinomatous Pleuritis Successfully Treated with Abemaciclib plus Letrozole Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; | 2023 |
Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; R | 2023 |
Synthesis and Characterization of Folic Acid-Functionalized DPLA-co-PEG Nanomicelles for the Targeted Delivery of Letrozole.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Carriers; Female; Folic Acid; Hormones; Humans; Letroz | 2023 |
Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Li | 2023 |
Letrozole-induced inflammatory arthritis and tendinopathy in pediatric rheumatology setting.
Topics: Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Child; Female; Humans; Letrozole; Mus | 2023 |
Ribociclib-induced visual hallucination in a patient with metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hallucinations; Huma | 2023 |
Trastuzumab, leuprorelin, letrozole, and palbociclib as first-line therapy in HER2-positive and hormone receptor-positive metastatic breast cancer: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; | 2023 |
High-Affinity Extended Bisphosphonate-Based Coordination Polymers as Promising Candidates for Bone-Targeted Drug Delivery.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Delivery Systems; Fema | 2023 |
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Genistein; Humans; Letrozole; | 2023 |
Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cytostatic Agents; Female; Humans; Letrozole; MCF | 2023 |
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Postmenopause; Tamoxif | 2023 |
Outcomes of random-start letrozole protocol with PGT-A in women with breast cancer undergoing fertility preservation.
Topics: Adult; Breast Neoplasms; Cryopreservation; Female; Fertility Preservation; Humans; Letrozole; Ovulat | 2023 |
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Latin America; Let | 2023 |
[ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib].
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Mutation | 2023 |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Le | 2023 |
The role of aromatase inhibitors in slim women with breast cancer-related lymphoedema: a reflective case series.
Topics: Aromatase Inhibitors; Breast Cancer Lymphedema; Breast Neoplasms; Female; Humans; Letrozole; Upper E | 2023 |
ASSOCIATION OF miRNA EXPRESSION PATTERN WITH OUTCOME OF LETROZOLE THERAPY IN BREAST CANCER PATIENTS.
Topics: Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Hormones; Human | 2023 |
ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies.
Topics: Biomarkers; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Letrozole | 2023 |
Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; I | 2019 |
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Topics: Alanine Transaminase; Aminopyridines; Aromatase Inhibitors; Aspartate Aminotransferases; Bone Neopla | 2020 |
Leukocytoclastic vasculitis associated with use of aromatase inhibitors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Vasculitis, Leukocyt | 2019 |
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug | 2020 |
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
Topics: Antigens, CD; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Prolifer | 2020 |
Time for a shift in molecular down staging in luminal breast cancer.
Topics: Aminopyridines; Breast Neoplasms; Female; Humans; Letrozole; Postmenopause; Purines; Receptor, ErbB- | 2020 |
Folic acid receptor-targeted solid lipid nanoparticles to enhance cytotoxicity of letrozole through induction of caspase-3 dependent-apoptosis for breast cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Drug Carriers; Drug Delivery Systems; | 2020 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neo | 2020 |
Unusual recurrent metastasizing benign breast papilloma: a case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Lymph Node Excision; Magnetic Re | 2020 |
De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Humans; Letroz | 2020 |
[Late Recurrence of Breast Cancer 32 Years after Surgery-A Case Report].
Topics: Aged, 80 and over; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Loc | 2019 |
The impact of letrozole administration on oocyte morphology in breast cancer patients undergoing fertility preservation.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cell Shape; Cryopreservation; Female; Fertility Pres | 2020 |
Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Biomarkers, Tumor; Breast Neoplasm | 2020 |
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dr | 2020 |
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Computer | 2020 |
Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Humans; Letroz | 2020 |
[A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Humans; Letrozole | 2020 |
Radiation recall myelitis following capecitabine: First case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; | 2020 |
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Li | 2020 |
Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Breast Neoplasms; Cell Count; Chemotherapy, Adjuvant; F | 2020 |
Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; Biomarkers | 2020 |
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 2020 |
In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2021 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2020 |
Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 2020 |
Complete response of leptomeningeal carcinomatosis secondary to breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Fe | 2020 |
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Topics: Adult; Aged; Breast Neoplasms; Estrogen Receptor alpha; Female; Humans; Letrozole; Lymphatic Metasta | 2021 |
Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
Topics: Breast Neoplasms; Female; Fertility Preservation; Humans; Letrozole; Neoplasm Recurrence, Local; Ovu | 2021 |
Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fertili | 2021 |
[Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report].
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy; Neoplasm Recurrence, Loc | 2020 |
Predictive Factors Increasing the Risk of Radiation Toxicity in Patients with Early Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; | 2021 |
Acquisition of Letrozole Resistance Through Activation of the p38/MAPK Signaling Cascade.
Topics: Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Pro | 2021 |
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2021 |
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibit | 2021 |
Polymorphisms of T- cell leukemia 1A gene loci are not related to the development of adjuvant letrozole-induced adverse events in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Breast Neoplasms; Female; Gene Frequ | 2021 |
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female | 2021 |
Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; | 2021 |
Ribociclib induced acute kidney injury: A case report.
Topics: Acute Kidney Injury; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2021 |
Delayed hypersensitivity reactions to multiple aromatase inhibitors followed by successful desensitization to letrozole.
Topics: Anti-Allergic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross Reactions; Desensitization, Immu | 2021 |
Long-term response on letrozole for gastric cancer: A case report.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Fatal Outcome; Female; H | 2021 |
Chemical inhibitor anticancer drugs regulate mechanical properties and cytoskeletal structure of non-invasive and invasive breast cancer cell lines: Study of effects of Letrozole, Exemestane, and Everolimus.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Cytoskeleton; Everolimus; Fe | 2021 |
IRIS METASTASIS FROM BREAST CANCER SUCCESSFULLY TREATED WITH ABEMACICLIB AND LETROZOLE.
Topics: Breast Neoplasms; Female; Humans; Iris Neoplasms; Letrozole; Retrospective Studies | 2023 |
Severe hemoperitoneum resulting from restart of letrozole after oocyte retrieval procedure: a case report.
Topics: Adult; Breast Neoplasms; Female; Fertility Preservation; Hemoperitoneum; Humans; Letrozole; Neoplasm | 2021 |
Diffuse optical tomography breast imaging measurements are modifiable with pre-surgical targeted and endocrine therapies among women with early stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Tomography, | 2021 |
Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Piperaz | 2021 |
Differential biological effects of aromatase inhibitors: Apoptosis, autophagy, senescence and modulation of the hormonal status in breast cancer cells.
Topics: Anastrozole; Androstadienes; Apoptosis; Aromatase Inhibitors; Autophagy; Biomarkers; Breast Neoplasm | 2021 |
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Female | 2022 |
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Piperazines; Pyridines | 2017 |
The prognostic significance of Cdc6 and Cdt1 in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; DNA Replication; Female; Gene Expr | 2017 |
Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrog | 2017 |
Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Carriers; Drug Combinations; Femal | 2017 |
Inhibition of 17beta-hydroxysteroid dehydrogenase type 7 modulates breast cancer protein profile and enhances apoptosis by down-regulating GRP78.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Breast Neo | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast | 2017 |
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Chorionic Gonadotropin; Female; Follicle Stimulating | 2017 |
Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells.
Topics: Breast Neoplasms; Cells, Cultured; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alp | 2017 |
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Hu | 2017 |
Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial.
Topics: Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; C | 2017 |
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomark | 2017 |
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; | 2018 |
[Indoleamine 2,3-Dioxygenase Activity during Letrozol Therapy for an Elderly Breast Cancer Patient].
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Indoleamine-Pyrrole 2,3, | 2017 |
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Topics: Adipose Tissue; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobu | 2018 |
Folate Conjugated Hybrid Nanocarrier for Targeted Letrozole Delivery in Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Survival; Drug Carri | 2017 |
Complexity of intermittent letrozole adjuvant therapy.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Letrozole; Nitriles; Triazoles | 2018 |
Combined Raloxifene and Letrozole for Breast Cancer Patients.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relatio | 2017 |
Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Breast Neoplasms; China; Fema | 2018 |
Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy.
Topics: Breast Neoplasms; Carbon; Diet; Female; Genistein; Humans; Letrozole; MCF-7 Cells; Metabolome; Metab | 2018 |
Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?
Topics: Breast Neoplasms; Case-Control Studies; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing | 2018 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; | 2018 |
The Study of Letrozole Extension (SOLE) revisited.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Longitudinal Studies; Postmenopau | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
[A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Duct | 2018 |
Verapamil as a culprit of palbociclib toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; P | 2019 |
Preparation and characterization of letrozole-loaded poly(d,l-lactide) nanoparticles for drug delivery in breast cancer therapy.
Topics: Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Drug Liberation; Emulsions; Female; Humans; | 2019 |
Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Germany; Humans; Letroz | 2018 |
Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Bronchi; Bronchial Neoplasms; | 2018 |
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analy | 2018 |
Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenal Cortex Hormones; Antineoplastic Agents; Breast N | 2018 |
Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells.
Topics: Antigens, Differentiation; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistanc | 2019 |
Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budgets; Female; H | 2018 |
Preparation and optimization of monodisperse polymeric microparticles using modified vibrating orifice aerosol generator for controlled delivery of letrozole in breast cancer therapy.
Topics: Aerosols; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutical; Delayed | 2018 |
Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; B | 2018 |
Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2019 |
Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; China; Cost-Benefit Analysis; Female | 2018 |
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort St | 2018 |
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Fe | 2019 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adj | 2018 |
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles | 2018 |
Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; China; Cost-Benefi | 2019 |
[Indoleamine 2,3-Dioxygenase Activity during Long-Term Letrozole Therapy for Hormone Receptor-Positive Breast Cancer].
Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy, Needle; Breast Neoplasms; Female; Humans; Indoleam | 2018 |
Hair analysis to discriminate voluntary doping vs inadvertent ingestion of the aromatase inhibitor letrozole.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure | 2019 |
Competing risks of extended adjuvant aromatase inhibitors.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Met | 2019 |
Paraneoplastic syndrome - a rare but treatable cause of non-thyroid-related extraocular muscle enlargement.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duc | 2019 |
Effect of letrozole added to gonadotropins in controlled ovarian stimulation protocols on the yield and maturity of retrieved oocytes.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Female; Fertility Preservation; Humans; Letrozole; Ov | 2019 |
Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast; Breast Neoplasms; Coho | 2019 |
Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cispla | 2019 |
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Topics: Androstadienes; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasm | 2019 |
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analy | 2019 |
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Mod | 2019 |
ER+/HER2+ breast cancer: are we really de-escalating?
Topics: Breast Neoplasms; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Receptor, ErbB-2 | 2019 |
Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up.
Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Letrozole; Neoplasms, Second Primary | 2019 |
Reply to K.-D. Yu et al.
Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Postmenopause; Tamoxifen | 2019 |
Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Argenti | 2019 |
Picosecond laser treatment for drug-induced melanonychia.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Age | 2019 |
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Follow-Up Studies; Humans; Kaplan-Meier Estima | 2019 |
Hormone Receptor-Positive Breast Cancer Choroidal Infiltrates before and after Systemic Aromatase Inhibitor Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Choroid Neoplasms; Female; Human | 2019 |
New evidence and hope for young patients with breast cancer.
Topics: Adaptation, Psychological; Breast Neoplasms; Hope; Humans; Letrozole; Zoledronic Acid | 2019 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2013 |
Does zoledronic acid have additive effect on suppression of plasma estrogen levels?
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Syner | 2013 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Densi | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor | 2013 |
Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; bcl-2-Associated X Protein; Blotti | 2013 |
Anti-Ri antibody-associated paraneoplastic brainstem encephalitis successfully treated after treating the underlying malignancy with letrozole.
Topics: Aged, 80 and over; Antibodies, Anti-Idiotypic; Antineoplastic Agents; Brain Stem Neoplasms; Breast N | 2013 |
Cutaneous leukocytoclastic vasculitis associated with letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitr | 2014 |
Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Topics: Actin Cytoskeleton; Amides; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Ce | 2013 |
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Topics: Aged; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Es | 2013 |
Tamoxifen therapy for patients with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; D | 2013 |
Tamoxifen therapy for patients with breast cancer - Authors' reply.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; | 2013 |
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Topics: Androgens; Androstane-3,17-diol; Aromatase Inhibitors; Breast Neoplasms; Dihydrotestosterone; Drug R | 2013 |
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Case- | 2013 |
Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Computational Biology; Female; Gene Expr | 2013 |
A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; General Surge | 2013 |
The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Estradiol; Female; Fertility Pres | 2013 |
Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Cryopreservati | 2013 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estra | 2013 |
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Proliferation; Drug Synergism; Elafin; Everoli | 2014 |
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
Topics: Adult; Breast Neoplasms; Cohort Studies; Comorbidity; Drug Therapy, Combination; Drug-Related Side E | 2013 |
Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Prolif | 2013 |
[Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug R | 2013 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease- | 2014 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic | 2013 |
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug-Related Side Effects and Advers | 2014 |
Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Com | 2014 |
[An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report].
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Human | 2013 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; | 2014 |
[A case of advanced breast carcinoma effectively treated postoperatively with tegafur-uracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hu | 2013 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Ne | 2015 |
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Body Mass Index; Breast | 2014 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: a controlled drug delivery system for treatment of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Cell Proliferation; Cell Survival; Dose-Response Relations | 2014 |
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2 | 2014 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics.
Topics: Antineoplastic Agents; Breast Neoplasms; Computational Biology; Drug Discovery; Gene Expression Prof | 2014 |
A joint test for progression and survival with interval-censored data from a cancer clinical trial.
Topics: Antineoplastic Agents; Bias; Breast Neoplasms; Clinical Trials as Topic; Data Interpretation, Statis | 2014 |
Dasatinib-letrozole gets split verdict.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dasatinib; F | 2014 |
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy].
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms | 2013 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Es | 2014 |
Radiation recall reaction with letrozole therapy in breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Br | 2014 |
Palbociclib ups PFS in HER2-/ER+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Depen | 2014 |
Is there any cumulative dose for trastuzumab?
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherap | 2015 |
Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adj | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast | 2014 |
Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Topics: Adipose Tissue; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured | 2014 |
Weight loss interventions and breast cancer survival: the time is now.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Telepho | 2014 |
Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocr | 2014 |
Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neop | 2014 |
Molecular changes in lobular breast cancers in response to endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Cohort Studies; Female; Human | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromat | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2015 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis | 2015 |
Morphea following radiation therapy in a patient with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Combi | 2015 |
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Su | 2014 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; | 2015 |
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Bre | 2015 |
Surgical resection of a liver metastasis from breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Liver Neoplasms; Lymph Node | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Topics: Animals; Anoikis; Aromatase; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Carcinoma, Duct | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosph | 2015 |
[Long-term survival of a breast cancer patient with carcinomatous pleuritis and carcinomatous cardiac tamponade successfully treated by multimodality therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cardiac Tamponade; Combined Modality Therapy; Female; | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; B | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; C | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival | 2015 |
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Aromatase Inhibitors; Biomarkers, Tu | 2015 |
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free S | 2015 |
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertilit | 2015 |
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertilit | 2015 |
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertilit | 2015 |
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertilit | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; | 2015 |
Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fertility Preservation; Fertilizat | 2015 |
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Ne | 2015 |
[Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Drug Combinati | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2015 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density C | 2016 |
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Ne | 2015 |
Drug Use Evaluation of Letrozole in Breast Cancer Patients at Regional Cancer Hospitals in Thailand.
Topics: Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Drug Utilization; Female; Follow-Up | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2015 |
[Multiple smooth colon stenosis in 76-year-old female patient].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diagnosis, Differential; Female; H | 2015 |
Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; C | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Brea | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Brea | 2015 |
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composi | 2016 |
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumo | 2015 |
A computational method for drug repositioning using publicly available gene expression data.
Topics: Antineoplastic Agents; Breast Neoplasms; Computational Biology; Databases, Genetic; Drug Repositioni | 2015 |
Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; | 2015 |
Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Drug Therapy, Combination; Fema | 2016 |
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumo | 2016 |
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinom | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Unilateral Internal Carotid Artery Occlusion After Letrozole Treatment in a Postmenopausal Woman with Breast Cancer.
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Breast Neoplasms; Carotid Artery Diseases; Carot | 2016 |
Assessing survival benefit when treatment delays disease progression.
Topics: Aromatase Inhibitors; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; | 2016 |
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvan | 2016 |
Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea | 2016 |
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cysteine-Rich Protein 61; Drug Resi | 2017 |
Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Female; | 2016 |
Twin delivery after IVF-ET with variable dose letrozole-FSH protocol of lower estradiol in a patient previously treated for breast cancer: a case report.
Topics: Adenocarcinoma, Mucinous; Adult; Aromatase Inhibitors; Breast Neoplasms; Embryo Transfer; Estradiol; | 2016 |
Evaluating Markers for Guiding Treatment.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; | 2016 |
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Topics: Animals; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; L | 2016 |
Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Coculture Techniques; | 2016 |
Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Huma | 2016 |
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2016 |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; DNA Mutational Analysis; Drug Administration Sc | 2017 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Ne | 2017 |
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Brea | 2017 |
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neo | 2016 |
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Germany; Humans; Integr | 2017 |
Ribociclib Lengthens Breast Cancer Survival.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as | 2016 |
A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Computer Simulation; Disease-Free Survival; Endpoint D | 2017 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Ci | 2017 |
Palbociclib improves survival in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Tri | 2017 |
Breast cancer: PALOMA-2 - hope beyond the threshold.
Topics: Breast Neoplasms; Humans; Letrozole; Piperazines; Pyridines | 2017 |
The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne | 2018 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservat | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Co | 2017 |
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; E | 2016 |
[Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Ful | 2016 |
Letrozole not superior to anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans | 2017 |
Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line.
Topics: Aromatase; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Flavones; Gene Express | 2017 |
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Implants; Breast Neoplasms; Carcin | 2017 |
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2017 |
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2017 |
Estimating efficacy in trials with selective crossover.
Topics: Antineoplastic Agents; Binomial Distribution; Biostatistics; Breast Neoplasms; Clinical Trials as To | 2017 |
Fertility preservation: a vital survivorship issue for young women with breast cancer.
Topics: Adult; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Follicle Stimulating Hor | 2008 |
Stopping treatment can reverse acquired resistance to letrozole.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Pr | 2008 |
Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Leukemia, Lymphocytic, Chro | 2009 |
Method to test whether late extended letrozole, rather than self- selection, improves the outcome in patients with breast cancer who have completed 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2008 |
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breas | 2008 |
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Topics: Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens; | 2008 |
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Topics: Animals; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cell Line, | 2008 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Abnormal cervical smear: a sign of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Letrozole; Middle Aged; | 2008 |
Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biom | 2008 |
A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Topics: Administration, Oral; Animals; Aromatase Inhibitors; Azasteroids; Breast Neoplasms; Cell Proliferati | 2008 |
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Sonographic evaluation of endothelial function in letrozole and tamoxifen users.
Topics: Aged; Aromatase Inhibitors; Brachial Artery; Breast Neoplasms; Carotid Artery, External; Case-Contro | 2008 |
Breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind M | 2008 |
A case of prolonged disease-free survival in a patient with choroidal metastasis from breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Choroid Neoplasms; Disease-Free Survival; Female; | 2009 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everoli | 2009 |
A case of Meigs syndrome mimicking metastatic breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; CA-125 Antigen; Carcinoma, Ductal, Breast; Diagnosis, Diffe | 2009 |
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neopla | 2009 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; A | 2009 |
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cell Count; Forkhead Transcription | 2009 |
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase | 2009 |
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Drug Resistance, Neoplasm; Fe | 2009 |
Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Stu | 2009 |
Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Female; | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagoni | 2009 |
Preservation of fertility in patients with cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fertility; Humans; Letrozole | 2009 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Knowledge discovery processing and data mining in karyometry.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Papillary; Cell Nucleus; Colonic Neo | 2009 |
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuv | 2010 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrat | 2004 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; | 2010 |
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breas | 2010 |
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breas | 2010 |
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Topics: Adult; Breast Neoplasms; Female; Genes, BRCA1; Humans; Infertility; Letrozole; Mutation; Nitriles; O | 2010 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 2009 |
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neop | 2009 |
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; D | 2009 |
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2009 |
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Brea | 2010 |
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apo | 2010 |
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; | 2010 |
Radiotherapy, antihormonal therapy, and personalised medicine.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; | 2010 |
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Topics: 3' Untranslated Regions; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Breast Neoplasms | 2010 |
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin E; Drug Resistance, Neo | 2010 |
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Bone De | 2010 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, | 2010 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2010 |
GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Female; Fertility; Follicle Stimulating Hormone; Gona | 2010 |
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Cell Line, Tum | 2010 |
Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antineoplastic Agents; Antineoplastic Agents, Horm | 2010 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2011 |
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Topics: Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-del | 2010 |
Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Injections, Spinal | 2011 |
The transdermal patches for site-specific delivery of letrozole: a new option for breast cancer therapy.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Letrozole; Mice | 2010 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Brea | 2011 |
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubici | 2011 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy P | 2010 |
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cluster Analysis; Female; Gene Expression Profiling; Gene Ex | 2012 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Human | 2010 |
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit | 2010 |
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole | 2010 |
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation | 2010 |
Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogens; Female; Huma | 2010 |
Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcino | 2010 |
Significance of ER-Src axis in hormonal therapy resistance.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Dasatinib | 2011 |
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2011 |
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplas | 2011 |
Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cryopreservation; Drug Administration Sche | 2011 |
Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cryopreservation; Drug Administration Sche | 2011 |
Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cryopreservation; Drug Administration Sche | 2011 |
Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cryopreservation; Drug Administration Sche | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; | 2011 |
Synthesis and in vitro studies of biodegradable thiolated chitosan hydrogels for breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug St | 2011 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Si | 2011 |
Aromatase inhibitors and xenograft studies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2011 |
[Significance of HER2 testing in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; | 2011 |
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans | 2011 |
Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cel | 2011 |
Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disea | 2011 |
Letrozole withdrawal response in locally advanced breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hepacivirus; Humans | 2011 |
Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.
Topics: Adult; Age Factors; Anti-Mullerian Hormone; Breast Neoplasms; Cryopreservation; Embryonic Developmen | 2011 |
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2011 |
Effective role of hormonal therapy in metastatic primary neuroendocrine breast carcinoma.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; | 2011 |
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic D | 2012 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2011 |
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Brea | 2011 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neopla | 2012 |
Choroidal and optic disc metastases from breast cancer and their response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brea | 2012 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2011 |
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Leiomyoma; Letrozole; Mi | 2011 |
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Frac | 2011 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; | 2012 |
Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report.
Topics: Adult; Breast Neoplasms; Female; Fertilization in Vitro; Gonadotropins; Humans; Letrozole; Male; Nit | 2012 |
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cl | 2012 |
[A case of an elderly breast cancer patient achieving partial response with toremifene without efficacy of letrozole as a preoperative primary endocrine therapy].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; | 2011 |
[Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2011 |
[A case of scalp metastases from breast cancer successfully treated with letrozole].
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Letrozole; | 2011 |
Primary breast cancer of the vulva: a case report.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Femal | 2012 |
Myocardial infarction due to coronary thrombus formation in a postmenopausal woman with breast cancer after initiation of letrozol therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Coronary Thrombosis; Electrocardiography; Female; Humans; Le | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Clinical Protocols; Embryo Implantation, Delayed; Est | 2011 |
[A case of liver metastasis of breast cancer responding to letrozole].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; | 2012 |
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltran | 2012 |
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, | 2012 |
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Mammography; Nitriles; Pilot Proj | 2012 |
The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Estradiol; Female; Fertility Prese | 2012 |
AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
Topics: Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cycli | 2012 |
Breast cancer associated with an accessory nipple.
Topics: Aged, 80 and over; Aromatase Inhibitors; Biopsy, Large-Core Needle; Breast Neoplasms; Choristoma; Fe | 2011 |
[A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole].
Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Femal | 2012 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasm | 2012 |
Long-term survival in an untreated patient with leptomeningeal carcinomatosis from breast primary.
Topics: Antineoplastic Agents; Breast Neoplasms; Chronic Disease; Female; Humans; Hypesthesia; Immunohistoch | 2013 |
Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2012 |
Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease Pr | 2010 |
Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer?
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; | 2012 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Ma | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasm | 2012 |
Successful combination: existing drugs boost cancer vaccine responses.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines | 2012 |
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Topics: Animals; Aromatase Inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding | 2012 |
Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Topics: Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Ampli | 2012 |
Macular oedema due to letrozole: a first case report.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Diagnosis, Differential; Female; Fluorescein Angiogra | 2012 |
[Endobronchial metastases from breast cancer: a clinicopathological and survival analysis].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Ductal, Breast; Chem | 2012 |
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; C | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inh | 2013 |
New ruthenium(II)-letrozole complexes as anticancer therapeutics.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Aromatase Inhibitors; Autophagy; Breast Neoplasms; C | 2012 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucle | 2012 |
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Disease-Free Survival; F | 2012 |
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neopl | 2013 |
Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Letrozole | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; Er | 2013 |
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Topics: Aged; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Breast Neopla | 2013 |
Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor | 2013 |
Letrozole: advancing hormone therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2012 |
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Citrus; Es | 2013 |
Uterine metastasis of lobular breast cancer during adjuvant letrozole therapy.
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobula | 2013 |
Rapid determination of letrozole, citalopram and their metabolites by high performance liquid chromatography-fluorescence detection in urine: Method validation and application to real samples.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents; Breast Neoplasms; Chromatography, H | 2013 |
[A case of advanced breast carcinoma treated with topical S-1 plus letrozole].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Combinations; Female; | 2012 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2013 |
Therapeutic mammaplasty--extending indications and achieving low incomplete excision rates.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; | 2013 |
18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen | 2013 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2001 |
Reversible pancytopenia caused by oral letrozole assumption in a patient with recurrent breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence | 2002 |
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Double | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hormone | 2003 |
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III | 2003 |
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; | 2003 |
New approaches to the understanding of tamoxifen action and resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Re | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-B | 2003 |
Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuva | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; An | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Ca | 2003 |
Role of biologic markers in patient selection and application to disease prevention.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Enzyme Inhi | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Makin | 2003 |
Letrozole after tamoxifen for breast cancer--what is the price of success?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2003 |
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2003 |
Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin.
Topics: Adult; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Br | 2003 |
Searching for the next tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Research; Ta | 2003 |
Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cont | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled C | 2003 |
Breast-cancer drug letrozole picks up where tamoxifen leaves off. But we don't know who stands to benefit the most from this follow-up approach.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2003 |
Top 10 health stories of 2003.
Topics: Aging; Angioplasty, Balloon, Coronary; Antineoplastic Agents; Breast Neoplasms; Dietary Carbohydrate | 2003 |
Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Hu | 2003 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chem | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled | 2004 |
Drugs may improve long-term outcomes after breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2004 |
New treatment boosts outlook for breast cancer survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitr | 2004 |
Role of endocrine therapy in the neoadjuvant surgical setting.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Fem | 2004 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dis | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Prime | 2004 |
Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Contraindicatio | 2004 |
Long-term insurance for breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Insurance, Long-Term | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Ni | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Human | 2004 |
Letrozole (Femara).
Topics: Administration, Oral; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration | 2004 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; | 2004 |
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase; Body Composition; Breast Neoplasms; Cell Division; Cell L | 2004 |
A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuva | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost- | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line | 2004 |
The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
New drugs reduce risk of death from breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
Letrozole sensitizes breast cancer cells to ionizing radiation.
Topics: Antineoplastic Agents; Aromatase; Breast Neoplasms; Cell Cycle; Cell Survival; Female; Flow Cytometr | 2005 |
Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Topics: Androgens; Androstenedione; Aromatase; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Ce | 2005 |
Letrozole better than tamoxifen in postmenopausal women.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles | 2005 |
[Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Fem | 2004 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; | 2005 |
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Topics: Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; ErbB Receptors; Female; Humans; Letro | 2005 |
Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Estrogen Antagonists; F | 2005 |
Diabetes insipidus caused by isolated intracranial metatstases in patient with breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Deamino Arginine Vasopressin; Diabetes Insipidus; Fatal Out | 2005 |
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Disease Progress | 2005 |
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast N | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Pro | 2005 |
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female | 2005 |
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Dr | 2005 |
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Br | 2005 |
Breast cancer's 'new era'.
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Nitriles; S | 2003 |
Letrozole for brain and scalp metastases from breast cancer--a case report.
Topics: Aromatase Inhibitors; Brain Neoplasms; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Le | 2006 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozol | 2005 |
Options for preservation of fertility in women.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Em | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cel | 2005 |
Aromatase inhibitors--a triumph of translational oncology.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adju | 2005 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female | 2006 |
Toxic epidermal necrolysis in patient with breast cancer receiving letrozole.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Fatal Outcome; Female; Humans; L | 2006 |
ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Topics: Acetyltransferases; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Carrier Proteins; Cell | 2006 |
Effectiveness of letrozole in the breast cancer treatment continuum.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Tria | 2006 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2005 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy | 2006 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Tria | 2006 |
Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Ne | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dat | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Humans; Letrozole; Nitri | 2006 |
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Dis | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Comb | 2006 |
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferat | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemot | 2006 |
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Huma | 2007 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combine | 2006 |
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Topics: Adult; Breast Neoplasms; Chorionic Gonadotropin; Cost-Benefit Analysis; Cryopreservation; Embryo Tra | 2006 |
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Topics: Adult; Breast Neoplasms; Chorionic Gonadotropin; Cost-Benefit Analysis; Cryopreservation; Embryo Tra | 2006 |
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Topics: Adult; Breast Neoplasms; Chorionic Gonadotropin; Cost-Benefit Analysis; Cryopreservation; Embryo Tra | 2006 |
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Topics: Adult; Breast Neoplasms; Chorionic Gonadotropin; Cost-Benefit Analysis; Cryopreservation; Embryo Tra | 2006 |
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Topics: Androgen Receptor Antagonists; Androgens; Androstenedione; Aromatase; Breast Neoplasms; Cell Growth | 2006 |
Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Est | 2006 |
Quality of life in a randomized control trial? Comments concerning MA 17.
Topics: Antineoplastic Agents, Hormonal; Bias; Breast Neoplasms; Chemotherapy, Adjuvant; Confounding Factors | 2006 |
Fertility preservation strategies for breast cancer patients.
Topics: Antineoplastic Agents; Breast Neoplasms; Evidence-Based Medicine; Female; Fertility; Humans; Letrozo | 2006 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Br | 2007 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans | 2007 |
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Re | 2006 |
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Topics: Animals; Apoptosis Regulatory Proteins; Aromatase; Aromatase Inhibitors; Blotting, Western; Breast N | 2006 |
[Correlation of hormone-metabolic status in breast cancer and effectiveness of adjuvant hormone therapy].
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; C-Peptide; Chemotherapy, | 2006 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2007 |
Cancer research. Budget pressure puts high-profile study in doubt.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Budgets; Controlled Clinical Trials a | 2007 |
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; C | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromat | 2007 |
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Topics: Androstadienes; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase | 2007 |
Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Con | 2008 |
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Fem | 2007 |
In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: description of a novel approach to fertility preservation.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cell Culture Techniques; Cryopreservation; Drug Admi | 2008 |
Clinical research. No lifeline for proposed breast cancer prevention trial.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Budgets; Clinical Trials as Topic; Fem | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cos | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit | 2008 |
NCI and the STELLAR trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nation | 2007 |
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Topics: Animals; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Cyclin D; Cyclin | 2008 |
Regression of choroidal metastasis from breast carcinoma following Letrozole therapy.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Choroid Neoplasms; Estrogen Receptor Modulators; Fem | 2007 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatas | 2007 |
Hope for axed cancer-prevention trial.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health | 2007 |
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Female; Humans; Letrozole; Neoplasm Metastas | 2007 |
Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene E | 2008 |
Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles | 2007 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Joint effects of body size, energy intake, and physical activity on breast cancer risk.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Body Size; Breast Neoplasms; E | 2009 |
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Topics: 3' Untranslated Regions; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA, Neoplasm; Female; H | 2008 |
Time to remove the subspecialty blinders: breast cancer does not exist in isolation.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Cause | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2008 |
Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Needle; Breast; Breast Neoplasms; Estrogens; Female | 2008 |
[A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].
Topics: Aged, 80 and over; Anastrozole; Breast Neoplasms; Endocrine System; Female; Humans; Letrozole; Neoad | 2008 |
Tolerance of adjuvant letrozole outside of clinical trials.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuv | 2008 |
Excellent response to letrozole in brain metastases from breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Cranial Irrad | 2008 |
An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Ce | 1995 |
Development, application and comparison of an enzyme immunoassay and a high-performance liquid chromatography method for the determination of the aromatase inhibitor CGS 20,267 in biological fluids.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Specificity; Aromatase Inhibitors; Breast | 1994 |
Oestrogen formation in breast: clinical and biological importance.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast; Breast Neo | 1996 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibito | 1997 |
Regulation of aromatase activity within the breast.
Topics: Adipose Tissue; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Enzyme Inhibitors; Female | 1997 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Divisi | 1998 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Toremifene and letrozole for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clin | 1998 |
Letrozole for advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 1998 |
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell | 1998 |
Macrophages, estrogen and the microenvironment of breast cancer.
Topics: Antineoplastic Agents; Aromatase; Breast; Breast Neoplasms; Carcinoma in Situ; Cell Division; Cell L | 1998 |
Letrozole: updated duration of response.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Pos | 1999 |
Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
Topics: Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Humans; | 1999 |
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; E | 1999 |
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors | 1999 |
Letrozole: which dose to be used?
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazol | 2000 |
Letrozole for the treatment of pretreated advanced breast cancer patients: preliminary report.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Mid | 2000 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhib | 2000 |
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Costs and Cost A | 2000 |
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Ne | 2000 |
From the Food and Drug Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Moda | 2001 |
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Agents; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Breast Neopla | 2001 |
Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?
Topics: Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letro | 2001 |
Aromatase inhibitors: treatment of advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Letrozo | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme I | 2001 |
Letrozole in second-line therapy of advanced breast cancer: more questions than answers.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as | 2001 |
False shortening of time to progression in letrozole 2.5-mg dose?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Re | 2001 |
New breast cancer drug.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Female; | 2002 |
Pre-operative endocrine therapy for postmenopausal women: when and why?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Le | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neopl | 2001 |
Aromatase and COX-2 expression in human breast cancers.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplas | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultu | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estr | 2001 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical | 2002 |
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Fem | 2002 |
Breast cancer studies challenge tamoxifen therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhi | 2000 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nit | 2002 |
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibit | 2002 |
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Stu | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Pha | 2002 |